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ABSTRACT 
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STUDIES ON THE INTERACTION OF A SINGLE DOMAIN OF PROTEIN 
G FROM STREPTOCOCCUS WITH HUMAN FC AND FAB 
 
By Nicola Mary Muir 
 
Protein G (SpG) is a Type III bacterial Fc receptor that binds selectively and non-
antigenically to both the Fc and Fab regions of IgG. Here studies are described aimed 
at understanding the individual contributions to complex stability made by amino acid 
residues known to make contacts with either the Fab or Fc. Specific amino-acid 
residues that contribute to these binding interactions via a network of hydrogen bonds 
have been identified and studied by a programme of site directed mutagenesis. Unique 
tryptophan residues (W42 or W14) have been used to facilitate equilibrium and pre-
equilibrium fluorescence studies to observe binding to Fc or Fab and to determine the 
Kd for the various equilibria. The effect of secondary substitutions of residues 
implicated in bond formation to either the Fc or Fab IgG fragment have been 
determined in order to generate SpG domains with a range of binding affinities for 
biotechnological uses. SpG species that only bind to Fc or Fab have also been 
developed. The mutant W42F has been shown by ITC studies to have lost the ability to 
bind to Fc, and the double mutant T15A-T16A shows no detectable binding to Fab. ITC 
and kinetic studies at various temperatures have been employed to characterise the 
thermodynamic parameters underlying binding of wild type or mutated SpG to Fc or 
Fab. Some restoration of Fc binding activity has been brought about by the placement 
of a tryptophan at residue 14 (E14W), which may be a useful protein for affinity 
chromatographic applications as a Kd in the micromolar range is ideal for affinity 
ligands where easy elution of the bound target protein is required. A dramatic 
reduction in the affinity of SpG for Fc has been obtained for the E26A mutation, and 
the N34 residue has been found to be significant in Fc binding, with a 50-fold decrease 
in affinity for the N34A mutation. The electrostatic nature of the interactions and their 
sensitivity to changes in pH has also been studied and results showed that Q31E has 
increased Kd by approximately 6-fold, demonstrating that a negative charge at this 
position is detrimental to binding. The lower affinity and the influence from the 
ionisable group would offer advantages for the elution of the Ig from the column.  
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INTRODUCTION 
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1.1 - Immunoglobulins 
The immune system is a network of cells and organs that has evolved to defend 
the body against attacks by foreign invaders. Every cell in the body carries 
distinctive molecules that distinguish it as ‘self’ and under normal conditions the 
body’s defences do not attack tissues that carry these self markers. Thus, the 
immune cells can coexist with other body cells in a state known as self-tolerance. 
Cells, destined to become immune cells, arise in the bone marrow from stem 
cells, some developing from lymphoid precursors, into small white blood cells 
called B- and T-lymphocytes. Foreign particles, such as bacteria or viruses, 
usually carry distinctive epitopes that protrude from their surfaces. These non-
self antigens are recognised by the body’s immune system triggering a humoral 
immune response, which responds by producing molecules known as 
immunoglobulins.  
 
The term “immunoglobulin” encompasses all globulin proteins associated with the 
immune system, including all antibody molecules. Antibodies are soluble proteins 
that are expressed on the cell surface of all B-lymphocytes where they function as 
the receptors for the antigen, and as the secreted products of the plasma cell. 
Each B-lymphocyte is programmed to make one specific antibody, and when it 
encounters its triggering antigen, along with various accessory cells, it gives rise 
to a clone of many large plasma cells. Each plasma cell is essentially a factory for 
producing that one specific antibody. 
 
The secreted antibody molecules circulate in the blood and lymph, and bind 
specifically to epitopes from the pathogen that elicited a humoral immune 
response, as illustrated in figure 1.1.   
 
 
 
 
 
 
 
 
 
Figure 1.1 - An illustration of the interaction between antibody and antigen             
 
Antibodies are produced by the immune system in response to the presence of an 
antigen. They may be free-floating in the serum and combine with antigen to 
form immune complexes, or maybe attached to cell-surface antigens thus acting 
as receptors. 
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This induces the B-lymphocytes to proliferate and differentiate into antibody-
secreting cells, which can then recruit other cells and molecules to destroy the 
pathogen. These functions are structurally separated in the antibody molecule, 
one part, the Fab, recognises antigen, while the other part, the Fc, engages the 
effector mechanisms that will eliminate it [Goward et al., 1993].  
 
1.1.1 - The structure of an immunoglobulin molecule 
Immunoglobulins (Igs) are composed of four polypeptide chains of varying length 
that are interconnected by covalent cysteine disulphide linkages (-S-S-) and non-
covalent bonds to form a Y-shaped molecule. There are two types of polypeptide 
chains: two light chains which consist of approximately 220 amino acid residues 
and two heavy chains of about 440 amino acids [Porter, 1973]. They are 
synthesised separately, but connected by -S-S- bonds. Sequence studies of 
various immunoglobulins have shown that both the heavy and light polypeptide 
chains contain repeated homologous sequences that are approximately 110 
residues in length [Schiffer et al., 1973]. These homologous regions fold 
individually into similar structural domains, arranged as a bilayer of antiparallel β-
sheets, and each domain contains an intra-chain disulphide bond. Figures 1.2 and 
1.3 represent adapted illustrations of immunoglobulin molecules. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 – A ribbon representation of mouse IgG2 
 
This three-dimensional ribbon representation of a mouse monoclonal antibody of 
subclass IgG2 illustrates the secondary structure of the alpha-carbon backbone 
traces. The beta strands are indicated as ribbons. The structure shows that most 
of the domains have one face in intimate contact with a second domain, thus the 
heavy and light V-region domains are in contact, as are the light chain C-region 
domain and heavy chain CH1 domain, and the two heavy chain CH3 domains 
[Harris et al., 1992].   
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Figure 1.3 - An adapted illustration of an immunoglobulin molecule 
 
An immunoglobulin molecule is presented together with the pattern of disulphide 
cross-links, which joins the heavy and light chains. The subscripts L and H refer to 
light and heavy chains respectively. C and V refer to regions of the sequence that 
are relatively constant or variable respectively. Digestion of the proline rich hinge 
region with proteolytic enzymes splits the antibody molecule into two Fab 
fragments. Each fragment contains a single κ or λ light chain linked by a 
disulphide bond to the NH2-terminal half of the heavy chain; and one Fc 
fragment, composed of the two terminal halves of the heavy chain combined by a 
disulphide bond. It is only the Fab fragments that bind antigen, indicating that 
the antibody-binding site is entirely in the Fab fragment. The putative binding 
sites for several Ig-binding proteins are indicated in red [To
nds Fab 
domain 
negawa, 1985]. 
 
The Ig molecule in its entirety is formed of twelve structural domains, of which 
eight are formed by two heavy chains and the remaining four by the light chains 
[Tonegawa, 1985]. Immunoglobulin heavy and light chains each contain an 
amino-terminal variable (V) region, which differs from one Ig to the next 
depending upon their level of sequence variation. The carboxyl-terminal half of 
the molecule contains a small number of constant (C) regions, which mediate the 
biological effector functions of the immune system, and thus determines the 
mechanism used to destroy antigen, and does not vary in the same way [Lucas, 
2001]. Antibodies are divided into five major classes, IgA, IgD, IgE, IgG and IgM, 
based on their constant region structure and immune function. 
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1.1.1.1 – Light and Heavy chains 
Light chains contain one variable domain (VL) and one constant domain (CL), and 
variations in the sequence of the CL domain have meant that the light chains can 
be of two classes, kappa (κ) and lambda (λ). A single immunoglobulin molecule 
can contain either κ light chains or λ light chains, but never both.  In humans 
60% of the light chains are kappa, and 40% are lambda, whereas comparatively, 
in mice 95% of the light chains are kappa, and only 5% are lambda [Porter, 
1973]. 
 
Heavy chains contain one variable domain (VH), and three (or four in the case of 
IgE and IgM) constant domains (CH1, CH2, CH3 and CH4). There are five classes 
of heavy chains, which give rise to the five classes of antibodies, IgA, IgD, IgE, 
IgG and IgM. Figure 1.4 represents the general structure of the five classes of 
secreted antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 – An illustration of the general structure of the five major    
immunoglobulin classes 
 
There are five major classes of secreted antibody, IgA, IgD, IgE, IgG and IgM. 
Light chains are shown in shades of grey and heavy chains in shades of blue; 
thick black lines indicate disulphide bonds [taken from Alzari et al., 1988]. 
 
 
 
 
 | 5  
 
IgA, IgD and IgG all contain only three CH domains, whereas IgE and IgM contain 
all four. Minor differences in the amino acid sequences of IgA and IgG have led to 
further classification of the heavy chains into subclasses. In humans there are 
two subclasses of IgA, IgA1 and IgA2, and IgG can be further divided into four 
subclasses IgG1, IgG2, IgG3 and IgG4 [Porter, 1973]. In mice there are four 
subclasses of IgG heavy chains IgG1, IgG2a, IgG2b and IgG3. 
 
1.1.1.2 – Hinge region and Fab fragments 
The IgA, IgD and IgG heavy chains also contain an extended peptide sequence 
between the CH1 and CH2 domains that has no homology with the other domains. 
This region is known as the hinge region, and is rich in proline residues and 
flexible, giving IgA, IgD and IgG segmental flexibility. IgE and IgM chains lack a 
hinge region, but have an additional 110 amino acid domain (CH2/CH2) instead, 
that has hinge-like features [Tonegawa, 1985]. Early digest studies performed on 
rabbit IgG [Porter, 1959], demonstrated that papain hydrolyses at this hinge 
region, the midpoint of the heavy chain. Digesting the immunoglobulin molecule 
before the heavy inter-chain disulfide bond produces two identical Fab (fragment 
antigen-binding) fragments, which contain the light chain and the VH and CH1 
domains of the heavy chain. The molecular size of an antibody is too large to 
study directly so the production of these fragments, which could be studied 
individually, meant that the clarification of the structure of immunoglobulins was 
revealed. The fragments produced by antibody digestion are summarised 
schematically in figure 1.3. 
 
Each Fab fragment is composed of one constant and one variable domain of the 
light chain linked by a disulphide bond to the heavy chain, which continued into 
the Fc fragment before it was cleaved, as shown in figure 1.3. Together this 
composition shapes the antigen-binding site at the amino-terminal end of the 
monomer, and the two variable domains bind their specific antigens. Also, as a 
result of the hinge region flexibility, the two Fab arms can assume various angles 
relative to each other when an antigen is bound.  
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Figure 1.5 – A ribbon representation of two Fab fragments 
 
Each Fab fragment contains two chains, a light and a heavy chain. The chains are 
not separated as depicted above. Each chain consists of two beta-sheet 
sandwiches, one the variable domain (V) and one the constant domain (C). 
Corresponding domains (VH+VL and CH+CL) are held together by hydrogen bonds 
and non-hydrophobic interactions.  
 
1.1.1.3 – Antigen-binding sites 
Various domains may associate to form discrete structural regions and the first 
110 amino acids at the N-terminal end of each heavy and light chain provides 
specificity for binding an epitope (the portion of an antigen bound by an 
antibody). This amino acid sequence of both the light and heavy chains shows 
great variation from antibody to antibody and constitutes the variable domains 
(containing hypervariable regions or complementarity determining regions CDRs) 
of the antibody [Padlan, 1994]. Each B-lymphocyte during early development 
becomes genetically programmed through a series of gene-splicing reactions to 
produce unique three-dimensional shapes capable of fitting an epitope with a 
complementary shape. The various genes that the cell splices together determine 
the order of the amino acids and this sequence determines the final three-
dimensional shape. Therefore, different antibody molecules produced by different 
B-lymphocytes will have different amino acid sequences to give them their unique 
shapes. These unique three-dimensional shapes are the antigen-binding sites, 
formed by folded VH and VL regions and can accommodate approximately four to 
seven amino acids [Mariuzza and Poljak, 1993]. 
 
The antigen-binding region is a unique feature of these molecules and 
distinguishes them from all other known proteins [Davies et al., 1990]. Each 
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immunoglobulin molecule has at least two antigen-binding sites so that it can 
either bind two molecules of antigen, or if the antigen is a cell with multiple 
copies of the antigen on its surface, it can form multiple attachments to a single 
cell surface.  
 
The variable region of an antibody molecule is further subdivided into 
hypervariable (HV) regions. Three segments of high variability can be identified in 
both the VH and VL domains and are denoted HV1, HV2 and HV3. The 
hypervariable regions, also known as CDRs, are where most of the variations 
occur and have a high ratio of different amino acids in a given position, relative to 
the most common amino acid in that position [Essen and Skerra, 1994]. The 
most variable part of the domain is the HV3 region. The regions between the 
hypervariable regions, which comprise the rest of the variable domain, show less 
variability and have more stable amino acid sequences. These are known as the 
framework regions and there are four such regions in each variable domain, 
designated FR1, FR2, FR3 and FR4. The framework regions form the β-sheets 
that provide the structural framework of the domain, whereas the hypervariable 
sequences correspond to three loops located at the outer edge of the β barrel, 
which are juxtaposed in the folded domain. This is shown in figure 1.6. 
 
Folding brings the hypervariable loops from each domain together to create a 
single hypervariable antigen-binding site at the tip of each arm of the molecule. 
The three hypervariable loops, or CDRs, determine antigen specificity by forming 
a surface, which is complementary to the antigen [Ward et al., 1989]. The FR 
regions form a beta-sheet structure creating a pocket of three-dimensional 
internal form, into which a part of an antigen molecule can fit closely and bind 
tightly, with little cross-reaction from different antigens [Foote and Winter, 1992]. 
This also serves as a scaffold to hold the hypervariable regions in position to 
contact the antigen. 
 
As already mentioned, the amino acid sequences of the CDRs are different in 
different antibodies, so therefore the shapes of the surfaces created by these 
CDRs are also different. Amino acid side chains in most or all of the hypervariable 
loops make contact with antigen and determine both the specificity and affinity of 
the interaction. Other parts of the variable region play little part in the direct 
contact with the antigen but provide a stable structural framework for the 
hypervariable loops and help determine their position and conformation.  
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 Figure 1.6 – A ribbon representation of the hypervariable regions 
 
The hypervariable regions lie in discrete loops of the folded structure. When the 
hypervariable regions or CDRs (also known as hypervariable loops), are 
positioned on the structure of a variable domain it can be seen in the above 
diagram that they lie in loops that are brought together in the folded structure. 
In the antibody molecule, the pairing of a heavy and a light chain brings together 
the hypervariable loops from each chain to create a single hypervariable surface, 
which forms the antigen-binding site at the tip of each arm. 
 
The strength of the interaction between a single antigen-binding site and its 
specific antigen epitope is known as the binding affinity. The antigen-binding 
specificity of an antibody resembles that of an enzyme binding to a substrate, 
and the higher the affinity, the tighter the association between the antigen and 
the antibody. Antibody affinity generally increases with repeated exposure to 
antigen, a process called affinity maturation, as B-lymphocytes with higher 
affinity antigen receptors are selected to produce larger clones of antibody-
secreting plasma cells [Borrebaeck et al., 1992], particularly in conditions where 
the concentration of epitope is low. 
 
Antigen-antibody interactions involve a variety of noncovalent forces that hold 
together the complex and contribute to binding. Electrostatic interactions occur 
between charged amino acid side chains, as in salt bridges, and interactions also 
occur between electric dipoles as in hydrogen bonds, or can involve short-range 
van der Waals forces and hydrophobic interactions. High salt concentrations, 
extremes of pH and detergents can disrupt this reversible interaction between 
antigen and antibody by weakening electrostatic interactions and/or hydrogen 
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bonds.  
 
1.1.1.4 - Fc fragments 
The other product of a papain digestion of an Ig is a fragment that contains the 
remainder of the two heavy chains, each containing a CH2 and CH3 domain. This 
fragment, shown in figure 1.7, was called Fc (fragment crystallising) because it 
was easily crystallized. It is composed of the carboxyl terminal portions of both 
heavy chains linked by a disulphide bond. The Fc portion is responsible for the 
biological activity of the antibody [Tonegawa, 1985]. 
 
Fc binds to various cell receptors and complement proteins, and evidence 
suggests that it is the CH2 domains that are of primary importance in determining 
Fc effector functions, such as complement activation (C1q binding) and Fc 
Receptor (Fc gamma R) binding [Goulding et al., 1992]. In this way, Fc mediates 
different physiological effects of antibodies, such as: opsonisation; cell lysis; mast 
cell, basophil and eosinophil degranulation and other processes. However, other 
parts of the molecule may also be critical, in particular the hinge region and hinge 
link, or lower hinge region, where the genetically determined hinge joins on to a 
part of the hinge encoded genetically as the N-terminal end of the CH2 domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 – A ribbon representation of the Fc fragment 
 
The bottom part of the “Y”, the C-terminal region of each glycoprotein chain is 
known as the Fc fragment. It is composed of two heavy chains that each 
contributes two constant domains, CH2 and CH3. 
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1.2 - Immunoglobulin-binding proteins  
Several species of infectious bacteria express immunoglobulin-binding proteins on 
their cell surfaces. When a bacterium infects a mammal it encounters a hostile 
environment, where it is attacked by the host’s immune system. The cell surfaces 
of some bacteria are covered with a number of proteins that may be involved in 
the mechanism of pathogenesis and they have to be robust to withstand the 
host’s hostile environment. There are a number of these cell surface proteins of 
pathogenic bacteria that are able to bind to a variety of host plasma proteins, 
such as the immunoglobulins and clotting factors, which accumulate after trauma. 
The ability to bind plasma proteins is thought to help the bacterium to colonise a 
site, including wounds [Goward et al., 1993]. The function of these cell surface 
proteins in vivo is still unclear, but it is thought that they coat themselves with 
host proteins, so that the bacterium is no longer recognised by the host’s defence 
mechanism as foreign and thus, enable it to avoid destruction. This, in turn, 
increases their virulence [Frick et al., 1992].  
 
The immunoglobulin-binding capabilities of some cell-surface proteins are 
interesting in that they are related to the site of infection. For example, the IgG-
binding proteins are found on bacteria present in the plasma, where IgG is the 
dominant antibody; the IgA-binding proteins are found on bacteria in mucosal 
secretion, where IgA is the major antibody; and IgD-binding proteins are found in 
the upper respiratory tract, which is a common site of infection for Haemophilus 
influenza and rich in IgD [Goward et al., 1993]. Although there is a lack of 
information to identify the role of these proteins in infectivity, their ability to 
interact with immunoglobulins in vitro without affecting their antigen-binding 
properties, makes them invaluable for a wide range of immunological techniques. 
 
Several cell surface immunoglobulin-binding proteins from microbial cell walls 
have been identified. Protein A from Staphylococcus aureus (S.aureus) [Verway, 
1940; Oeding et al., 1964; Boyle and Reis, 1987], protein G from Streptococci 
groups C and D [Kronvall, 1973], protein H from Streptococci group A [Akesson 
et al., 1990], protein D from Haemophilus influenza [Forgsren and Grubb, 1979] 
and protein L from Peptostreptococcus magnus [Myhre and Erntell, 1985]. The 
relative binding sites on IgG for proteins A, G and L are identified in figure 1.3, 
and their primary sequence organisation is shown in figure 1.8. 
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 Protein A 
 
 
 
D A B C M W S E 
 
 
 Protein G 
 
 
  
C3  A2 A1 S B1 B2 A3 C1 M D1 W C2 D2 
 
 
 Protein L 
 
 
 
Figure 1.8 - Primary sequence organisation of Ig-binding proteins A, G, and L   
 
All cell surface Ig-binding proteins share similar primary sequence organisation.  
The secretion signal peptide sequences (red area S) and regions that interact 
with the cell wall (green area W) and cell membrane (green area M) are shown. 
The blue areas indicate the regions that are involved in binding to 
immunoglobulins, the number of which is dependent on the strain of bacteria. 
The other pale grey areas denote various repetitive regions of the proteins which 
demonstrate further binding functions [Goward et al., 1993].  
 
 
Protein Source Ligand Comments 
Protein
A 
Staphylococcus 
aureus 
IgG Fab (VHIII) + Fc (CH2/CH3 
interface); IgA Fab; IgE Fab; 
IgM Fab; α2-macroglobulin and 
Kininogen 
Binds all Igs except IgG3 
and possesses a three α-
helix structure  
 
 
Protein
G 
 
Streptococci  
Group C and G 
 
 
IgG Fab (CH1) + Fc (CH2/CH3 
interface);  Human serum 
albumin; α2-macroglobulin and 
Kininogen 
 
Only binds IgG, with a 
much broader range and 
possesses a four β-strand 
and one α-helix structure 
 
Protein 
L 
 
Peptostreptococcus 
magnus 
 
IgG Fab VL kappa chains; HSA; 
α2-macroglobulin and 
Kininogen 
 
 
Binds to kappa light chains 
of Igs and possesses a 
four β-strand and one α-
helix structure 
 
Protein
D 
 
 
Haemophilus 
influenza 
 
IgD 
 
Only Gram-negative Ig-
binding protein 
 
Protein
H 
 
Streptococcus 
pyogenes  
Group A 
 
IgG Fc (CH2/CH3); HSA and α2-
macroglobulin 
  
Binds only to human and 
rabbit IgG 
 
Table 1.1 - Comparison of bacterial cell surface Ig-binding proteins  
  
S  A  C1  B3  W  M B1 B2 B4 C2  B5 
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1.2.1 - Protein A (SpA) 
Staphylococcal protein A (SpA) is a Type 1 bacterial Fc receptor found on the 
surface of, or secreted by the cell wall of, the bacterium S. aureus. SpA is the 
most extensively characterised of the immunoglobulin-binding proteins and was 
first isolated in 1940 by Verway [Verway, 1940], and was later identified in 1964 
by Oeding [Oeding et al., 1964].  
 
1.2.1.1 - Structure of SpA  
The gene for SpA has been cloned and over-expressed in Escherichia coli (E.coli) 
[Duggleby and Jones, 1983] and [Lofdahl et al., 1983], and the DNA sequence 
has been determined [Uhlén et al., 1984a and 1984b]. Sequence studies have 
shown that the SpA molecule consists of six regions. The extracellular part of SpA 
consists of a series of five highly homologous regions [Sjödahl, 1977a and 
1977b], each able to bind specifically to the Fc region of certain classes of 
immunoglobulin. In addition to the mutual homology between the regions, there 
is also significant internal homology within the regions [Sjödahl, 1977b]. The five 
functional monovalent Fc-binding domains are composed of approximately 60 
amino acids each consecutively arranged in the order E, D, A, B and C, from the 
N-terminus of the protein [Moks et al., 1986].   
 
The C-terminal part of SpA, the sixth region designated as domain X, is a cell wall 
binding domain comprising of 180 amino acid residues, which does not bind to 
the Fc portion. Its structure X shows a repetitive region, Xr, followed by a 
constant region, Xc [Uhlén et al., 1984]. The Xr region consists of an octapeptide 
sequence repeated twelve times, and it is thought to be involved in the binding to 
peptidoglycan of the cell wall. Region Xc represents a non-repeated 
carboxyterminal domain containing an extended stretch of hydrophobic amino 
acids, implying a cell membrane association [Uhlén et al., 1984]. A comparison of 
the Ig-binding domains of SpA is illustrated in figure 1.8.   
 
1.2.1.2 - Structure of a single Ig-binding domain from SpA  
The three-dimensional structure of Ig-binding domains of SpA (SpAB) has been 
extensively studied using NMR and X-ray crystallography, and determined as free 
proteins or Ig-bound complexes. These structural analyses revealed that all of 
these SpA Ig-binding domains adopt a classical “anti-parallel” three helical bundle 
fold, as shown in figure 1.9. Each domain is composed of three nearly perfectly 
anti-parallel α-helices in orientation, with the first helix tilting slightly away from 
the other two helices. Helices II and III are anti-parallel to one other with helix I 
 | 13  
 
tilted at a ~30° angle with respect to the other two helices [Gouda et al., 1992]. 
 
 
α-helix 1
COOH 
α-helix 3 
NH2 
α-helix 2
Figure 1.9 – A ribbon representation of the B domain of SpA   
 
The three-dimensional structure of a single IgG-binding domain fragment B of 
SpA is composed of three anti-parallel α-helices. The figure illustrates the B 
domain viewed perpendicular to the α-helices. 
 
1.2.1.3 - Interaction with Fc  
Interest in SpA is based on its unique reactivity to immunoglobulins (Igs), defined 
by Forsgren and Sjöquist [Forsgren and Sjöquist, 1966]. They concluded that 
SpA’s reactivity is directed to the Fc region of IgG. Further studies have shown 
that binding occurs through the Fc region to SpA on the surface of bacteria 
[Forsgren and Forsum, 1970], thus eliciting the ability to behave as an Fc 
receptor. The affinity and stoichiometry of the interaction between SpA and the Fc 
region has also been studied and results have shown that the binding site for SpA 
is localised at the CH2-CH3 domain interface [Lancet et al., 1978]. However, it 
has been demonstrated that one molecule of SpA is only able to bind two IgG 
molecules [Sjöquist et al., 1972]. 
 
SpA interacts with the Fc component of immunoglobulin from most mammalian 
species, including man. The class of immunoglobulin bound is predominantly IgG, 
but interactions are restricted to certain subgroups of IgG, namely IgG1, IgG2 
and IgG4. The inability of human IgG3 to form a complex with SpA has been 
explained by the presence of the positive charge of arginine 435 [Deisenhofer, 
1981]. The substitution of arginine 435 in IgG3 from histidine 435 present in the 
other IgG subclasses in the Fc fragment, results in a steric clash between arginine 
435 and other residues [Björck et al., 1984b]. SpA can also bind to human IgE 
and in some species with IgA and IgM as well [Lindmark et al., 1983]. Subclass 
specificity has also been suggested for human IgA, with SpA binding only to IgA2 
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and not IgA1 [Surolia et al., 1982].   
The three-dimensional structure of a single IgG-binding domain fragment B (FB) 
bound to human Fc was initially determined by X-ray crystallographic analysis at 
2.8Å resolution [Deisenhofer, 1981]. The crystal data indicated that two anti-
parallel helical regions and a disordered C-terminal region exist in the Fc-bound 
FB. Furthermore, it has been demonstrated that the FB forms two contacts with 
the Fc fragment in the crystal [Deisenhofer, 1981]. Contact one is predominantly 
hydrophobic, and involves residues Gln10-Leu18 existing in the first helical 
region, and residues Glu26-Asp37 in the second helical region, together with 
those involved in the binding to IgG at the site located between CH2 and CH3. 
Contact two is smaller and involves residues Gln33, Ser34 and Asp37, which are 
located in the C-terminal segment of the second helical region, as well as Asp38 
and Gln41 [Nilsson et al., 1987]. Figure 1.9 represents a three-dimensional 
ribbon diagram of the B domain of SpA and figure 1.10 represents a three-
dimensional ribbon diagram of the B domain of SpA and the Fc fragment. 
Fc fragment 
 
                                     
SpA 
   
 α-helix 2 α-helix 1 
CH3 
CH2 
Fc 
fragment 
Figure 1.10 – A ribbon representation of the B domain of SpA interacting with the 
CH2/CH3 interface of an IgG Fc fragment  
 
In this crystal structure complex the binding site for the B domain of SpA (gold) 
is localised at the CH2/CH3 domain interface of the Fc region of IgG (red). Only α-
helices 1 and 2 were found by x-ray crystallographic analysis at 2.8Å resolution. 
Two contacts are formed with the Fc fragment in the crystal, with contact one 
involving residues from the first and second helical regions, together with 
residues involved in the binding to the IgG at the CH2/CH3 interface. Contact two 
is smaller and involves residues located in the C-terminal segment of the second 
helical region. PDB accession code: 1FC2. 
 
However, NMR studies of the structure of SpAB in solution identified a third α-
helix corresponding to the unstructured region in the x-ray crystal structure. 
Thus, the ten residues that were thought to form the majority of the contact 
points with the Fc fragment, actually forms a third C-terminal α-helix [Torigoe, 
1990a and 1990b]. This α-helix is packed against the other two forming an anti-
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parallel three helical bundle, and NMR studies have shown the second and third 
α-helices to be in intimate contact regardless of whether the domain is in free 
solution or bound to IgG [Gouda et al., 1992]. More recent NMR analyses have 
concluded that the absence of helix III in the Fc complex is due to crystal 
contacts [Gouda et al., 1998]. A further NMR study into an engineered Ig-binding 
Z domain of SpA, supports all previous findings and also demonstrates that there 
is not a large conformational rearrangement of the three-helix Ig-binding 
domains upon Fc binding [Zheng et al., 2004]. 
 
1.2.1.4 - Interaction with Fab  
In recent years an additional site for the interaction of SpA with the 
immunoglobulin molecule has been located in the Fab region, the Ig fragment 
responsible for antigen recognition, involving a site on the Ig heavy chain 
[Lindmark et al., 1983; Sasso et al., 1991]. This Fab-binding by SpA is mediated 
by the V domains and is associated with certain VH genes. The VH genes of family 
III encode all human immunoglobulins that are targets for Fab binding, but not all 
VHIII encoded molecules are bound, thus binding is a marker of a group of 
human VH genes, a subset of VHIII [Ibrahim et al., 1993a]. Figure 1.11 
represents a ribbon diagram of the interaction between the B domain of SpA and 
the Fab fragment of an IgG molecule. 
 
 
 
SpA VH 
VL 
α-helix 1 
α-helix 2 
α-helix 3 
Fab 
fragment 
CH1 
 
Figure 1.11 – A ribbon representation of the B domain of SpA interacting with the 
VHIII domain of a Fab fragment of an IgG molecule  
CL 
 
The interaction of SpA (gold) with the immunoglobulin molecule has been located 
in the variable region of the Ig heavy chain. In the complex, α-helices II and III 
of SpA Ig-binding domain interact with the variable region of the Fab (blue) 
heavy chain (VH) through framework residues, without the involvement of the 
hypervariable regions implicated in antigen recognition. PDB accession code: 
1DEE. 
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 1.2.1.5 - Interaction with Fc and Fab 
Previous studies have suggested that not all of the five homologous domains of 
SpA were involved in the Fab interaction [Ibrahim, 1993b], and it was suggested 
that Fab-binding was confined to the D domain [Roben et al., 1995]. However, 
more recent studies have demonstrated that all five domains show affinity for 
both Fab and Fc [Jansson et al., 1998]. Thus, SpA possesses two distinct Ig-
binding activities, with each domain able to bind Fc and Fab, with a distinct 
specificity for the Fab region of some IgA, IgE, IgG and IgM. Figure 1.12 
represents a ribbon diagram of the interaction between the B domain of SpA and 
both the Fc portion and VHIII domain of Fab fragment of an IgG molecule.  
 
The site responsible for Fab binding is structurally different from the domain 
surface that mediates Fc binding. The interaction with Fc involves residues in 
helix I of SpA, with lesser involvement of helix II. With the exception of residue 
Gln32, a minor contact in both complexes, none of the residues that mediate Fc 
binding are involved in Fab binding. The Fc and Fab structures form a sandwich 
around the opposite faces of helix II, without any evidence of steric hindrance of 
either interaction; with the variable region (VHIII) lying toward the antigen-
binding end of Fab and the Fc bound Ig projecting away from the complex.  
 
 
SpA 
Fc fragment 
CH2 
CH3 
α-1 α-3 
α-2 
VHIII 
domain of 
Fab 
fragment 
Figure 1.12 – A ribbon representation of the interaction between the B domain of 
SpA interacting with both the Fc and Fab fragments of an IgG 
molecule 
 
SpA possesses two distinct Ig-binding activities, with each domain able to bind Fc 
and Fab simultaneously.  Here SpA is complexed with Fc and Fab to illustrate how 
the site responsible for Fab binding is structurally separate from the domain 
surface that mediates Fc binding. The Fab and Fc are shown to form a sandwich 
around the opposite faces of helix II of SpA. The structure of SpA is shown in 
gold, the CH2/CH3 interface of the Fc fragment is shown in red and the VH domain 
of Fab is shown in blue. PDB accession code: 1FC2 and 1DEE. 
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 Recent X-ray crystallography studies have reported the structure of domain D of 
SpA complexed with the Fab fragment of human IgM antibody [Graille et al., 
2000], as shown in figure 1.13. In this complex, domain D assumes the triple α-
helical bundle reported for domains B and E, and it is helix I and III which is 
reported to interact with the Fab, via a surface composed of four VH region β-
strands: B, C, D and E. The site of interaction on Fab is remote from the Ig light 
chain and the heavy chain constant region, and is mediated by thirteen heavy 
chain residues, six of which are in framework region β strands, with the other 
seven located in the VH framework region interstrand loops on the side farthest 
from the antigen-binding pocket. The interaction also involves eleven residues 
from domain D, Gln26, Gly29, Phe30, Gln32, Ser33 and Asp36 of helix II; Asp37 
and Gln40 in the loop between helix II and helix III; and Asn43, Glu47 and Leu51 
of helix III [Graille et al., 2000]. 
 
 
Figure 1.13 - An illustration of the interaction between the D domain of SpA 
interacting with both the Fc and Fab fragments  
 
This model illustrates an individual SpA domain showing dual reactivity with both 
Fc and Fab fragments. Helix I and II of the SpA domain in the Fab-domain D 
complex and the previously determined Fc-domain B complex have been 
superimposed. The VHIII Fab surface is shown as cyan, the Fc fragment surface 
is shown in grey and the single domain of SpA is represented by a red ribbon 
[Graille et al., 2000]. 
 
1.2.2 - Protein G (SpG) 
Protein G (SpG) is a Type III bacterial Fc receptor found on the surface of, or 
secreted by the cell wall of, the β-haemolytic Gram-positive bacterium 
Streptococcus of the C and G strains [Kronvall, 1973]. Less is known about SpG 
than about SpA, primarily because SpG was not purified until 1984 [Björck and 
Kronvall, 1984]. However, interest in SpG has been maintained due to its ability 
to bind with IgG of different subclasses of most mammalian species. 
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 β-haemolytic streptococci comprise a large and biological diverse group of 
microorganisms, and can be differentiated into groups in which the specific 
antigens are carbohydrates. Group C and G streptococci may inhabit various parts 
of the human body and cause severe and even fatal infections with 
indistinguishable clinical symptoms, the most common being pharyngitis 
[Efstratiou, 1989] and septicaemia [Auckenthaler et al., 1983]. Studies have 
shown no difference in the structure of SpG when isolated from tonsillar strains 
and blood isolates, thus suggesting that SpG is not a virulence determinant, and 
may be involved in more basic biological events [Sjöbring et al., 1991]. 
 
1.2.2.1 - Structure of SpG 
The gene for SpG has been cloned and can now be isolated from bacterial over-
expression systems [Fahnestock et al., 1986; Guss et al., 1986]. Analysis of the 
amino acid sequence revealed a primary organisation similar to the genes of SpA 
and other Ig-binding proteins [Guss et al., 1986]. For SpA, the part responsible 
for IgG binding consists of five highly homologous units with sizes ranging from 
50 residues to 61 [Uhlén et al., 1984a]. In contrast, the corresponding part of 
SpG consists of three domains namely C1, C2 and C3, with each of these units 
containing 55 amino acid residues with two spacers of 16 residues, D1 and D2. A 
comparison of the amino acid composition of regions C1, C2 and C3 is presented 
in figure 1.14, and illustrates how their sequences are highly homologous, with 
only six residues varying between them. It is also striking that regions D1 and D2 
have been exactly conserved [Guss et al., 1986].   
 
It is not known why the SpG genes from strains G148 and GX7809 consist of two 
and three IgG-binding domains, respectively, while the SpA gene consists of five 
IgG-binding domains. However, it has been suggested that the number of IgG 
receptors may affect the strength and the kinetics of binding to different IgG 
molecules form different species [Olsson et al., 1987]. Different strains may have 
adopted this receptor response to various external environments. 
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Figure 1.14 - A comparison of the amino acid composition of the Ig-binding 
domains of SpG 
 
A comparison of the three C Ig-binding domain and the two D linker regions is 
presented as sequence alignments to achieve maximal homology. Identical amino 
acid residues are indicated with a blue bar, silent mutations, which have not 
altered the amino acid, are marked with a blue cross, and amino acids that have 
changed are marked with the appropriate amino acid letter, in red. The 
comparison indicates highly homologous sequences between the C1, C2 and C3 
Ig-binding domains, with only six amino acids varying between them. The linker 
regions D1 and D2 have been exactly conserved. Fahnstock isolated a two IgG-
binding domain SpG strain GX7809 and labelled the domains B1 and B2 
[Fahnestock et al., 1986], whereas Guss isolated a three IgG-binding domain SpG 
strain G148 and labelled the domains C1, C2 and C3 [Guss et al., 1986]. As 
illustrated above, the sequences of C1 and B1, and C3 and B2 are identical, 
containing the same six amino acid variations. C2, a hybrid of C1 and C3, contains 
four amino acids variations from C1 and two from C3 [Olsson et al., 1987].  
 
Following the IgG-binding domains there are cell wall-binding (W) and 
membrane-binding (M) domains near the C-terminus, which are involved in cell 
wall interactions. The sequence of region W is highly regular, with the first part 
being rich in proline residues followed by a pentapeptide consensus sequence, 
which is repeated six times. The whole region is very hydrophilic and secondary 
structure prediction by Chou and Fasman procedures [Chou and Fasman, 1974] 
illustrate low probabilities for the presence of alpha and beta structures. These 
predictions are comparable with other cell wall-binding regions of proteins such as 
SpA [Uhlén et al., 1984a]. It has been suggested that this structure might serve 
to orient the protein on the outer surface of the cells, and thus sterically facilitate 
the function of the molecule [Uhlén et al., 1984b]. 
 
Apart from the IgG-binding domains and the cell wall-spanning region the SpG 
gene also contains a third independent repetitive structure A and B. N-terminal 
regions A1, B1, A2, B2 and A3 are highly conserved when compared with each 
other, which strongly suggests an important biological function. Studies have 
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shown that these regions are involved in the binding to human serum albumin 
(HSA) [Åkerström et al., 1987]. This would indicate that SpG is a bi-functional 
receptor possessing two independent regions with affinity to albumin and IgG. 
 
1.2.2.2 - Structure of a single Ig-binding domain from SpG 
High-resolution three-dimensional structures of the single IgG-binding domains 
from SpG have been determined by NMR spectroscopy [Gronenborn et al., 1991; 
Lian et al., 1992] and X-ray crystallography [Achari et al., 1992; Derrick and 
Wigley, 1992; Gallagher et al., 1994; Derrick et al., 1994; Sauer-Eriksson et al., 
1995]. All domains have the same arrangement of secondary structure, 
consisting of a central α-helix and a four-stranded β-sheet, as presented in figure 
1.15. NMR has shown that the two inner strands of the β-sheet, β1 and β4, are 
parallel to one another, and the two outer strands, β2 and β3 are anti-parallel to 
the two inner strands, β1 and β4 respectively [Lian et al., 1991]. Strands β1 and 
β2 are connected by a type I turn, whereas strands β3 and β4 are connected by 
an unusual six-residue turn. The long axis of the helix lies at approximately 140° 
to the axes of β2 and β3, and lies diagonally across the β-sheet with an angle of Ω 
~ -40° [Gronenborn et al., 1991].   
 
 
β-strand 3 
α-helix β-strand 4 
COOH 
β-strand 1 
β-strand 2 
NH2 
 
Figure 1.15 – A ribbon representation of an Ig-binding domain of SpG   
 
The three-dimensional structure of a single IgG-binding domain (B1) of SpG 
consists of a central α-helix and a four-stranded β-sheet. NMR has shown that the 
two inner strands of the β-sheet, β1 and β4, are parallel to one another, and the 
two outer strands, β2 and β3 are anti-parallel to the two inner strands, β1 and β4 
respectively. The long axis of the helix lies at approximately 140° to the axes of 
β2 and β3, and lies diagonally across the β-sheet with an angle of Ω ~ -40° 
[Gronenborn et al., 1991].   
 
The single B1 and B2 IgG-binding domains of SpG are very stable, and differential 
scanning calorimetry studies have demonstrated extreme thermal stability with 
melting temperatures of 87.5°C and 79.4°C, respectively [Alexander et al., 1992]. 
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This feature is unusual considering the small size of each of the domains and the 
absence of disulphide bridges or tight ligand binding. It has been suggested that 
this unusual stability for a small protein is due to a number of factors. Firstly, the 
involvement of nearly all the residues in the regular secondary structure ensures 
that a large number of hydrogen bonds stabilises the protein. The secondary 
structure content of SpG is 95% compared to an average 75% in other proteins, 
with a total of 45 atoms participating in hydrogen bonds [Gronenborn et al., 
1991].   
 
Secondly, the interior of SpG is highly hydrophobic, while the exterior is very 
hydrophilic. The increase in heat capacity of the unfolded state is directly related 
to the amount of hydrophobic surface that is buried in the folded state relative to 
the unfolded state [Achari et al., 1992]. Thus, the B domain appears to be stable 
because it efficiently buries a significant hydrophobic surface in spite of its small 
size. Nine hydrophobic residues are completely buried, with only five hydrophobic 
residues exposed to solvent [Gronenborn et al., 1991; Alexander et al., 1992].   
 
However, the features mentioned above are probably not sufficient in their own 
right to fully account for the stability of SpG. The overall polypeptide fold of the 
protein may itself play a key role in stabilising the protein. In particular, the 
hydrogen bonds between the N-terminal and C-terminal strands, β1 and β4, 
which constitute the two internal strands of the four stranded β-sheet, and their 
network of hydrophobic interactions with the overlaying helix, require disruption 
before unfolding can be accomplished. Thus, unfolding is highly cooperative and 
involves all parts of the protein structure simultaneously.   
 
1.2.2.3 - Interaction with Fc  
The structures of isolated Fc-binding repeats of SpG have been well documented 
and successfully determined by NMR and X-ray crystallography [Gronenborn et 
al., 1993; Sauer-Eriksson et al., 1995]. NMR data have provided the structure of 
the Fc-binding domain B1 of SpG [Gronenborn et al., 1991], and the contact 
regions of the B1 IgG-binding domain, when complexed with human Fc, identified 
[Gronenborn et al., 1993]. Figure 1.16 represents a ribbon diagram of the 
interaction between the B1 domain of SpG and the Fc fragment. Results show 
that the interaction site with Fc lies within the α-helix, β-strand three and the loop 
that connects them.  
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Figure 1.16 – A ribbon representation of an Ig-binding domain of SpG interacting 
with the CH2/CH3 interface of the Fc fragment from an IgG 
molecule 
 
In this complex, the B1 Ig-binding domain of SpG (gold) binds Fc (red) at the 
hinge region that connects the CH2 and CH3 domains. The interactions with Fc lies 
within the α-helix and β-strand three of SpG, and involves residues 35 to 45, 
which are situated in the C-terminal part of the α-helix, the N-terminal part of β-
strand 3, and the extended loop region connecting these two structures. The 
residues that interact with SpG are situated within loop regions of Fc [Sauer-
riksson et al., 1995]. PDB accession code: 1FCC. 
, blocks the interaction between IgG•Fc 
et al., 1992]. 
k of hydrogen 
onds and salt links, involving mainly charged and polar residues. 
E
 
Corroboratory evidence has come from studies that demonstrated that a small 11 
residue peptide fragment involving residues 35 to 45, situated in the C-terminal 
part of the α-helix, the N-terminal part of β-strand 3, and the extended loop 
region connecting these two structures
and SpG [Frick 
  
The crystal structure of the C2 domain in complex with Fc was solved by Sauer-
Eriksson et al., (1995). The B1 domain is equivalent to the C1 domain, and the 
amino acid sequences of the C1 and C2 domains are identical except for residues 
5 and 6. Thus, it might be assumed that the structures of C1 and C2 are identical 
[Olsson et al., 1987]. Studies confirmed that SpG binds Fc at the interface region 
that connects the CH2 and CH3 domains. There are three residues of the CH2 
domain of Fc, which are involved in the interfacial interactions, namely Ile253, 
Ser254 and Gln311. In the CH3 domain, there are two areas which contribute to 
the interface, namely Glu380 and Glu382 and the residues His433 to Gln438 
[Sauer-Eriksson et al., 1995]. These residues that interact with SpG are situated 
within loop regions of Fc. The residues in SpG that interact with Fc have been 
identified as Glu27, Lys28, Lys31, Gln32, Asn35, Asp40, Glu42 and Trp43. The 
interfacial interactions between Fc and SpG consist of a networ
b
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 1.2.2.4 - Interaction with Fab 
SpG has been shown to interact with the Fab regions of IgG, but with a 10-fold 
lower affinity than that determined for the Fc region (Bjorck and Kronvall, 1984). 
NMR and X-ray crystallography has been used to study complexes of SpG 
domains with Fab fragments [Derrick and Wigley, 1992; Lian et al, 1994; Derrick 
and Wigley, 1994; Sauer-Eriksson et al, 1995]. In this complex, the outer second 
β-strand of SpG, at the edge of the β-sheet, forms an anti-parallel extension with 
the last β-strand of the CH1 domain of IgG, thus extending the β-sheet into SpG 
[Derrick and Wigley, 1994]. Figure 1.17 illustrates the interaction between the B1 
omain of SpG and the Fab fragment of an IgG molecule.  
 
d
SpG 
Fab fragment 
CH1 
β-strand 2 
 
 
Figure 1.17 – A ribbon representation of an Ig-binding domain of SpG interacting 
with the CH1 domain of a Fab fragment  
 
The overall structure of the SpG:Fab complex is presented. In this complex, the 
outer second β-strand of the B1 Ig-binding domain of SpG, at the edge of the β-
sheet, forms an anti-parallel interaction with the last β-strand of the C 1 domain 
f IgG, thus extendin
H
g the β-sheet into SpG. [Derrick and Wigley, 1992]. PDB 
ccession code: 1IGC. 
o
a
 
The atoms involved in these interactions are predominantly from the backbone of 
the CH1 domain of the IgG, but include both backbone and side-chain atoms from 
the binding domain of SpG. The alpha-beta structure of SpG in solution is 
conserved on binding to Fab, and this complex is stabilised through a network of 
hydrogen bonds from the last β-strand of the CH1 domain to the second β-strand 
in SpG. A second, minor region of contact occurs between the C-terminal end of 
the α-helix in SpG and the first β-strand of the CH1 domain [Derrick and Wigley, 
1994]. This complex is stabilised further by the association of exposed non-polar 
residues from Fab and SpG, providing a continuous hydrophobic core, which is 
shielded from solvent [Derrick and Wigley, 1992]. The SpG and Fab complex 
provides an explanation for the wide specificity of SpG for immunoglobulins, as 
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the interactions involve backbone atoms of a highly conserved sequence in CH1 
Tashiro and Montelione, 1995].  
g interactions for these fragments occur in different regions of the 
otein.  
  
[
 
1.2.2.5 - Interaction with Fc and Fab 
SpG binds selectively to both the Fc and Fab regions of most mammalian IgGs, 
and SpG has also been reported to bind F(ab')2 fragments. Previous studies have 
indicated that the binding of Fc and Fab to SpG does not interfere with one 
another [Erntell et al., 1983], suggesting that there are independent and 
separate binding regions for both Fab and Fc fragments of IgG on the SpG 
molecule [Erntell et al., 1988]. Figure 1.18 illustrates the specific amino acid 
residues of SpG that contribute to both Fc and Fab binding sites, indicating that 
the bindin
pr
NH2 
COOH 
β-strand 2 β-strand 3 
α-helix 
 
Figure 1.18 − A ribbon representation of SpG indicating both Fc and Fab binding 
regions 
 
Specific amino-acid residues that contribute to these binding interactions via a 
network of hydrogen bonds have been identified. The Fc binding region, α-helix 
nd β-strand 3, is shown in red; and the Fab binding region, a
2
α-helix and β-strand 
, is shown in blue. 
rand 
3 to bind predominantly to the interface of CH2-CH3 heavy chains of IgG-Fc.  
 
It has been suggested that the elongated structure of the SpG molecule 
[Åkerström and Björck, 1986] permits the simultaneous binding of both Fab and 
Fc fragments [Erntell et al., 1988]. Figure 1.19 demonstrates SpG in complex 
with both Fc and Fab fragments, and clearly demonstrates how the site 
responsible for Fab binding is structurally separate from the domain surface that 
mediates Fc binding. SpG uses its β-strand 2 to form an anti-parallel interaction 
with the last β-strand of the CH1 domain of IgG-Fab and the α-helix and β-st
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Figure 1.19 – A ribbon representation of the interaction between SpG and both Fc 
and Fab fragments of an IgG molecule 
 
SpG is complexed with Fc and Fab fragments to illustrate how the site 
responsible for Fab binding is structurally separate from the domain surface that 
mediates Fc binding. The structure of SpG is shown in gold, the CH2/CH3 
interface of the Fc fragment is shown in red and the CH1 domain of Fab is shown 
in blue. PDB accession code: 1FCC and 1IGC. 
 
1.2.2.6 - Reactivity with immunoglobulins 
Studies have shown that SpG expresses separate, repetitively arranged domains 
for both IgG and human serum albumin (HSA), and has also been found to 
interact with plasmin together with α2-macroglobulin (α2M) and kininogen, two 
proteinase inhibitors of human plasma [Sjöbring et al, 1989]. SpG has also been 
shown to bind all varieties of rat and mouse monoclonal antibodies and a large 
number of polyclonal IgGs from cow, goat, rabbit and mouse.  
 
SpA has been an extremely useful chemical reagent, used in a variety of 
immunochemical and immunological techniques. However, its usefulness has 
been affected by the fact that some species and subclasses of IgG do not react 
with this protein. In contrast, SpG has been demonstrated to be more generally 
IgG binding, with all mammalian IgG molecules showing affinity [Åkerström and 
Björck, 1986]. This makes SpG a potentially useful tool where binding and 
detection of IgG antibodies are required. Studies have also demonstrated higher 
affinity for the binding of SpG to IgG than SpA [Åkerström et al, 1985], especially 
for rat and goat polyclonal IgG and human IgG3, thus suggesting the binding site 
on SpG is subtly different from that on SpA due to the presence of a single helix.   
 
SpG is responsible for the binding of both human serum albumin (HSA) and IgG, 
and these reactions occur at different sites on the SpG molecule. Albumin-binding 
has been located to be the amino-terminal half and the IgG-binding to the 
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carboxyl-terminal half of the bacterial cell wall molecule [Åkerström et al., 1987]. 
This means that SpG has evolved separate binding sites for IgG Fc, IgG Fab and 
albumin. The albumin-binding activity of SpG resides in the amino-terminal 56 
amino acid peptide, which contains sequence unit A3 and part of B2, as shown in 
figure 1.8. This sequence is repeated three times in the SpG structure reported 
by Guss et al. 1986, and twice in the sequence of Fahnestock et al. 1986, and 
corresponds to amino acid residues 104 to 140, 179 to 215 and 254 to 290.  It 
has also been shown that some strains of C and G streptococci bind HSA poorly 
[Wideback and Kronvall, 1982], whereas IgG-binding is consistently high. This 
suggests that the IgG-binding domains (C repeats) are associated with essential 
biological functions, whereas the albumin-binding A and B repeats seem less 
indispensable.   
 
Apart from IgG and albumin, SpG also shows affinity for plasmin, kininogen and 
α2-macroglobulin [Sjöbring et al., 1989]. Studies have also demonstrated that Ig-
binding proteins, namely SpA and PpL, interact with α2-macroglobulin and 
kininogen with the same pH optima for the binding of these proteins to IgG. The 
interaction between SpG and α2-macroglobulin has been characterised in most 
detail as this protein is a major plasma protein, which has the capacity to block a 
wide range of proteinases [Barrett and Starkey, 1973]. It has been shown that 
α2-macroglobulin and IgG compete for the same binding sites in the C domains of 
SpG [Sjöbring et al., 1989], despite the lack of structural similarities between the 
two, and with IgG being bound with double the affinity of α2-macroglobulin. It 
has also been shown that this interaction takes place irrespective of whether α2-
macroglobulin is complexed with proteinase or not, and that SpG does not 
influence the binding of proteinases to either α2-macroglobulin or kininogen 
[Sjöbring et al., 1989].  
 
Proteolytic activity is important for the multiplication and tissue penetration of 
microorganisms, and the binding of these proteinase inhibitors from the infected 
host with the streptococcal cell surface through interaction with SpG could 
interfere with a variety of proteolytic events. Alternatively, proteolytic inhibition 
can be beneficial to the parasite by helping the bacteria to avoid proteolytic 
attack by host enzymes. α2-macroglobulin also has immunoregulatory functions 
through interactions with lymphokines and immune complexes [James, 1980], 
these functions also provide advantages to the host, as α2-macroglobulin: 
proteinase complexes at the bacterial surfaces facilitate phagocytosis of the 
bacteria [Sjöbring et al., 1989]. Thus, it is unclear why SpG has retained its 
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binding affinity for α2-macroglobulin. 
1.2.3 - Protein L (PpL) 
Protein L is a novel immunoglobulin-binding protein that has been isolated from 
the surface of bacteria belonging to the anaerobic species Peptostreptococcus 
magnus (P. magnus) [Myhre and Erntell, 1985]. It has been shown that protein 
binds an immunoglobulin through a variable domain light-chain interaction, giving 
rise to the name PpL [Björck, 1988]. It is a multi-domain protein, which is 
expressed at the surface of some strains of the anaerobic bacterium [Björck, 
1988], and appears to be correlated to bacterial virulence [Kastern et al., 1990].  
 
PpL is preferentially expressed by strains of P. magnus isolated from patients with 
bacterial vaginosis [Ricci et al., 2001], and only strains that express PpL possess 
the PpL-encoding gene, which can bind different classes of immunoglobulin to 
their cell surface with high affinity. This is thought to dramatically change their 
surface properties and the binding of different classes of Ig could influence 
important cellular and molecular events, which are significant to a balanced 
coexistence between the host and parasite [Kastern et al., 1990]. P. magnus are 
normally found on most body surfaces, where they are members of the 
indigenous flora of the skin, the oral cavity and gastrointestinal and genitourinary 
tracts, and are also causative agents in a variety of infections.  
 
Studies have shown that PpL312 (PpL from P. magnus strain 312) induces in vitro 
mediator release from human basophils and mast cells isolated from lung 
parenchyma and skin tissues, which could be one possible virulence mechanism 
[Patella et al., 1990]. The releasing activity of PpL appears to be mediated by an 
interaction with the kappa-light chains of IgE present on human basophils and 
mast cells to induce the release of pro-inflammatory mediators. These results 
were the first to indicate that a bacterial SpA associated with bacterial virulence 
[Kastern et al., 1990] can induce the release of preformed histamine and de novo 
synthesised chemical mediators from human inflammatory cells. SpA also acts 
through an IgE-dependent mechanism, but induces the release of mediators from 
basophils by interacting through the F(ab’)2 region of polyclonal IgE on the 
basophil membrane. It does not activate lung and skin mast cells [Genovese et 
al., 2000]. SpG, however, failed to induce the release of mediators from either 
basophils or mast cells.   
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 1.2.3.1 - Structure of PpL 
PpL is an elongated fibrous protein, and the gene encoding PpL has been 
sequenced from two strains of Peptostreptococcus, strain 312 (PpL312) [Kastern 
et al., 1992] and strain 3316 (PpL3316) [Murphy et al., 1994]. The primary 
structure of PpL from both strains shows 59% homology, comprising of a 
hydrophobic signal sequence, an NH2-terminal domain, and a repeated region 
with Ig-binding activity, with each domain containing approximately 72 to 76 
amino acid residues. PpL312 possesses five homologous Ig-binding domains, 
namely B1-B5 [Kastern et al., 1992], whereas PpL3316 possesses four homologous 
Ig-binding domains, C1-C4, and four albumin-binding domains, D1-D4 [Murphy et 
al., 1994]. The sequence of these Ig-binding domains within each strain shows 
80% homology, with only 60% homology between these strains. A comparison of 
the Ig-binding domain sequences of PpL312 and PpL3316 is shown in figure 1.20.  
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Figure 1.20 – A comparison of the Ig light chain-binding domain sequences of 
PpL312 and PpL3316 
 
The amino acid residues comprising the Ig light chain-binding domains from both 
strains of Peptostreptococcus magnus PpL, PpL312 and PpL3316, are presented as 
sequence alignments and compared. Regions of homology between the two 
strains are shown in red.  Residue numbering is that given by Wikström et al., 
1993 and Murphy et al., 1994 for strains 312 and 3316 respectively. 
 
Following a spacer region of 8 amino acids, there are additional non-related 
repeated regions of unknown function, and further downstream there is a highly 
hydrophilic cell wall-spanning domain and the transmembrane COOH-terminal 
region. The COOH-terminal regions, seen in other Gram-positive bacterial cell 
surface proteins, are thought to mediate the binding of the PpL to the bacterial 
cell wall [Kastern et al., 1992].   
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 1.2.3.2 - Structure of a single Ig-binding domain from PpL  
The three-dimensional solution structure of a single Ig-binding domain of PpL has 
been investigated by using 1H NMR [Wikström et al., 1993; Wikström et al., 
1994; Wikström et al., 1995]. The first of the five homologous Ig light chain-
binding domains of PpL312, the B1 domain, is 76 amino acid residues in length 
(Lys80 to Gly155), and has been shown to adopt a well-defined structure in 
solution. The domain consists of a 15 residue (Glu78 to Glu94), highly flexible 
disordered N-terminus followed by a 61 residue (Val95 to Gly155), folded unit 
comprising a four-stranded β-sheet with a central α-helix crossing over on top. 
The three-dimensional structure of PpL is presented in figure 1.21. 
 
 
NH2 
COOH 
α-helix 
β-strand 3 
β-strand 4 
β-strand 1 
β-strand 2 
Figure 1.21 – A ribbon representation of an Ig-binding domain of PpL 
 
The three-dimensional structure of PpL is composed of a disordered N-terminal 
polypeptide segment, followed by a folded portion composed of a central α-helix 
packed against a four stranded β-sheet, with a -1, +3x, -1 topology. The 
orientation of the α-helix runs almost parallel with the β-sheet, at an angle of -10° 
[Kastern et al., 1992]. 
        
The N- and C- terminal strands of the B1 domain, β1 (Val95 to Phe103) and β4 
(Tyr147 to Ala154) respectively, form a central parallel pair of strands which 
places the β2 (Ser107 to Gly115) and β3 (Glu137 to Arg144) strands on opposite 
sides of the domain [Wikström et al., 1993]. The α-helix involves residues 
Phe117 to Leu131, and crosses the β-sheet at an angle of -10°. The segment 
following the helix (Lys132) is a compact loop connecting the helix to the third β-
strand (Gly137). Both the helix and β-sheet, which shows a characteristic right-
handed twist, combine their hydrophobic surfaces into an inner hydrophobic core.  
 
The disordered polypeptide segments are similarly charged, and comprise the N-
terminus. These regions are present in all five domains, and have been proposed 
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to function as linking segments between Ig-binding domains, and were thought to 
facilitate the interaction with Ig light chains by increasing the individual flexibility 
of the domains [Wikström et al., 1993; Wikström et al., 1994]. Recent NMR 
studies have confirmed that the flexible N-terminal is not involved in binding, as 
there are no major conformation changes upon binding [Wikström et al., 1995]. 
 
1.2.3.3 - Interaction with Ig light chains 
PpL possesses specific binding sites for human immunoglobulin, and early studies 
demonstrated that PpL bound Fab and F(ab’)2, but not Fc fragments, implying a 
reactive site in the Fab portion of the molecule [Myhre and Erntell, 1985]. 
Reactivity was shown with human Ig molecules, regardless of heavy chain class, 
through interaction with Ig kappa light chain binding sites, exclusively located in 
the VL domain [Nilson et al., 1992]. No binding interactions occur with the CL 
domain. The κ and λ light chains are representative of the major human variable 
region (VL) subgroups, comprising four VκI, VκII, VκIII and VκIV subgroups, and five 
VλI, VλII/V, VλIII, VλIV and VλVI subgroups. The interaction between PpL and the 
variable light chains is limited to the κ-chains and, more specifically, to proteins 
of the VκI, VκIII and VκIV subgroups. No binding occurs with proteins of the VκII 
subgroup or with any λ light chain subgroups [Nilson et al., 1992].   
 
1H-15N NMR spectroscopy studies were utilised to define the interaction between 
an Ig-binding domain of PpL (B1) and the variable domain of human Ig κ-chain 
strand [Wikström et al., 1995]. Results show that the Ig-binding region of the 
PpL domain involves residues in the second β-strand (residues 109-114), the C-
terminal residues of the α-helix (residues 127, 129-131) and the loop connecting 
the α-helix with the third β-strand (residues 132-133 and 136) [Wikström et al., 
1995]. Figure 1.22 represents a three-dimensional ribbon representation of PpL 
interacting with the VL domain of Fab. VL domain residues important for the 
interaction with PpL have been localised and comprises parts of three β-strands 
that are all in close proximity (8-11, 19-23 and 72-74). Thus, PpL binds to the 
outer surface of the framework region of the VL domain, primarily involving the 
second β-strand [Enokizono et al., 1997].  
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Figure 1.22 – A ribbon representation of an Ig-binding domain of PpL interacting 
with the VL region of Fab 
 
A three-dimensional ribbon representation of a single Ig-binding domain of PpL 
and the VL region of a Fab fragment is presented. Strand β2 of PpL interacts with 
an Fab VL β strand, forming a continuous β sheet with the Fab through a β-zipper 
interaction [Wikström et al., 1995]. PDB accession code: 1MHH. 
 
1.2.3.4 - Interaction with F(ab’)2 
Recent crystallography studies have shown that an Ig-binding domain of PpL has 
two distinct regions that can interact with kappa light chains and is capable of 
binding two Fab fragments (F(ab’)2) simultaneously [Graille et al., 2001]. The 
crystal structure of human antibody F(ab’)2 complexed through its VL region to a 
PpL Ig-binding domain has been resolved to 2.7 Å, and revealed that the single 
PpL domain is positioned between the VL regions of two Fab fragments. A three-
dimensional ribbon representation of an Ig-binding domain of PpL•F(ab’)2 
complex is presented in figure 1.23.  
 
The interaction between PpL and the first VL domain involves 13 residues from 
the Fab molecule and 12 residues from the PpL Ig-binding domain [Graille et al., 
2001]. Ten of the residues from the Fab fragment involved in the interaction are 
located in framework region one without contacting the hypervariable loops, thus 
not affecting the antigen-binding site. The remaining three residues being Lys107 
from the segment connecting the VL to the CL region, Glu143 from the CL region 
and Arg24 from the second β-strand. All of the twelve residues in the PpL domain 
are located mainly on the second β-strand and the α-helix. This first interface is 
characterised by the formation of six hydrogen bonds positioned between the 
second β-strand of PpL and β-strand A from the first Fab fragment. These 
hydrogen bonds join the β-sheets of the Fab and PpL into a unique sheet through 
a β-zipper interaction [Graille et al., 2001]. 
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The interaction between PpL and the second VL domain involves 15 residues from 
the Fab fragment and 14 residues from the PpL domain. The amino acid side 
chains contributed by the Fab fragment to the interaction are located on β-
strands A and B, with some participation from β-strands D and E. It has also been 
shown that ten of these residues are also involved in the first interface. The 
residues donated from PpL are located on the third β-strand and the α-helix, but 
none of these residues are involved in the first interaction. Again six hydrogen 
bonds are formed, with two additional salt bridges mediating the interaction.  
 
 
VL VL 
VH    VH    
PpL 
CH1    
Classical interface 
“Wikström site” 
Non-classical interface 
“Graille site” 
β-2 
CL CL 
β-3 
CH1    
Figure 1.23 - A ribbon representation of an Ig-binding domain of PpL interacting 
with the VL region of two Fab fragments 
 
A three-dimensional ribbon representation of two human antibody Fab fragments 
and a single PpL domain complex is presented. The structure contains two Fab 
molecules sandwiching a single PpL domain, which contacts similar VL framework 
regions of two light chains via independent interfaces. The first interface involves 
residues located on β2 and the α-helix, six hydrogen bonds join the β sheets of 
the Fab and the PpL into a unique sheet through a β zipper interaction. The 
second interface involves residues located mainly on β3 and the α-helix, and is 
mediated by six hydrogen bonds and two salt bridges [Graille et al., 2001]. PDB 
accession code: 1HEZ. 
 
1.2.3.5 - Reactivity with immunoglobulins 
PpL is of great interest because the interaction is with the light chains of the 
immunoglobulin carrying the kappa isotype. Specifically, PpL targets the 
framework regions of the kappa chain VL domain [Enokizono et al., 1997], 
without interfering with the antigen-binding capacity of the antibody, which 
involves the hypervariable regions [Ǻkerström and Björck, 1989]. Compared to 
the other Ig-binding proteins, PpL has the advantage of interacting with Ig 
regardless of the class specific heavy chains, and can be used to detect Ig of all 
classes that contain kappa chains. However, the reactivity with human kappa 
chains is limited to the κI, κIII and κIV subgroups, with approximately 65% of 
human immunoglobulins carrying kappa light chains [Kastern et al., 1990], while 
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light chains of the κII subgroup show no affinity for PpL [Nilsson et al., 1992]. 
The dissociation constant (Kd) between PpL and kappa chains is 1.5 x 109 M-1, 
compared with 1 x 1010 M-1 for IgG, IgM and IgA [Kastern et al., 1990]. Studies 
have also shown that the binding of PpL is highly dependent upon the tertiary 
structural integrity of the kappa chain VL domain [Nilsson et al., 1992]. 
 
PpL also binds to the light chains of immunoglobulins from species other than 
man, such as human, baboon, chimpanzee, pig, mouse, rat, rabbit and guinea 
pig, but not to cow or goat Ig [De Chateau et al., 1993]. 
 
Cell surface proteins from Gram-positive bacteria are known to bind a number of 
serum proteins other than immunoglobulins. These proteins include albumin, 
fibrininogen, α2-macroglobulin and kininogen [Sjöbring et al., 1989]. Studies 
have shown that in addition to binding Ig, peptostreptococcal strain PpL3316 binds 
human serum albumin (HSA), and also contains extra sets of different repeat 
units to the kappa light chain-binding units that both peptostreptococcal strains, 
PpL312 and PpL3316, display [Murphy et al., 1994]. Western blot analysis has 
demonstrated that the function of the PpL3316 D1-D4 units is to bind albumin, and 
this separate location of albumin-binding regions to the Ig-binding regions is 
similar to that found in SpG [Björck et al., 1987]. A comparison of the D repeats 
with the N-terminal regions, A1, B1, A2, B2 and A3, of SpG shows considerable 
sequence homology with 67% shared amino acid sequence identity [Murphy et 
al., 1994].    
 
Due to its site of interaction on VL domains PpL also binds single chain Fv (scFv) 
antibodies. ScFv antibodies are single chain fragments of Ig consisting of heavy 
and light chain variable domains covalently linked together by a designed peptide 
linker sequence, which links the carboxyl terminus of the VL sequence to the 
amino terminus of the VH. This is the smallest possible fragment of an antibody 
which still retains an intact antigen binding site [Bird et al., 1988]. Kd values 
were shown to be between 1.4 and 4.5 x 109 M-1 when tested with scFv 
antibodies [Åkerström et al., 1994], compared to those obtained for the binding 
of PpL to isolated VL domains at 0.9 x 109 M-1 [Nilsson et al., 1992], 
demonstrating that PpL was not influenced by the introduction of the peptide 
linker. Results also showed that all VL domains belonging to the κI subgroup 
bound to PpL, regardless of which VH domain it was connected to, suggesting that 
the binding is independent of the VH domain. Thus, all available data are 
indicative that the binding of PpL to the VL domain is independent of the 
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interactions with antigen, VH domains and CL domains [Åkerström et al., 1994]. 
1.2.4 - Protein H 
Protein H is a surface protein of Group A Streptococcus pyogenes (S. pyogenes), 
belonging to the M protein family, which interacts with the constant Fc region of 
IgG [Gomi et al., 1990]. An IgG-binding fragment is released from the 
streptococcal surface by an extracellular cysteine proteinase produced by the 
bacteria. This fragment covers the entire surface-exposed part of the molecule, 
and exhibits high affinity for IgG, one of the most abundant soluble extracellular 
human proteins. S. pyogenes is an important human pathogen causing primary 
disease manifestations such as pharyngitis, impetigo and tonsillitis, which may 
lead to serious sequelae including rheumatic fever and glomerulonephritis 
[Kihlberg et al., 1999].   
 
Studies suggest that protein H is always complexed with IgG, and when the 
protein H•IgG complexes are released from the surface of the bacteria, they are 
capable of activating the classical complement pathway, but prevent the 
activation of complement when associated with the bacterial surface [Berge et al., 
1997]. Complement plays an important role in defence against pathogenic micro-
organisms by facilitating antigen clearance and generating an inflammatory 
response. The complement reaction amplifies the initial antibody-antigen reaction 
and converts the reaction into a more effective defence mechanism. As the 
antigen becomes coated with complement reaction products, it is more readily 
phagocytosed by phagocytic cells that bear receptors for these complement 
products. Protein H belongs to the M protein family, which specifically binds to the 
complement proteins factor H and C4b-binding protein that regulates complement 
activation. S. pyogenes also expresses a surface-associated peptidase, which 
degrades C5a, a chemotactic fragment of C5 [Berge et al., 1997]. These effects 
provide a selective advantage to S. pyogenes and may help to explain how Ig-
binding surface proteins contribute to the virulence of this human pathogen. 
When the protein H•IgG complexes are released complement is activated, which 
leads to its breakdown in the vicinity of the bacteria, thus preventing assembly 
and activation of complement at the bacterial surface. Conversely, complement 
activation will generate C5a and therefore attract phagocytic cells. S. pyogenes 
then efficiently and simultaneously releases the biologically active fragment of a 
C5a peptidase which destroys C5a [Kihlberg et al., 1999]. To initiate complement 
activation away from the bacterium and to inactivate the C5a that is generated 
represents a sophisticated microbial defence mechanism. 
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 Protein H has also been shown to bind HSA, α2-macroglobulin and IgG, and the 
Ig-binding domains have been identified as the C1-C3 domains [Åkesson et al., 
1990]. Studies have also demonstrated that although the affinity for human IgG 
is ten times lower than that of proteins A and G, protein H showed the same 
binding patterns as these proteins. Thus, protein H binds at the CH2/CH3 interface 
on the Fc of IgG, and results show that this binding is competitive with that of 
SpA and SpG, despite the complete lack of sequence homology between the Ig-
binding domains of these proteins [Åkesson et al., 1994]. Protein H also interacts 
with α2-macroglobulin in vivo, which could have implications for virulence, as α2-
macroglobulin is the major proteinase inhibitor in human plasma and exhibits 
affinity for the three main Ig-binding proteins A, G and L [Sjöbring et al., 1989]. 
The reactivity with Ig classes from various species other than human has been 
identified and is limited to the IgG of baboons, rabbits and pigs [Åkesson et al., 
1994].  
 
1.2.5 - Protein D 
Protein D is a surface protein of the bacterial species Haemophilus influenza (H. 
influenza), and is the only Ig-binding receptor to date that has been identified in 
a Gram-negative bacterium [Ruan et al., 1990]. H. influenzae is known to cause 
invasive and non-invasive diseases in children and adults, and can cause 
pneumonia in the elderly and immune-compromised patients [Sasaki and 
Munson, 1993]. This bacterium was first identified to be capable of binding IgD 
[Forsgren and Grubb, 1979], with affinity for all four IgD myeloma proteins. 
Protein D interacts with the highest affinity to the Fc region on an IgD molecule 
and can also interact with the Fab region. The constant parts of the heavy chains 
both in the Fab and Fc fragments have been identified as the contact regions for 
the interaction with the protein [Ruan et al., 1990]. Unfortunately the structure of 
protein D has not yet been determined, however, since Haemophilus influenzae 
colonises the upper respiratory tract, protein D can be used to study bacteria-IgD 
interactions on lymphocytes and in secretion, which may play an important role in 
pathogenesis and host defence in upper respiratory tract infections. 
 
1.2.6 - Comparison of Ig-binding proteins A, G and L 
1.2.6.1 - Proteins A and G  
Immunoglobulin-binding proteins are important reagents for a variety of 
biochemical and immunological applications. Staphylococcal SpA and 
streptococcal SpG are examples of cell-surface proteins that bind to the constant 
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Fc region of mammalian IgG with the advantage that they do not interact with 
the antigen-binding part of the antibody. SpA and SpG share no sequence or 
structural homology even though they compete for the same binding site on Fc, 
at the hinge region that links the second and third constant domains of the heavy 
chain (CH2/CH3 interface). The interaction with Fc is comparable for both 
proteins, and it has been suggested that the α-helix of SpG might occupy the 
same position as the first helix of SpA [Gronenborn et al., 1993]. This is 
supported by similar contact regions when complexed with Fc, involving residues 
located mainly on the N-terminal helix of SpA, and residues within the α-helix and 
β-strand three of SpG. Conversely, although these interactions seem similar, it 
has been shown that the helix of SpG does not coincide with any of the helices of 
SpA when complexed with Fc. The interfacial interactions in the two complexes 
are also very different. The interface between Fc and SpG consists of a network of 
hydrogen bonds and salt links, involving mainly charged and polar residues, 
whereas the SpA•Fc complex is stabilised by non-specific hydrophobic 
interactions and fewer polar contacts.   
 
Crystallography data has shown that by superimposing the two complexes, about 
one-quarter of SpG overlaps with about one-third of SpA. The helix of SpG makes 
an angle of approximately 45° to the plane formed by the two longest helices of 
SpA. Two helices of SpA are shown to be located mostly on the CH2 side of the Fc 
molecule, whereas the helix of SpG lies wedged in the CH2-CH3 cleft [Sauer-
Eriksson et al., 1995], thus the two helices cannot bind to the same region of Fc 
simultaneously. Figure 1.24 presents a ribbon representation of the SpA•Fc 
complex superimposed with the SpG•Fc complex.   
 
Comparatively, SpG does offer some other similarities with SpA. Both proteins are 
flanked by, and interact with, three loops from Fc. Four residues from Fc, Ile253, 
Ser254, Gln311 and Asn434, are particularly important because their side chains 
interact with side chains of both SpA and SpG. Several of the Fc residues interact 
with both proteins, which are possible because the third β-strand in SpG is 
situated in approximately the same region on Fc as the first α-helix of SpA 
[Tashiro and Montelione, 1995]. These and other interactions involving main-
chain atoms in these three loops suggest how the two proteins compete for 
binding to Fc. However, SpA and SpG each have a set of unique interactions with 
Fc, which accounts for the differences strategies in Fc binding. 
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Figure 1.24 – A superimposed ribbon representation of SpA and SpG interacting 
with an Fc fragment from an IgG molecule 
 
Crystallography data have shown that by superimposing the two complexes, 
about one-quarter of SpG overlaps with about one-third of SpA. Two helices of 
SpA are shown to be located mostly on the CH2 side of the Fc molecule, whereas 
the helix of SpG lies wedged in the CH2-CH3 cleft, thus the two helices cannot 
bind to the same region of Fc. The two superimposed CH2/CH3 interfaces of Fc 
are shown in green and yellow, SpA is shown in red and SpG is shown in blue. 
The bottom picture represents a top view of the superimposed complexes [Sauer-
Eriksson et al., 1995].  
 
1.2.6.2 - Proteins G and L 
CH2 
SpG and PpL share many common features; such is the extent of these that it 
has been proposed that a transfer of gene fragments may have occurred between 
these two infective bacteria [Goward et al., 1993]. In spite of different binding 
specificities, the Ig-binding domains of PpL and SpG demonstrate a similar 
structural fold, both having a central alpha helix on top of a mixed four-stranded 
beta-sheet in a (-1, +3x, -1) topology [Wikström et al., 1994]. The first two β-
strands are also of the same length in both proteins, containing nine amino acids 
residues apiece. Figure 1.25 presents an adapted three-dimensional ribbon 
comparison of PpL-VL and SpG-CH1 interactions. 
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Figure 1.25 – A ribbon comparison of PpL-VL and SpG-CH1 interactions 
 
The interaction between proteins G and L and a Fab fragment is accomplished by 
an alignment of β-strands. Strand β2 of both domains interacts with, respectively, 
a Fab VL (blue) or a Fab CH1 (green) β strand, and the similarities of their 
interactions are clearly demonstrated. In both cases β2 extends a β-sheet of the 
Fab through a β-zipper interaction. This interaction involves five main-chain 
hydrogen bonds in the SpG-CH1 interface, but only three hydrogen bonds in the 
PpL-VL first interface, and is represented by coloured lines [Graille et al., 2001]. 
 
In spite of the overall resemblance of the Ig-binding domains of SpG and PpL, 
several differences are found when their three-dimensional structures are 
compared. One main structural difference is the orientation of the α-helices, 
where the α-helix in PpL runs almost parallel to the β-sheet at an angle of Ω ~-
10°, whereas in SpG it runs diagonally across the β-sheet with an angle of Ω ~-
40°. This arises from a difference in the length of the loop between the α-helix 
and the third β-strand, which is one residue shorter in PpL. This is the region of 
SpG that is responsible for Fc binding, so therefore, the shorter loop in PpL may 
help to explain the inability of PpL to bind Fc [Graille et al., 2001].   
 
Other differences pertain not only to the helix orientation, but also to differences 
in the turns between the β-strands, as well as the lengths of strands β3 and β4. 
The turns connecting the first two β-strands differ in that in SpG, strands β1 and 
β2 are connected by a type I β-turn, while in PpL the linking segment is a five 
residue turn. The turns between strands β3 and β4 in SpG is a six residue turn as 
opposed to a distorted type I’ β-turn in PpL [Wikström et al., 1994]. Also in PpL 
the length of strands β3 and β4 is eight amino acid residues, whereas in SpG the 
corresponding strands are only five residues long.  
 
Both proteins L and G use their second β-strands when interacting with the 
framework region on the VL domain of kappa light chain and the CH1 region in 
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IgG Fab respectively [Wikström et al., 1996], thus burying equivalent surface 
areas upon binding, and this also shares similar features. In both interactions the 
second β-strand, extends a β-sheet of the Fab through a β-zipper interaction, 
involving five main-chain hydrogen bonds in the SpG-CH1 interface [Derrick and 
Wigley, 1994], but only three hydrogen bonds are involved in the PpL-VL first 
interface [Graille et al., 2001]. However, although this second β-strand is 
important for Fab binding with both proteins G and L, different parts of the strand 
participate in the interaction. In the contact between PpL and the Ig light chain 
variable domain, residues from almost the whole strand are affected, whereas the 
first turn and the two N-terminal thirds of the second β-strand are involved in the 
binding of SpG to CH1.  
 
When the primary and tertiary structures of the Ig-binding domains of L and G 
are compared, the third β-strands are the most homologous. The involvement of 
this strand in the interaction between L and kappa chain is highly unlikely since 
PpL cannot inhibit the binding of SpG to Fc. The least homologous and surface-
exposed regions in the comparison are the second β-strand, parts of the α-helix 
and the loop following the helix [Wikström et al., 1994]. 
 
Streptococci and staphylococci bacteria strains are virulent and cause a range of 
clinical infections in humans, but their respective Ig-binding proteins cannot be 
unambiguously assigned a role in the virulence of the bacteria. Peptostreptococci 
is a member of the normal flora on most body surfaces, and are even found in 
the same habitats as streptococci, such as the human intestinal and genital 
tracts, and compared to staphylococci and streptococci are much less virulent. 
However, strains of P. magnus that have the PpL gene are more frequently 
connected with clinical infections suggesting that PpL is a virulence determinant. 
This is in contrast to SpG, even though it is expressed in group C and G 
streptococci strains isolated from patients with severe clinical infections.   
 
The reason why PpL-expressing bacteria appear more virulent is not fully 
understood, although it is thought that this could be that Ig bound to PpL or SpG 
at the bacterial surface is exposed differently. An antibody bound to PpL through 
light chain interactions can also bind to Fc receptors on host cells, whereas the Fc 
region of IgG antibodies bound to SpG is blocked. Furthermore, PpL-expressing 
Peptostreptococci strains can bind all classes of Ig, and are also capable of 
inducing histamine release from human basophils and mast cells by binding to 
and cross-linking surface IgE [Patella et al., 1990]. Thus, PpL and SpG seem to 
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have been assigned functionally different roles, regardless of their similar 
structural organisation. 
 
1.3 - Applications of cell surface Ig-binding proteins 
Of the cell surface Ig-binding proteins SpA was the method of choice for many 
preparative and analytical purposes in immunology. It has been employed in the 
purification and analysis of human antibodies on Sepharose affinity columns, and 
for the fractionation of subclasses, which are difficult to separate by other means. 
SpA is also utilised in the detection of immunoglobulin in an ELISA, used as a 
solid phase adsorbant for isolating antigen-antibody complexes, membrane 
antigens and receptors. Finally, SpA has proven useful for the study of antigens 
and receptors on the surface of intact cells, and for the detection of antibody-
secreting cells [Goding, 1978]. 
 
The ability of SpA’s to bind immune complexes has promoted its use of SpA as a 
therapeutic agent in cancer and transplants. 20-30% of patients with organ 
transplants reject the new tissue due to the production of anti-histocompatability 
(anti-HLA) antibodies [Palmer et al., 1989]. Extracorporeal immunoadsorption 
with immobilised SpA can be used to remove these anti-HLA antibodies, since the 
majority of these are IgG, prior to the operation. This technique has been used 
successfully in kidney transplants without side effects, and is more effective than 
traditional plasma exchange methods [Palmer et al., 1989, Barocci et al., 1993]. 
Binding SpA to immune complexes has also been used in extracorporeal shunt 
therapy for cancer therapy [Bansal et al., 1978. 
 
SpG has a much broader specificity for IgG, and its resistance to denaturation 
either by temperature or urea, give this protein immense potential as an 
immunological tool. In antibody purification, SpG offers a means of separating 
IgG from other immunoglobulins and could be used for a wider selection of 
mammalian antibodies than SpA. Affinity for a wider range of species and 
subclasses would put less constraint on the IgG that could be used in ELISA 
where immunoglobulin-binding proteins can be used in place of a secondary 
antibody. Its greater stability should also make this protein less susceptible to 
degradation by host proteases, making it a better choice than SpA, as a fusion 
protein in expression vectors [Nilsson et al., 1992]. 
 
PpL represents a new tool for the binding and detection of immunoglobulins. The 
advantage of using PpL is that it possesses the ability to interact with all classes 
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of immunoglobulin, which possess Ig kappa light chains. Thus, the specific 
interaction between PpL and the immune system could be of significance to the 
understanding of the host-parasite relationship. PpL has potential use for the 
isolation of antigen-binding VL domains and scFv fragments prepared from 
monoclonal antibodies or produced in recombinant DNA systems [Nilson et al., 
1992]. The use of recombinant antibodies in the form of scFv fragments is 
becoming increasingly common, and it has been shown that both PpL and SpA 
may be valuable tools for the purification of such recombinant antibodies from 
crude cell culture media [Åkerström et al., 1994]. In addition they can be used as 
detectors of antibodies in immunoblotting and immunocytochemistry as they do 
not impair antigen-binding to the antibody fragments. 
 
Protein H also has considerable potential as an immunological tool. Its specificity 
for human IgG enables purification of human monoclonal IgG antibodies from a 
culture medium [Åkesson et al., 1990]. Its affinity for IgG is lower than that of 
SpA or SpG, but is sufficiently high for immunoglobulin purification. The benefit of 
this lower affinity is, however, advantageous as the elution of human IgG from 
immobilised Protein H requires less denaturing conditions. 
 
Thus, it can be noted that, at present, no particular Ig-binding protein is without 
limitations. 
 
1.4 - Applications of recombinant antibody fragments 
The unique ability of antibodies to specifically recognise and bind with high 
affinity to virtually any type of antigen, such as microorganisms, larger parasites, 
viruses and bacterial toxins, rendering them harmless has made them interesting 
molecules for medical and scientific research. Since monoclonal antibody (mAb) 
technology was developed in 1975 [Köhler and Milstein, 1975], the isolation and 
production of mAbs against protein, carbohydrate and nucleic acids antigens has 
resulted in a rapid development of the use of antibodies and their fragments in 
diagnostics, human therapeutics and as fundamental research tools [Porter et al., 
1988]. Applications outside research and medicine include consumer uses such as 
the use of antibodies in shampoos to prevent dandruff [Dolk et al., 2005] or in 
toothpaste to prevent against tooth decay [Joosten et al., 2003].  
However, using production systems based on mammalian expression is 
expensive, producing antibodies in bulk amounts is difficult and the low stability 
and solubility of some antibodies under specific (harsh) conditions presents major 
 | 42  
 
problems. Therefore, the use of recombinant human monoclonal antibodies is 
becoming increasingly popular due to their advantages compared to conventional 
monoclonal or polyclonal antibodies. The production of recombinant antibodies is 
much faster compared to conventional antibody production and they can be 
generated against an enormous number of antigens. In contrast, in the 
conventional method, many antigens prove to be non-immunogenic or extremely 
toxic, and therefore cannot be used to generate antibodies in animals. Moreover, 
increasing the affinity and specifity of recombinant antibodies is very simple and 
relatively fast, and large numbers of different antibodies against a specific antigen 
can be generated in one selection procedure [Hudson, 1999]. 
Recombinant antibodies and their fragments now represent over 30% [Holliger 
and Hudson, 2005] of all biological proteins undergoing clinical trials for diagnosis 
and therapy. Over recent years, important advances have been made in the 
design, selection and production of new types of engineered antibodies. 
Innovative selection methods have enabled the isolation of high-affinity cancer-
targeting and antiviral antibodies, the latter capable of redirecting viruses for 
gene therapy applications. In other strategies for cancer diagnosis and 
immunotherapy, recombinant antibody fragments have been fused to 
radioisotopes, drugs, toxins, enzymes and biosensor surfaces, effectively 
enhancing the human immune response in anti-cancer vaccines and T cell 
recruitment strategies [Hudson, 1999]. The growth of therapeutic antibodies is 
therefore dependent on the development of new approaches for faster antibody 
development, improved methods of selection and optimisation, alternatives for 
production, as well as the evaluation for novel applications [Glasgow et al., 
2006].  
 
In the future, such recombinant antibodies may form the basis for the treatment 
of autoimmune diseases, but there remains a long way to go.  
 
1.5 - Aims and objectives 
The aim of this research is to study a single Ig-binding domain construct of SpG, 
with respect to its stability and binding interactions with both Fc and Fab 
fragments of IgG molecules. The 208 bp Ig-binding domain gene was based on 
the sequence for SpG-C2, which is a hybrid of the C-terminus of the C1 domain 
and the N-terminus of the C3 domain. This domain was chosen due to its 
combined characteristics of its counterparts. Despite being almost identical in 
sequence, C1 has a lower affinity for IgG, but is more stable and has a higher 
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melting temperature than C3.  
 
 
The aim of this research is to study the role of the individual interfacial 
interactions between Fc and SpG, which consist of a network of hydrogen bonds 
and salt links, involving mainly charged and polar residues. An additional aim of 
this research is to study the role of various amino acids that form the major 
contact regions in the binding of SpG with Fab, as very little is known of the 
binding properties and characteristics of this interaction. To facilitate these 
studies a program of site-directed mutagenesis will be carried out. 
 
Thus, it may prove possible to generate a library of constructs that offer a range 
of binding affinities to enable different biotechnological uses. For example, to 
remove Ig or Ig complexes from sera, a high affinity SpG ligand would be 
beneficial. Alternatively, an affinity ligand with a lower affinity would offer 
advantages for the elution of the Ig from the column.  
 
Finally, the stability of the constructs is to be studied using guanidine 
hydrochloride denaturation experiments, using both fluorimetry and circular 
dichroism (CD). Since the product must offer, not only the appropriate affinity, 
but also be thermodynamically stable. The binding properties of these mutant 
constructs will then be characterised thoroughly to obtain affinity constants by a 
combination of fluorescence titration and isothermal titration calorimetry (ITC), 
and kinetic measurements of real-time binding using stopped-flow fluorescence 
spectroscopy.  
 
 
 
 
 
CHAPTER 2.0 
 
     MATERIALS  
AND  
METHODS 
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2.1 - General chemicals and specific materials 
To enable the interaction of SpG with Fc and Fab fragments to be studied, a 
selection of microbiological, DNA and protein analysis techniques were employed 
using a wide range of general chemicals and specific materials. General chemicals 
were obtained from Fisher Scientific, Loughborough, UK and Sigma Chemical 
Company Ltd, Poole, Dorset. Specialised chemicals, kits and services were 
purchased from the following companies: 
  
• Agarose: Flowgen, Rockland, USA. 
 
• Agar No.1: Lab M, Bury, Lancaster, UK. 
 
• Dithiothreitol; DNase 1: Roche Molecular Biochemicals, East Sussex, UK. 
 
• Mis-match oligonucleotide primers for site-directed mutagenesis; DNA 
Sequencing: MWG-Biotech, Milton Keynes, UK.  
 
• Protogel (30%acrylamide/0.8%bis-acrylamide): National Diagnostics, 
Hessle, Hull, UK. 
 
• Pfu DNA polymerase; Restriction and modification enzymes with respective 
buffers: Promega, Chilworth, Southampton, UK. 
 
• QIAprep Spin miniprep Kit; QIAquick Gel Extraction Kit; QIAquick 
Nucleotide Removal Kit; QIAquick PCR Purification Kit: Qiagen Ltd., 
Crawley, West Susssex, UK. 
 
• Tryptone; Yeast Extract: Melford Laboratories, Ipswich, Suffolk, UK. 
 
• 100bp DNA ladder: New England Biolabs, Hitchin, Herts, UK. 
 
• Human Fc fragments were kindly provided by Prof. M. Glennie, Tenovus 
Labs, Southampton General Hospital, UK. 
 
• Plasmid vector containing Fab gene and purified Fab protein were kindly 
provided by Dr. A.G. Popplewell, UCB-Celltech, Slough, UK. 
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2.2 - Preparation of buffers and common reagents 
2.2.1 - Media 
2.2.1.1 - Luria-Broth 
Routine growth of bacterial cultures was achieved using Luria-Broth (LB) 
(tryptone 10 g/litre, yeast extract 5 g/litre, NaCl 5 g/litre) and supplemented with 
antibiotics, ampicillin (50 μg/ml) or tetracycline (7.5 μg/ml). LB was solidified for 
plates by the addition of 1.5% w/v agar no.1. 
 
2.2.2 - 6X Gel Loading Buffer 
Gel loading buffer (0.25% w/v bromophenol blue, 30% v/v glycerol) was used to 
increase the density of the DNA sample to ensure that the DNA dropped evenly 
into the wells of agarose gels (section 2.4.3).   
 
2.2.3 - 1X and 10X TBE Buffer 
1X TBE buffer was diluted from a 10X TBE stock (108 g Tris, 55 g Boric acid, 9.3 
g Na2EDTA/litre distilled water) for the preparation of agarose and as a running 
buffer during agarose gel electrophoresis (section 2.4.3). 
 
2.2.4 - TE Buffer 
Sterile TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA) was used during the 
preparation of phenol/chloroform extraction of DNA (section 2.4.2.1).  
 
2.2.5 - Sonication Buffer 
Sonication buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EGTA, 0.1 mM EGTA, 0.5% v/v 
Triton X100) was used to resuspend pelleted cells, which had been harvested 
from overnight cultures, grown to express recombinant SpG (section 2.5.1). The 
cell paste was used immediately or stored frozen at -20 °C. 
 
2.2.6 – SpG Purification Buffers 
Buffer A (20 mM Tris-HCl pH 8.0) was used to pre-equilibrate a Q-Sepharose 
anion exchange column, and as part of a linear gradient with elution buffer B (20 
mM Tris-HCl pH 8.0, 1 M NaCl) (section 2.5.1). 
 
2.2.7- Buffer for Extracting Fab from Periplasm  
Periplasmic extraction buffer (20 mM Tris-HCl pH 8.0, 10 mM EDTA, 20% 
sucrose, 1 ml broad range protease inhibitors) was used to resuspend pelleted 
cells that had been harvested from a 32 hour fermentation culture, grown to 
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express recombinant Fab, and to extract the Fab protein from the resulting cell 
suspension (section 2.5.2). 
 
2.2.8 - Fab Purification Buffers 
Buffer A (100 mM Tris pH 8.0, 0.5 M NaCl) was used to pre-equilibrate a 50 ml 
PpL column bound (5 mg/ml) to the NHS-Sepharose column medium, and as part 
of a linear gradient with elution buffer B (50 mM citrate, pH 2.2) (section 2.5.2).  
 
2.2.9 - SDS High-Resolution Polyacrylamide Gel 
A 6 ml high-resolution 17.5% acrylamide separating gel (3.5 ml 30% w/v 
protogel, 2.4 ml 3.6 M Tris-HCl pH 9.3, 0.06 ml 10% w/v SDS, 0.03 ml 25% w/v 
APS, 0.010 ml TEMED) was used for SDS-PAGE electrophoresis (section 2.5.3). 
The gel was completed with a 4 ml stacking gel (0.600 ml protogel, 1.6 ml 3.6M 
Tris-HCl pH 8.85, 1.7 ml distilled water, 0.04 ml 10% SDS, 0.02 ml 25% APS, 
0.005 ml TEMED). 
 
2.2.10 - 5X SDS High-Resolution Running Buffer 
1X SDS running buffer was diluted from a 5X SDS running buffer stock (30.25 g 
Tris, 142.63 g glycine, 10 g SDS/litre distilled water) and used during SDS gel 
electrophoresis (section 2.5.3). 
 
2.2.11 - 2X Reducing Sample Buffer 
Sample buffer (2 ml glycerol, 4 ml 10% SDS, 5 ml distilled water, 4 ml 2-
Mercaptoethanol, 15 mg bromophenol blue) was used to increase the density of 
the SpG samples to ensure that the protein dropped evenly into the wells of SDS 
gels during electrophoresis (section 2.5.3).  
 
2.2.12 - Non-Reducing Sample Buffer 
Non-reducing sample buffer (2 ml glycerol, 4 ml 10% SDS, 5 ml distilled water, 
15 mg bromophenol blue) was used to increase the density of the protein sample 
to ensure that the Fab protein samples dropped evenly into the wells of SDS gels 
during electrophoresis (section 2.5.3).  
 
2.2.13 - Coomassie Brilliant Blue Stain 
Coomassie brilliant blue stain (454 ml methanol, 96 ml acetic acid, 454 ml 
distilled water, 2.5 g Coomassie blue/litre distilled water) was used to stain SDS 
polyacrylamide gels (section 2.5.3). 
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2.2.14 – Gel Destain Solution 
Destain (180 ml methanol, 100 ml acetic acid, 1720 ml distilled water) was used 
to destain SDS polyacrylamide gels (section 2.5.3). 
 
2.2.15 – 20 mM Potassium Phosphate Buffer 
20 mM potassium phosphate (75 ml 1M K2HPO4, 5 ml 1 M KH2PO4/920 ml distilled 
water), with varying pH, was used for dialysis (4 litres 20 mM KPO4 buffer) and 
the preparation of protein for Fc and Fab binding characterisation studies (section 
2.6 and 2.7). 
 
2.2.16 – 20 mM Triple Buffer System 
A triple buffer system (75 ml K2HPO4, 5 ml KH2PO4, 80 ml 1M Tris-HCl, 80 ml 1 M 
sodium acetate/3760 ml distilled water), ranging from pH 4.0 to pH 9.0, was used 
for dialysis and the preparation of protein used for pre-equilibrium studies 
(section 2.6.3), to determine the effect of pH on Fc and Fab binding. 
 
2.3 - Microbiological Methods 
2.3.1 - Sterilisation 
All media, stock solutions, pipette tips and microfuge tubes were sterilised by 
downstream displacement autoclaving at 121 °C, 15 lb/sq.inch, for 20 minutes.  
Glassware was sterilised by heating to 160 °C for 2-3 hours. Heat labile stock 
solutions such as antibiotics, IPTG and salt supplements were sterilised through 
0.45 μm Millipore disposable filters. 
 
2.3.2 – Bacterial Strains  
2.3.2.1 - E.coli JM103  
JM103 cells were used for the expression and storage of SpG and Fab [Messing et 
al., 1981]. 
Genotype:-Δ(lacproAB),supE,thi,rsplL.endA,SbcB15,[F’,traD36,proA,lacIqZΔM15]  
 
2.3.2.2 - Antibiotic resistance 
The genes for the SpG and Fab proteins used in this study were in vectors that 
confer different bacterial antibiotic resistance to host bacteria. The SpG 
expression vector (AP10-2 modified pQE-30) confers ampicillin resistance, and 
thus 50 µg/ml ampicillin was present in all SpG bacterial cultures. The Fab vector 
(pTTOD) confers tetracycline resistance, and 7.5 µg/ml tetracycline was present 
in all Fab bacterial cultures.  
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2.3.2.3 - Storage of bacterial strains 
Bacterial strains containing plasmid DNA and antibiotic resistant gene were stored 
as streaks on LB-plates (section 2.2.1.1) supplemented with the appropriate 
antibiotic. Non-transformed cells were stored on LB-plates with no antibiotic 
present. These plates are viable stored at 4 °C for up to 4 weeks and used to 
produce overnight cultures.  
 
For long-term storage of strains, 5 ml cultures were grown up in LB (section 
2.2.1.1) to mid-log phase, at which point the cells were harvested and 
resuspended in 800 μl of LB and 200 μl sterile glycerol. These can be stored at -
70 °C for approximately two years. 
 
2.3.2.4 - Growth of bacterial strains 
Individual colonies of transformed ligations or streaks of transformed plasmid 
DNA (section 2.3.3) were used to inoculate 10 ml LB (section 2.2.1.1) containing 
the appropriate antibiotic. These cultures were incubated at 37 °C overnight with 
shaking at 200 rpm, and used for the expression of protein (section 2.5.1) or 
DNA preparation (section 2.4.1). 
 
2.3.3 - Transformation of E.coli 
2.3.3.1 - Preparation of competent cells 
Bacterial cells were made competent for the uptake of DNA by the method of 
Cohen et al., [1972]. This technique induces a transient state of competence in 
the recipient bacteria, during which they are able to take up DNA derived from a 
variety of sources, and then used to confer bacterial antibiotic resistance. 
 
A 10 ml culture grown overnight of the host strain E.coli, was diluted 1:1000 in 
LB and grown to mid-log (OD600nm ~0.5) at 37 °C with shaking. The cells were 
harvested by centrifugation for 5 minutes in a bench top centrifuge, and 
resuspended in 5 ml ice-cold 50 mM calcium chloride. The cells were incubated on 
ice for a further 30 minutes, and then centrifuged as before, and resuspended in 
a final volume of 1 ml ice-cold 50 mM calcium chloride. The competent cells were 
kept on ice and used within 24 hours.  
 
2.3.3.2 - Transformation of plasmid DNA 
Aliquots of competent cells, 200 μl, were mixed with 20-200 ng plasmid DNA, or 
whole ligation reactions, and incubated for 45 minutes on ice. The cells were 
heat-shocked at 42 °C for 90 seconds to facilitate the uptake of DNA, and 
incubated on ice for a further 5 minutes to allow recovery.  0.8 ml of LB was 
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added to the cells and incubated at 37 °C for 1 hour to enable some initial 
expression of the antibiotic gene product conferring antibiotic resistance to the 
cells. Successful transformants were selected by plating the cells onto the 
relevant selective media, and incubated overnight at 37 °C. 
 
2.4 - Molecular Biology Techniques 
All molecular biology techniques were performed on the synthetic gene encoding 
a single Ig-binding domain of SpG, SpGC2-1, as described in Maniatis et al., 
[1982]. 
 
2.4.1 - DNA preparation   
This method is based upon the alkaline lysis of the bacterial cells followed by 
adsorption of the DNA onto silica in the presence of high salt [Birnboim and Doly, 
1979]. The bacteria is harvested and lysed by sodium hydroxide and SDS under 
alkaline conditions in the presence of RNase A. The SDS solubilises the 
phospholipid and protein components of the cell membrane, leading to lysis and 
release of the cell contents, whereas the alkaline conditions denature the 
chromosomal and plasmid DNA. Under optimal lysis time this procedure allows 
the maximum release of plasmid DNA without the release of chromosomal DNA.  
The lysate is subsequently neutralised and adjusted to high salt binding 
conditions, ready for purification on a silica-gel membrane. The high salt 
concentration causes the denatured proteins, chromosomal DNA, cellular debris 
and SDS to precipitate, while the smaller plasmid DNA renatures and stays in 
solution. The separation of the plasmid is based on the precipitation of the cell 
wall-bound chromosomal DNA with insoluble complexes that contain salt, 
detergent and protein. Washing and eluting the plasmid DNA ensures that 
endonucleases are efficiently removed, which is essential with endA+ strains, 
such as JM103, since they can reduce the quality of DNA. These cells also 
produce large amounts of carbohydrates that are released during lysis and can 
inhibit enzyme activities if they are not completely removed [Vogelstein and 
Gillespie, 1979]. 
 
Double-stranded plasmid DNA was prepared from 10 ml cultures grown in Luria 
broth for 16 hours at 37 °C, shaking at 200 rpm. Each 10ml culture had been 
inoculated with a single colony and contained the appropriate antibiotic selection. 
The DNA was extracted and purified using a QIAprep spin miniprep kit, by 
following the manufacturer’s recommendations. 
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2.4.2 - DNA purification   
One of the most popular methods to purify DNA is that of Birnboim and Doly, 
[1979], as described and utilised by the QIAprep spin miniprep kit (section 
2.4.1). However, subsequent purification after various enzymatic reactions is 
necessary before further DNA applications can be performed. 
 
2.4.2.1 - Phenol/chloroform extraction of DNA 
The standard procedure used in molecular cloning to purify nucleic acids is 
phenol/chloroform extraction. The removal of contaminating proteins is achieved 
by extracting aqueous solutions of nucleic acids with phenol: chloroform, and 
chloroform [Sambrook et al, 1989]. Such extractions are utilised whenever it is 
necessary to inactivate and remove enzymes that are used in one step of a 
cloning operation before proceeding to the next. The phenol: chloroform solution 
denatures any proteins present in the DNA sample, and this de-proteinisation is 
more efficient as two organic solvents are used instead of one. The nucleic acids 
partition into the aqueous phase and the denatured proteins form the organic 
phase. Back extraction of the organic phase and the interface is also performed to 
achieve optimum recovery by the addition of TE buffer (section 2.2.4). This is 
repeated until there are no proteins visible at the interface of the organic and 
aqueous phases, which is seen as a white interface. A subsequent extraction with 
chloroform removes any lingering traces of phenol from the preparation, and the 
nucleic acids are recovered by precipitation with ethanol. 
 
Contaminating proteins were removed from DNA solutions by phenol: chloroform 
extraction. 100 μl phenol: chloroform solution was added to 100 μl DNA sample in 
a sterile microfuge tube. The mixture was vortexed for 30 seconds, allowed to 
stand for 1 minute before another 30 second vortex. The tube was then 
centrifuged for 4 minutes, and the upper aqueous layer was separated from the 
lower organic phase and transferred to a fresh tube. The procedure was then 
repeated by back extracting using TE buffer in place of the phenol: chloroform 
solution. The two upper layers were pooled and an equal volume of chloroform 
was added to remove any remaining traces of phenol. Nucleic acids were 
recovered by precipitation with 2½ times the initial volume of absolute ethanol 
and 1/10th volume of 3 M sodium acetate pH 5.5 at -70 °C, for 20 minutes. This 
was followed by centrifugation for 10 minutes. A 70% ethanol wash was then 
performed to remove any residual salts, followed by another centrifugation for 10 
minutes. The resulting pellet was air dried and resuspended with sterile analar 
water. 
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2.4.2.2 - Nucleotide removal  
A QIAquick nucleotide removal kit was used to purify oligonucleotides and DNA 
fragments up to 10 kilobases (kb) from enzymatic reactions such as 
dephosphorylation, ligations and restrictions digests [Birnboim and Doly, 1979]. 
The procedure is based upon the selective binding properties of the silica-gel 
membrane utilised in the spin columns. The special buffers provided are 
optimised for the efficient recovery of DNA and the removal of contaminants.  The 
adsorption of oligonucleotides greater than 17 bases and DNA fragments up to 10 
kb to the silica-gel membrane is promoted by the binding buffer and occurred in 
the presence of a high concentration of chatrophic salts, which modify the 
structure of water [Volgelstein and Gillespie, 1979]. During the DNA adsorption 
step, unwanted primers and impurities, such as salts and enzymes, do not bind 
and flow through the membrane. An ethanol-containing buffer quantitatively 
washes salts away, and any residual buffer that may interfere with subsequent 
enzymatic reactions, is removed by an additional centrifugation. 
 
DNA fragments and oligonucleotides were purified by removing unwanted primers 
<10 bases, enzymes and contaminating salts and incorporated nucleotides using 
the QIAquick nucleotide removal kit, by following the manufacturer’s 
recommendations. 
 
2.4.2.3 - Agarose gel extraction  
A QIAquick gel extraction kit was used to purify extracted DNA fragments 
between 70 base pairs (bp) and 10 kb from standard or low-melting agarose gels 
in 1X TBE buffer (section 2.2.3). This procedure is based on the same principles 
as illustrated by the QIAquick nucleotide removal kit (section 2.4.4.2) [Vogelstein 
and Gillespie, 1979].   
 
DNA fragments ranging from 70 bp to 10 kb were extracted from agarose gels in 
TBE buffer and purified by removing primers, enzymes, such as restriction and 
phosphatases, and salts using the QIAquick gel extraction kit by following the 
manufacturer’s recommendations. 
 
2.4.3 - Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used to separate, identify and purify 
DNA fragments [Sharp et al., 1973]. It is simple and rapid to perform, and 
capable of resolving fragments that cannot be separated adequately by other 
procedures, such as density gradient centrifugation. Agarose, which is extracted 
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from seaweed, is a linear polymer of galactopyranose derivatives. Agarose gels 
can be cast by melting the agarose powder in the presence of the desired buffer, 
until a clear, transparent solution is achieved, which is then poured into a mould 
and allowed to harden. Upon hardening, the agarose forms a matrix, the density 
of which varies depending on the concentration of agarose. When an electric field 
is applied across the gel, DNA, which is negatively charged at a neutral pH, 
migrates towards the anode. The linear DNA fragment of any given size will 
migrate at different rates through the matrix of the agarose gel. Gel loading 
buffer (section 2.2.2) is mixed with the DNA to increase the density of the sample 
to ensure that the DNA drops evenly into the well. The added colour from the 
bromophenol blue makes the loading process easier, and contains dyes that move 
towards the anode at predictable rates. 
 
The location of both single- and double-stranded DNA within the gel can be 
determined directly by staining with low concentrations of a fluorescent 
intercalating ethidium bromide dye, and detected by the direct examination of the 
gel under ultraviolet light. Ethidium bromide contains a planar group that 
intercalates between the stacked bases of DNA. The fixed position of this group 
close to the bases causes the dye bound to the DNA to display an increased 
fluorescent yield compared to that of the dye in free solution [Sharp et al., 1973]. 
 
Identification, sizing and purification of DNA fragments were performed using 
submerged horizontal agarose gel electrophoresis. Agarose 0.5%-2.0% w/v in 1X 
TBE buffer (section 2.2.3) was heated until all agarose had dissolved. Upon 
cooling to approximately 45 °C, 0.1 μg/ml ethidium bromide was added. The gel 
solution was poured onto the gel plate with a comb, and allowed to set. The comb 
was removed and the gel placed into a tank containing 1X TBE buffer. The 
samples were prepared using 6x gel loading buffer (section 2.2.2) and 
approximately 2-10 µl was loaded into the wells. The gel was run at 100 volts and 
the resulting separated DNA fragments were visualised under UV light. Images of 
the gels were obtained by using the Syngene Gene Genius gel documentation 
system. 
 
2.4.4 - Mutagenesis 
Mutagenesis is the alteration of a DNA sequence by specific chemical or 
enzymatic methods. Cloned genes allow mutagenesis to be much more precise by 
replacing specific bases in a gene, or specific amino acids at selected sites in the 
protein, a procedure known as site-directed mutagenesis.  
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2.4.4.1 - Oligonucleotide mutagenic primers 
Mis-match mutagenic oligonucleotide and flanking pQE-30 vector primers were 
produced and purified by MWG-Biotech, and dissolved in sterile distilled water to 
obtain a final 100 pmol/µl concentration.  
 
2.4.4.2 - PCR-based site-directed mutagenesis  
Polymerase chain reaction (PCR) amplification is used to amplify a segment of 
DNA that lies between two regions of a known sequence. The two oligonucleotides 
are used as primers for a series of synthetic reactions that are catalysed by a 
DNA polymerase [Saiki et al., 1988]. These primers have different 
complementary sequences that lie on the opposite strands of the template DNA, 
and flank the segment of DNA to be amplified. The template DNA is first 
denatured by heating, at approximately 95 °C, in the presence of a large molar 
excess of each of the two primers and four dNTPs. The reaction is cooled to a 
temperature that allows the primers to anneal to their target sequences, between 
35 °C and 55 °C, after which the annealed primers are extended with DNA 
polymerase at approximately 72 °C. The cycle of denaturation, annealing and 
DNA synthesis is repeated many times. The products of one cycle of amplification 
serves as a template for the next, allowing each successive cycle to double the 
amount of desired DNA product [Erlich et al., 1988]. The product of this reaction 
is a segment of double-stranded DNA, which is defined by the 5’ termini of the 
oligonucleotides primers, and the distance between the primers defines its length. 
 
PCR-based site-directed mutagenesis was employed for introducing point 
mutations, using the principles of splicing by overlap extension (SOE-ing) [Horton 
et al., 1989]. A modified two-sided SOE-ing method was used for the production 
of all SpG mutations, and requires three separate PCR reactions to produce the 
final mutant gene product. PCR reactions A and B were set up according to the 
reaction mix shown in table 2.1, with one reaction mix prepared per sample. The 
two-sided SOE-ing mutagenesis reactions were prepared on ice, and each of the 
components was added in order whilst mixing gently.  
 
The PCR amplification products A and B were analysed by 2% agarose gel 
electrophoresis (section 2.4.3), and fragments corresponding to the correct size 
were excised and purified using a QIAquick gel extraction kit (section 2.4.2.3).  
PCR products A and B were then used to produce the final mutagenic product PCR 
C according to the reaction mix shown in table 2.2.  
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Reagent Volume (µl) 
25 mM MgCl2 1 
10x Pfu DNA polymerase buffer 2.5 
Template plasmid DNA 1 
Mutagenic primer (100 pmol/µl) 0.5 
Flanking pQE-30 primer (100 pmol/µl) 0.5 
2 mM dNTPs 2.5 
DMSO 2 
Sterile distilled water 14 
Pfu DNA polymerase enzyme (3u/µl) 1 
TOTAL volume 25  
 
Table 2.1 - Reaction mix for PCR A and B 
 
 
 
Reagent Volume (µl) 
25 mM MgCl2 1 
10x Pfu DNA polymerase buffer 2.5 
Product from PCR A 1 
Product from PCR B 1 
Flanking pQE-30 primer 2 (100 pmol/µl) 0.5 
Flanking pQE-30 primer 1 (100 pmol/µl) 0.5 
2 mM dNTPs 2.5 
DMSO 2 
Sterile distilled water 7 
Pfu DNA polymerase enzyme (3u/µl) 1 
TOTAL volume 25  
 
Table 2.2 - Reaction mix for PCR C 
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For both sets of PCR reactions, Pfu DNA polymerase was added to the reaction 
mix last to ensure that the 3’-5’ exonuclease proofreading ability of the enzyme 
did not degrade the single-stranded primers. All reactions were also overlaid with 
a drop of mineral oil to prevent the mixture evaporating at the high 
temperatures, before being amplified in a TechGene thermal cycler. Each PCR 
was performed using optimised thermal cycling parameters shown in table 2.3.  
 
 
Temperature (°C) Time (minutes) 
95 1 
95                  0.5      repeated     
50                  0.5          20 
72                    1        cycles 
72 5 
4 ∞ 
 
Table 2.3 - Thermal cycling parameters for two-sided SOE-ing reactions 
 
2.4.5 - Restriction digestion of DNA 
Restriction endonucleases are used to manipulate DNA by binding specifically to 
double-stranded DNA, and cleaving it at specific sites within or adjacent to a 
particular sequence known as the recognition sequence. The cuts in the two 
strands are frequently staggered, which create single-stranded overhangs or 
sticky ends, and allow the two strands to link up by base pairing to form 
recombinant DNA in vitro [Nathans and Smith, 1975].  
 
Bam HI and Hind III restriction digests were performed on plasmid DNA, pQE-30 
vector, and the PCR gene products excised and purified from agarose gel. The 
mixture for a typical restriction digest is outlined in table 2.4.  
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Reagent Volume (µl) 
DNA 25 
10x Restriction enzyme buffer E 4 
Restriction enzyme Bam HI (10 u/µl) 2 
Restriction enzyme Hind III (10 u/µl) 2 
Sterile distilled water 7 
TOTAL VOLUME 40 
 
Table 2.4 - Reaction mix for restriction digest 
 
The mixture was incubated at 37 °C for eight hours, and the resulting gene 
fragments were excised and purified using a QIAquick gel extraction kit (section 
2.4.2.3).   
 
2.4.6 - Dephosphorylation of vector 
Following the restriction digestion of vector DNA, the 5’ phosphate group was 
removed from linear DNA molecules to reduce self-ligation in a process known as 
dephosphorylation. Phosphatase buffer was added along with 2 units of calf 
intestinal alkaline phosphatase (CIAP), a dimeric glycoprotein, and incubated at 
37 °C for 40 minutes. CIAP activity was then destroyed by incubation at 65 °C for 
20 minutes. The vector DNA was then purified using the methods of either 
phenol/chloroform extraction followed by ethanol precipitation (section 2.4.2.1) 
or by using the QIAquick nucleotide removal kit (section 2.4.2.2). 
 
2.4.7 - Ligation of gene fragment into vector 
Ligation of a segment of foreign DNA to a linearised plasmid vector involves the 
formation of new bonds between phosphate residues located at the 5’-termini of 
double-stranded DNA and adjacent 3’-hydroxyl residues [Ullrich et al., 1977].  
The formation of phosphodiester bonds between adjacent 5’-phosphate and 3’-
hydroxyl residues is catalysed in vitro by bacteriophage T4 DNA ligase 
[Zimmerman and Pheiffer, 1983].   
 
“Sticky-end” ligations were performed using 1 unit/µl T4 DNA ligase and 20-100 
ng vector DNA with varying amounts of insert DNA, as shown in table 2.5. The 
mixture transferred to a 2 litre water bath at 25 °C, and then incubated at 4 °C 
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for 16 hours. The entire ligation product was then transformed into E.coli JM103 
cells (section 2.3.3) and plated onto LB-agar plates supplemented with the 
appropriate antibiotic. 
  
Reagent Ligation 
control 
1:1 ratio  
(v:v) 
1:3 ratio  
(v:v) 
1:7 ratio 
(v:v) 
Vector 1 4 1 1 
Gene insert 0 4 3 7 
10x T4 DNA ligase buffer 1 1 1 1 
T4 DNA ligase (1 u/µl)  0.5 0.5 0.5 0.5 
Sterile distilled water 7.5 0.5 4.5 0.5 
TOTAL VOLUME 10 10 10 10 
 
Table 2.5 - Reaction mix for ligation of gene fragment into vector 
 
2.5 - Protein Analysis Techniques 
2.5.1 - Production of SpG 
2.5.1.1 - Expression of recombinant Ig-binding proteins  
One colony was grown overnight in 10 ml LB (section 2.2.1.1) containing 50 
µg/ml ampicillin at 37 °C, and 2 ml was used to inoculate a 2 litre conical flask 
containing 700 ml LB and 50 µg/ml ampicillin. Six flasks were set up and 
incubated, with shaking at 37 °C for 4-5 hours. The E.coli carrying the desired 
recombinant SpGene in the pQE-30 expression vector were induced by the 
addition of 0.6 mM isopropyl-β-D-thiogalactoside (IPTG), a non-hydrolysable 
analogue whose structure is shown in figure 2.1, into the culture medium OD600nm 
0.600–0.900.  
 
 
 
 
 
 
Figure 2.1 – A diagrammatic representation of the structure of IPTG  
 
Isopropyl-β-D-thiogalactoside (IPTG) is a synthetic artificial inducer of the lac 
operon. The lac operon in E.coli is an example of a dual control system enabling 
gene transcription to be switched on and off by gene regulation proteins. IPTG is 
used in contrast to the lac operon’s natural inducer allolactose (a minor product 
of β-galactosidase action), because IPTG cannot be hydrolysed and broken down 
in the cell by β-galactosidase [Bell and Lewis, 2000].  
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This analogue exhibits control over expression and allows cell growth to reach a 
maximum [Galloway et al., 2003] before cell resources are converted to target 
gene expression, thereby ensuring that on induction, the maximum amount of 
foreign protein is produced [Patnaik, 2001].   
 
The cultures were grown overnight with shaking at 37 °C. The cells were 
harvested by centrifugation using a Beckman, Avanti XPI centrifuge at 6,000 rpm 
at 4 °C for 20 minutes. The supernatant was discarded and the cells resuspended 
in 30 ml of sonication buffer (section 2.2.5). The cell paste was used immediately 
or stored frozen at -20 °C. 
 
2.5.1.2 - Extraction of recombinant Ig-binding proteins from E.coli  
The cells, resuspended in buffer, were transferred to a 50 ml Oakridge tube, 
where 5 mg lysozyme and 200 µl 2 mg/ml DNase I were added to hydrolyse any 
released DNA. As extracts from cell disruption may contain proteases, they need 
to be inactivated to prevent the protein from being degraded. This was achieved 
through the inhibition of proteases and the subsequent addition of 1 ml of a broad 
range protease inhibitor cocktail and 50 µl of 1 mM phenylmethanesulfonyl 
fluoride (PMSF), which targets serine proteases such as trypsin, and thiol 
proteases such as papain. After 45 minutes incubation on ice, the cells were 
placed in a 100 ml sonication vessel and salt ice water bath, and disrupted by 
sonication using an XL-2020 sonicator fitted with a ½ inch probe, for 10 
consecutive minutes of 30 seconds with 30 second intermissions at setting 
number eight. Insoluble cellular debris was removed by centrifugation at 18,000 
rpm for 30 minutes at 4 °C using a Beckman J2-21 centrifuge.  
 
2.5.1.3 - Purification of recombinant Ig-binding proteins 
The soluble cell extract was removed from the pellet and partially purified by heat 
treatment at 80 °C for 45 minutes, with occasional stirring. The insoluble 
denatured proteins were removed by centrifugation at 15,000 rpm for 20 minutes 
at 4 °C.  
 
2.5.1.4 - Anion-exchange chromatography 
The refined supernatant from the heat treatment was loaded at a rate of 1.5 
ml/min onto a 60 ml Q-Sepharose fast flow anion exchange column, pre-
equilibrated in buffer A, pH 8.0 (section 2.2.6). The Ig-binding domains of SpG 
have an isoelectric point of 4.2 [Achari et al., 1992], so the proteins will have a 
negative charge above this pH. Anion-exchange, a form of ion-exchange 
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chromatography, is therefore the most appropriate technique to use for the 
purification of SpG [Lian et al., 1992].  
 
The column was washed for 180 minutes with buffer A to remove any unbound 
proteins A, using a Bio-Rad Biologic LP system. Anion-exchange chromatography 
was then employed utilising a linear salt gradient, from 0 to 0.25 M NaCl in buffer 
B, pH 8.0 (section 2.2.6), run over 600 minutes to elute bound protein. Fractions 
of 7.5 ml were collected over 80 tubes from the elution gradient, which started 
from 100 minutes into the wash to ensure that all the desired protein was 
collected. The purification gradient was also followed by the conductivity of the 
eluting buffer B and UV (OD280nm). This provided a spectral analysis of the column 
fractions, which was used to determine the presence of SpG. 
 
10 µl of the fractions containing SpG were separated on a high-resolution 17.5% 
SDS-PAGE gel (section 2.5.3), to examine the purity of protein obtained. 
Fractions were pooled according to purity, and concentrated by an ammonium 
sulphate precipitation at the 80% saturation level (section 2.5.4). 
 
2.5.2 - Production of Fab protein 
2.5.2.1 - Expression of recombinant Fab fragments by fermentation 
To allow the interaction of SpG with Fab fragment to be studied extensively, it 
was essential that enough Fab protein was available. This was achieved by 
employing a modified pTTOD vector [Humphreys et al., 2002]. The pTTOD vector, 
kindly supplied by UCB-Celltech, Slough, had been optimised for the expression of 
Fab in E.coli. It was used to clone the wild-type Fab heavy and light chains genes, 
of known sequence, which are encoded separately in different reading frames.  
 
An extraction and purification system was devised by Dr SL Harrison and Dr AJ 
Cossins to produce large quantities of the recombinant Fab fragments using 
fermentation [Cossins, 2006]. A 2.2 L New Brunswick Scientific BioFlo 110 
Modular Benchtop Fermenter was used, with 1.5 L of SM6E media, pH 7.0, for the 
48 hour fermentation of JM103 E.coli cells containing the pTTOD vector with the 
genes for wild-type Fab. 1 mM IPTG was used to induce the cells. Dr Harrison and 
Dr Cossins provided all cell yields for this study [Cossins, 2006].  
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2.5.2.2 - Periplasmic extraction of recombinant Fab protein 
Each Fab light and heavy chain has an N-terminal ompA signal sequence, which 
targets the translated protein to the periplasm where the chains can fold and 
associate. To selectively release the periplasmic contents of the cell without 
disrupting the cytoplasmic membrane, and to minimise the amount of 
contaminating proteins in the extract, an extraction protocol based on osmotic 
shock was employed.  
 
Cells containing Fab protein were harvested from the fermenter and resuspended 
in periplasmic extraction buffer (section 2.2.7). Osmotic shock was achieved by 
using this solution, which also contained protease inhibitors to prevent 
degradation of extracted proteins and DNase I to hydrolyse any released DNA. 
The resulting cell suspension was incubated overnight at 30 °C with 200 rpm 
shaking. Following extraction, the cellular debris was removed from the cell 
suspension by centrifugation at 17,000 rpm for 20 minutes at 4 °C, to obtain the 
soluble periplasmic extract. 
 
2.5.2.3 - Purification of recombinant Fab protein 
The soluble periplasmic extract was removed from the pellet and partially purified 
by heat treatment at 60 °C for 45 minutes, with occasional stirring. The insoluble 
denatured proteins were removed by centrifugation at 17,000 rpm for 20 minutes 
at 4 °C.  
 
2.5.2.4 - Affinity chromatography using immobilised PpL 
The refined supernatant from the heat treatment was loaded at a rate of 1.5 
ml/min onto a 50 ml column of PpL bound (5 mg/ml) to NHS-Sepharose, pre-
equilibrated in buffer A, pH 8.0 (section 2.2.8). The column was washed for 
approximately five column volumes with buffer A to remove any unbound 
proteins, using a Bio-Rad Biologic LP system. Affinity bound proteins were then 
eluted with a gradient of 0-50 mM buffer B, pH 2.2 (section 2.2.8), over three 
column volumes. Fractions of 7.5 ml were collected from the elution gradient into 
tubes containing 1 ml 1 M K2HPO4, pH 9.5 to neutralise the elution buffer. The 
purification gradient was also followed by the conductivity of the eluting buffer B 
and UV (OD280nm).  
 
In addition, to obtain highly pure samples of Fab following PpL affinity 
purification, a 1 ml concentrated sample was applied to a Superdex 200 Hi-Load 
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16/60 gel filtration column, and the purified Fab collected. This was performed by 
Dr A Cossins [Cossins, 2006].  
 
10 µl of the fractions containing antibody fragments were separated on a high-
resolution non-reducing 17.5% SDS-PAGE gel (section 2.5.3), to examine the 
purity of protein obtained. Fractions were pooled according to purity, and 
concentrated by an ammonium sulphate precipitation at the 80% saturation level 
(section 2.5.4). 
 
2.5.3 - SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were routinely separated by gel electrophoresis using a discontinuous 
Tris-glycine system [Laemmli, 1970].  
 
A high-resolution separating gel containing 17.5% acrylamide was used (section 
2.2.9). SpG samples were run under reducing conditions, whereas Fab was run 
under non-reducing conditions. All gels were run in a Biometra tank at 20-30 
amps, until the bromophenol blue dye had reached the bottom. The gel was 
stained using Coomassie brilliant blue stain (section 2.2.13) for two hours, 
agitating at room temperature, and destained by diffusion into destain solution 
(section 2.2.14) until blue bands were visible against a clear background.  
 
2.5.4 - Ammonium sulphate precipitation 
An 80% ammonium sulphate precipitation was achieved by the addition of 56.1 g 
of solid ammonium sulphate per 100 ml of protein solution. The solid was added 
slowly to the protein solution and stirred constantly to distribute the salt and to 
prevent the inclusion of any unwanted proteins in the precipitate. Once 
solubilisation had been achieved, the solution was centrifuged at 15,000 rpm for 
20 minutes at 4 °C. The pellet was retained and resuspended in a minimal volume 
of 80% ammonium sulphate solution and stored at 4 °C. Prior to use, protein 
samples were dialysed overnight at 4 °C against 4 litres of the required buffer to 
remove the ammonium sulphate. 
 
2.5.5 - Estimation of protein concentration  
2.5.5.1 - Bicinchoninic assay 
Protein concentrations were estimated by spectral analysis at 280nm or a 
bicinchoninic acid (BCA) assay based on chemical principles.   
 
Impure protein samples were quantified using the BCA technique [Smith et al., 
1985]. The protein to be analysed was reacted with Cu2+ and bicinchoninic acid 
| 63  
 
resulting in the production Cu+. The Cu+ is chelated by the BCA, which converts 
the pale-green colour of the free BCA to a purple colour of the copper-BCA 
complex. The absorbance was read at 570 nm using a Dynex MX5 microtitre plate 
reader. The concentration of unknown proteins was determined using a standard 
calibration curve of varying known concentrations of BSA. 
 
2.5.5.2 - Spectrophotometric determination  
Pure protein samples were quantified using spectral analysis. The absorption 
spectra of a 50 fold diluted 1 ml protein sample was measured in a 1 ml quartz 
cuvette with a 1 cm light path in the near UV range between 240-340 nm, using a 
Hitachi U-2000 spectrophotometer. This procedure was repeated using dialysis 
buffer (section 2.2.15), and this value was subtracted from the protein sample to 
form a baseline. According to the Beer Lambert Law, the absorption of the 
solution is proportional to the molar concentration of the protein, thus by 
applying this concept, the concentration of the protein can be determined. 
Mathematically, the Beer Lambert Law can be expressed in equation 2.1. 
 
A = εCl        (equation 2.1) 
 
Where, A is absorbance, ε is molar absorptivity or extinction coefficient in 
litres/mole/cm, C is concentration in moles/litre, and l is path length of the 
sample cell in cm.  
 
The molar extinction co-efficient value for each protein was calculated from the 
amino acid sequence using values of ε280 = 1280, 5690 and 0 litre.mole-1.cm-1 for 
tyrosine, tryptophan and phenylalanine respectively [Gore, 2000]. The spectrum 
of the long UV absorbing amino acids, tryptophan, tyrosine and phenylalanine is 
presented in figure 2.2. 
 
 
 
 
 
 
 
 
Figure 2.2 – The absorption spectra of the aromatic amino acids 
 
Typical absorption spectra for the aromatic amino acids are presented. Proteins 
contain three aromatic amino acids; tryptophan, tyrosine and phenylalanine, of 
which tyrosine and tryptophan are the major absorbing species. These amino 
acids and disulphide bonds will principally absorb light in the near UV, in the 
range of 250-300nm [Weber and Teale, 1957]. 
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In addition to the absorption spectrum being used to quantify protein 
concentrations, it also provides information about certain properties of the protein 
solution, which is important in evaluating the quality of the protein. Such 
information includes the identity of dominant aromatic groups and the presence 
of aggregated protein. 
 
2.6 - Determination of protein binding 
2.6.1 - Fluorescence measurements 
All fluorescence measurements were made using a Hitachi F-2000 
spectrofluorimeter with a 150 watt xenon power supply. Slit widths were routinely 
set to 5nm, and the photomultiplier voltage to either 400 or 700 volts depending 
on the sensitivity required, and a thermally jacketed cuvette holder maintained 
the temperature at 15 °C. Protein samples were at 10 µM in 20 mM potassium 
phosphate buffer, pH 8.0 (section 2.2.15) and filtered to minimise light 
scattering. Scans were run at 60 nm/minute and excitation wavelength set at 
both 280 nm and 295 nm.   
 
All measurements were corrected, where necessary, for the inner filter effect 
using the formula in equation 2.2. 
 
Fcorr = Fobs x 10(0.5 Aex + 0.5 Aem)             (equation 2.2) 
 
Where the Aex is the absorbance of the sample measured at the excitation 
wavelength, and Aem is the absorbance at the emission wavelength. 
 
2.6.2 - Fluorescence titrations 
All titrations were performed using 1µM human Fc and aliquots of 100 µM SpG 
diluted in 20 mM potassium phosphate buffer (section 2.2.15), unless otherwise 
stated. Excitation wavelengths were kept at 280 nm or 295 nm and emission was 
measured at 340 nm. Readings were averaged and corrected for the inner filter 
effect and dilution, before they were used in subsequent calculations. 
 
2.6.3 - Stopped-Flow fluorescence spectroscopy  
All stopped-flow measurements were performed with an Applied Photophysics 
SX.17MV stopped-flow apparatus to enable fluorescence emission from the mixed 
solutions of SpG and the appropriate ligand to be observed. 2 ml drive syringes 
were used for each sample, equilibrated at either 15 °C or 25 °C unless otherwise 
stated, maintained by a Grant LTD6G circulator water bath. Protein solutions were 
prepared in 20 mM potassium phosphate buffer (sections 2.2.15) at either pH 6.0 
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or pH 8.0, which had been previously filtered and de-gassed. Studies to 
determine the effect of pH on the interaction of SpG, with both Fc and Fab, were 
performed using a triple buffer system (section 2.2.16) to buffer a wide range of 
pH. 
 
To determine the rate of association, protein solutions were mixed at a 1:1 v/v 
mixing ratio between the ligand, Fc or Fab, which was kept at a constant initial 
concentration of 1 µM and 3 µM respectively, and with initial concentrations of 
SpG proteins varying between 60 µM and 100 µM. All measurements were 
scanned at an excitation wavelength of 280 nm, and tryptophan fluorescence 
emission was measured directly with a 335 nm glass cut-off filter. The rate of 
dissociation was determined by either the competitive displacement of Fc from a 
preformed 2:1 6 µM SpG:3 µM Fc complex with buffer, or the competitive 
displacement of Fab from a preformed 1:1 3 µM SpG:3 µM Fab complex with 30 
µM non-fluorescent SpG mutant construct. 
 
Stopped flow runs were completed using the maximum rate of data sampling, 
either set to 1000 data points at lower protein concentrations, and 400 data 
points at higher protein concentrations to reduce the amount of noise. Each run 
was performed in triplicate, with data being averaged and analysed using a single 
exponential curve fitting algorithm, using equation 2.3. 
 
Ft = F0exp(-kt) + C             (equation 2.3) 
 
Where F0 and Ft are the fluorescence intensities at time 0 and time t respectively, 
k is the rate constant for the reaction and C is a constant. 
 
Data are presented as reaction progress curves, which were averaged as three 
sets of triplicate traces. 
 
2.6.4 - Isothermal Titration Calorimetry (ITC) 
ITC measurements were performed using a MicroCal VP-ITC MicroCalorimeter.  
SpG and ligands, Fc or Fab, were dialysed together overnight in 20 mM potassium 
phosphate buffer, pH 8.0 (section 2.2.15), otherwise an energy change due to 
buffer dilution will be observed. All protein solutions and buffers were degassed 
for 20 minutes prior to use. The cell was loaded with 10 µM Fc or 20 µM Fab, and 
the syringe was filled with 400-600 µM SpG, unless otherwise stated. The 
MicroCal VP-ITC system was under computer control, and a standard protocol was 
followed using an initial injection of 2 µl, preceded by varying number of 
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injections of 5-7 µl depending on the nature of the protein•ligand interaction, 
with titrations being performed at 15 °C.  All data obtained were analysed using 
the manufacturer’s Origin™ software. 
 
2.7 – Conformational Stability Determination 
2.7.1– Denaturation studies 
Denaturation studies were carried out using guanidine hydrochloride at a stock 
solution of 6 M solution in 20 mM potassium phosphate buffer (section 2.2.15), 
which was filtered prior to use. For accurate determination of guanidine 
hydrochloride concentrations after filtration, the refractive index of the solutions 
were measured and calculated using equation 2.4 [Pace et al., 1986].  
 
[Gdn-HCl] = 57.147(ΔN) + 38.68(ΔN)2 – 91.60 (ΔN)3           (equation 2.4) 
 
Where, ΔN is the difference between the refractive index of the denaturant and 
the refractive index of the buffer used.  
 
Controlled unfolding measurements were made in Gdn-HCl at increasing 
concentrations from 0-6 M. The final Gdn-HCl concentration with 10 µM SpG was 
determined by refractometry as before. The change in protein fluorescence was 
followed at an excitation wavelength of 280nm, and the fluorescence emission 
was measured at 350 nm. Each sample was pre-incubated at 15 °C for two hours 
to reach thermal equilibrium before being measured. 
 
2.7.2 - Circular Dichroism (CD) 
CD measurements were carried out using a Jasco J-720 CD spectropolarimeter.  
Spectra were measured in both the near and far UV range. Spectra in the far UV 
range, 190-250 nm, were measured in triplicate at room temperature using a 
0.01 cm light path with a scan speed of 50 nm/min. Spectra in the near UV 
range, 250-330 nm, were measured in triplicate, again at room temperature 
using a 0.5 cm light path with a scan speed of 20 nm/min. Spectra were obtained 
using protein at a concentration of 100 µM, in 20 mM potassium phosphate 
buffer, pH 8.0 (section 2.2.15), with a response time of 4 seconds, band-width of 
1.0 nm, resolution of 0.2 nm, and sensitivity between 20-50 mdeg. All data 
obtained were analysed using the manufacturer’s Standard Analysis software. 
 
Data sets shown are accumulations of nine spectral scans, adjusted for buffer 
signal, and expressed as Molar ellipticity (θ=deg.cm2.dmol-1). 
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3.1 - Introduction 
The aim of this research is to study a single Ig-binding domain of SpG, which was based 
on the sequence for SpGC2-1 designed by Walker [Walker, 1994], a hybrid of the C-
terminus of the C1 domain and the N-terminus of the C3 domain. Specific amino acid 
residues that contribute to the Fc or Fab binding interactions via a network of hydrogen 
bonds were identified and studied by a programme of site-directed mutagenesis. This 
allowed information on the importance of these individual amino acids in the encoded 
protein to be obtained, the key residues that are critical for these interactions to be 
identified and the contribution of a specific amino acid residue to the biological function 
of SpG to be evaluated. To achieve these objectives, both currently available and new 
mutant constructs of D-SpGC2-1 were used to alter the Fc and Fab binding affinities from 
that of the wild-type protein.  
 
3.2 - Mutagenesis 
Mutagenesis is the alteration of a DNA sequence by specific chemical or enzymatic 
methods, and is a fundamentally important DNA technology. DNA mutagenesis is used in 
many applications, such as DNA structural analysis, protein expression studies and 
structure-function relationships in cloned gene products. Cloned genes allow 
mutagenesis to be much more precise by replacing specific bases in a gene, or specific 
amino acids at selected sites in the protein.  
 
3.2.1 - PCR-based site-directed mutagenesis  
3.2.1.1 - The polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a relatively new and versatile in vitro technique 
for amplifying defined target DNA sequences present within a source of 
DNA. Since the first reports describing this technology in the mid 1980s, there have 
been numerous applications in both basic and clinical research, including fundamental 
technologies such as DNA sequencing and mutagenesis, both of which can be 
accomplished using PCR-based methods.  
 
A schematic representation of PCR is shown in figure 3.1. The template DNA is first 
denatured by heating, at approximately 94 °C, in the presence of a large molar excess of 
each of the two primers and DNA precursors, the four deoxynucleoside triphosphates 
(dNTPs) dATP, dCTP, dGTP and dTTP. The primers move around by Brownian motion, 
which results in hydrogen bonds being constantly formed and broken between them and 
the single-stranded template. They bind specifically to complementary DNA sequences at 
the target site and initiate the synthesis of new DNA strands, which are complementary 
to the individual DNA strands of the target DNA segment, and which overlap each other. 
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The sequence of the primers that complement the template exactly are more stable, and 
on this small section of double-stranded DNA (made up of the template DNA and 
primer), the DNA polymerase can attach and start copying the template. Once there are 
a few bases copied, the stability of the primer-template complex is so strong between 
the template and the primer that it no longer breaks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cycle 1:  
Cycle 3:  
Extension at 72 °C 
 
Cycle 2:  
Annealing between 35-55 °C 
 
 
Denaturation at 94 °C 
 
 
Figure 3.1 - An adapted schematic representation of PCR 
 
There are three major steps in a PCR, which are repeated for approximately 30-40 
cycles. During denaturation, at 94 °C, the double-stranded DNA melts open to two 
strands of single-stranded DNA. During annealing, at approximately 54 °C, the primers 
are moving around and bind specifically to complementary DNA sequences at the target 
site. The synthesis of new DNA strands is initiated and the DNA polymerase attaches and 
starts copying the template. The polymerase adds dNTPs from 5' to 3', reading the 
template from 3' to 5' side, and bases that are complementary to the template DNA are 
coupled to the primer on the 3' side [Ban, 2006].  
The reaction is then cooled to a temperature (between 35 °C and 55 °C) that allows the 
primers to anneal to their target sequences, after which the annealed primers are 
extended with DNA polymerase at approximately 72 °C, the ideal working temperature 
for the polymerase. The bases that are complementary to the template DNA are coupled 
to the primer on the 3' side, as the polymerase adds dNTPs from 5' to 3', reading the 
template from 3' to 5' side.  
The expected product of this reaction is a segment of double-stranded DNA and is 
produced at the end of the second cycle. It is identified by the 5’ termini of the 
oligonucleotides primers, and its length is defined by the distance between the primers. 
The product is then amplified in every subsequent cycle of denaturation, annealing and 
DNA synthesis, with the products of one cycle of amplification serving as a template for 
the next. This allows each successive cycle to double the amount of desired DNA product 
[Erlich et al., 1988], leading to an exponential increase in product. 
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 3.2.1.2 - PCR-based mutagenesis 
The polymerase chain reaction has proven to be particularly useful for a wide range of 
mutation procedures and applications, and PCR mutagenesis procedures make it possible 
to modify and engineer any target DNA sequence. 
 
To permit the selective amplification of a specific target DNA sequence within a 
heterogeneous collection of DNA sequences, some prior DNA sequence information from 
the target sequence is required. This information is used to design two mutagenic 
oligonucleotide primers, which are often about 15 25 nucleotides long and specific for 
the target sequence. The sequence of these primers is perfectly complementary to the 
gene sequence in the region to be mutated, but with a single codon difference at the 
intended mutation site. This difference is complementary to the desired mutant 
nucleotide sequence rather than the original, which leads to the replication of a certain 
region, and allows for insertions, deletions or point mutations in the gene of interest.  
 
Two further oligonucleotides are used as primers and have different complementary 
sequences that anneal on the opposite strands of the template DNA, and flank the 
segment of DNA to be amplified. New DNA synthesis is achieved in a series of synthetic 
reactions that are catalysed by a thermostable DNA polymerase [Saiki et al., 1988], to 
create a complementary full-length sequence containing the desired mutation. The newly 
formed heteroduplex is then used to transform cells, and the desired mutant genes can 
be identified by screening for the mutation. 
 
3.2.2 - PCR-based site-directed mutagenesis using splicing by overlap 
extension  
 
PCR-based site-directed mutagenesis using the principles of Splicing by Overlap 
Extension (SOE-ing) [Ho et al., 1989] was employed for this research for the deletion 
and insertion of sequences, as well as introducing point mutations into the SpG gene. 
Two-sided SOE-ing is a sequence-independent method for site-directed mutagenesis. It 
is based on the idea that a PCR product can be engineered by adding or changing 
sequences at its ends, so that the product itself can be used to prime DNA synthesis in a 
subsequent overlap extension reaction to create mutant or recombinant molecules 
[Horton, 1995].  
 
3.2.2.1 - Mis-match primers 
PCR based site-directed mutagenesis using splicing by overlap extension (see section 
2.4.4.2) was employed to mutate the proposed Fc and Fab residues. SOE-ing requires 
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the use of two successive polymerase chain reactions and four primers; two flanking 
primers and two mutagenic primers. The two flanking primers, A and B, were designed 
to anneal to a region outside the gene to include any restriction digest site, whereas the 
mutagenic primers were designed to anneal to the gene to introduce the desired 
mutation. This results in an amplified product with a specific pre-determined mutation of 
choice located in a central segment. This is illustrated below in figure 3.2. 
 
 
 
 
 
 
 
Flanking 
Primer A 
5’ 
   3’ 
 8 bases 
 8 bases  16 bases 
 16 bases 
Mutagenic  
Primer C 
Oligo#2 
Mutagenic 
Primer D 
Oligo#1 
 Flanking 
 Primer B 
3’ 
5’ 
 
Figure 3.2 – An adapted schematic diagram of mis-match primer design 
 
Oligonucleotide primers were 27 bases in length with the mis-match codon for each 
designated mutant central to the primer, illustrated by the grey rectangle. 
 
All oligonucleotide primers were approximately 27 nucleotide bases in length, unless 
otherwise stated, and the mis-match mutation within the primer was placed at a unique 
site. The upper strand mutagenic primer, primer C, was ordered as oligo#2 and the 
central mis-match codon was flanked on its 5’ side by 8 bases and by 16 bases on its 3’ 
side, complimentary in sequence to the template DNA. The lower strand mutagenic 
primer, primer D, was ordered as oligo#1, and again the mutation mis-match codon was 
central, flanked on its 5’ side by 8 bases and by 16 bases on its 3’ side anti-sense in 
sequence to the template DNA.  
 
By employing a primer design and sequence alignment software program, DNA Star, all 
primer sequences were studied for dimer and hairpin formation. The 27 nucleotide 
primer was sufficient to ensure site-specific annealing of the primer to the template DNA. 
All primers were produced in the 5’ to 3’ orientation, allowing them to bind to the DNA 
template produced in the cloning vector.   
 
3.2.2.2 - Pfu DNA polymerase 
Pfu DNA polymerase is a thermostable enzyme found in the hyperthermophilic 
Pyrococcus furiosus [Lundberg et al., 1991], where it functions in vivo to replicate the 
organism's DNA. Pfu DNA polymerase was employed during this research to catalyse the 
polymerisation of nucleotides into double-stranded DNA, in the 5’ to 3’ direction, during 
each extension step in all PCR performed. 
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The main difference between Pfu and alternative thermostable DNA polymerases, such 
as Taq [Eckert and Kunkel, 1990], is Pfu's thermostability and 'proofreading' properties. 
Unlike Taq, Pfu possesses 3’ to 5’ exonuclease proofreading activity, which corrects 
nucleotide-misincorporation errors as it works its way along the DNA from the 3’ to the 
5’ end. This means that Pfu DNA polymerase-generated PCR fragments comprise of 
fewer errors than Taq-generated PCR inserts [Cline et al., 1996]. It is recommended for 
use in PCR and primer extension reactions that require high fidelity. 
 
3.2.2.3 - SOE-ing PCR  
SOE-ing involves two successive series of PCR. The first PCR involves two parallel 
reactions, PCR 1 and 2, which leads to the initial amplification of two over-lapping 
segments of DNA containing an introduced mutation. The two mutagenic primers 
incorporate the desired nucleotide changes at the mutation site, and the generated 
fragments have a 5’-terminal overlap, as illustrated in figure 3.3. 
 
The product fragments, AD and BC, may vary in size depending on the position of the 
mutation in the gene, and are purified to remove the original primers. The purified 
amplified fragments are then combined in a subsequent 1:1 (mol:mol) ratio fusion 
reaction, PCR 3, in which the overlapping ends are denatured and allowed to reanneal. 
This allows the DNA polymerase Pfu to extend the 3’ end of each strand with recessed 
ends to serve as a primer for the 3’ extension of the complementary strand. Thereafter, 
the resulting full length fusion product with the introduced mutation in a central segment 
can be further amplified by PCR using the outer primers A and B only [Ho et al., 1989]. 
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Flanking 
Primer B 
 
(4)  
 
  3’ 5’  
 Final mutant fusion product 
 
Figure 3.3 - An adapted schematic diagram of PCR-based site-directed mutagenesis by 
overlap extension 
 
Modified two sided splicing by overlap extension SOE-ing method of site-directed 
mutagenesis is presented. (1) Primers A and D are used to amplify the template to 
produce the product AD. (2) Primers B and C are used to produce product BC. (3) AD and 
BC are combined in a new PCR with primers A and B. (4) A final fragment is produced, 
which has the desired mutations encoded in primers C and D. The initial double-stranded 
DNA is represented by a red rectangle; synthetic primers are represented by lines with 
arrows indicating the 5’ to 3’ orientation; the site of mutagenesis is represented by a 
small grey rectangle; and PCR products are represented by blue and green rectangles 
[Ho et al., 1989].   
 
3.3 - Construction of the gene for SpGC2-1  
3.3.1 - Gene manipulation  
A synthetic gene encoding a single Ig-binding domain was constructed from chemically 
synthesised oligonucleotides and placed in an appropriate plasmid vector, PKK223-3, to 
direct expression in E.coli [Walker, 1994]. This 208 bp       Ig-binding domain gene was 
originally based on the sequence for the C2 domain [Goward et al., 1990], which is a 
hybrid of the C-terminus of the C1 domain and the N-terminus of the C3 domain created 
by gene duplication, mutation and recombination [Olsson et al., 1987]. Alterations were 
made to the 3’ end of the SpGC2 gene, which included three stop codons to ensure 
effective termination of transcription at the end of the gene, an additional six residues 
(residues MTPAVS) were incorporated at the N-terminus to facilitate cloning and 
expression and a     C-terminal cysteine was introduced for possible immobilisation onto 
Sepharose to create an IgG purification column [Walker, 1994]. Figures 3.5 and 3.7 
present the entire nucleotide sequence for the SpGC2-1 gene, together with the amino 
acid sequence it encodes.  
3.3.2 - Expression vectors of SpGC2-1 gene 
3.3.2.1 - Expression vector PKK223-3 
The expression vector PKK223-3, presented in figure 3.4, was initially chosen for the 
expression of the SpGC2-1 gene. It provides transcriptional control via the strong tac 
promoter, which is upstream from the multiple cloning site (MCS), and the strong rrnB 
ribosomal terminator downstream for control of protein expression. rrnB transcription 
terminators stabilise the plasmid by inhibiting read-through transcription initiated from 
the tac promoter in the parent plasmid. The tac promoter is a hybrid of the lac and trp 
promoter sequences, and is stronger than either. This sequence is recognised and bound 
by the lac repressor, which prevents the initiation of downstream DNA by E.coli 
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polymerase. Repression is alleviated by a non-hydrolysable analogue, such as isopropyl-
β-D-thiogalactoside (IPTG), which binds to the repressor preventing it binding to the 
promoter [Bell and Lewis, 2000]. In order for the synthetic gene to be expressed 
directly, translation initiation elements, that were originally provided by the DNaseI gene 
sequence [Worrall and Connolly, 1990] as with the expression of other Ig-binding 
proteins, had to be introduced.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 – A schematic representation of expression plasmid vector PKK223-3 
 
The expression plasmid vector, PKK223-3, was used to over express SpG from a cloned 
gene in E.coli. This is achieved by the presence of a strong tac promoter upstream from 
the MCS and the strong rrnB ribosomal terminator downstream for control of protein 
expression.   
 
Direct expression was achieved using synthetic linkers constructed from the Shine-
Dalgarno site from the DNaseI sequence. This sequence has already been incorporated 
into the PKK223-3 vector in an AP07-2 construct for the direct expression of SpA 
[Popplewell, 1991], and was adapted for the SpG gene. A linker sequence was designed 
to encode six amino acids before the start of the C2 domain as found in the native linker 
of SpG. The sequence chosen is adapted from that used by Lian [Lian et al., 1992], and 
exchanges a methionine for the native leucine as the first amino acid, providing the 
codon required for the initiation of translation. The synthetic gene for the single Ig-
binding domain of SpG was renamed D-SpGC2-1.  
 
             EcoR1                      Sacl   Ncol(blocked) 
    PKK vector ------  ** *** **        ------------- Linker 
5’  gaa aca gaa ttc gat ttc tag gag gtg agc tcc atg act ccg gct gtt 
3’  ctt tgt ctt aag cta aag atc ctc cac tcg agg tac tga ggc cga caa 
                                                Met Thr Pro Ala Val 
     Kpnl(blocked)                                 1   2   3   4   5 
     ------ Domain 1     
    agt acc tac aaa ctg gtt atc aac ggt aaa acc ctg aaa ggt gaa acc 
    tca tgg atg ttt gac caa tag ttg cca ttt tgg gac ttt cca ctt tgg 
    Ser Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly Glu Thr 
     6   7   8   9  10  11  12  13  14  15  16  17  18  19  20   21    
 
    acc acc gaa gct gtt gac gct gct acc gct gaa aaa gtt ttc aaa cag 
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    tgg tgg ctt cga caa ctg cga cga tgg cga ctt ttt caa agg ttt gtc 
    Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln 
    22  23  24  25  26  27  28  29  30  31  32  33  34  35   36 37 
 
    tac gct aac gac aac ggt gtc gac ggt gaa tgg acc tac gac gac gct 
    atg cga ttg ctg ttg cca cag ctg cca ctt acc tgg atg ctg ctg cga 
    Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala 
    38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  
 
           Bst Ell                               Pstl Hind lll 
          ---------                     --------  ----- 
    acc aaa acc ttc acg gtt acc gaa tgc taa tag tga ctg cag cca agc 
    tgg ttt tgg aag tgc caa tgg ctt acg att atc act gac gtc ggt tcg 
    Thr Lys Thr Phe Thr Val Thr Glu Cys *** *** *** 
    54  55  56  57  58  59  60  61  62 
            
    --        PKK223-3 vector 
    ttc tgt ttt ggc gga tga 3’ 
    aag aca aaa ccg cct act 5’ 
         
Figure 3.5 - Nucleotide sequence for the wild-type synthetic gene D-SpGC2-1 coding for a 
single Ig-binding domain based on SpG in PKK223-3 vector 
 
The entire nucleotide sequence for wild-type D-SpGC2-1 gene, together with the amino 
acid sequence it encodes is presented in PKK223-3 vector. Red bases denote the vector 
PKK223-3 sequence; black bases signify the wild-type D-SpGC2-1 gene sequence; blue 
bases indicate the position of restriction sites within the sequence; pink bases denote 
the linker sequence; purple bases signify blocked cloning site; *** *** represents the 
Shine-Dalgarno site; and *** *** represents the stop codons.  
 
3.3.2.2 - Expression vector pQE-30 
The successful expression and purification of the gene construct is required to effectively 
achieve the aims of this research. However, despite repeating the identical induction 
conditions stated by Walker [Walker, 1994], expression levels of D-SpGC2-1 dropped 
considerably since the time that the construct was made. Many attempts were made to 
rectify this problem, which was eventually overcome by the successful cloning of the D-
SpGC2-1 gene into the N-terminal 6xHis tagged pQE-30 over-expression vector, with high 
levels of expression of the 6xHis-tagged           D-SpGC2-1 protein being achieved. Figure 
3.6 presents an adapted schematic diagram of the pQE-30 over-expression vector. At pH 
8.0, the His tag is small, largely uncharged, and therefore, does not affect secretion, 
compartmentalisation or folding of the fusion protein within the cell. Later studies show 
that the presence of the 6xHis tag does not interfere with the structure or function of the 
purified protein, and also allows the immobilisation of the protein on metal-chelating 
surfaces for protein interaction studies.    
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Figure 3.6 - An adapted schematic representation of the 6xHis-tagged pQE-30 over-
expression vector 
 
A high-level expression of 6xHis-tagged proteins can be achieved in E.coli using the 
QIAexpress pQE-30 vector. The vector has been N-terminally tagged with 6 consecutive 
histidine residues (6xHis tag). The 0SpGC2-1 gene was cloned into the vector at the 
restriction sites Bam HI and Hind III, such that there are no additional residues 
introduced between the RGS-His tag and the start of the protein sequence [Qiagen]. 
  
3.3.2.3 - Sub-cloning D-SpGC2-1 gene into pQE-30 vector 
PCR and restriction enzyme digests were used to clone the gene constructs into the 
6xHis tagged pQE-30 expression vector, as previously described in section 2.4.4.2 and 
2.4.5 respectively. Bam HI and Hind III restriction sites were introduced at the start and 
end of the D-SpGC2-1 genes respectively, by PCR using specifically designed 
oligonucleotide primers.   
 
Bam HI and Hind III restriction enzyme digests were then performed on the PCR gene 
products obtained and the 6xHis tagged pQE-30 vector, as shown in figure 3.8, and the 
appropriate fragments excised and extracted from agarose gel (section 2.4.2.3). The 
pQE-30 vector was dephosphorylated to prevent self-ligation (section 2.4.6). Various 
ligation mixtures were set up, with appropriate controls, to give final vector: insert µl 
ratios of 1:1, 1:3 and 1:7. The ligation control grew no colonies, and the ligation ratios 
grew between 50 to 100 colonies for all gene constructs. This ratio difference was high 
enough to be certain that the ligation had been successful. Ligation products were 
transformed into E.coli JM103 cells (section 2.4.7) and used to produce plasmid DNA.  
 
       pQE-30 vector       * *** ***                            -------                      
 5’  aca gaa ttc att aaa gag gag aaa tta act atg aga gga tcg cat cac  
 3’  tgt ctt aag taa aat tga ctc ttt aat tga tac tct cct agc gta gtg 
                                           Met Arg Gly Ser His His                      
                                  
                  6X HIS TAG         BamH 1                                                        
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    --------------- -------                                                     Domain 1 starts 
    cat cac cat cac gga tcc acc ccg gct gtt acc ggt acc tac aaa ctg 
    gta gtg gta gtg cct agg tga ggc cga caa tgg cca tgg atg ttt gac 
    His His His His Gly Ser Thr Pro Ala Val Thr Gly Thr Tyr Lys Leu 
                                                     1   2   3   4 
               
    gtt atc aac ggt aaa acc ctg aaa ggt gaa acc acc acc gaa gct gtt 
    caa tag ttg cca ttt tgg gac ttt cca ctt tgg tgg tgg ctt cga caa 
    Val Ile Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val 
     5   6   7   8   9  10  11  12  13  14  15  16  17  18  19  20   
 
    gac gct gct acc gct gaa aaa gtt ttc aaa cag tac gct aac gac aac 
    ctg cga cga tgg cga ctt ttt caa agg ttt gtc atg cga ttg ctg ttg 
    Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn 
    21  22  23  24  25  26  27  28  29  30  31  32  33  34  35   36   
                                                      - 
    ggt gtc gac ggt gaa tgg acc tac gac gac gct acc aaa acc ttc acg 
    cca cag ctg cca ctt acc tgg atg ctg ctg cga tgg ttt tgg aag tgc 
    Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr 
    37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52   
 
 Bst Ell                                                  HindIII                                 ----
---                     -------                 pQE-30 vector 
    gtt acc gaa tgc taa tag tga aag ctt aat tag ctg agc ttg gac tcc 3’  
    caa tgg ctt acg att atc act ttc gaa tta atc gac tcg aac ctg agg 5’ 
    Val Thr Glu Cys *** *** *** 
    53  54  55  56      
 
Figure 3.7 - Nucleotide sequence for the wild-type synthetic gene D-SpGC2-1     coding for 
a single Ig-binding domain based on SpG in pQE-30 vector  
 
The entire nucleotide sequence for wild-type D-SpGc2-1 gene, together with the amino 
acid sequence it encodes is presented. Red bases denote the vector pQE30-1 sequence; 
black bases signify the wild-type D-SpGc2-1 gene sequence; blue bases indicate the 
position of restriction sites within the sequence; * *** *** represents the Shine-
Dalgarno site; and *** *** *** represents the stop codons.  
 
The D-SpGC2-1 constructs were then sequenced to check that the sequences have been 
correctly inserted into the pQE-30 vector at the designated restriction sites. To be 
certain of the insertion of the genes into the pQE-30 plasmid vector, an analytical 
restriction enzyme digest was also performed on three samples of plasmid DNA for each 
gene construct, prepared as described in section 2.4.5. Figure 3.8 presents 2% agarose 
gels illustrating the 208 bp gene fragment successfully released from the pQE-30 
plasmid vector, indicating that the            D-SpGC2-1 genes had been successfully 
inserted into the 6xHis tagged pQE-30 vector. 
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 WT D-SpGC2-1  
pQE-30 vector          
 pQE-30 vector      
 uncut  
DNA  
 B/H cut 
DNA  1000 bp  
100 bp 
ladder  500 bp  
  
Figure 3.8 - Two 2% agarose gels illustrating the successful cloning of wild-type D-
SpGC2-1 genes into pQE-30 vector  
 
These two 2% agarose gels illustrate Bam HI and Hind III restriction enzyme digests 
performed on both the 6xHis tagged pQE-30 vector (first gel) and wild-type D-SpGC2-1 
pQE-30 DNA (second gel).  
 
3.3.2.4 - Gene nomenclature 
Several groups have reported complete or partial DNA sequences for the gene for SpG in 
their research [Guss et al., 1986; Fahnestock et al., 1986; Olsson et al., 1987; Goward 
et al., 1990; Lian et al., 1991 and 1994; Gronenborn et al., 1993 and 1996; Sauer-
Eriksson et al., 1995; Derrick et al., 1999], all of which employ various numbering 
systems. The exclusive tryptophan residue in the amino acid sequence is used to 
compare these different nomenclatures.  
 
The work of Walker [Walker, 1994] on SpG, uses the same nomenclature employed by 
Lian et al [Lian et al., 1991 and 1994] and Derrick et al [Derrick et al., 1999] in which 
the tryptophan residue is number 48 (W48) in the sequence. This is also the same 
nomenclature presented in figure 3.5, which shows the SpG sequence cloned into the 
PKK223-3 vector that was initially chosen for the expression of the         D-SpGC2-1 
gene.  
 
Gronenborn et al., [1993 and 1996], who studied the X-ray structure of the B1 domain 
in complex with Fc, and Sauer-Eriksson et al., [1995] who identified key residues of the 
C2 domain in complex with Fc, have both published research using another 
nomenclature, where the tryptophan residue is number 43 (W43) in the sequence.   
 
However, in comparison, the gene sequences previously published by Fahnstock et al., 
[1986] who isolated a two IgG-binding domain SpG and labelled the domains B1 and B2, 
and Guss et al., [1986] who isolated a three IgG-binding domain SpG and labelled the 
domains C1, C2 and C3, employ a different numbering system. A comparison of the 
nucleotide sequences for the three Ig-binding C domains of SpG isolated by Guss et al is 
208 bp  
gene 
fragment 
1000 bp  
200 bp  
 500 bp  
100 bp 
ladder 
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presented in figure 3.9.  
 
  
  W42 
 
Figure 3.9 - A comparison of nucleotide sequences for the three Ig-binding C domains of 
wild-type SpG  
 
A comparison of the nucleotide sequences for the three Ig-binding C domains of wild-
type SpG, together with the amino acid sequence it encodes is presented. The sequences 
are aligned to achieve maximum homology and the comparison is based on the C1 
domain. Identical triplets are indicated with a bar and altered nucleotide triplets, which 
do not alter the amino acid, are marked with an asterisk. Tryptophan residue number 42 
is highlighted in red [Guss et al., 1986].   
 
The C2 domain of SpG is a hybrid of the C1 and C3 domains, and the gene sequence of 
this domain, cloned into the pQE-30 expression vector, was used throughout this 
research. This particular sequence of amino acids, presented in figure 3.7, corresponds 
to the same nomenclature proposed by Guss et al and Fahnestock et al, where the 
tryptophan residue is number 42 (W42) in the sequence.  
 
 
 
 
3.4 - Construction of D-SpGC2-1 mutants 
 
3.4.1 - Rationale of choosing specific D-SpGC2-1 Fc and Fab mutants 
The C domain of SpG has two main attributes. Firstly, its ability to bind IgG non-
immunogenically via the interaction with both Fc and Fab regions, and secondly, it’s 
unique and stable folded structure. Studies determining any differences in both binding 
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and stability were initially achieved by site-directed mutagenesis. By introducing site-
directed changes at specific positions in the protein sequence, it is possible to test 
hypotheses about protein stability and function. The amino acid residues that were 
chosen for mutation were selected for their possible involvement in each of SpG’s 
characteristics.  
 
3.4.1.1 - Studying the effect of mutagenesis on the binding of SpG 
A single Ig-binding domain of SpG has been shown to bind to the Fc portion of IgG 
[Gronenborn et al., 1993; Sauer-Eriksson et al., 1995], and also to the Fab portion 
[Derrick and Wigley, 1992; Lian et al, 1994; Derrick and Wigley, 1994]. It is possible to 
make a direct comparison of the binding of SpG to these fragments of IgG. In the 
complex with Fab, the second strand of the β-sheet plays a major role in the interaction, 
together with the loop at the loop at the carboxyl-terminal end of the helix. In contrast, 
the regions most affected by the binding of Fc are the helix, the third strand of the β-
sheet, and the intervening loop, illustrated in figure 3.10. 
 
 COOH 
 β-strand 2 β-strand 3 
α-helix 
NH2 
 
Figure 3.10 − A ribbon representation of SpG indicating both Fc and Fab binding regions 
 
Specific amino-acid residues that contribute to both Fc and Fab binding interactions 
have been identified. The Fc binding region, α-helix and β-strand 3, is shown in red; the 
Fab binding region, α-helix and β-strand 2, is shown in blue. 
It is therefore clear, that SpG binds quite differently to the constant domains in Fab and 
Fc, and binds edge-on to the CH1 domain of Fab [Derrick and Wigley, 1992] rather than 
in a cleft between CH2 and CH3 of Fc [Diesenhofer, 1981]. It is particularly notable that a 
small protein of just 56 residues is able to recognise two different protein surfaces 
specifically. This is achieved by the two almost completely non-overlapping sets of 
residues on its surface.  
 
Mutagenesis of the key residues in D-SpGC2-1, that are critical for both interactions, will 
identify the contribution of a specific amino acid to the biological function of this domain.  
 
3.4.1.2 - Studying the effect of mutagenesis on the stability of SpG 
The principal stabilising element in all globular proteins is the hydrophobic core, the 
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group of hydrophobic residues that is shielded from solvent in the native state structure 
[Northey et al., 2002]. The role and packing of residues in the hydrophobic core has 
been shown to be important for the structure and stability of a variety of proteins [Kellis 
et al., 1989; Eriksson et al., 1992; Richards and Lim, 1993; Munson et al., 1996].  
 
The C2 Ig-binding domain of SpG, upon which the D-SpGC2-1 gene is based, is a very 
stable, small protein, with a large proportion of its residues (95%) being involved in its 
ordered secondary structure or forming part of the hydrophobic core. The involvement of 
nearly all of the residues in the regular secondary structure ensures that a large number 
of hydrogen bonds stabilise the protein, with over 70% of amide nitrogen and carbonyl 
oxygen atoms participating in hydrogen bonds. This large number of hydrogen bonds 
includes 44 backbone to backbone, 9 backbone to side chain and 5 side-chains to side-
chain interactions [Achari et al., 1992]. When SpG is complexed with Fc and Fab, the 
hydrogen bond network is continued, and stabilises these interactions.  
 
The stability of the C2 domain of SpG can also be attributed to its unique folded 
structure, which renders it unusually stable without disulphide bridges, and the 
hydrophobic core, which is formed by the four-stranded β-sheet and the four-turn α-
helix. This structure results in a very tightly packed hydrophobic core, which comprises 
of 16 amino acid side chains. These include Tyr2, Leu4, Ile6, Gly8, Leu11, Thr15, Thr17, 
Val25, Phe29, Tyr32, Ala33, Val38, Trp42, Tyr44, Phe51 and Val53, with six of these 
residues possessing hydrogen-bonding capabilities [Achari et al., 1992]. This is 
illustrated in figure 3.11. 
Specific amino acid residues that have been shown to contribute to the stability of SpG’s 
interaction with Fc and Fab via an extensive network of hydrogen bonds were also 
studied by a programme of site-directed mutagenesis. 
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Figure 3.11 – Ribbon representations of the hydrophobic core of an Ig-binding domain of 
SpG  
 
The three-dimensional structure of a single Ig-binding domain of SpG is presented, 
illustrating the very tightly packed hydrophobic core. The hydrophobic core lies between 
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the β-sheet and the α-helix, and includes 16 amino acid side chains [Achari et al., 1992].  
 
3.4.2 - Molecular modelling 
By employing molecular modelling, via DeepView – Swiss Protein Data Bank (PDB) 
Viewer, the proposed D-SpGC2-1 mutants implicated in both Fc and Fab interactions were 
studied. This was to minimise potentially disruptive amino acid substitutions, particularly 
those that could affect the secondary structure and conformational stability of SpG. Ray-
traced quality images of the molecular structures, generated from DeepView - Swiss-
PDBViewer, were achieved using Persistence Vision POV-Ray.  
 
When creating a mutant protein, the effect on stability should be monitored, as changes 
in affinity and activity can result from the deformation of secondary and tertiary 
structure, which is not always due to the direct involvement from the substituted amino 
acid side chain. When performing site-directed mutagenesis, it is important to consider 
these structural implications, together with the size and polarity of the amino acid side-
chains. Substitutions are normally made as conservative as possible, and involve 
introducing small amino acid side-chains as they are more easily accommodated into the 
structure [Chou et al., 1974].  
 
It should also be noted that when mutating a small protein such as SpG, residues 
forming the hydrophobic core should be packed tightly together with no steric overlaps 
or spaces. Studies have revealed that amino acids may have a particular propensity for 
secondary structure over another [Chou and Fasman, 1974]. This consideration must be 
taken into account when considering the substitution, as well as size and polarity of the 
side-chains.  
 
3.4.3 - Sequencing of D-SpGC2-1 mutant constructs 
All D-SpGC2-1 mutant constructs were checked to ensure that the sequences contained 
the mutated amino acids and had been correctly inserted into the pQE-30 vector at the 
designated restriction sites, and this was accomplished by dideoxynucleotide sequencing, 
performed by MWG-Biotech. 
 
This chain termination technique utilises fluorescently labelled 2’,3’-dideoxynucleotide 
triphosphates (ddNTPs - ddATP, ddCTP, ddGTP and ddTTP), which are  added to the 
reaction in addition to deoxynucleotides (dNTPs). DNA extension will occur as normal, as 
in PCR, until the DNA polymerase randomly incorporates a fluorescently labelled ddNTP 
(see figure 3.12). Therefore, once a ddNTP is incorporated into the newly synthesised 
DNA strand, it can no longer be elongated due to the absence of the 3’-OH group. This 
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leads to the termination of the reaction because it cannot form a phosphodiester bond 
with the next deoxynucleotide.  
 
 
Figure 3.12 - An adapted illustration of the formula for a dNTP and a ddNTP 
 
The formula for a deoxynucleotide (dNTP) is shown on the left and the formula for a 
dideoxynucleotide (ddNTP) on the right. The ddNTP has a hydrogen atom at the 3’ 
carbon in the place of the -OH group as with the dNTP [Lander et al., 2001]. 
 
The sequences of the samples can then be ascertained by separating out the DNA 
fragments by size on a polyacrylamide gel, and establishing the last ddNTP that was 
incorporated into the strand, as each fragment being one base longer than the previous 
[Lander et al., 2001]. Sequencing software is then applied to analyse the DNA sequence. 
 
 
 
 
 
3.5 - Construction of D-SpGC2-1 Fc binding mutants 
In order to study the various amino acids involved in the interaction of D-SpGC2-1 with 
Fc, and any changes in the structure of SpG that may occur on formation of the 
complex, key amino acid residues, identified in both the major and minor regions of 
contact with the Fc CH2 and CH3 domains, were chosen for mutation. Mutations in 
corresponding positions to these residues and neighbouring residues were also 
considered. This complex is stabilised through a network of hydrogen bonds, and the 
importance and effect of these bonds to the stability and nature of the complex by 
removing these key residues was to be investigated.   
 
3.5.1 - Selection of a suitable template for Fc mutants 
The selection of a suitable template DNA to be used in the PCR for the proposed mutants 
was considered. To enable Fc binding to SpG to be studied, the wild type D-SpGC2-1 
pQE-30 template DNA was used. The wild-type template contains a unique tryptophan at 
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position 42 on β-strand 3, which was employed to report binding, as shown in figure 
3.13.  
 
  
β-strand 3 
W42 
 β3 
SpG 
Fc fragment  
CH2    COOH 
 W42 
 
NH2 
CH3 
Figure 3.13 – Ribbon representations of an Ig-binding domain SpG illustrating the 
position of W42 residue and its involvement in the interaction with Fc 
 
The three-dimensional structure of a single Ig-binding domain of SpG is presented in the 
first figure, illustrating the position of tryptophan 42 (W42) on β-strand 3. In complex 
with Fc, presented in the second figure, SpG binds the hinge region at the CH2-CH3 
interface of the Fc fragment. The interaction site predominantly involves β-strand 3 of 
SpG, with important contact residues including tryptophan 42 (W42), which was 
employed to report binding [Walker et al., 1995]. 
 
 
 
 
 
 
3.5.2 - Selection of Fc contact residues for mutation 
Various IgG-binding domains of SpG have been shown to bind Fc at the hinge region 
that connects the CH2 and CH3 domains, and the contact regions of this complex have 
been identified [Gronenborn et al., 1991; Achari et al., 1992; Sauer-Eriksson et al., 
1995]. Results show that the interaction site with Fc lies within     C-terminal part of the 
α-helix, the N-terminal part of β-strand 3, and the extended loop region connecting 
these two structures.  
 
There are three residues of the CH2 domain of Fc, which are involved in the interfacial 
interactions, namely Ile253, Ser254 and Gln311. In the CH3 domain, there are two areas 
which contribute to the interface, namely Glu380 and Glu382 and the residues His433 to 
Gln438 [Sauer-Eriksson et al., 1995]. These residues that interact with SpG are situated 
within loop regions of Fc. The residues in SpG that interact with Fc have been identified 
as Glu26, Lys27, Lys30, Gln31, Asn34, Asp39, Glu41 and Trp42. The nature of these 
interfacial interactions between Fc and SpG consists of a network of hydrogen bonds and 
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salt links, involving mainly charged and polar residues. It was decided to mutate a 
selection of these residues from both the major and minor contact regions, namely 
residues Glu26, Lys27, Gln31, Asn34, Glu41 and Trp42. An overview of the position of 
these Fc contact residues in SpG is shown below in figure 3.14. 
 
 
W42 
K27 
E26 
   Q31  N34 
E41 
SpG 
Fc  
 fragment  
Figure 3.14 – A ribbon representation of the proposed residues involved in the 
interaction between D-SpGC2-1 and Fc, selected for mutation 
 
The proposed residues of D-SpGC2-1 selected for mutation are presented, namely Glu26, 
Lys27, Gln31, Asn34, Glu41 and Trp42. These residues are located on          β-strand 3 of 
SpG (shown in gold), and have been implicated in the interaction with the Fc (shown in 
red). 
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3.5.2.1 - Mutation of glutamate 26 to alanine (E26A) 
One of two glutamate residues implicated in the major interfacial interaction of SpG with 
Fc, is situated on the C-terminal end of the α-helix, namely Glu26. This residue forms 
hydrogen bonds with the amide hydrogen of Fc residues Ile253 and Ser254. These Fc 
residues have been shown to be involved in this interaction with SpG, and are both 
located on the loop region between β-strand 2 and 3 of the CH2 domain. Glu26 also 
forms part of a stabilising hydrogen network, with the carbonyl oxygen forming a 
hydrogen bond with the amide hydrogen of the side-chain of     D-SpGC2-1 residue 
lysine, Lys30.  
 
Figure 3.15 illustrates the proposed E26A mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamate 26 with alanine, the hydrogen bonds with the Fc residues and D-
SpGC2-1 residue will be lost, thus disrupting the hydrogen bond network and weakening 
the complex.  
 
  
Ser254        Ser254 
      Ile253 
E26  E26A 
      Ile253 
K30 K30 
Figure 3.15 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant E26A 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Glu26. This residue forms part of a hydrogen network, illustrated 
by green dotted lines, with Fc (shown in red) residues Ser254 and Ile253, and D-SpGC2-1 
residue Lys30. The second figure shows the effect of mutating the glutamate residue to 
an alanine.  
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3.5.2.2 - Mutation of lysine 27 to alanine (K27A) 
The only lysine residue to be implicated in the interfacial interaction of SpG with Fc, is 
also situated on the C-terminal end of the α-helix next to Glu26, namely Lys27. This 
residue forms a single hydrogen bond with the carbonyl oxygen on the side-chain of the 
Fc residues Glu380, which is located on β-strand 3 of the CH3 domain.  
 
Figure 3.16 illustrates the proposed K27A mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have on the local environment. It is 
proposed that by replacing lysine 27 with alanine, the hydrogen bond with the Fc residue 
will be lost.  
 
  
K27 K27A 
Glu380  Glu380 
Figure 3.16 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant K27A 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Lys27. This residue forms part of a hydrogen network, illustrated 
by green dotted lines, with Fc (shown in red) residue Glu380. The second figure shows 
the effect of mutating the lysine residue to an alanine.  
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3.5.2.3 - Mutation of glutamine 31 to alanine (Q31A)  
Glutamine is also implicated in the major interfacial interaction of SpG with Fc, and is 
located around the middle of the α-helix, namely Gln31. The nitrogen atom of this 
residue’s side-chain forms a hydrogen bond with the carbonyl oxygen of the side-chain 
of Fc residue Gln438. This Fc residue has been shown to be involved in this interaction 
with D-SpGC2-1, and is located on β-strand 9 of the CH3 domain. Gln31 also forms part of 
a stabilising hydrogen network, with its carbonyl oxygen forming a hydrogen bond with 
the carbonyl oxygen of the side-chain of D-SpGC2-1 residue aspartate, Asp35.  
 
Figure 3.17 illustrates the proposed Q31A mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamine 31 with alanine, the hydrogen bonds with both the Fc residue and D-
SpGC2-1 residue will be lost.  
 
  
D35  D35 
Q31 
 Gln438   Gln438 
 Q31A 
Figure 3.17 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant Q31A 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Gln31. This residue forms part of a stabilising hydrogen network, 
illustrated by green dotted lines, with Fc (shown in red) residue Gln438, and D-SpGC2-1 
residue Asp35. The second figure shows the effect of mutating the glutamine residue to 
an alanine.  
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3.5.2.4 - Mutation of glutamine 31 to glutamate (Q31E)  
It was also decided to mutate glutamine at position 31 to a glutamate residue.  
 
Figure 3.18 illustrates the proposed Q31E mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamine 31 with a glutamate residue, the hydrogen bond with the Fc residue 
will be lost, but the one with the D-SpGC2-1 residue will remain intact.  
 
  
D35 D35 
  Gln438  Gln438 
Q31       Q31E 
Figure 3.18 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant Q31E 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Gln31. This residue forms part of a stabilising hydrogen network, 
illustrated by green dotted lines, with Fc (shown in red) residue Gln438, and D-SpGC2-1 
residue Asp35. The second figure shows the effect of mutating the glutamine residue to 
a glutamate.  
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3.5.2.5 - Mutation of glutamine 31 to histidine (Q31H)  
It was also decided to mutate glutamine at position 31 to a histidine residue. Histidine 
was used to substitute glutamine in this mutant construct as it is also a polar amino acid, 
which tends to favour the formation of a helical structure. The residue often serves a role 
in stabilising the folded structures of proteins [Park et al., 1997].  
 
Figure 3.19 illustrates the proposed Q31H mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamine 31 with a histidine residue, the hydrogen bond with the Fc residue 
will be lost, but the one with the D-SpGC2-1 residue will remain intact.  
 
 
  
D35  D35 
 Gln438   Gln438 
Q31 
Q31H 
Figure 3.19 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant Q31H 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Gln31. This residue forms part of a stabilising hydrogen network, 
illustrated by green dotted lines, with Fc (shown in red) residue Gln438, and D-SpGC2-1 
residue Asp35. The second figure shows the effect of mutating the glutamine residue to 
a histidine.  
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3.5.2.6 - Mutation of asparagine 34 to alanine (N34A)  
Asparagine is implicated in the major interfacial interaction of SpG with Fc, and is located 
at the C-terminal end of the α-helix, namely Asn34. The oxygen atom of this residue’s 
side-chain forms a hydrogen bond with the amide hydrogen of the side-chain of Fc 
residue Asn434. This Fc residue has been shown to be involved in this interaction with 
SpG, and is located on the loop region between β-strand 2 and 3 of the CH3 domain.  
 
Asn34 also forms part of a vast stabilising hydrogen network, with the same amide 
hydrogen forming a hydrogen bond with the carbonyl oxygen of the side-chain of D-
SpGC2-1 residue valine, Val38. Asparagine 34 continues this vast hydrogen bond network 
by forming hydrogen bonds with two other Fc residues. This time its amide hydrogen 
forms a hydrogen bond with the carbonyl oxygen of the backbone of Fc residue Tyr436, 
and also the carbonyl oxygen of the backbone of Fc residue His433. It was decided to 
mutate this asparagine residue to an alanine to disrupt the binding of the asparagine 
residue with its corresponding Fc residues through the hydrogen bond network.  
 
Figure 3.20 illustrates the proposed N34A mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing asparagine 34 with an alanine residue, the hydrogen bonds with the three Fc 
residues will be lost.  
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 Tyr436  Tyr436 
V38 V38 
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Figure 3.20 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant N34A 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Asn34. This residue forms part of a stabilising 
hydrogen network, illustrated by green dotted lines, with Fc (shown in red) residues 
His433, Asn434 and Tyr436, and D-SpGC2-1 residue Val38. The second figure shows the 
effect of mutating the asparagine residue to an alanine.  
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3.5.2.7 - Mutation of asparagine 34 to aspartate (N34D)  
It was also decided to mutate asparagine at position 34 to an aspartate residue, as their 
structures are similar. The aim of this mutation was to affect the binding of the 
asparagine residue with its corresponding Fc residues through the hydrogen bond 
network.  
 
Figure 3.21 illustrates the proposed N34D mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing asparagine 34 with an aspartate residue, the hydrogen bonds with Fc residues 
Asn434 and Tyr436 will be lost. The hydrogen bond with His433 is maintained, but it 
moves from the oxygen atom on the backbone to the nitrogen atom on the imidazole 
side-chain ring. 
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Figure 3.21 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant N34D 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Asn34. This residue forms a hydrogen bond, 
illustrated by green dotted lines, with Fc (shown in red) residues His433, Asn434 and 
Tyr436, and D-SpGC2-1 residue Val38. The second figure shows the effect of mutating 
the asparagine residue to an aspartate.  
 
| 93  
 
3.5.2.8 - Mutation of glutamate 41 to alanine (E41A)  
The other glutamate residue implicated in the major interfacial interaction of SpG with 
Fc, is situated on the N-terminal end of β-strand 3, namely Glu41. This residue forms a 
hydrogen bond with the amide hydrogen of Fc residue Gln311. This Fc residue has been 
shown to be involved in this interaction with SpG, and is located on the loop region 
between β-strand 8 of the CH2 domain. Alanine was chosen again to substitute the 
Glu41, as with Glu26 residue, to disrupt the binding of the glutamate residue with its 
corresponding Fc residue through the hydrogen bond.  
 
Figure 3.22 illustrates the proposed E41A mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamate 41 with an alanine residue, the hydrogen bond with the Fc residue is 
lost. 
 
 E41 Gln311 
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Figure 3.22 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant E41A 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Glu41. This residue forms part a hydrogen bond, illustrated by 
green dotted lines, with Fc (shown in red) residue Gln311. The second figure shows the 
effect of mutating the glutamate residue to an alanine.  
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3.5.2.9 - Mutation of glutamate 41 to glutamine (E41Q)  
It was also decided to mutate glutamate at position 41 to a glutamine residue, as their 
structures are similar. The aim of this mutation was to affect the binding of the 
glutamate residue with its corresponding Fc residue through its hydrogen bond.  
 
Figure 3.23 illustrates the proposed E41Q mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing glutamate 41 with a glutamine residue, the hydrogen bond with the Fc residue 
will be lost.  
 
  
 Gln311   Gln311 
 E41 
 E41Q 
Figure 3.23 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant E41Q 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Glu41. This residue forms a hydrogen bond, illustrated by green 
dotted lines, with Fc (shown in red) residue Gln311. The second figure shows the effect 
of mutating the glutamate residue to a glutamine residue.  
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3.5.2.10 - Mutation of tryptophan 42 to phenylalanine (W42F)  
The unique tryptophan residue in the D-SpGC2-1 gene has been implicated in the 
interfacial interaction with Fc is situated on the N-terminal end of β-strand 3, namely 
Trp42 [Walker et al., 1995]. However, this tryptophan residue does not appear to form 
any hydrogen bonds with neighbouring residues. Conversely, it is in close proximity with 
the hydrogen network centralised around asparagine residue 34. The aim of this W42F 
mutation was to generate a domain devoid of tryptophan and therefore, virtually non-
fluorescent.  
 
Figure 3.24 illustrates the proposed W42F mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing tryptophan 42 with a phenylalanine residue, the hydrogen bond network 
between Asn34 and the three Fc residues will not be affected. The interaction involves β-
strand 3 of D-SpGC2-1, with important contact residues including tryptophan 42 (W42), 
which has been clearly implicated in binding by the studies of Walker [1994]. 
Furthermore, the loss of the natural fluorophore permits the placement of other unique 
tryptophan residues that may be permit other binding reactions to be studied (see 
section 3.6.1). 
 
  
W42 
W42F 
V38 V38 
N34 N34 
His433 His433 
Asn434 Asn434 
Tyr436 Tyr436 
Figure 3.24 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant W42F 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Trp42. This residue is in close proximity to a stabilising hydrogen 
network, illustrated by green dotted lines, with Fc (shown in red) residues His433, 
Asn434 and Tyr436, and D-SpGC2-1 residue Val38. The second figure shows the effect of 
mutating the tryptophan residue to a phenylalanine.  
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3.5.2.11 - Mutation of tryptophan 42 to tyrosine (W42Y) 
It was also decided to mutate tryptophan at position 42 to a tyrosine residue. It is 
already known that tryptophan’s substitution with phenylalanine dramatically reduces 
the binding interaction of D-SpGC2-1 with Fc [Walker, 1994]. Therefore, the aim of this 
W42Y mutation was to see if the replacement by the more polar tyrosine had the same 
effect.  
 
Figure 3.25 illustrates the proposed W42Y mutation and its position in complex with Fc, 
also demonstrating the effect that this mutation will have. It is proposed that by 
replacing tryptophan 42 with a tyrosine residue, the surrounding hydrogen bond network 
with the three Fc residues is not affected. Modelling studies suggest that when 
tryptophan is mutated to a tyrosine a hydrogen bond is formed with Asn434 with the 
possibility that this interaction may restore Fc binding. Also, the fluorescence properties 
of the protein will be changed. 
 
  
W42Y 
W42 
Asn434 Asn434 
V38 V38 
His433 His433 
Tyr436 Tyr436 
Figure 3.25 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant W42Y 
 
The proposed residue of D-SpGC2-1 (shown in gold) selected for mutation is presented in 
the first figure, namely Trp42. This residue is in close proximity to a stabilising hydrogen 
network, illustrated by green dotted lines, with Fc (shown in red) residues His433, 
Asn434 and Tyr436, and D-SpGC2-1 residue Val38. The second figure shows the effect of 
mutating the tryptophan residue to a tyrosine.  
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3.5.2.12 - Mutation of cysteine 56 to alanine (C56A)  
Cysteine has not been implicated in any interfacial interactions between SpG and Fc or 
Fab. However, it was decided to mutate this unique cysteine to an alanine to prevent 
cross-linking between D-SpGC2-1 domains and also with Fab and Fc molecules. The 
unique cysteine residue is situated on the C-terminal end of         β-strand 4, namely 
Cys56.  
 
Figure 3.26 illustrates the position of the cysteine residue on D-SpGC2-1.  
 
  
COOH 
COOH 
NH2 Cys56 
Cys56 
NH2 
Figure 3.26 – Ribbon representations of D-SpGC2-1, illustrating the position of the    
cysteine residue 
 
The proposed amino acid residue of D-SpGC2-1 selected for mutation is presented in the 
first figure, namely Cys56. This residue is located at the C-terminal end of the β-strand 4 
of D-SpGC2-1 (shown in gold). The second figure shows a different orientation of D-
SpGC2-1.  
 
3.5.3 - Mis-match primers for Fc contact residue mutants  
Mutagenesis of the key residues in D-SpGC2-1, critical for the interaction with Fc, will 
identify the contribution of a specific amino acid to the biological function of SpG. For 
each mutant construct, two oligonucleotide primers were designed that were capable of 
effecting these desired mutations and complied with criteria stated in section 3.2.2.1. 
The sequence of these primers was complementary to the gene sequence in the region 
to be mutated, but with a single codon difference at the intended mutation site. All 
primers were sufficiently long enough to ensure site-specific annealing of the primer to 
the template DNA, and were produced in the 5’ to 3’ orientation, allowing them to bind 
to the DNA template produced in the cloning vector. In addition, codons preferred by 
E.coli were used wherever possible for the substituted amino acids. The final design for 
each oligonucleotide primer is presented in figure 3.27.  
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E26A – oligo#1: 5’ – GCT GCT ACC GCT GCT AAA GTT TTC AAA – 3’  
E26A – oligo#2: 5’ – TTT GAA AAC TTT AGC AGC GGT AGC AGC – 3’   
 
K33A – oligo#1: 5’ – CT ACC GCT GAA GCT GTT TTC AAA CAG TAC G – 3’ 
K33A – oligo#2: 5’ – C GTA CTG TTT GAA AAC AGC TTC AGC GG – 3’ 
 
Q31A – oligo#1: 5’ – A GTT TTC AAA GCT TAC GCT AAC GAC AA – 3’ 
Q31A – oligo#2: 5’ – ACC GTT GTC GTT AGC GTA AGC TTT GAA AA – 3’ 
 
Q31E – oligo#1: 5’ – T GAA AAA GTT TTC AAA GAA TAC GCT AA – 3’ 
Q31E – oligo#2: 5’ – ACC GTT GTC GTT AGC GTA TTC TTT GGA – 3’ 
 
Q31H – oligo#1: 5’ – CT GAA AAA GTT TTC AAA CAT TAC GCT A – 3’ 
Q31H – oligo#2: 5’ – ACC GTT GTC GTT AGC GTA ATG TTT GAA – 3’ 
 
N34A – oligo#1: 5’ – TC AAA CAG TAC GCT GCT GAC AAC GGT G – 3’ 
N34A – oligo#2: 5’ – C ACC GTT GTC AGC AGC GTA CTG TTT GA – 3’ 
 
N34D – oligo#1: 5’ – AAA CAG TAC GCT GAC GAC AAC GGT GTC – 3’ 
N34D – oligo#2: 5’ – GAC ACC GTT GTC GTC AGC GTA CTG TTT – 3’ 
 
E41A – oligo#1: 5’ – C GGT GTC GAC GGT GCT TGG ACC TAC G – 3’ 
E41A – oligo#2: 5’ – GTC GTA GGT CCA AGC ACC GTC GAC ACC – 3’ 
 
E41Q – oligo#1: 5’ – GTC GAC GGT CAG TGG ACC TAC GAC GAC GCT – 3’ 
E41Q – oligo#2: 5’ – GTC GTA GGT CCA CTG ACC GTC GAC ACC – 3’ 
 
W42F – oligo#1: 5’ – GTC GAC GGT GAA TTC ACC TAC GAC GAC – 3’ 
W42F – oligo#2: 5’ – GTC GTC GTA GGT GAA TTC ACC GTC GAC – 3’ 
 
W42Y – oligo#1: 5’ – C GAC GGT GAA TAC ACC TAC GAC GAC GCT – 3’ 
W42Y – oligo#2: 5’ – GTC GTC GTA GGT GTA TTC ACC GTC GAC – 3’ 
 
C56A – oligo#1: 5’ – ACG GTT ACC GAA GCT TAA TAG TGA AA – 3’ 
C56A – oligo#2: 5’ – AG CTT TCA CTA TTA AGC TTC GGT AAC C – 3’ 
 
Figure 3.27 – Mis-match primers for the production of D-SpGC2-1 Fc mutants  
 
For each mutant construct, two oligonucleotide primers were designed. Mutant codons 
are emboldened in red. 
 
3.6 - Construction of D-SpGC2-1 Fab binding mutants 
In order to study the various amino acids involved in the interaction of D-SpGC2-1 with 
Fab, and any changes in the structure of D-SpGC2-1 that may occur on formation of the 
complex, key amino acid residues, identified in both the major and minor regions of 
contact with the Fab CH1 domain, were chosen for mutation. Mutations in corresponding 
positions to these residues and neighbouring residues were also considered. This 
complex is stabilised through a network of hydrogen bonds, and the importance and 
effect of these bonds to the stability and nature of the complex by removing these key 
residues was to be investigated.   
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3.6.1 - Selection of a suitable template for Fab mutants 
The selection of a suitable template DNA to be used in PCR mutagenesis for the 
proposed Fab mutants was considered. As previously mentioned, D-SpGC2-1 possess a 
unique tryptophan residue at position 42, located on β-strand 3, which is known for its 
important role in Fc binding. Its substitution with phenylalanine dramatically reduces the 
binding interaction of D-SpGC2-1 with Fc, with a 300-fold decrease in affinity [Walker et 
al., 1995]. Therefore, by using the existing W42F   D-SpGC2-1 construct, Fab binding can 
be studied without the intercession of any Fc interactions. However, the removal of the 
tryptophan in the W42F mutation created a non-fluorescent protein, meaning Fab 
binding studies would not be possible using fluorescent spectroscopy.  
 
The re-introduction of a tryptophan residue at an alternative position, however, would 
allow the effect of Fab mutations to be probed in fluorescent studies. Residue Glu14 is 
located on β-strand 2 of D-SpGC2-1 and is adjacent to residues Thr15 and Thr16, forming 
two hydrogen bonds with Lys212 from Fab. The side-chain of Glu14 can be seen to be 
pointing away from the complex, so it was decided to incorporate a tryptophan residue 
at this position, as shown in figure 3.28, which is close to the proposed Fab binding site. 
 
   
SpG 
SpG 
E14W 
E14 
Lys212 Lys212 
Fab 
fragment Fab 
fragment 
Figure 3.28 – Ribbon representations of D-SpGC2-1 in complex with the CH1    domain of 
Fab, illustrating the position of E14W mutant, as it acts as a reporter for 
Fab binding 
 
In these complexes, the Ig-binding domain of D-SpGC2-1 binds the CH1 of the Fab 
fragment. As shown, E14W mutant is located on β-strand 2 of D-SpGC2-1 (shown in 
gold). It forms part of a stabilising hydrogen network, illustrated by green dotted lines, 
with Lys212 on β-strand 7 of the CH1 domain of Fab (shown in blue).    
 
The Fc mutant W42F D-SpGC2-1 pQE-30 was initially used as template DNA to make the 
E14W mutant, and the successive double mutant, E14W-W42F             D-SpGC2-1 pQE-
30, was then employed as a template for subsequent Fab mutants. This mutant allows 
the binding of Fab to D-SpGC2-1 to be studied exclusively, as its ability to bind Fc has 
been removed with the W42F mutant [Walker, 1994]. Subsequent mutations will be 
used to reduce the Fab binding affinity to D-SpGC2-1, which can be reported back by 
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fluorescence studies from the tryptophan E14W residue, illustrated in figure 3.29.  
 
  
SpG 
SpG E14W 
E14W Fc 
fragment 
β-2 
W42 
Fab 
fragment 
CH1 
Fab 
fragment 
Figure 3.29 – Ribbon representations of D-SpGC2-1 in complex with the CH1 domain of 
Fab and Fc illustrating the position of tryptophan residues  
 
In the first complex, the Ig-binding domain of D-SpGC2-1 binds the CH1 of the Fab 
fragment (shown in blue). E14W mutant is located on β-strand 2 of D-SpGC2-1 (shown in 
gold) and can act as a reporter group solely for Fab binding. The second complex shows 
how D-SpGC2-1 can bind both the CH1 of the Fab fragment and Fc (shown in red) at the 
CH2-CH3 interface. Both tryptophan residues, E14W mutant and W42, can act as reporter 
groups for Fab and Fc binding, respectively.    
 
 
Wild-type D-SpGC2-1 pQE-30 DNA was also used as a template for the single mutant 
E14W, which was designed to be employed as a control for all experiments undertaken 
in this study. This E14W-W42 construct comprises two tryptophan residues and the 
second image in figure 3.40 illustrates their positions in             D-SpGC2-1. It is 
proposed that tryptophan at position 14 (E14W) may act as a reporter for the binding of 
D-SpGC2-1 to the CH1 domain of Fab, and that tryptophan at position 42 (W42) may act 
as a reporter for the binding of D-SpGC2-1 to the CH2-CH3 interface of Fc.  
 
3.6.2 - Selection of Fab contact residues for mutation 
Single Ig-binding domains of SpG has been shown to bind to Fab by forming an anti-
parallel interaction with the last β-strand of the CH1 domain of Fab [Derrick and Wigley, 
1992; Lian et al., 1994; Derrick and Wigley, 1994; Sauer-Eriksson et al., 1995]. SpG’s 
interaction with Fab lies predominantly within β-strand 2, but also involves a minor 
region at the C-terminal end of the α-helix [Derrick and Wigley, 1994]. The amino acid 
residues that form the major contact regions have been identified, and the site of 
interaction spans residues Lys9 to Thr16 from β-strand 2 on SpG and Ser209 to Lys216 
from the 7th β-strand of the CH1 domain of Fab. In addition, residues Tyr32 to Gly37 
from the C-terminal end of the α-helix of SpG and Pro125 to Tyr129 on the 1st β-strand 
of the CH1 domain of Fab constitute the minor contact region [Derrick and Wigley, 1994].  
 
The positions of these residues are illustrated in figure 3.30. The first figure shows how 
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these two sites of contact are stacked together. The atoms involved in these interactions 
can be principally found on the backbone of the CH1 domain of the IgG, but include both 
backbone and side-chain atoms from the binding domain of SpG, involving hydrogen 
bonds and van der Waal forces, but no salt bridges. The complex is stabilised through a 
network of hydrogen bonds contributed by the last β-strand of the CH1 domain to the 
second β-strand in SpG, and is further stabilised by the association of exposed non-polar 
residues from Fab and SpG, providing a continuous hydrophobic core, which is shielded 
from solvent [Derrick and Wigley, 1992].  
 
   
E14W 
SpG SpG 
T10 
T15 T16 
Fab 
fragment 
Y32 
N36 
Fab 
fragment 
Figure 3.30 – Ribbon representations of the contact residues involved in the interaction 
between SpG and Fab  
 
SpG has been shown to bind to Fab by forming an anti-parallel interaction with the last 
β-strand of the CH1 domain of Fab. The site of interaction spans residues Lys9 to Thr16 
from β-strand 2 on SpG and Ser209 to Lys216 from the 7th β-strand of the CH1 domain of 
Fab. In addition, residues Tyr32 to Gly37 from the C-terminal end of the α-helix of SpG 
and Pro125 to Tyr129 on the 1st β-strand of the CH1 domain of Fab constitute the minor 
contact region [Derrick and Wigley, 1994].    
 
Using this information, six residues were selected to be mutated and used to study and 
characterise the binding affinity of Fab to D-SpGC2-1, which can be reported back by 
fluorescence studies from the tryptophan E14W residue. A selection of residues from 
both the major and minor contact regions, namely residues Thr10, Glu14, Thr15, Thr16, 
Tyr32 and Asn36 were chosen for their side-chain involvement in the interaction with 
Fab. An overview of the position of these Fab contact residues in D-SpGC2-1 is shown in 
the second image in figure 3.30. 
 
3.6.2.1 - Mutation of threonine 10, 15 and 16 to alanine (T10A, T15A and                    
T16A)  
 
Three threonine β-strand 2 amino acid residues were selected to be mutated, namely 
Thr10, Thr15 and Thr16. These threonine amino acids appear to play important roles in 
the stabilising hydrogen bond network and have been shown to constitute the major 
contact region. Threonine 10 forms a hydrogen bond with Fab residue Lys215 located on 
the 7th β-strand on the CH1 domain. Threonine 15 forms a hydrogen bond with Ser209 
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and Thr211, with threonine 16 also forming hydrogen bonds with Ser209 and in addition, 
with Ser210. It was decided to mutate each of these residues to alanine.  
    
The aim of this mutation was to disrupt the extensive hydrogen bond network involved 
in the binding of the three threonine residues with their corresponding Fab residues, 
illustrated in figure 3.31. This may disrupt the high stability of D-SpGC2-1, which is 
thought to be linked to such extensive interactions [Bouvignies et al., 2005]. The binding 
interface, which usually consists of protein surfaces as with    D-SpGC2-1 binding with 
either Fc or Fab, is generally more hydrophilic than the interior, and studies have shown 
that these binding interfaces tend to form more hydrogen bonds than protein interiors 
[Xu et al., 1997]. 
 
 
T10 
T16 T15 
E14W 
Lys215 
Thr211 
Ser209 
Lys212 
Figure 3.31 – Ribbon representation of the three threonine residues involved in the 
interaction between D-SpGC2-1 and Fab  
 
The three threonine residues of D-SpGC2-1 selected for mutation is presented, namely 
Thr10, T15 and T16. These residues are located on β-strand 2 of D-SpGC2-1 (shown in 
gold), and forms part of a hydrogen network, illustrated by green dotted lines, with 
Lys215, Thr211 and Ser209 respectively. These are located on β-strand 7 of the CH1 
domain of Fab (shown in blue).  
 
 
 
 
Alanine was chosen to substitute all three threonine residues to disrupt the hydrogen 
bond network. Successive figures 3.32, 3.33 and 3.34 illustrate the proposed T10A, 
T15A and T16A mutations and their positions in the complex with Fab respectively. The 
figures also demonstrate that these substitutions will remove hydrogen bonds to Fab.  
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T10 T10A 
Lys215 Lys215 
Figure 3.32 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T10A 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr10. This residue forms a hydrogen bond, 
illustrated by a green dotted line, with Fab (shown in blue) residue Lys215. The second 
figure shows the effect of mutating the threonine residue to an alanine.  
 
 
 
  
T15A T15   T16 T16 
Thr211 
  
Ser209 Thr211 Ser209 
Figure 3.33 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T15A 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr15. This residue forms part of a hydrogen 
network, illustrated by green dotted lines, with Fab (shown in blue) residue. The second 
figure shows the effect of mutating the threonine residue to an alanine.  
 
  
T16A 
T16 
T15 T15 
Thr211  Ser209 Ser209 Thr211 
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Figure 3.34 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T16A 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr16. This residue forms part of a hydrogen 
network, illustrated by green dotted lines, with Fab (shown in blue) residue Ser209. The 
second figure shows the effect of mutating the threonine residue to an alanine.  
 
Figure 3.35 illustrates the proposed double mutant T15A-T16A mutation and its position 
in the complex with Fab respectively. This double mutation will remove two hydrogen 
bonds to Fab simultaneously.  
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Figure 3.35 – Ribbon representations of the amino acid side-chains involved in the 
proposed double mutant T15A-T16A 
 
The proposed amino acid residues of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr15 and Thr16. These residues form part of a 
hydrogen network, illustrated by green dotted lines, with Fab (shown in blue) residues 
Ser209 and Thr211. The second figure shows the effect of mutating both threonine 
residues to alanine.  
 
 
 
 
 
 
 
 
 
3.6.2.2 - Mutation of threonine 10, 15 and 16 to serine (T10S, T15S and                    
T16S)  
 
It was also decided to mutate these three threonine residues at positions 10, 15 and 16 
to serine residues, to effectively reduce the length of the side chain by one methyl 
group. Successive figures 3.36, 3.37 and 3.38 illustrate the proposed T10S, T15S and 
T16S mutations and their positions in the complex with Fab respectively, also 
demonstrating the effect that these mutations will have. It is possible that by replacing 
threonine 10 with serine, the hydrogen bond with its corresponding Fab residue may 
remain intact, but may be in a different orientation. 
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T10S 
T10 
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Figure 3.36 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T10S 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr10. This residue forms a hydrogen bond, 
illustrated by a green dotted line, with Fab (shown in blue) residue Lys215. The second 
figure shows the effect of mutating the threonine residue to serine.  
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Ser209 
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Figure 3.37 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T15S 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Thr15. This residue forms a hydrogen bond, 
illustrated by a green dotted line, with Fab (shown in blue) residue Lys215. The second 
figure shows the effect of mutating the threonine residue to serine.  
  
T16S 
T16 
T15 T15 
Thr211 Thr211 Ser209 Ser209 
Figure 3.38 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant T16S 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
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presented in the first figure, namely Thr16. This residue forms a hydrogen bond, 
illustrated by a green dotted line, with Fab (shown in blue) residue Lys215. The second 
figure shows the effect of mutating the threonine residue to serine.  
 
| 107  
 
3.6.2.3 - Mutation of tyrosine 32 to phenylalanine (Y32F) 
The presence of the polar hydroxyl group in the side-chain enables tyrosine to be always 
involved in hydrogen bonds when it is found in the interior of proteins [Chen et al., 
2005]. This also applies to D-SpGC2-1, as all three tyrosine residues are involved in the 
hydrophobic core. Tyr32 forms part of a stabilising hydrogen network, with its backbone 
oxygen atom forming hydrogen bonds with both the amide hydrogen atom of the 
backbone and the side chain amide hydrogen of       D-SpGC2-1 residue Asn36.  
  T16A 
Thr211 
 
This asparagine residue in turn forms a hydrogen bond with the nitrogen atom on the 
backbone of Fab residue Val128. The hydrogen bond network surrounding this residue is 
presented in figure 3.39.  
 
 
Pro126 
N36 
Val128 
Y32 
Figure 3.39 – A ribbon representation of the amino acid side-chains and hydrogen bond 
network surrounding the proposed mutant Y32F 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented, namely Tyr32. This residue is located at the C-terminal end of the α-helix of 
D-SpGC2-1, and forms part of an extensive hydrogen bond network, illustrated by green 
dotted lines, with Pro126. Tyr32 also forms backbone hydrogen bonds with Asn36, 
which in turn forms hydrogen bonds with Val128. Both Fab residues are located on β-
strand 1 of the CH1 domain (shown in blue).  
 
Tyrosine 32 is also implicated in the minor interfacial interaction of SpG with Fab, and is 
located at the C-terminal end of the α-helix. The tyrosine’s side-chain forms a hydrogen 
bond with the oxygen atom of the backbone of Fab residue Pro126 located on the first β-
strand of the CH1 domain. It was therefore decided to mutate this tyrosine residue to a 
phenylalanine to explore the consequence on the binding interaction. 
 
 
 
 
Figure 3.40 illustrates the proposed Y32F mutation and its position in complex with Fab. 
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Y32F Y32 
Pro126 Pro126 
Figure 3.40 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant Y32F 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Try32. This forms part of a hydrogen bond network, 
illustrated by a green dotted line, with Fab (shown in blue) residue Pro126. The second 
figure shows the effect of mutating the tyrosine residue to phenylalanine.  
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3.6.2.4 - Mutation of asparagine 36 to alanine (N36A)  
Asparagine 36 has been implicated in the minor interfacial interaction of SpG with Fab, 
and is situated on the C-terminal end of the α-helix. The oxygen atom of this residue’s 
side-chain forms a hydrogen bond with the amide hydrogen atom on the backbone of 
Fab residue Val128. This Fab residue is located on the first β-strand of the CH1 domain. 
Asn36 also forms part of a stabilising hydrogen network, with its side-chain amide and 
its backbone amide each forming a hydrogen bond with the oxygen atom of the 
backbone of D-SpGC2-1 residue Tyr32. This tyrosine residue in turn completes the 
hydrogen network, with its side-chain forming a hydrogen bond with Fab residue, 
Pro126. It was decided to mutate this asparagine residue to an alanine.  
 
Figure 3.41 illustrates the proposed N36A mutation and its position in complex with Fab, 
also demonstrating the effect that this mutation will have.  
 
  
Pro126 
Pro126 
Val128 Val128 
N36 N36A 
Y32 Y32 
Figure 3.41 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant N36A 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Asn36. This residue forms part of a hydrogen bond 
network, illustrated by green dotted lines, with Fab (shown in blue) residue Val128 and 
D-SpGC2-1 residue Tyr32. The second figure shows the effect of mutating the asparagine 
residue to an alanine.  
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3.6.2.5 - Mutation of asparagine 36 to aspartic acid (N36D)  
It was also decided to mutate asparagine 36 to the structurally conservative aspartate 
residue. Figure 3.42 illustrates the proposed N36D mutation and its position in complex 
with Fab, also demonstrating the effect that this mutation will have. In this case it is 
proposed that the mutation will not affect the hydrogen bond with its corresponding Fab 
residue.  
 
  
Y32 Y32 
Pro126 
Pro126 
N36 
Val128 N36D Val128 
Figure 3.42 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant N36D 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Asn36. This residue forms part of a hydrogen bond 
network, illustrated by green dotted lines, with Fab (shown in blue) residue Val128 and 
D-SpGC2-1 residue Tyr32. The second figure shows the effect of mutating the asparagine 
residue to an aspartate.  
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3.6.2.6 - Mutation of asparagine 36 to glutamine (N36Q) 
It was also decided to mutate asparagine at position 36 to a glutamine residue which 
retains an amide group on the side-chain although the latter has one more methylene 
group in it. Figure 3.43 illustrates the proposed N36Q mutation and its position in 
complex with Fab, also demonstrating the effect that this mutation will have. It is 
proposed that by replacing asparagine 36 with glutamine, the hydrogen bond with its 
corresponding Fab residue will be lost.  
 
  
Y32 Y32 
Pro126 Pro126 
N36Q N36 
Val128 Val128 
Figure 3.43 – Ribbon representations of the amino acid side-chains involved in the 
proposed mutant N36Q 
 
The proposed amino acid residue of D-SpGC2-1 (shown in gold) selected for mutation is 
presented in the first figure, namely Asn36. This residue forms part of a hydrogen bond 
network, illustrated by green dotted lines, with Fab (shown in blue) residue Val128 and 
D-SpGC2-1 residue Tyr32. The second figure shows the effect of mutating the asparagine 
residue to a glutamine.  
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3.6.3 - Mis-match primers for Fab mutant D-SpGC2-1 constructs 
Two oligonucleotide primers were designed that were capable of effecting these desired 
mutations and complied with criteria stated in section 3.2.2.1. The final design for each 
oligonucleotide primer is presented in figure 3.44. 
  
 
T10A – oligo#1: 5’ – ATC AAC GGT AAA GCT CTG AAA GGT TGG – 3’ 
T10A – oligo#2: 5’ – GGT GGT CCA ACC TTT CAG AGC TTT ACC – 3’      
        
T10S – oligo#1: 5’ – ATC AAC GGT AAA AGT CTG AAA GGT TGG – 3’ 
T10S – oligo#2: 5’ – GGT GGT CCA ACC TTT CAG ACT TTT ACC – 3’      
 
E14W – oligo#1: 5’ – TG AAA GGT TGG ACC ACC ACC GAA GCT G – 3’  
E14W – oligo#2: 5’ – GT GGT GGT CCA ACC TTT CAG GGT TTT A – 3’   
 
T15A – oligo#1: 5’ – AA GGT TGG GCT ACC ACC GAA GCT GTT G – 3’ 
T15A – oligo#2: 5’ – TC GGT GGT AGC CCA ACC TTT CAG GGT T – 3’ 
 
T15S – oligo#1: 5’ – AA GGT TGG AGT ACC ACC GAA GCT GTT G – 3’ 
T15S – oligo#2: 5’ – TC GGT GGT ACT CCA ACC TTT CAG GGT T – 3’ 
 
T16A – oligo#1: 5’ – GT TGG ACC GCT ACC GAA GCT GTT GAC G – 3’ 
T16A – oligo#2: 5’ – GC TTC GGT AGC GGT CCA ACC TTT CAG G – 3’ 
 
T16S – oligo#1: 5’ – GT TGG ACC AGT ACC GAA GCT GTT GAC G – 3’ 
T16S – oligo#2: 5’ – GC TTC GGT ACT GGT CCA ACC TTT CAG G – 3’ 
 
T15A-T16A – oligo#1: 5’ – AA GGT TGG GCT GCT ACC GAA GCT GTT G - 3’ 
T15A-T16A – oligo#2: 5’ – GC TTC GGT AGC AGC CCA ACC TTT CAG G – 3’ 
 
Y32F – oligo#1: 5’ – TC AAA CAG TTC GCT AAC GAC AAC GGT G – 3’ 
Y32F – oligo#2: 5’ – TC GTT AGC GAA CTG TTT GAA AAC TTT T – 3’ 
 
N36A – oligo#1: 5’ – CT AAC GAC GCT GGT GTC GAC GGT GAA T – 3’ 
N36A – oligo#2: 5’ – TC GAC ACC AGC GTC GTT AGC GTA CTG T – 3’ 
 
N36D – oligo#1: 5’ – TAC GCT AAC GAC GAC GGT GTC GAC GGT GAA T – 3’ 
N36D – oligo#2: 5’ – ACC GTC GAC ACC GTC GTC GTT AGC GTA CTG – 3’ 
 
N36Q – oligo#1: 5’ – TAC GCT AAC GAC CAG GGT GTC GAC GGT GAA T – 3’ 
N36Q – oligo#2: 5’ – ACC GTC GAC ACC CTG GTC GTT AGC GTA – 3’ 
 
 
Figure 3.44 – Mis-match primers for the production of D-SpGC2-1 Fab mutants  
 
For each mutant construct, two oligonucleotide primers were designed. Mutant codons 
are emboldened in red and the E14W mutation present in all mutations, as the reporter 
group for fluorescence studies, is in bold. 
 
 
 
 
 
| 113  
 
3.7 - Production of D-SpGC2-1 Fc and Fab mutant constructs 
PCR-based site-directed mutagenesis of the wild-type direct expression construct gene, 
D-SpGC2-1 pQE-30, was performed using two-sided Splicing by Overlap Extension (SOE-
ing) for the production of all D-SpGC2-1 mutations. This was achieved by using the 
specifically designed oligonucleotides, presented in figures 3.26 and 3.44, and two 
flanking primers pQE-30 forward and pQE-30 reverse. The final design for each of the 
flanking oligonucleotide primer is presented below in figure 3.45.  
 
pQE-30 forward oligo: 5’ – AAA ATA GGC GTA TCA CGA GGC – 3’ 
pQE-30 reverse oligo: 5’ – AGC TGA ACG GTC TGG TTA TAG GTA CA – 3’ 
 
Figure 3.45 – Flanking primers used for the production of D-SpGC2-1 mutants  
 
For each mutant construct, two flanking oligonucleotide primers were designed. All 
primers were sufficiently long enough to ensure annealing of the primer to the cloning 
vector DNA, and were produced in the 5’ to 3’ orientation.  
 
Two PCR reactions, A and B, were set up according to table 2.1, with one reaction mix 
prepared for each desired mutant. PCR amplification products, A and B, were analysed 
by 2% agarose gel electrophoresis (section 2.4.3). Examples of PCR products A and B 
are presented in figure 3.46, illustrating how each product can vary in size depending on 
the position of the point mutation. Fragments corresponding to the correct size were 
excised and purified using a QIAquick gel extraction kit (section 2.4.2.3).  
 
  
Figure 3.46 - Two 2% agarose gels illustrating the successful PCR-based site-directed 
mutagenesis for the production of D-SpGC2-1 Fc and Fab mutant 
constructs  
 
These two 2% agarose gels illustrate examples of PCR products A and B produced by 
PCR-based site-directed mutagenesis, performed on D-SpGC2-1 pQE-30 template DNA for 
all D-SpGC2-1 Fc and Fab mutant constructs.  
 
 
PCR products A and B were then used to produce the final mutagenic product PCR C, 
according to the reaction mix shown in table 2.2. Examples of PCR gene product C are 
presented in figure 3.47, illustrating how each product is always the same size, 654 bp. 
100 bp  
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500 bp  
200 bp  
1000 bp  
PCR  
 A  
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B  
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Fragments corresponding to the correct size were excised and purified using a QIAquick 
gel extraction kit (section 2.4.2.3).  
 
  
100 bp  
ladder 
1000 bp  
500 bp  
654 bp 
gene 
fragment 
PCR Gene Product C  
Figure 3.47 - A 2% agarose gel illustrating the successful PCR-based site-directed 
mutagenesis for the production of D-SpGC2-1 Fc and Fab mutant constructs  
 
This 2% agarose gel illustrates examples of PCR gene product C produced by PCR-based 
site-directed mutagenesis, performed on PCR products A and B for all         D-SpGC2-1 Fc 
and Fab mutant constructs.  
 
Bam HI and Hind III restriction enzyme digests were then performed on the mutant PCR 
gene products obtained, as described in section 2.4.5, and the 6xHis tagged pQE-30 
vector, as previously shown in figure 3.8. The appropriate fragments were excised and 
extracted from agarose gel (section 2.4.2.3) and used to clone into Bam HI and Hind III 
digested 6xHis tagged pQE-30 expression vector. Figure 3.48 presents examples of the 
successful restriction digests performed on PCR product C to yield the 208 bp D-SpGC2-1 
gene fragment. 
 
 
100 bp  
ladder 
500 bp  
1000 bp  
200 bp  
208 bp 
gene 
fragment 
Uncut 
PCR  
 C 
Bam HI/Hind III 
digest on PCR 
gene product C 
 
Figure 3.48 - A 2% agarose gel illustrating the successful restriction digest performed 
on PCR gene product C  
 
This 2% agarose gel illustrates examples of Bam HI and Hind III restriction digests 
performed on PCR gene product C. The yielded 208 bp gene fragments were excised and 
extracted, and subsequently cloned into pQE-30 vector.  
The cloning was then carried out as described in section 3.3.2.3 above. Ligation products 
were transformed into E.coli JM103 cells (section 2.4.7) and used to produce mutated 
plasmid DNA. All D-SpGC2-1 mutant constructs were then checked to ensure that the 
sequences contained the mutated amino acids and had been correctly inserted into the 
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pQE-30 vector at the designated restriction sites. This was accomplished by 
dideoxynucleotide sequencing, performed by MWG-Biotech. 
 
3.8 - Expression and purification of D-SpGC2-1 
The induced protein was extracted from the cytoplasm by sonication and the preparation 
of crude cell extract is critical in determining the total amount of desired protein 
available for purification. Heat treatment was then employed as an initial step in the 
purification of D-SpGC2-1 from the soluble fraction, followed by anion-exchange 
chromatography. The very high denaturation temperatures determined for IgG-binding 
domains C1 and C3 [Alexander et al., 1992] is easily exploited for this procedure and 
has already been used successfully by several groups [Lian et al., 1992; Achari et al., 
1992] in the purification of these domains. The denaturation temperature stated for the 
C1 domain, which shares the most homology to the C2 domain upon which the D-SPGC2-
1 constructs were based, is 87.5 °C. Heat treatment at 80 °C was found to be most 
effective temperature for purification, without the significant loss of the desired protein.  
 
The IgG-binding domains of SpG possess an isoelectric point (pI) of 4.2 [Achari et al., 
1992], so above this pH, the proteins will have a net negative charge. This means that 
anion-exchange chromatography was thought to be the most appropriate method to 
purify D-SpGC2-1 at pH 8.0. Anion-exchange has previously been used by Lian et al 
[1992] to purify similar SpG IgG-binding domains.  
 
3.8.1 - Expression and purification of D-SpGC2-1 pQE-30 constructs   
All D-SpGC2-1 pQE-30 proteins were expressed and purified according to conditions 
stated in sections 2.5.1.1 to 2.5.1.4. Figure 3.49 presents a typical elution profile 
obtained from a Q-Sepharose column using a linear salt gradient (see sections 2.5.1.1. 
to 2.5.1.4), illustrating the absorbance peaks at 280 nm and conductivity of each 
fraction. Purified domain is typically eluted when the conductivity reaches between 4.5 
and 22 mS at pH 8.0, which corresponds to fractions 18 to 50 taken from the larger 
peak and the subsequent smaller peak.  
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 Figure 3.49 - A typical elution profile of D-SpGC2-1 obtained from a linear gradient, 
illustrating the absorbance peaks at 280nm and conductivity for each 
fraction number   
 
D-SpGC2-1 pQE-30 proteins were expressed and purified on a Q-Sepharose matrix 
column. A typical elution profile obtained illustrates the absorbance of the collected 
fraction samples at 280 nm, and the corresponding conductivity. The absorbance at 280 
nm is denoted by the black line, and the conductivity is denoted by the grey line. 
Fractions were analysed by 17.5% SDS polyacrylamide gels. 
 
The detection of expression of all D-SpGC2-1 pQE-30 constructs was performed by 
running fraction samples on a high-resolution separating gel containing 17.5% 
acrylamide under reducing conditions, as described in section 2.5.3. Figure 3.50 presents 
two typical 17.5% SDS polyacrylamide gels of samples taken from the collected eluate in 
the specified region. Fractions were pooled according to purity, and concentrated by an 
ammonium sulphate precipitation at the 80% saturation level (section 2.5.4). 
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Figure 3.50 - Two typical 17.5% SDS polyacrylamide gels of fraction samples collected 
from the purification of D-SpGC2-1 protein  
2 mg/ml 
wild-type  
D-SpGC2-1 
 34   36    38   40   42   44   46    48   50 
pure  
protein  
G 
pure  
protein  
G 
2 mg/ml 
wild-type  
D-SpGC2-1 
 Fractions 18   20   22   24   26    28   30   32 
HT 
s/n 
  
Two high-resolution reducing 17.5% SDS gels were used to analyse the fraction samples 
collected from the linear gradient employed to purify all D-SpGC2-1 protein constructs. A 
2 mg/ml sample of purified wild-type SpG was used as a control, as well as a sample 
taken from the heat-treated supernatant (HT s/n). Samples shown above from fractions 
18 to 50 inclusive were judged and pooled and stored at 4 °C as an 80% (NH4)2 SO4 
precipitate. 
 
These SDS gels exhibit a very high level of protein expression that was representative 
for both wild-type and mutant 6xHis-tagged D-SpGC2-1 constructs, and demonstrates 
that pure protein has been obtained. This protein can now provide a model for 
subsequent characterisation of SpG’s interactions with Fc and Fab and for further studies 
into determining any differences in both binding and stability. 
 
The expression and purification procedures employed in this study should be applicable 
for the production of the wild-type D-SpGC2-1, as well as mutant constructs, as they are 
not IgG-binding dependent. This means that any protein that cannot be produced using 
these methods must be significantly structurally altered, and therefore will not provide a 
valid model for characterisation studies.  
 
All of the mutants were made, expressed and purified like wild-type D-SpGC2-1, except 
for the mutant K33A, occupying a position in the α-helix. This mutation involves the only 
lysine to be implicated in the interfacial interaction of SpG with Fc, and is situated on the 
C-terminal end of the α-helix next to Glu26. Lys33 forms a single hydrogen bond with 
the side-chain of the Fc residue Glu380, which is located on β-strand 3 of the CH3 
domain. This mutant could not be expressed, suggesting that the insertion of an alanine 
residue into the helix at this position disrupted the structure in some way. An 
incompletely folded protein is considered more susceptible to degradation than a folded 
one, so it is likely that the protein was degraded on formation by host E.coli proteases.  
3.9 - Expression and purification of Fab 
Fab consists of VH–CH1 (Fab heavy chain) and VL–CL (Fab light chain), in which the two 
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polypeptide chains are linked covalently by a C-terminal disulphide bond. To allow the 
interaction of Fab with D-SpGC2-1 to be studied extensively, it was essential that enough 
Fab protein was available. This was achieved by employing a modified pTTOD vector 
[Humphreys et al., 2002]. The pTTOD vector, kindly supplied by UCB-Celltech, Slough, 
had been optimised for the expression of Fab in E.coli, and is shown below in figure 
3.51.  
 
Figure 3.51 – An adapted schematic diagram of the pTTOD vector used for cloning and 
expression of Fab  
 
The Fab gene is cloned in at the EcoR I and Pst I restriction sites, and is encoded in two 
sections, with the heavy and light chains produced separately.  
 
The pTTOD vector was used to clone the wild-type Fab heavy and light chains genes, of 
known sequence, which are encoded separately in different reading frames. The amino 
acid sequences of the humanised Fab heavy and light chains are shown in figure 3.52.  
 
Heavy Chain: 
 
EVQLVESGGGLVQPGGSLRLSCAFSGFSLSTSGVGVGWVRQAPGKGLEWVAHIWDGDESYNPSLKTQFTISKDTSKNTVYLQ
MNSLRAEDTAVYYCARNRYDPPWFVDWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDTHTCAA 
 
 
Light Chain: 
 
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFA
TYYCQQGKMLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
Figure 3.52 - Amino acid sequence of the heavy and light chains  
 
The pTTOD vector encodes the heavy and light chains of humanised mouse Fab 8516 
separately. Each chain has an N-terminal ompA signal sequence, which targets the 
translated protein to the periplasm where the chains can fold and associate [UCB-
Celltech]. 
The expression and purification of Fab protein, was achieved in a similar way as with D-
SpGC2-1, by cell growth, induction and harvest methods. However, a lower yield of Fab 
was achieved using this technique, so a slightly different extraction and purification 
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system was devised to produce larger quantities of the recombinant Fab fragments using 
fermentation. The use of E. coli for the expression of Fab can be difficult, as each Fab 
may be tolerated by the bacteria to a different degree [Lin et al., 2006]. Therefore, the 
growth conditions that relate to protein expression have to be optimised for each 
particular construct used [Humphreys, et al., 2002].  
 
An E.coli fermentation system uses simple conditions and involves two methods for the 
expression of recombinant antibody fragments.  
 
 
external environment 
protein layer 
lipopolysaccharide 
outer membrane 
cell wall and periplasm 
cytoplasmic membrane 
cytoplasm 
 
Figure 3.53 – An adapted schematic representation of the pathways for protein 
expression in gram-negative bacteria  
 
The general secretory pathway in gram-negative bacteria is presented. Secreted 
recombinant Fab protein follows the pathway indicated by the red arrows [Pugsley, 
1993]. 
 
The first method simply expresses the protein in the cytoplasm. Alternatively, if both 
chains of Fab possess an N-terminal ompA (outer membrane protein A) signal peptide 
sequence, then the protein is maintained in a loosely folded conformation bound to 
ompA for translocation across the cytoplasmic membrane into the periplasm, from where 
the ompA is inserted into the outer membrane. The second method targets the fragment 
to the periplasmic space between the cytoplasmic and outer membrane. Cleavage of the 
ompA signal sequence releases the protein into the periplasm, where the protein folds 
and adopts it tertiary and quaternary structure. In the periplasm there are a number of 
proteins that contribute to the folding, such as catalysing the formation of disulphide 
bonds. In the latter method, osmotic shock is used to release the folded protein from the 
periplasmic space into the culture medium. This expression system should therefore, 
produce a fully folded and functional antibody fragment [Pugsley, 1993]. The periplasm 
is the ideal subcellular location for Fab expression since its oxidising environment 
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enables the formation of intra- and inter-chain disulphide bonds [Debarbieux and 
Beckwith, 1998]. 
 
Bacterial expression of wild-type Fab was carried out successfully for this study, with the 
48 hour fermentation of JM103 E.coli cells containing the pTTOD vector. The Fab protein 
initially expresses as separate light and heavy chains, which associate and fold in the 
periplasm. However, it is the heavy chains that are of particular interest in this study, as 
SpG has been shown to bind to Fab by forming an anti-parallel interaction with the last 
β-strand of the CH1 domain. Average wet cell yields obtained from the fermentation 
expression system, outlined above, ranged from 70 to 280 g. 
 
The Fab protein was then extracted from the periplasm of these cells by osmotic shock 
using a sucrose solution with EDTA, based on that used by Neu and Heppel [1965]. The 
preparation of crude cell extract is critical in determining the total amount of desired 
protein available for purification, and it is preferable to selectively release the 
periplasmic contents of the cell without disrupting the cytoplasmic membrane. This 
minimises the amount of contaminating proteins in the extract. Fab fragments can be 
purified with a simple aqueous periplasmic heat extraction that removes the bulk of the 
host cytoplasmic and membrane proteins. Heat treatment at 60 °C was found to be most 
effective temperature for purification, without the significant loss of the desired protein.  
  
3.9.1 - Expression and purification of Fab heavy chain CH1   
Fab proteins were expressed and purified according to conditions stated in sections 
2.5.2.1 to 2.5.2.4. The theoretical pI of Fab heavy chain is 9.1 and the light chain is 6.7 
[Fujii et al., 2007]. Therefore, attempts were made to use cation-exchange 
chromatography to purify the Fab fragment from the refined supernatant obtained from 
the heat treatment at pH 2.2. It was also initially thought that the high pI of the Fab 
fragment would be unlikely to be similar to that of the contaminant proteins. However, 
the purification of Fab fragments from the periplasm of E.coli using cation-exchange 
chromatography also resulted in the co-purification of some E.coli host proteins, having 
similar functional pI’s. This problem was also encountered by Humphrey et al [Humphrey 
et al., 2004], who identified contaminating proteins, such as periplasmic phosphate 
binding protein, that possessed similar pI values. Therefore other methods had to be 
employed. Other workers in the laboratory had success in the use of an affinity column 
comprised of single B domains of protein L immobilised onto NHS-Sepharose (Cossins, 
2006). This column is able to bind Fab and kappa light chain but not heavy chain.  The 
supernatant from the heat treatment was applied to a 50 ml column of immobilised 
protein L domain equilibrated in 100 mM Tris buffer containing 0.5 M NaCl at pH 8.0. The 
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column was then washed with loading buffer until the eluate was optically clear at 280 
nm and then a linear gradient of 0 to 50mM citrate buffer at pH 2.2 also containing 0.5 
M NaCl. Figure 3.54 presents a typical elution profile obtained from a Protein L-
Sepharose illustrating the absorbance peaks at 280 nm and conductivity for each 
fraction. Purified Fab is typically eluted when the conductivity reaches between 6 and 9 
mS at pH 2.2, which corresponds to fractions 44 to 50 taken from the large peak.   
 
 
Figure 3.54 - A typical elution profile of wild-type Fab obtained from a linear gradient, 
illustrating the absorbance peaks at 280nm and conductivity for each 
fraction number   
 
Wild-type Fab protein was expressed and purified on a NHS-Sepharose matrix column. A 
typical elution profile obtained illustrates the absorbance of the collected fraction 
samples at 280 nm, and the corresponding conductivity. The absorbance at 280 nm is 
denoted by the black line, and the conductivity is denoted by the grey line.  
 
The detection of expression of the Fab fragments were performed by running fraction 
samples on a high-resolution non-reducing separating gel containing 17.5% acrylamide 
under reducing conditions, as described in section 2.5.3. Figure 3.55 presents two typical 
non-reducing 17.5% SDS polyacrylamide gels of samples taken from the collected 
elutent in the specified region. Fractions were pooled according to purity, and 
concentrated by an ammonium sulphate precipitation at the 80% saturation level 
(section 2.5.4). 
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Figure 3.55 - Two typical non-reducing 17.5% SDS polyacrylamide gels of fraction 
samples collected from the purification of Fab protein  
  
Two high-resolution non-reducing 17.5% SDS gels were used to analyse the fraction 
samples collected from the linear gradient employed to purify wild-type Fab protein. A 
sample taken from the heat-treated supernatant (HT s/n) is shown. All samples shown 
above from fractions 44 to 50 inclusive were pooled and stored at 4 °C as an 80% 
(NH4)2 SO4 precipitate. 
 
These SDS gels exhibit a standard level of protein expression that was representative for 
wild-type Fab protein, and demonstrates that relatively pure protein has been obtained. 
However, these gels also show that the use of the Fab pTTOD vector resulted in the 
production of several different antibody fragments as well as the desired Fab protein. 
The presence of kappa light chain that has not associated with heavy chain was 
expected, as the two chains are translated separately to associate and fold in the 
periplasmic space. The fractions that contained both Fab and light chain were not pure 
enough to be used, and were pooled and applied to a Superdex 200 Hi-Load 16/60 
column gel filtration column. This additional chromatographic step is required to ensure 
total separation of Fab from the contaminating proteins. The other fragment that 
resulted from the cation-exchange chromatography purification of Fab was identified as a 
small κ-light chain fragment. This high expressing protein is a domain antibody (dAb) 
that consists of only the VL domain of Fab and has been shown to bind to protein L 
[Cossins, 2006].  
 
The wild-type Fab pTTOD protein prepared as described, together with standard Fab 
kindly donated by UCB-Celltech, can now be employed in the subsequent 
characterisation of SpG’s interactions with Fab. 
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3.10 - Discussion 
A 208 bp single Ig-binding domain gene construct of SpG, based on the wild-type SpGC2-
1 gene encoding the C2 domain, was successfully cloned into the pQE-30 vector. Specific 
amino acid residues that contribute to the Fc and Fab binding interactions via a network 
of hydrogen bonds were identified and effectively modified by a programme of two-sided 
SOE-ing site-directed mutagenesis. An extensive series of mutant proteins were 
produced and a high level of expression for the wild-type, Fab and all but one of Fc 
mutant constructs were achieved. 
 
Further characterisation of these Fc and Fab mutants will allow information on the 
importance of these individual amino acids in the encoded protein to be obtained. Also 
identifying the key residues that are critical for these interactions allows the contribution 
of a specific amino acid to the biological function of SpG to be evaluated.  
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4.0 - Introduction 
All protein molecules are linear polypeptide chains of amino acids that adopt and 
fold into specific three-dimensional structures, known as native states. This 
generates a biologically active structure that is required for specific interactions, 
allowing proteins to play an important role in the mechanism and control of a 
broad spectrum of cellular processes, as well as to perform intricate biological 
functions. These range from the translocation of proteins across membranes to 
the regulation of cellular events in the cell cycle [Radford and Dobson, 1999]. 
Christian Anfinsen, 1973, proposed that the information needed to specify a 
protein’s complex structure is encoded in its amino acid sequence and it has been 
shown that under suitable conditions, globular proteins will spontaneously fold to 
their native states. Since Anfinsen’s famous protein refolding studies, subsequent 
theoretical and experimental work has provided further information and 
understanding into the principles involved in the mechanisms of protein folding. 
Complementary analytical and computational studies representing idealised 
models of proteins have also provided valuable insights into the prediction of 
protein-folding mechanisms and the three-dimensional structures of proteins [Kim 
and Baldwin, 1982; Kim and Baldwin, 1990; Evans and Radford, 1994].  
 
Contributions from non-covalent interactions, such as hydrogen-bonding, van der 
Waal’s, hydrophobic and electrostatic interactions, govern the folding of proteins 
to their native structures. The net contribution of these interactions in the folded 
state relative to the unfolded state governs the stability. 
 
The correct three-dimensional structure is essential for the protein to function, 
and misfolding usually produces inactive proteins with different properties [Nilsson 
and Anderson, 1991]. Misfolded proteins are responsible for several diseases, 
such as Alzheimer’s disease [Hoozemans et al, 2005], cystic fibrosis [Sato et al., 
1996], alpha-1-antitrypsin deficiency [James et al., 1999] and prion-related 
illnesses including Creutzfeldt-Jakob disease (CJD) and Bovine Spongiform 
Encephalopathy (BSE) [Horwich and Weissman, 1997], and are all associated with 
the aggregation of misfolded proteins into insoluble plaques [Ramirez-Alvarado et 
al., 2003]. Therefore, by understanding the processes, which govern protein 
folding, medical intervention of these diseases may be achieved.  
 
Information regarding the secondary and tertiary structure of a protein can be 
obtained from its spectral properties, using fluorescence and circular dichroism 
(CD) techniques, as well as from experiments using chaotropic reagents. 
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Fluorescence responds to changes in the environment of fluorophores (tryptophan 
and tyrosine residues in proteins) and therefore, changes in the tertiary structure. 
Whereas circular dichroism in the far UV range, follows changes in the symmetry 
of the peptide backbone and therefore, the secondary structure of proteins. The 
proposed study into the conformation stability due to mutagenesis of a domain of 
SpG will allow the contribution of a specific amino acid to the parameters 
associated with the native state and biological function of SpG to be evaluated. CD 
and the use of the chaotropic reagent, guanidine-hydrochloride (Gdn-HCl), were 
employed as versatile tools to probe the native structure of SpG, Fc and Fab 
mutant constructs, and any changes in structure or stability. 
 
4.1 – Protein folding 
Protein folding is the physical process by which an unfolded polypeptide chain 
becomes highly compact and folds into a specific native and functional three-
dimensional, tertiary structure [Baker, 2000].  
 
4.1.1 – Sequence, folding and structure 
Every protein originates as a polypeptide, which is translated from a sequence of 
mRNA as a linear chain of amino acids in the peptidyl-transferase site of the 
ribosome from the N-terminus. The elongating polypeptide then moves across the 
narrow ribosome channel and emerges at the exit site from the ribosome into the 
cytoplasm. This polypeptide can be described as a random coil, as it does not 
possess any developed three-dimensional structure or long-range interactions 
[Dinner et al., 2000]. After leaving the ribosome, the polypeptide chain goes 
through a number of steps, known as the folding pathway, before it folds into its 
native protein structure.  
 
Studies using data and propositions from both experimental [Kuwajima 1992; 
Ptitsyn, 1995; Baldwin, 1995, 1996 and 1999] and theoretical studies [Dill and 
Chan, 1997; Nyemeyer et al., 1998] have suggested that protein folding is divided 
into two stages [Arai and Kuwajima, 2000]. The first stage involves the formation 
of a molten globule state from the unfolded polypeptide chain, which is a flexible 
intermediate where the protein forms its basic structural framework, but with no 
specific side-chain packing. The second stage involves the formation of the native 
state from the molten globule state, where the specific tertiary structure is 
assembled with precise hydrophobic interactions and side-chain packing. This 
subsequent folding often requires specific molecules called molecular chaperones 
to help in the formation of the precise native state. However, more recent studies 
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have indicated that these two steps may not be as distinct from one another as 
previously thought, and that co-translational protein folding is a more accurate 
model [Basharov, 2003].  
 
Co-translational protein folding is the folding of the polypeptide chain whilst it is 
being synthesised on the ribosome. Thus, while the ribosome joins residues to the 
elongating polypeptide, either α-helices, β-sheets or the definite conformation can 
be formed in any N-terminal part of the polypeptide that has emerged from the 
ribosome. This is thought to occur because synthesis of an entire polypeptide 
chain may take seconds, whereas secondary structure formation and compaction 
of a polypeptide chain takes less than one second [Roder and Colon, 1997]. 
However, although it is known that any notable conformational changes of a 
synthesised polypeptide are prevented by the narrow ribosome channel, 20-28 Å 
[Ramakrishnan, 2002], alternative studies have shown that proteins exhibit 
folding activity whilst still bound to the ribosome [Fedorov and Baldwin, 1997]. In 
addition, recent spectroscopic studies coupled with quantitative kinetic analysis, 
suggest that folding is facilitated by the rapid formation of compact intermediates 
with some native-like structural features, and as shown by Ptitsyn, formation of 
compact globular intermediates only takes a few seconds [Ptitsyn, 1995].  
 
The interior of the protein’s tertiary structure is tightly packed and is closer to a 
solid than liquid phase [Klapper, 1971]. The bonds that are formed in the interior 
of the protein are weak in comparison to covalent bonds. However, weak 
interactions have an advantage in that they are less rigid and provide the protein 
with more flexibility and dynamics, and the protein is compensated by their vast 
number. The tight packing of the core is thought to give a considerable 
contribution to protein stability [Pace et al. 2004]. In contrast, the surface of the 
protein consists of a majority of polar and charged side chains, which are very 
important for protein solubility [Malissard and Berger, 2001], and as proteins 
increase in size, the proportion of buried charged amino acids also increases 
[Kajander et al., 2000].  
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4.2 – Thermodynamic and kinetic control of protein folding 
The majority of proteins fold spontaneously into their native structure in aqueous 
solution, but the folding process must satisfy two conditions, one thermodynamic 
and one kinetic [Eaton et al., 2000]. The thermodynamic consideration is that a 
protein must adopt a single, folded conformation, whereas the kinetic requirement 
is that a protein must fold to the native structure on an appropriate timescale 
[Baker and Agard, 1994]. For most proteins, the native structure is under 
thermodynamic control and corresponds to a minimum Gibbs free energy, ranging 
from -5 to -15 kJmol-1 [Yon, 1997].  
The duration of the folding process varies depending on the size of the protein. 
Large proteins require minutes or hours to fold as a result of steric hindrances 
compared to smaller proteins, which tend to fold in milliseconds and fast protein 
folding reactions are completed within a few microseconds [Baldwin, 1994]. It has 
also been determined that α-helical proteins, which have a larger fraction of 
sequentially short-range contacts, fold faster than mixed α/β or β-sheet proteins, 
which have a larger fraction of long-range contacts [Dinner et al., 1996]. An 
unfolded protein has a vast number of accessible conformations, particular in its 
side-chains, and these various conformations differ only in the angle of rotation 
around the bonds of the backbone and amino side-chains. When a native protein 
folds, the side-chains in the hydrophobic core are restricted to a single 
conformation [Dinner et al., 2000].  
 
4.3 – Conformational stability 
Conformation stability generally refers to the structural arrangement of a protein 
and the overall conformation of a protein is independent of its stability. It can also 
be defined as the free energy difference between the native folded state and the 
unfolded state under physiological conditions [Pace et al., 1996]. To function as a 
protein, a polypeptide chain must possess a unique native state that is stable at a 
physiological temperature and be able to fold into its native structure within a 
reasonable time, milliseconds to minutes, at that temperature.  
 
The majority of folded proteins have a hydrophobic core in which side-chain 
packing stabilises the folded state, together with charged side-chains on the 
solvent-exposed surface that interact with surrounding water molecules [Northey 
et al., 2002]. This structural uniqueness is characteristic of native proteins and is 
essential for them to express their biological functions. The compact native 
structure of a globular protein also contains bonds of different types, including 
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covalent bonds, ionic bonds, hydrogen bonds, sulphur bonds and van der Waals 
bonds. Hydrogen bonds play an important role in the stabilisation of structural 
elements such as α-helices and β-sheets [Myers and Pace, 1996]. 
 
However, the polarity of amino acids and hydrophobic effects between the protein 
and surrounding solvent are the main factors involved in driving the formation of 
the native structure [Calloni et al., 2003]. In aqueous solutions polar amino acids 
tend to be hydrophilic and attract polar water molecules, while non-polar residues 
are hydrophobic. These hydrophobic amino acids interact unfavourably with water 
molecules and are more inclined to associate with each other. This results in the 
water molecules rearranging their network to compensate for this event, leading 
to an increased ordering of the water [Northey et al., 2002]. The hydrophobic core 
is important for the stability of the native structure [Viguera et al., 2002].  
 
4.4 – Conformational stability of SpG 
The stability and folding characteristics of SpG has been extensively studied 
experimentally [Kuszewski et al., 1994; Park et al., 1997 and 1999; McCallister et 
al., 2000; Brown and Head-Gordon, 2004], and has proven to be an excellent 
model for conformation stability studies. The spacial arrangements of the 
secondary-structure elements in which an α-helix is positioned diagonally across a 
β-sheet, is very stable [Sauer-Eriksson et al., 1995]. Its three-dimensional 
structure is known [Akerstrom et al., 1985; Gronenborn et al., 1991; Gallagher et 
al., 1994], as well as its thermodynamic properties characterised [Alexander et 
al., 1992]. 
 
Previous studies have shown that SpG folds through at least two pathways. The 
fast pathway exhibits two-state kinetics with a transition state ensemble resulting 
in β-hairpin 2 [Huyghues-Despointes et al., 2006]. This is assisted by the α-helix 
and the overall folding mechanism seems to be consistent with a nucleation-
condensation mechanism [Daggett and Fersht, 2003a]. The slower folding 
pathway involves an early intermediate [Park et al., 1997 and 1999] that is 
characterised by hydrophobic contacts involving the third β-strand interacting with 
β-strands 1 and 2 [Brown and Head-Gordon, 2004]. The intermediate precedes 
the rate-limiting barrier of folding, which separates the unfolded state from the 
early folding intermediate, and is lower in free energy relative to the unfolded 
state [Brown and Head-Gordon, 2004].  
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4.5 – Determination of conformational stability using circular 
dichroism  
Circular dichroism (CD) is a form of light absorption spectroscopy that measures 
the difference in the absorption of right- and left-circularly polarised light when 
plane polarized light passes through an optical active sample solution [Woody, 
1995]. This difference in absorbance is due to the fact that the extinction 
coefficients for the two types of polarized light are different [Fersht, 1999]. A 
schematic illustration of circular dichroism is presented in figure 4.1.  
 
 
 
 
Figure 4.1 – An adapted schematic illustration of circular dichroism 
 
In order for a molecule to produce a CD signal it must be chiral and absorb light.  
Plane-polarised light can be divided into its constituent equal intensity left- and 
right-circularly polarised light beams. When a chiral molecule absorbs plane-
polarised light, left- and right-circularly polarised light will be absorbed to 
different extents. The differential absorbance of the two circular components by a 
chiral medium converts the plane-polarised light into elliptically polarised light, 
giving rise to the observed CD signal [Woody, 1995].   
 
Light is a transverse electromagnetic wave consisting of an oscillating electric (E) 
field and a magnetic (H) field. Linear polarised light is composed of right (R) and a 
left (L) circularly polarized waves at right angles relative to each other and of 
equal amplitude and 90° difference in phase. In contrast, elliptically polarized light 
consists of two perpendicular waves of unequal amplitude, which differ in phase 
by 90° [Wen-Chuan et al., 2005]. A comparison of methods for achieving 
polarization is shown in figure 4.2. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Adapted illustration showing how right and left circularly polarized 
light combine under certain conditions  
 
Diagrams showing how right and left circularly polarized light combine if (A) the 
two waves have the same amplitude, the result is plane-polarized light or (B) the 
amplitudes differ, the result is elliptically polarized light [Kelly et al., 2005].  
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The angle of optical rotation of an optically active sample varies with the 
frequency of the radiation. The rotation of the plane is due to the difference in 
refractive indices for R and L circularly polarised light, nR and nL. CD is the 
difference in the absorption intensity of R and L circularly polarized light (IR and 
IL) which arise due to structural asymmetry. The amplitude of the stronger 
absorbed component will be smaller than that of the less absorbed component. In 
addition, a CD spectrum is the variation of IL - IR with frequency of radiation. The 
absence of regular structure results in zero CD intensity, while an ordered 
structure results in a spectrum, which can contain both positive and negative 
signals. For CD measurements, in principle two light sources are needed, one for L 
and the other for R circularly polarized light, each provided with a monochromator 
for wavelength selection. However, L and R light may be generated from a single 
source [Wen-Chuan et al., 2004].  
 
4.5.1 - Use of CD to study proteins 
CD is a widely used technique for studying the conformation of chiral peptide and 
protein molecules in solution as it is uniquely sensitive to the asymmetry of the 
system. Chiral molecules are optically active and have the ability to rotate the 
plane of plane polarised light. The peptide bond is naturally chiral and therefore 
always optically active. CD spectra can be measured with any frequency of 
electromagnetic radiation at which the compound absorbs, but in practice, the 
majority of CD spectroscopy involves the ultraviolet-visible regions of the 
spectrum. For randomly oriented samples, such as solutions, a net CD signal will 
only be observed for chiral molecules, which are ones that cannot be 
superimposed on their mirror images [Sreerama and Woody, 1993].  
 
The protein CD spectrum is divided into three regions, the far-UV (≈190-250 nm), 
the aromatic region of the near-UV (≈250-320 nm) and the near-UV-visible region 
(≈300-700 nm), and different chromophores in proteins contribute to these 
regions. The peptide bond is the principal element whose spectrum is detected in 
protein studies by CD. It exists in many conformations depending on its precise 
location in the protein, and the spectrum obtained is a result of an average of the 
various conformation parameters.  
 
It has been shown that CD spectra are very sensitive to the secondary structures 
of polypeptides and proteins, and wavelengths between 260 nm and 180 nm can 
be analysed for the different secondary structural types, such as alpha helices, 
parallel and anti-parallel beta sheets, turns and random coils [Johnson, 1990]. 
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This can then be employed to estimate the contribution of α-helices and β-sheets 
to the overall secondary structure. This is illustrated by the reference spectra 
presented in figure 4.3, which show 100% alpha-helix, beta-sheet and random 
coil spectra for the three different conformations of proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 – Circular dichroism spectra of the characteristic secondary 
structures  
 
Absorption in the far UV region is largely due to the peptide backbone, and is 
highly dependent on the secondary structure formed by the protein. The CD 
spectra observed for the α-helical, β-sheet and random coil are shown in black, 
red and green respectively. Based on spectra from http://www.jgiqc.llnl.gov 
 
The CD signal due to α-helices is characterised by negative ellipticity showing 
minima at 208 nm and 222 nm and one positive peak at 192 nm. In contrast, β-
sheets have a characteristic positive peak at 195 nm and a negative peak of 
similar magnitude around 216 nm. Random coil typically shows a negative CD 
signal below 200 nm, with a positive peak occurring around 218nm.  
 
The far-UV region is reflective of the environment resulting from the contributions 
from side-chain chromophores, such as the aromatic amino acids, (tryptophan, 
tyrosine and phenylalanine), with additional contributions from cysteine residues 
involved in disulphide bonds. The near-UV region can provide information about 
the localised environment of the aromatic amino acids, thus allowing information 
to be obtained about the protein tertiary structure [Kahn, 1979].   
 
4.5.2 - Determination of conformational stability of D-SpGC2-1  
All CD measurements were made in a Jasco J-720 CD spectropolarimeter at a 
protein concentration of 100 µM in 20 mM potassium phosphate buffer pH 8.0, at 
room temperature. Spectra were acquired in a 0.01 cm cell path length at a       
50 nm/min scan speed. Each spectrum was measured in mdeg and expressed in 
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Molar Ellipticity (θ=deg.cm2.dmol-1), which eliminates inconsistencies in 
concentration and path length between samples, and allows a direct comparison 
to be made between proteins. The spectra shown are accumulations of nine 
spectral scans, which were averaged and baseline-corrected by subtraction of a 
buffer blank. All CD spectra were analysed using the manufacturer’s Standard 
Analysis software. 
 
4.5.3 – Far-UV CD analysis of Wt D-SpGC2-1  
Secondary structure can be determined by CD spectroscopy in the far-UV spectral 
region (190-250 nm). At these wavelengths the chromophore is the peptide bond, 
and the signal arises when it is located in a regular, folded environment. The CD 
signal reflects an average of the entire molecular population, and alpha-helix, 
beta-sheet and random coil structures each give rise to a characteristic shape and 
magnitude of CD spectrum.   
 
The far-UV spectra of 100 µM Wt D-SpGC2-1 construct and 20 mM potassium 
phosphate buffer, pH 8.0 were measured between 190 and 250 nm, by CD. The 
spectrum obtained for the 20 mM potassium phosphate buffer was then 
subtracted from that obtained for the wild-type protein to correct for the baseline, 
and is presented in figure 4.4.   
 
Figure 4.4 – Far-UV CD spectra of corrected Wt D-SpGC2-1  
 
Far-UV CD spectrum of purified 100 µM Wt D-SpGC2-1 in 20 mM potassium 
phosphate buffer, pH 8.0 is presented. Measurements were taken at room 
temperature in a 0.01 cm path length cell. Nine scans were collected from 190 to 
250 nm, averaged and baseline corrected by subtraction of blank buffer. Each 
spectrum was analysed as molar ellipticity (deg.cm2.dmol-1).  
The far-UV spectrum obtained for wild-type D-SpGC2-1 shows a wavelength 
characteristic of α-helical content, with a minima in ellipticity at 209 and 210 nm. 
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However, the secondary structure of SpG has a high β-strand content compared 
to the occurrence of just one α-helix. The expected secondary structural content 
for D-SpGC2-1, calculated from the number of residues in each structural element 
determined by X-ray crystallography and NMR, was 46% β-strand, 27% α-helix 
and 27% random coil. However, the strong spectral contribution of the α-helix can 
obscure the true β-strand content of a protein and can give rise to errors in the 
estimation of the secondary structural components. 
 
4.5.4 – Far-UV CD analysis of Fc D-SpGC2-1 mutant constructs  
Purified D-SpGC2-1 mutant constructs were analysed by far-UV CD to determine if 
the mutation had affected the secondary structure of the protein. This was 
important as any changes in binding affinity might be attributed to the specific 
side-chain alterations. Far-UV spectra of engineered D-SpGC2-1 mutant constructs 
are shown in figures 4.5 and 4.6, and compared to the CD spectrum obtained for 
the Wt D-SpGC2-1 protein.  
 
Figures 4.5 and 4.6 show that the mutations E26A, Q31A, Q31E, Q31H, N34A, 
N34D, E41A and E41Q have little effect on the CD spectra in comparison to that of 
the D-SpGC2-1 wild-type protein. 
 
Figure 4.6b also presents a comparison between wild-type D-SpGC2-1 with the 
sole cysteine mutation C56A D-SpGC2-1. Again, the far-UV CD spectrum for this 
mutation is very similar to that of wild-type protein, again suggesting that the 
side-chain replacement of the cysteine residue by an alanine residue has not 
altered the structure of D-SpGC2-1.  
 
In figure 4.6c the two mutants have very similar spectra, both different to that of 
the wild-type protein. This is due to the loss of the tryptophan indole side-chain 
that contributes negative ellipticity in this region. 
 
Although the far-UV CD spectra of proteins are generally dominated by peptide 
contributions, aromatic side-chains may also make significant contributions to the 
secondary structure analysis [Woody, 1994]. This is especially true for proteins 
with low α-helix content, such as immunoglobulins and their respective binding 
proteins, such as SpG. CD bands in the 225-235 nm region are sometimes seen, 
which can be attributed to tyrosine or tryptophan side-chains.  
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Figure 4.5 – The far-UV CD spectra measured for Fc D-SpGC2-1 mutants 
 
Far-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared to that of wild-type. 
Measurements were taken at room temperature in a 0.01 cm path length cell. 
Nine scans were collected from 190 to 250 nm, averaged and baseline corrected 
by subtraction of blank buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1). 
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Figure 4.6 – The far-UV CD spectra measured for Fc D-SpGC2-1 mutants 
 
(c) 
 
Far-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared to that of wild-type. 
Measurements were taken at room temperature in a 0.01 cm path length cell. 
Nine scans were collected from 190 to 250 nm, averaged and baseline corrected 
by subtraction of blank buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
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4.5.5 – Near-UV CD analysis of Wt D-SpGC2-1   
Information about a protein’s tertiary structure can be obtained from the CD 
spectrum of a protein in the near-UV spectral region (250-350 nm). At these 
wavelengths the chromophores are the aromatic amino acids and disulfide bonds, 
and the CD signals they produce are sensitive to the overall tertiary structure of 
the protein.  
 
If a protein retains secondary structure, but no side-chain packing as in an 
incorrectly folded or molten-globule structure, the signals in the near-UV region 
will be nearly zero. Conversely, the presence of significant near- UV signals is a 
good indication that the protein is folded into a well-defined structure. 
Furthermore, the near-UV CD spectrum can be sensitive to small changes in 
tertiary structure due to protein-protein interactions and/or changes in solvent 
conditions. The signal strength in the near-UV CD region is much weaker than that 
in the far-UV CD region due to the lower number of contributing residues.  
 
The near-UV CD spectrum of 100 µM Wt D-SpGC2-1 construct and 20 mM 
potassium phosphate buffer, pH 8.0 was measured in the 250-350 nm regions and 
that for 20 mM potassium phosphate buffer was subtracted from that obtained for 
the wild-type protein to correct for the baseline, and is presented in figure 4.7.   
 
Signals in the region from 250-270 nm are attributable to phenylalanine residues, 
signals from 270-290 nm are attributable to tyrosine, and those from 280-300 nm 
are attributable to tryptophan. Disulfide bonds give rise to broad, weak signals 
throughout the near-UV spectrum [Woody, 1978]. The near-UV spectrum obtained 
for wild-type D-SpGC2-1 shows wavelength contributions characteristic of both 
tyrosine and tryptophan content, with ellipticity signals corresponding to 
wavelength regions of 270-300 nm. This presence of significant near-UV signals is 
a good indication that the domain from wild-type D-SpGC2-1 is folded into a well-
defined structure. 
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Figure 4.7 – Near-UV CD spectra of corrected Wt D-SpGC2-1  
 
Near-UV CD spectrum of purified 100 µM Wt D-SpGC2-1 in 20 mM potassium 
phosphate buffer, pH 8.0 is presented. Measurements were taken at room 
temperature in a 0.5 cm path length cell. Nine scans were collected from 250 to 
350 nm, averaged and baseline corrected by subtraction of the spectrum of 
buffer. Each spectrum was analysed as molar ellipticity (deg.cm2.dmol-1).  
 
4.5.6 – Near-UV CD analysis of D-SpGC2-1 mutant constructs  
The characteristics of near-UV spectropolarimetry can be employed to detect any 
changes in the environment of one or more aromatic residues due to amino acid 
substitutions bought about by the site-directed mutagenesis [Shortle, 1989].  
 
Near-UV spectra of engineered D-SpGC2-1 mutant constructs are shown in figures 
4.8 and 4.9, and compared to the CD spectrum obtained for the Wt D-SpGC2-1 
protein. Examination of these data reveals that the majority of the mutant 
constructs display spectra comparable to that of wild-type D-SpGC2-1, with only 
slightly varying differences in molar ellipticity. Signals in the region from 250-270 
nm are attributable to phenylalanine residues, signals from 270-290 nm are 
attributable to tyrosine, and those from 280-300 nm are attributable to 
tryptophan. Disulphide bonds give rise to broad weak signals throughout the near-
UV spectrum [Woody, 1978]. The overall shape of each spectrum is very similar to 
that of the wild-type domain. The differences in molar ellipticity may be due to 
small errors in the estimation of the concentrations of proteins and/or due to 
fluctuation in the lamp intensity. In general, these spectra confirm that the 
aromatic side-chains are packed in a folded structure. 
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Figure 4.8 – The near-UV CD spectra measured for Fc D-SpGC2-1 mutants 
 
Near-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared to that of wild-type. 
Measurements were taken at room temperature in a 0.5 cm path length cell. Nine 
scans were collected from 250 to 350 nm, averaged and baseline corrected by 
subtraction of the spectrum of buffer. Each spectrum was analysed as molar 
ellipticity (deg.cm2.dmol-1).  
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Figure 4.9 – The near-UV CD spectra measured for Fc D-SpGC2-1 mutants 
 
Near-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared with wild-type. Measurements 
were taken at room temperature in a 0.5 cm path length cell. Nine scans were 
collected from 250 to 350 nm, averaged and baseline corrected by subtraction of 
the spectrum of buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
 | 141  
 
4.5.7 – Far-UV CD analysis of D-SpGC2-1 mutant constructs 
designed to probe the interaction with Fab 
Purified D-SpGC2-1 mutant constructs were analysed by far-UV CD to determine if 
the mutation had grossly affected the secondary structure of the protein. This is 
important as then any changes in binding affinity could be attributed to misfolding 
of the proteins. Figure 4.10 presents a comparison between wild-type and E14W-
W42F D-SpGC2-1. This far-UV CD spectrum shows that the insertion of a 
tryptophan reporter group at the alternative position of E14W to allow the 
interaction between SpG and Fab to be probed, compares very well to that of wild-
type D-SpGC2-1. Both spectra are characteristic of a protein with some α-helical 
content, with minima in ellipticity at 210 and 220 nm. This suggests that the 
E14W-W42F mutation has not affected the secondary structure of the C2 domain 
of SpG. It is noticeable that the addition of W14 to the W42F construct restores 
the ellipticity between 205-230 nm to that of the wild-type protein, confirming 
that tryptophan contributes to this part of the spectrum. 
 
 
 
Figure 4.10 – The far-UV CD spectra measured for Wt and E14W-W42F D-SpGC2-1 
 
Far-UV CD spectra of purified 100 µM Wt and E14W-W42F D-SpGC2-1 in 20 mM 
potassium phosphate buffer pH 8.0 is compared. Measurements were taken at 
room temperature in a 0.01 cm path length cell. Nine scans were collected from 
190 to 250 nm, averaged and baseline corrected by subtraction of the spectrum of 
buffer. The spectrum was analysed as molar ellipticity (deg.cm2.dmol-1).  
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Therefore, further far-UV spectra of D-SpGC2-1 mutant constructs designed to 
alter Fab binding are shown in figures 4.11 and 4.12, and compared to the CD 
spectrum obtained for the E14W-W42F D-SpGC2-1 protein. Examination of these 
spectra reveals that the majority of these mutant constructs display spectra 
comparable to that of E14W-W42F D-SpGC2-1, with only slight differences in molar 
ellipticity. All spectra are characteristic of proteins with α-helical content, 
suggesting that these mutations have not grossly affected the overall secondary 
structure of the C2 domain of SpG. The exception to this is presented in figure 
4.11, which presents a comparison between E14W-W42F D-SpGC2-1 with domains 
containing threonine replacements T10A and T10S. The far-UV CD spectrum for 
the T10S mutant overlays the spectrum of E14W-W42F perfectly. In contrast, the 
far-UV CD spectrum for the T10A mutant shows a significant reduction in the CD 
signal in the far-UV CD spectra, which may be due to folding differences.  
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Figure 4.11 – The far-UV CD spectra measured for Fab D-SpGC2-1 mutants 
 
Far-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared with wild-type. Measurements 
were taken at room temperature in a 0.01 cm path length cell. Nine scans were 
collected from 190 to 250 nm, averaged and baseline corrected by subtraction of 
the spectrum of buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
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Figure 4.12 – The far-UV CD spectra measured for Fab D-SpGC2-1 mutants 
 
Far-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared with wild-type. Measurements 
were taken at room temperature in a 0.01 cm path length cell. Nine scans were 
collected from 190 to 250 nm, averaged and baseline corrected by subtraction of 
the spectrum of buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
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4.5.8 – Near-UV CD analysis of D-SpGC2-1 mutant constructs 
engineered to probe the interaction with Fab 
Purified D-SpGC2-1 mutant constructs were analysed by near-UV CD to determine 
if the mutation had affected the secondary structure of the protein. Figure 4.13 
presents a comparison between wild-type and E14W-W42F D-SpGC2-1. This near-
UV CD spectrum shows that the insertion of a tryptophan reporter group at the 
alternative position of E14W to allow the interaction between SpG and Fab to be 
probed, compares very well to that of wild-type D-SpGC2-1. Thus, the presence of 
the tryptophan 14 compensates for the spectral changes noted when tryptophan 
42 is substituted by phenylalanine.  
 
 
Figure 4.13 – Near-UV CD spectra measured for Wt and E14W-W42F D-SpGC2-1  
 
Near-UV CD spectrum of purified 100 µM Wt and E14W-W42F D-SpGC2-1 in 20 mM 
potassium phosphate buffer, pH 8.0 is compared. Measurements were taken at 
room temperature in a 0.5 cm path length cell. Nine scans were collected from 
250 to 350 nm, averaged and baseline corrected by subtraction of the spectrum of 
buffer. The spectrum was analysed as molar ellipticity (deg.cm2.dmol-1) 
 
Further near-UV spectra of engineered D-SpGC2-1 mutant constructs are shown in 
figures 4.14 and 4.15, and compared to the CD spectrum obtained for the E14W-
W42F D-SpGC2-1 protein.  
 
The CD data suggest that the T10A D-SpGC2-1 mutation may lead to serious 
disruption of the natural folding of the domain indicated by both the far and near 
UV spectral changes. 
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Figure 4.14 – The near-UV CD spectra measured for Fab D-SpGC2-1 mutants 
 
Near-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared with wild-type. Measurements 
were taken at room temperature in a 0.5 cm path length cell. Nine scans were 
collected from 250 to 350 nm, averaged and baseline corrected by subtraction of 
the spectrum of buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
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Figure 4.15 – The near-UV CD spectra measured for Fab D-SpGC2-1 mutants 
 
Near-UV CD spectra of purified 100 µM protein samples, as indicated, in 20 mM 
potassium phosphate buffer pH 8.0 are compared with wild-type. Measurements 
were taken at room temperature in a 0.5 cm path length cell. Nine scans were 
collected from 250 to 350 nm, averaged and baseline corrected by subtraction of 
the spectrum of buffer. Each spectrum was analysed as molar ellipticity 
(deg.cm2.dmol-1).  
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4.6 – Determination of conformational stability using 
denaturation with Gdn-HCl 
The reverse of the folding process is known as protein denaturation, whereby the 
native structure of a protein is disrupted. The unfolded state (U) can be defined as 
the maximally unfolded state of a protein, in which the backbone NH groups are 
fully solvent exposed, and the denatured state (D) can be defined as the lowest 
energy non-native state under a defined set of conditions.  The denatured state 
could also be a folding intermediate if placed in conditions that promote folding.   
A fully denatured protein lacks both tertiary and secondary structure and exists as 
a random coil ensemble of unfolded structures. In certain solutions and under 
some conditions proteins will not fold into their biologically functional forms. High 
temperatures, high concentrations of solutes and extremes of pH will cause 
proteins to unfold or denature. A protein’s surroundings also play an essential role 
in the final conformation of the protein. An aqueous environment favours 
hydrophilic residues on the surface, whereas non-aqueous or non-polar 
environment favours hydrophobic residues on the surface.  
 
Studies of protein folding have shown that small proteins can be denatured and 
refolded in a reversible fashion, using denaturants such as heat, urea, or 
guanidine hydrochloride (Gdn-HCl) [Anfinsen, 1973; Ahmad et al., 1992]. Since 
the denatured states are less compact than the native state, the viscosity of the 
solution can be used as a measure of denaturation/renaturation. Likewise, the 
amino acid side-chains in the differing states i.e. in different environments. The 
wavelength of maximum fluorescence intensity and the lifetime of the 
fluorescence decay are very sensitive to the environment of the aromatic amino 
acids. Changes in the fluorescent properties of the aromatic amino acids, 
particularly tryptophan, can be used to measure protein folding/unfolding events. 
This permits the further understanding of protein folding, protein stability, as well 
as the understanding of the nature of the native and denatured states. 
 
The use of chemical denaturants, such as urea and guanidinium chloride, shown in 
figure 4.16, has played a central role in protein-folding experiments. Almost all 
proteins can be unfolded and remain soluble at sufficiently high denaturant 
concentrations, and both denaturants favour the denatured state by increasing the 
solubility of the unfolded protein in an aqueous solution.  
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 Urea ion Guanidinium ion 
Figure 4.16 – A schematic illustration of urea and guanidinium ions 
 
These illustrations show the two most commonly used chemical denaturants in 
folding studies, urea and guanidinium ions.  
 
The chemical action of chaotropic agents is still poorly understood. In 8 M urea 
and in 6 M Gdn-HCl, proteins approach a random coil state, and it is thought that 
this is a result of the disruption to both the hydrogen bonds and hydrophobic 
interactions. Another theory of the mechanism can be defined by the denaturant 
binding model [Tanford, 1968; Pace and Vanderburg, 1979]. In this model the 
denaturant molecules bind to peptide groups and side-chains, creating a shell 
around the folded and the unfolded polypeptide chain, presented in figure 4.17. As 
the concentration of denaturant increases, the unfolded state will be favoured, 
since it has a larger surface area exposed to the solvent, where more molecules 
can bind. The driving force for denaturation with chemical denaturants is therefore 
proportional to the change in exposed surface area going from the native to the 
denatured state. 
out 
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Figure 4.17 – The denaturant binding model  
 
This denaturant binding model represents chemical denaturation. The grey dots 
represent the chemical denaturant and the black lines represent the various 
states of the protein polypeptide. The denaturant molecules bind to peptide 
groups and side-chains and thereby create a shell around the native (N) folded 
and the unfolded denatured (D) polypeptide chain. 
 
In addition, chemical denaturation is often a reversible process. This is possible 
since the hydrophobic groups of the unfolded chain are shielded by the 
denaturants, which prevent aggregation. The fact that the process is reversible 
and that the protein approaches a maximum unfolded state is important to allow 
the conformational transitions to be measured. 
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4.6.1 - Calculating the conformational stability of D-SpGC2-1 by 
equilibrium denaturation with Gdn-HCl 
Further characterisation studies using solvent denaturation were carried out to 
determine the conformational stability of a domain of wild-type SpG and mutant 
constructs. By using spectral techniques to follow the process, equilibrium 
thermodynamic and kinetic measurements were made.  
 
A two-state model of denaturation for a single domain protein is employed in 
these studies, and refers to the reversible disruption of protein structure where 
only the fully folded native and the fully unfolded denatured states are populated, 
as shown below.  
Folded (F) = Unfolded (U)  
 
If, for example, fluorescence spectroscopy is used to follow the unfolding and 
assuming the denatured protein fully refolds when the denaturant is removed, the 
fraction of unfolded protein, FU, can be calculated using equation 4.1.  
 
FU = (yF – y)/(yF – yU)            (equation 4.1) 
 
and the fraction of refolded protein FF, is given using equation 4.2 [Pace, 1986]. 
 
FF = (y – yU)/(yF – yU)              (equation 4.2) 
 
Where, y is the observed fluorescence at a chosen concentration of denaturant, 
and yF and yU are the fluorescence characteristics of the folded and unfolded 
conformation, respectively. yF and yU are determined by the extrapolation of the 
pre- and post-transition region of the unfolding curve, occurring at low and high 
concentrations of denaturant, respectively. 
 
The equilibrium, Keq, for the unfolding process is given by equation 4.3 [Pace, 
1986]. 
 
Keq = FU/FF = (yF – y)/(y – yU)                         (equation 4.3) 
 
The stability of a protein’s conformation is equal to the difference in free energy 
between the folded and unfolded denatured states, ΔGU, and can be calculated 
from equation 4.4.  
 
ΔGU = -RT ln Keq                          (equation 4.4) 
Where Keq is the equilibrium constant for unfolding in the two-state model, 
calculated using equation 4.3. Combining these two equations, equation 4.5 can 
be derived. 
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ΔGU = -RT ln Keq = -RT ln [(yF – y)/(y – yU)]          (equation 4.5) 
 
Therefore, the difference in free energy between the folded and unfolded states 
(ΔGU) and hence, the conformational stability of a protein can be derived from the 
fraction of unfolded and folded protein (Keq). There is a linear dependence of ΔGU 
with the denaturation concentration along the transition region of the unfolding 
curves, see equation 4.6.    
 
ΔGU = ΔGU0 – m [Gdn-HCl]                              (equation 4.6) 
 
Thus, in a plot of ΔGU against denaturant concentration, the slope of the line yields 
m, the dependence of ΔGU on the denaturant concentration (kJmol-1M-1), and the 
intercept yields ΔGU0 (kJmol-1), the difference in free energy between the unfolded 
and folded state in the absence of denaturant. In addition, the mid-point of 
unfolding is given by equation 4.7, which is the concentration of denaturant that 
corresponds to when the protein is 50% unfolded.  
 
[Gdn-HCl]½ = ΔGU0/m                        (equation 4.7) 
 
Thus, the ΔGU0 value can also be calculated and compared with the estimate given 
graphically. The calculated ΔGU0 value is given by multiplying the m value by the 
mid-point value.  
 
4.6.2 – Determination of conformational stability of Wt D-SpGC2-1 
by equilibrium denaturation with Gdn-HCl 
Denaturation studies on Wt D-SpGC2-1 were carried out using guanidine 
hydrochloride at a stock solution of 6 M solution in 20 mM potassium phosphate 
buffer, which was filtered prior to use. For accurate determination of guanidine 
hydrochloride concentrations after filtration, the refractive index of the solutions 
were measured and calculated using the following equation [Pace et al., 1986]:  
 
[Gdn-HCl] = 57.147(ΔN) + 38.68(ΔN)2 – 91.60 (ΔN)3        (equation 4.8) 
 
Where, ΔN is the difference between the refractive index of the denaturant and 
the refractive index of the buffer used.  
 
To ascertain that the assumption of the reversible denaturation of protein 
structure is correct, refolding studies were carried out on Wt D-SpGC2-1. A 1 ml 
solution containing 10 µM Wt D-SpGC2-1 in 6M Gdn-HCl was added to 1ml of      
10 µM Wt D-SpGC2-1 in 0 M Gdn-HCl. The 2 ml solution (3 M) was left to 
equilibrate and induce protein refolding before its fluorescence emission spectrum 
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was determined. The spectrum of the refolded protein was compared with the 
fluorescence emission spectrum of Wt D-SpGC2-1 in 0 M, 3 M and 6 M Gdn-HCl. 
Figures 4.18 and 4.19 present fluorescence emission spectra for both the Wt and 
E14W-W42F D-SpGC2-1 constructs, which also served as templates for the other 
mutant constructs.  
 
These figures show that 6 M Gdn-HCl causes an approximate 75% drop in 
fluorescence intensity and a red shift of between 2 and 10 nm for 3 M and 6 M 
Gdn-HCl, respectively. This is as a result of a significant solvent change, 
hydrophobic to hydrophilic, that occurs around residues in the interior of the 
protein when a protein is denatured. The tryptophan in D-SpGC2-1, (W42 in the 
wild-type construct and W14 in the E14W-W42F construct), absorbs light at 275-
295 nm and re-emits at 330-340 nm. Its fluorescence is sensitive to polarity 
changes in the environment, and when exposed to a non-polar solution 
(hydrophobic core) the fluorescence intensity is normally high, and when 
transferred to a more polar solvent during unfolding, the signal is usually reduced 
[Alston et al., 2004]. At the same time the fluorescence maximum is shifted to a 
longer wavelength [Swaminathan et al., 1994]. With the E14W-W42F construct, 
the fluorescence maximum is shifted to a longer wavelength when compared to 
that obtained for the wild-type protein. This suggests the tryptophan at position 
14 is more solvent exposed in the unfolded state. 
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Figure 4.18 - Emission spectra for Wt D-SpGC2-1 in Gdn-HCl 
 
The effect of increasing the concentration of denaturant on the emission spectra, 
obtained for 10 µM Wt D-SpGC2-1 in 0 M, 3 M and 6 M Gdn-HCl, and the refolding 
of 3 M. Protein samples were excited at 280 nm and fluorescence emissions were 
measured between 300 and 450 nm. All spectra were measured in triplicate and 
corrected for the buffer fluorescence. The red line denotes the intercept of the 
spectrum at 350 nm, which is used to determine a denaturation curve. 
 
 
 
Figure 4.19 - Emission spectra for E14W-W42F D-SpGC2-1 in Gdn-HCl 
 
The effect of increasing the concentration of denaturant on the emission spectra, 
obtained for 10 µM E14W-W42F D-SpGC2-1 in 0 M, 3M and 6 M Gdn-HCl. Protein 
samples were excited at 280 nm and fluorescence emissions were measured 
between 300 and 450 nm. All spectra were measured in triplicate and corrected 
for the buffer fluorescence. The red line denotes the intercept of the spectrum at 
350 nm, which is used to determine a denaturation curve. 
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Figure 4.20 shows a typical Gdn-HCl denaturation curve for Wt D-SpGC2-1, and 
figure 4.21 presents a typical plot demonstrating the linear dependence of ΔGF 
against Gdn-HCl concentration. Data were analysed using equations 4.1 to 4.8. 
 
The linear dependence of ΔGF against Gdn-HCl concentration for wild-type D-
SpGC2-1 allows parameters of equilibrium Gdn-HCl denaturation to be obtained. 
The value of ΔGU0 was calculated from the mid-point concentration of Gdn-HCl and 
the m value, and an average value of 14.09 ±1.83 kJmol-1 was obtained. This 
gives the conformational stability of Wt D-SpGC2-1, i.e. the difference in free 
energy of the unfolded state relative to that of the folded state. The intercept on 
the graph of ΔGU0 against denaturant concentration suggests a higher value of 
15.5 kJmol-1. The relationship of plotting ΔGU0 in the transition region against the 
concentration of Gdn-HCl was first seen by Tanford [Tanford, 1968] and gives an 
empirical straight line with a slope. In these studies, the proportionality factor 
across the transition region (m) was found to be -5.87 ±0.56 kJmol-1M-1, which 
reflects the ratio between the number of bound molecules in the two states, 
whereby the denaturant binds to the protein and favours the unfolded state. 
Proteins that possess high m values are more sensitive to denaturants and 
possess steeper transition slopes [Lindberg et al., 2002]. The concentration of 
Gdn-HCl at which half the protein denatures (ΔGU=0) is 2.40 ±0.08 M. At this 
transition mid-point, the stability of the denatured state and the native state are 
the same and they are equally populated at 2.40 M Gdn-HCl. These values can be 
used to compare the conformational stabilities of the D-SpGC2-1 mutant 
constructs. 
 
Comparative studies by Walker [1994] gave values of -7.26 kJmol-1M-1 and 3.09 M 
under similar conditions for the proportionality factor across the transition region 
(m) and the concentration of Gdn-HCl when half the protein had denatured ([Gdn-
HCl]½), respectively.  
 
Other related studies by Alexander [Alexander et al., 1992] provides ΔG values 
calculated by differential scanning calorimetry of approximately 28 and 23 kJmol-1 
at 25 °C for the C1 and C3 binding domains of SpG, respectively. In addition, 
previous work by Walker on the C2 binding domain [Walker, 1994] gives a ΔG 
value of 22.46 kJmol-1 obtained at 25 °C, pH 6.0 by equilibrium Gdn-HCl 
denaturation. Both of these values are higher than the ΔG value 14.09 kJmol-1 
obtained here for the C2 binding domain of SpG by equilibrium Gdn-HCl 
denaturation, at 15 °C, pH 8.0. This is most likely to be due to the different 
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experimental conditions. Furthermore, work conducted here and by Walker [1994] 
is based on the C2 domain, which is a hybrid of the C-terminus of the C1 domain 
and the N-terminus of the C3 domain, and it is unlikely that the different amino 
acid sequence of the hybrid will not permit comparison with the C1 and C3 
domains. In addition, these results could indicate that the introduction of a 6x His-
tag at the N-terminal end of the protein has slightly altered the effect of Gdn-HCl 
on the denaturation of D-SpGC2-1.    
 
Further studies by Kuszewski and co-workers [Kuszewski et al., 1994] have 
employed equilibrium unfolding studies to establish the equilibrium unfolding 
curve of the B1 domain of SpG as a function of Gdn-HCl at pH 4.0, 5 °C. Although 
experimental conditions vary in these studies, results obtained show that the 
unfolding transition is a two-state mechanism, with the transition mid-point 
occurring at 3 M Gdn-HCl. Data also gives a ΔGU0 intercept value of 4.8 kcal mol-1, 
which is equal to 20.08 kJmol-1. This also compares well with data obtained by 
Alexander [Alexander et al., 1992]. 
 
It was also found that both the pre- and post-transition regions of the 
denaturation curve did not always give a flat baseline. This was also found in 
previous denaturation studies on D-SpGC2-1 by Walker [Walker, 1994]. 
Alternatively, other studies have shown an independence of yF and yU on Gdn-HCl 
concentration [Jackson and Fersht, 1991; Pace et al., 1988], and it is now 
accepted that the slope of the baseline should be taken into consideration during 
the calculation of fU and fF for each concentration of Gdn-HCl used [Jackson et al., 
1993; Pace et al., Lim et al., 1992].   
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 Ff = a = (y–yu)/(yf-yu) 
y 
a 
b 
yf 
Fu = b = (yf–y)/(yf-yu) 
yu 
Figure 4.20 – A typical Gdn-HCl denaturation curve for Wt D-SpGC2-1  
 
The denaturation curve shows the result of plotting the percentage of unfolding of 
Wt D-SpGC2-1 at 350 nm against concentrations of Gdn-HCl, pH 8.0 at 15 °C. From 
the sigmoidal curve obtained, pre- (yf), post- (yu) and transitional (y) regions are 
defined and are used to calculate the free energy change (ΔGU) between folded 
and unfolded conformations.  
 
 
ΔGU0 = 14.09 ±1.83 kJmol-1  
m = -5.87 ±0.56 kJmol-1M-1  
[Gdn-HCl] when 50% unfolded 
= 2.40±0.08 M 
 
Figure 4.21 – A typical linear relationship between ΔGU and [Gdn-HCl] for Wt  
D-SpGC2-1  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the Wt D-SpGC2-1. From the denaturation curve presented in figure 4.21, 
the transitional region is used to calculate the free energy change ΔGU between 
folded and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is given as ΔGU in the absence of denaturant. 
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4.6.3 - Determination of conformational stability of D-SpGC2-1 
mutant constructs designed to perturb Fc binding 
interactions 
Equilibrium denaturation studies were also carried out on mutant constructs of   
D-SpGC2-1 to determine the effect of these mutations on the conformational 
stability of the domain. This was important since any changes in binding affinity 
might be due to differently folded proteins. Mutational studies offer a versatile 
means to probe protein structure, but point mutations may result in small, but 
measureable changes in structure or stability. In contrast, some proteins may be 
very tolerant to amino acid substitutions and it is uncommon for a single site 
change to completely alter the basic fold of a protein. However, mutations may 
affect one or more of the parameters associated with the native state and function 
of a protein. For example, some mutations may inhibit protein binding without 
dramatically affecting the stability of the protein. In contrast, other mutations may 
directly affect the ability of a protein to fold correctly and retain its native 
structure [Dinner et al., 2000]. 
 
As before, controlled unfolding measurements were made with 10 µM Fc D-SpGC2-
1 mutant constructs in Gdn-HCl at increasing concentrations from 0-6 M, and the 
final Gdn-HCl concentration was determined by refractometry using equation 4.8. 
The change in protein fluorescence was followed using an excitation wavelength of 
280 nm; emission was measured at 350 nm. Each sample was pre-incubated at 
15 °C for two hours to reach thermal equilibrium before being measured. 
 
Six of the eight residues within the α-helix and β-strand 3 of a domain of SpG that 
have been identified to be involved in the interfacial interactions with the loop 
regions of Fc (Glu26, Lys27, Lys30, Gln31, Asn34, Asp39, Glu41 and Trp42) 
[Sauer-Eriksson et al., 1995] were mutated to different side-chains to characterise 
the interaction. However, Lys27 did not express protein so could not be 
characterised any further.  
 
Data were again analysed using equations 4.1 to 4.8. Typical plots demonstrating 
the linear dependence of ΔGF against Gdn-HCl concentration of engineered D-
SpGC2-1 Fc mutant constructs are shown in figures 4.22 to 4.23, and compared to 
that obtained for the Wt D-SpGC2-1 protein. The parameters characterising the 
equilibrium denaturation of the D-SpGC2-1 Fc mutant constructs by Gdn-HCl are 
summarised in table 4.1. 
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 E26A D-SpGC2-1 ΔGU0 = 17.22 ±0.44 kJmol-1  
m = -7.10 ±0.12 kJmol-1M-1  
[Gdn-HCl] when 50% unfolded 
= 2.43 ±0.11 M 
 
 
Q31E D-SpGC2-1 
ΔGU0 = 12.12 ±0.43 kJmol-1  
[Gdn-HCl] when 50% unfolded 
= 2.23 ±0.04 M 
m = -5.43 ±0.08 kJmol-1M-1  
 
 
N34A D-SpGC2-1 
ΔGU0 = 9.81 ±1.38 kJmol-1  
m = -3.90 ±0.01 kJmol-1M-1  
[Gdn-HCl] when 50% unfolded 
= 2.52 ±0.37 M 
 
 
Figure 4.22 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fc  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
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 N34D D-SpGC2-1 
ΔGU0 = 13.58 ±0.50 kJmol-1  
m = -5.68 ±0.01 kJmol-1M-1  
[Gdn-HCl] when 50% unfolded 
= 2.39 ±0.10 M 
 
 
m = -5.62 ±1.20 kJmol-1M-1  
ΔGU0 = 13.35 ±3.22 kJmol-1  
E41Q D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.37 ±0.07 M 
 
 
 
C56A D-SpGC2-1 
m = -5.21 ±1.23 kJmol-1M-1  
ΔGU0 = 12.83 ±2.70 kJmol-1  
[Gdn-HCl] when 50% unfolded 
= 2.47 ±0.07 M 
 
 
Figure 4.23 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fc  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
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 D-SpGC2-1 
construct 
ΔGU0 
intercept  
(kJ.mol-1) 
± std dev. n≥2 
ΔGU0 
calculated  
(kJ.mol-1) 
± std dev. n≥2 
m  
(kJ.mol-1M-1) 
± std dev. n≥2 
[Gdn-HCl]  
50% unfolded  
(M) 
± std dev. n≥2 
WT 14.09 ±1.83 14.26 -5.87 ±0.56 2.40 ±0.08 
E26A 17.22 ±0.44 17.28 -7.10 ±0.12 2.43 ±0.11 
Q31E 12.12 ±0.43 12.10 -5.43 ±0.08 2.23 ±0.04 
N34A 9.81 ±1.38 9.82 -3.90 ±0.01 2.52 ±0.37 
N34D 13.58 ±0.50 13.58 -5.68 ±0.01 2.39 ±0.10 
E41Q 13.35 ±3.22 13.31 -5.62 ±1.20 2.37 ±0.07 
W42F ND ND ND ND 
W42Y ND ND ND ND 
C56A 12.83 ±2.70 12.87 -5.21 ±1.23 2.47 ±0.07 
Table 4.1 – Summary of the parameter values characterising the Gdn-HCl 
equilibrium denaturation of D-SpGC2-1 mutant constructs designed 
to perturb Fc binding interactions  
 
These results demonstrate the effect of each mutation on the parameters of 
unfolding. Mutant constructs W42F and W42Y D-SpGC2-1 were omitted from these 
studies as the tryptophan residue, which acts as a fluorescent probe, has been 
removed. This results in a non-fluorescent protein, which makes fluorimetric 
determination of equilibrium denaturation difficult. Replacing tryptophan with a 
tyrosine residue, although an aromatic amino acid, is not fluorescent enough to 
act as a probe in these studies. Comparison of the parameters characterising 
equilibrium Gdn-HCl unfolding obtained for the majority of the mutant constructs 
studied, compare reasonably well with values obtained for wild-type D-SpGC2-1. 
Mutants Q31E, N34D, E41Q and C56A have little effect on the conformational 
stability of D-SpGC2-1. E26A D-SpGC2-1, however, has an approximate 1.5-fold 
increased conformational stability value from 14.09 ±1.83 to 17.22 ±0.44 kJ.mol-1 
when compared to WT D-SpGC2-1. This increase is due to an increased m value 
rather than a higher [Gdn-HCl]½ value, which suggests that the mutant is more 
co-operatively folded. N34A D-SpGC2-1 shows a decreased conformational 
stability, with an approximate 1.7-fold decreased ΔGU0 intercept value from 14.09 
±1.83 to 9.81 ±1.38 kJ.mol-1 when compared to wild-type D-SpGC2-1. Thus, this 
mutation may well have led to a disturbed secondary structure with possible 
consequences to the binding reaction.  
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4.6.4 - Determination of the conformational stability of D-SpGC2-1 
mutant constructs designed to perturb Fab binding 
interactions 
 
Equilibrium denaturation studies were also carried out as before on purified Fab D-
SpGC2-1 mutant constructs designed to probe the interactions with Fab. Key amino 
acid residues, identified in both the major and minor regions of contact with the 
Fab CH1 domain, were chosen for mutation. The site of interaction spans residues 
Lys9, Thr10, Leu11, Lys12, Gly13, Glu14, Thr15 and Thr16 from β-strand 2 on 
SpG, with residues Tyr32, Ala33, Asn34, Asp35, Asn36 and Gly37 from the C-
terminal end of the α-helix of SpG constituting the minor contact region [Derrick 
and Wigley, 1992; Lian et al., 1994; Derrick and Wigley, 1994; Sauer-Eriksson et 
al., 1995]. Six of these fourteen residues, from both the major and minor contact 
regions were chosen for mutation, namely residues Thr10, Glu14, Thr15, Thr16, 
Tyr32 and Asn36. The effect of these mutations on the stability of the domain was 
investigated.  
 
These mutants all require a tryptophan reporter group other than W42, which 
needs to be removed to eliminate binding to Fc. Thus, these mutations were made 
on the E14W-W42F D-SpGC2-1 template. Stability studies were therefore, carried 
out on this “control” protein. 
 
4.6.5 – Determination of the conformational stability of E14W-
W42F D-SpGC2-1 by equilibrium denaturation with Gdn-HCl 
Figure 4.24 shows a typical Gdn-HCl denaturation curve for E14W-W42F D-SpGC2-
1, and figure 4.25 presents a typical plot demonstrating the linear dependence of 
ΔGF against Gdn-HCl concentration.  
 
The value of ΔGU0 intercept was calculated as 14.31 ±1.76 kJmol-1, for the 
conformational stability of E14W-W42F D-SpGC2-1, and this compares well with 
the ΔGU0 intercept value calculated as 14.09 ±1.83 kJmol-1 for Wt D-SpGC2-1. In 
these studies, the proportionality factor across the transition region (m) was found 
to be -5.29 ±0.51 kJmol-1M-1, and the concentration of Gdn-HCl at which half the 
protein had denatured (ΔGU=0) was 2.70 ±0.07 M. Typical plots demonstrating 
the linear dependence of ΔGF against Gdn-HCl concentration of these D-SpGC2-1 
constructs are shown in figures 4.26 to 4.29, and compared to that obtained for 
the E14W-W42F D-SpGC2-1 protein. The parameters characterising the equilibrium 
denaturation of these D-SpGC2-1 mutant constructs by Gdn-HCl are summarised in 
table 4.2. 
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Figure 4.24 – A typical Gdn-HCl denaturation curve for E14W-W42F D-SpGC2-1  
 
The denaturation curve shows the result of plotting the percentage of unfolding of 
E14W-W42F D-SpGC2-1 at 350 nm against increasing concentrations of Gdn-HCl, 
pH 8.0 at 15°C. From the sigmoidal curve obtained, pre-, post- and transitional 
regions are defined and are used to calculate the free energy change (ΔGU) 
between folded and unfolded conformations.  
 
 
m = -5.29 ±0.51 kJmol-1M-1  
ΔGU0 = 14.31 ±1.19 kJmol-1  
[Gdn-HCl] when 50% unfolded 
= 2.70 ±0.07M 
 
Figure 4.25 – A typical linear relationship between ΔGU and [Gdn-HCl] for E14W-
W42F D-SpGC2-1  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the E14W-W42F D-SpGC2-1. From the denaturation curve presented in 
figure 4.52, the transitional region is used to calculate the free energy change ΔGU 
between folded and unfolded conformations using the equation ΔGU = ΔGU0 – 
m[Gdn-HCl]. ΔGU0 is given as ΔGU in the absence of denaturant. 
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 m = -8.42 ±0.69 kJmol-1M-1  
ΔGU0 = 19.56 ±1.19 kJmol-1  T10A D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.33 ±0.05 M 
 
 
m = -5.63 ±2.06 kJmol-1M-1  
ΔGU0 = 14.68 ±7.06 kJmol-1  
T10S D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.55 ±0.32 M 
 
m = -6.15 ±0.41 kJmol-1M-1  
ΔGU0 = 17.33 ±0.98 kJmol-1  T15A D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.82 ±0.03 M 
Figure 4.26 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fab  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
 
 | 164  
 
 m = -6.93 ±0.51 kJmol-1M-1  
ΔGU0 = 16.77 ±1.66 kJmol-1  
T15S D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.42 ±0.06 M 
 
 
m = -6.19 ±1.27 kJmol-1M-1  
ΔGU0 = 13.23 ±2.88 kJmol-1  
T16A D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.12 ±0.04 M 
 
m = -5.33 ±0.22 kJmol-1M-1  
ΔGU0 = 13.06 ±0.60 kJmol-1  
T16S D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.45 ±0.01 M 
 
Figure 4.27 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fab  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
 | 165  
 
 m = -8.30 ±0.84 kJmol-1M-1  
ΔGU0 = 18.72 ±2.31 kJmol-1  
T15A-T16A D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.25 ±0.06 M 
 
 
 
m = -4.85 ±0.19 kJmol-1M-1  
ΔGU0 = 12.22 ±1.25 kJmol-1  
Y32F D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.52 ±0.16 M 
 
m = -5.23 ±0.36 kJmol-1M-1  
ΔGU0 = 14.79 ±0.81 kJmol-1  
N36A D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.83 ±0.04 M 
Figure 4.28 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fab  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
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 N36D D-SpGC2-1 
m = -7.50 ±1.13 kJmol-1M-1  
ΔGU0 = 13.51 ±2.13 kJmol-1  
[Gdn-HCl] when 50% unfolded 
= 1.79 ±0.04 M 
 
 
m = -4.97 ±0.13 kJmol-1M-1  
ΔGU0 = 13.10 ±1.71 kJmol-1  
N36Q D-SpGC2-1 
[Gdn-HCl] when 50% unfolded 
= 2.63 ±0.28 M 
 
 
Figure 4.29 – A typical linear relationship between ΔGU and [Gdn-HCl] for Fab  
D-SpGC2-1 mutants  
 
The plot shows the linear relationship betweenΔGU and the concentration of Gdn-
HCl for the protein samples indicated. From the denaturation curve, the 
transitional region is used to calculate the free energy change ΔGU between folded 
and unfolded conformations using the equation ΔGU = ΔGU0 – m[Gdn-HCl]. ΔGU0 is 
given as ΔGU in the absence of denaturant. 
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These results demonstrate the effect of each mutation on the parameters of 
unfolding with tryptophan 14 in the E14W-W42F construct acting as a fluorescent 
probe for these studies. Comparison of the parameters characterising equilibrium 
Gdn-HCl unfolding obtained for the majority of the mutant constructs studied, 
compare very well with values obtained for E14W-W42F D-SpGC2-1.  
 
As can be seen from table 4.2 the mutations T10S, T16A, T16S, Y32F, N36A, 
N36D and N36Q have little effect on the conformational stability of D-SpGC2-1.  
 
 
 
D-SpGC2-1 
construct 
ΔGU0 intercept  
(kJ.mol-1) 
± std dev. n≥2 
ΔGU0 
calculated  
(kJ.mol-1) 
± std dev. n≥2 
m  
(kJ.mol-1M-1) 
± std dev. n≥2 
[Gdn-HCl]  
at 50% unfolded  
(M) 
± std dev. n≥2 
E14W-W42F 14.31 ±1.76 14.28 -5.29 ±0.51 2.70 ±0.07 
T10A 19.56 ±1.19   19.62 -8.42 ±0.69 2.33 ±0.05 
T10S 14.68 ±7.06 14.37 -5.63 ±2.06  2.55 ±0.32 
T15A 17.33 ±0.98   17.34 -6.15 ±0.41  2.82 ±0.03 
T15S 16.77 ±1.66 16.77 -6.93±0.51 2.42 ±0.06 
T16A 13.23 ±2.88 13.23 -6.24 ±1.27 2.12 ±0.04 
T16S 13.06 ±0.60 13.06 -5.33 ±0.22 2.45 ±0.01 
T15A-T16A 18.72 ±2.31 18.68 -8.30 ±0.84 2.25 ±0.06 
Y32F 12.22 ±1.25 12.23 -4.85 ±0.19 2.52 ±0.16 
N36A 14.79 ±0.81 14.80 -5.23 ±0.36  2.83 ±0.04 
N36D 13.51 ±2.13 13.42 -7.50 ±1.13 1.79 ±0.04 
N36Q 13.10 ±1.71 13.08 -4.97 ±0.13 2.63 ±0.28 
Table 4.2 – A summary table of the free energy values characterising the 
denaturation of D-SpGC2-1 Fab mutant constructs  
 
 
T10A D-SpGC2-1, however, has significantly increased the ΔGU0 intercept value 
from 14.31 ±1.76 to 19.56 ±1.19 kJ.mol-1 when compared to E14W-W42F D-
SpGC2-1. This increase is largely due to an increased m value.  
 
T15A D-SpGC2-1 has increased the ΔGU0 intercept value from 14.31 ±1.76 to 
17.33 ±0.98 kJ.mol-1 when compared to E14W-W42F D-SpGC2-1, but not as 
significantly as its neighbouring T10A mutant. T15S D-SpGC2-1 has also increased 
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the ΔGU0 intercept value from 14.31 ±1.76 to 16.77 ±1.66 kJ.mol-1 when 
compared to E14W-W42F D-SpGC2-1, but not as significantly as its neighbouring 
T10A and T15A mutants. Again, this increase is due to an increased m value.  
 
Double mutant T15A-T16A D-SpGC2-1 also shows an effect on the conformational 
stability of SpG, with an increased ΔGU0 intercept value from 14.31 ±1.76 to 
18.72 ±1.38 kJ.mol-1 when compared to E14W-W42F D-SpGC2-1. This increase is 
due to an increased m value.  
 
These data by themselves cannot be used to deduce detailed facts about the gross 
protein folding. However, together with binding data presented in chapter 5.0, it 
may be possible to draw more conclusions. However, in almost all cases the ΔGU0 
value suggests the domains are well folded. 
 
4.7 – Discussion 
In this chapter fluorescence was employed to study the conformational stability 
and the unfolding of D-SpGC2-1 and its mutant constructs designed to probe the 
interaction with Fc or Fab, respectively. Tryptophan 42 and the introduction of a 
tryptophan residue at position 14 in D-SpGC2-1 has allowed these residues to be 
exploited as reporter groups for exclusively monitoring stability changes in the 
mutant constructs.  
 
For the mutations made to explore Fc binding, namely E26A, Q31E, N34A, N34D, 
E41Q, W42F and W42Y, only the N34 substitution led to major consequences on 
protein stability. It may be significant that these mutations also led to changes in 
binding characteristics, see table 5.5 and 6.1. 
 
For the mutations designed to explore Fab binding interactions none led to 
significantly reduced stabilities, indeed mutants with decreased affinities for Fab 
had, if anything, slightly higher conformational stability than wild-type.  
 
 
 
 
 
 
 
  
 
 
CHAPTER 5.0 
 
EQUILIBRIUM AND  
PRE-EQUILIBRIUM 
     BINDING STUDIES     
  OF SPG-FC BINDING 
INTERACTION 
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5.1 – Introduction 
Specific interactions between proteins play a crucial role in a variety of biological 
processes and many activities depend on the ability of proteins to form complexes 
with other proteins to function. Proteins must interact with very high specificity 
and the recognition process is usually intricate and involves formation of many 
specific intermolecular contacts. Knowledge of the stability of complexes and the 
arrangement of proteins in a complex, together with the identification of specific 
amino acid residues involved in these interactions, is fundamental in 
understanding the regulatory, kinetic and recognition properties of proteins. 
Protein–protein interactions are a result of optimisation of the binding affinity with 
the generation of specificity. Thermodynamic, kinetic and structural studies of 
protein–protein interactions have shown how proteins interact rapidly, tightly and 
in a specific manner [Perozzo et al., 2004]. 
 
There are many factors that control the rate of chemical reactions. These include 
the size and charge of ligands, the concentration of the reactants and 
environmental conditions, such as pH and temperature. There are a number of 
approaches that can be used in the study of protein-protein binding interactions 
for measuring equilibrium and pre-equilibrium binding constants. These include 
fluorescence titrations, stopped-flow fluorescence and Isothermal Calorimetry 
(ITC), and have all been proven to be powerful techniques in measuring 
equilibrium constants [Holdgate and Ward, 2005]. One method of monitoring a 
reaction is through spectroscopy. If the reactant or product exhibits a change in 
spectral properties as a function of reaction time, this method can usually be 
employed. A conventional cell is adequate for reactions with half-lives greater 
than a couple of minutes, however, reactions that are over within a second or 
milliseconds need specialised equipment. Of all the spectroscopic techniques that 
are available to study protein-protein interactions, fluorescence probably offers 
the greatest versatility of applications, most likely because of its inherent 
sensitivity and simplicity of use.  
 
5.2 - Mechanism of equilibrium 
For any reaction to be at equilibrium, the rates of the forward and reverse 
reactions have to be equal. Reactions that are non-reversible are said to go to 
completion, and after the reaction occurs the reaction mixture contains only 
products and any left over excess reactants. The products do not break down to 
reform reactants.  
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At equilibrium, the equilibrium association constant (Ka) equals the product of the 
concentrations of product divided by the concentrations of reactants.  
 
In the reaction such as that described below, a protein (P) reversibly binds a 
ligand (L) to form a complex (P•L). 
 
    kass (M-1s-1) 
P + L =                 P•L                                      (equation 5.1) 
     kdiss (s-1) 
 
The forward velocity of the reaction vf = kass [P][L] and the reverse velocity    
Vr = kdiss [P.L] 
 
At equilibrium vf = vr and therefore, kass [P][L] = kdiss [P•L]. Hence,       
 
kdiss/kass = [P][L]/[P•L]                             (equation 5.2) 
 
Similarly, 
 
kass /kdiss = [P•L]/[P][L] = Ka                                                (equation  5.3) 
 
Kd = [P][L]/[P•L]            (equation 5.4)  
 
Thus, Kd may be determined by measurements of the association and 
dissociation rates of reaction or from the equilibrium concentrations of the 
reactants and products.        
 
Equilibrium constants are determined in order to quantify chemical equilibria and 
describe the strength of binding or affinity between proteins and their ligands. If 
the Ka is large, products of the reaction are favoured and the reaction lies 
towards complex formation, whereas if the Ka is small, dissociation of the 
complex is favoured.  
 
5.2.1 – Association and dissociation rate constants 
Kinetic binding experiments can be used to determine the association and 
dissociation rate constants of molecular interactions and thus allow a separate 
estimate of equilibrium constants and maybe shed light on the reaction pathways 
of protein-protein interactions [Holdgate and Ward, 2005]. The velocity of 
complex formation is dependent upon the concentrations of each of the reactants 
(P and L) and is therefore a second order process with a rate constant (kass) with 
units of M-1 s-1. The velocity of the dissociation process (kdiss) is proportional to 
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the concentration of the complex (P•L) and has a first order rate with units of s-1, 
as shown in equation 5.1.  
                            
5.3 - Binding interactions of D-SpGC2-1  
Association and dissociation of complexes are distinct events and are influenced 
by non-covalent intermolecular interactions with different forces contributing to 
either. The rate of association is determined by long-range electrostatic forces, 
whereas the rate of dissociation is determined by short range interactions and the 
co-operativity between them [Schreiber and Selzer, 1999]. Therefore, 
characterisation of reversible interactions in terms of binding, stoichiometry, 
kinetics and thermodynamics enables the examination of these parameters.    
 
Close examination of the X-ray crystallographic data of [Achari et al., 1992; 
Derrick and Wigley, 1992; Gallagher et al., 1994; Derrick et al., 1994; Sauer-
Eriksson et al., 1995] has been undertaken in order to identify specific amino acid 
residues that may be critical to this binding interaction. Those residues so 
identified have then been substituted in a program of site directed mutagenesis 
and the mutated proteins produced.  The effect of such mutations on the kinetic, 
equilibrium and thermodynamic parameters of the binding reaction have been 
investigated using fluorescence spectroscopy employing both equilibrium studies, 
which will provide information on the binding affinity and number of binding sites, 
and pre-equilibrium studies, which will determine rates at which equilibrium is 
reached and may identify structural changes. Studies were also carried out using 
isothermal titration Calorimetry (ITC) to study the thermodynamics of complex 
formation and further will allow information on the contribution of a specific 
amino acid to the biological function of SpG to be evaluated.  
 
5.4 – Principles of fluorescence spectroscopy  
Fluorescence is the result of a three-stage process that occurs in certain 
molecules, such as polyaromatic hydrocarbons, called fluorophores. When these 
molecules absorb photons of light and are excited to a higher electronic state, the 
absorbed energy can be released by the emission of a photon of light. This is 
luminescence, and when this release of energy is virtually immediate this is called 
fluorescence, thus it is this light energy, which is studied during fluorescence 
spectroscopy.   
 
Stage one of the fluorescence process involves the absorption of a photon of the 
incident radiation (excitation) by a fluorophore, which gives rise to transitions 
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from the ground state (S0) to an excited electronic state as governed by the laws 
of quantum mechanics, illustrated in figure 5.1. Stage two is the excited-state 
lifetime, which exists for a finite time typically 1 to 10 nanoseconds. Within this 
time, the fluorophore may be affected by conformational changes and is subject 
to a multitude of possible interactions within its molecular environment. As the 
electron returns to ground state, it may arrive at one of the vibrational levels of 
S0, S1 or S2, consequently losing some energy in the form of heat. Within a large 
population of molecules, the probability of dropping from the excited state to any 
vibrational level in the ground state is what determines the shape of the 
fluorescence spectrum, from where fluorescence emission occurs, stage three. 
This means that the emission spectrum of the fluorophore is dependent upon 
these chemical and physical properties of the environment in which it has been 
placed. It is this phenomenon that establishes fluorescence as an important 
biochemical technique.  
 
In the majority of molecules, the vibrational levels overlap with those of the first 
excited state, resulting in all the absorbed energy being lost in a non-radiative 
manner, which is heat. However, not all the molecules initially excited by 
absorption, in stage one, return to the ground state S0 by fluorescence emission. 
Other processes such as collisional quenching and Fluorescence Resonance 
Energy Transfer (FRET) may also remove molecules from the S1 state. The 
fluorescence quantum yield, which is the ratio of the number of fluorescence 
photons emitted to the number of photons absorbed, is a measure of the relative 
extent to which these processes occur.   
 
Excess energy may be absorbed which allows an electron within the molecule to 
attain a higher electronic vibrational energy. This extra vibrational energy is 
quickly dispersed in the form of heat, and as a result the electron drops to the 
lowest vibrational level of the excited state (S1). The excited electron then returns 
to the ground state either by emitting light or by a non-radiative transition. Due 
to energy being lost during this process, emitted light will have a lower energy 
and thus, will have a longer wavelength.  
 
 =              (equation 5.5) 
 
Where,  is the energy,  is Planck’s constant and  is frequency, which is equal 
to 1/λ wavelength.  
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Hence,  
 
 = /λ             (equation 5.6) 
As  is a constant, the larger the λ, the lower the energy of the photon. 
 
This difference between the excitation and emission wavelength maxima is 
termed the “Stokes shift”. The Stokes shift represents the energy lost whilst the 
molecule was in the excited state. The Stokes shift is fundamental to the 
sensitivity of fluorescence techniques because it allows the emitted fluorescence 
photons to be easily distinguished from the excitation photons, and can be 
detected against a low background in fluorescent studies. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 – An schematic illustration of the fluorescence process 
 
Fluorescence is light emitted by molecules returning to their ground state after 
being initially excited by light of a specific wavelength [Lakowicz, 1999]. This 
diagram illustrates the electronic basis of the phenomenon of fluorescence, as 
first suggested by Russian scientist Professor Alexander Jabloński.  Fluorescence 
is the phenomenon in which absorption of light of a given wavelength by a 
fluorescent molecule is followed by the emission of light at longer wavelengths. 
Excitation of a molecule leads to electrons attaining a higher electronic and 
vibrational energy status (S1). On returning to ground state (S0), an electron may 
arrive at one of the vibrational levels of the S0 state, consequently losing its 
excess energy both radiatively and non-radiatively [Lakowicz, 1999]. 
 
Fluorescence detection has three major advantages over other light-based 
techniques; high sensitivity, speed and safety. Sensitivity is an important issue 
because the fluorescence signal is proportional to the concentration of the 
substance being investigated. Since this is a non-invasive technique, fluorescence 
does not interfere with the sample, in that they are usually not affected or 
destroyed in the process and no hazardous by-products are produced. The 
excitation light levels required to generate a fluorescence signal are low, reducing 
the effects of photo-bleaching of the sample. 
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5.4.1 – Fluorescence properties of proteins 
The fluorescence of protein molecules originates from three aromatic amino acids, 
tryptophan, tyrosine and phenylalanine (see figure 5.2), and the fluorescence 
spectrum of a protein is composed of contributions from these residues. Although 
other factors, such as cofactors, may also contribute. 
   
Generally, aromatic ring systems are planar, and electrons are shared over the 
whole ring structure [Weber and Teale, 1957]. Molecules require a rigid aromatic 
ring or ring system to keep the vibrational energy (and its loss) to a minimum. 
The fluorescence of a protein is normally dominated by the contribution from the 
tryptophan residues as its Molar Extinction Coefficient of excitation light is  
considerably higher than that of tyrosine and phenylalanine, although its quantum 
yield of emission is approximately the same as that of tyrosine, as shown in table 
5.1.  
 
 
 
 
 
 
 
Figure 5.2 – The aromatic amino acids 
 
The aromatic amino acids, shown above, exhibit ultraviolet radiation absorption 
properties with large extinction coefficients.   
 
Amino Acid ϕF ε  
(M-1cm-1)       
λ 
(nm) 
Tryptophan 0.13 5600 280 
Tyrosine 0.14 1450 275 
Phenylalanine 0.024 300 260 
 
Table 5.1 – Summary of the fluorescent properties, quantum yield, molar 
extinction coefficient and the wavelength, of the aromatic amino 
acids  
[Gore, 2000] 
 
When the tryptophan residue becomes buried within a hydrophobic environment, 
such as within a protein molecule, spectral changes occur. The quantum yield 
increases and a shift to a shorter wavelength in the emission maximum also 
occur. A value of 320 nm to 330 nm for an emission maximum is indicative of a 
very hydrophobic environment, and that the tryptophans are deeply buried within 
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the protein. Conversely, if the emission maximum of a protein is nearer 348 nm, 
one can presume that the tryptophan residue(s) are on the surface of the protein 
exposed to solvent [Kuipers and Gruppen, 2007].   
 
5.4.2 – Emission spectra 
Fluorescence spectroscopy can be applied as a non-quantitative method at an 
early stage in protein equilibrium studies. Emission wavelength scans are 
performed with the purified protein in the absence and presence of its ligand, 
using a fixed excitation wavelength and variable emission wavelength. The 
binding of the ligand may often be visualised as a change in the spectrum of the 
protein and shifts in emission maxima are the most indicative of actual binding, 
as well as increases or decreases of the peak fluorescence intensity.  
 
5.5 - Determining emission spectra of D-SpGC2-1 and its 
complex with Fc 
In order to carry out binding studies between a domain of SpG and Fc using 
fluorescence, a measureable change in fluorescence must occur upon complex 
formation. To establish whether or not a spectral change does occur upon 
binding, the emission spectra for Wt D-SpGC2-1 and Fc, both in free solution, and 
in complex were determined, and are presented in figure 5.3.  
 
 
 
Figure 5.3 - Emission spectra for Wt D-SpGC2-1 and Fc in complex 
 
The figure shows the emission spectra obtained for 200 nM Wt D-SpGC2-1, 200 nM 
Fc and the SpG•Fc complex. Protein samples were excited at 280 nm and 
fluorescence emissions were measured between 300 and 450 nm. All spectra 
were measured in triplicate and corrected for the buffer fluorescence. The inset 
shows the fluorescence change upon complex formation, calculated by 
subtracting the observed fluorescence intensity of the complex from the 
theoretical fluorescence intensity of the complex.  
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The spectra presented show that fluorescence intensity obtained for wild-type    
D-SpGC2-1 displays an emission maximum at 340 nm, whereas the peaks of the 
Fc spectra and the complex spectra are both at 330 nm. The spectra also show 
that the fluorescence intensity obtained for the SpG•Fc in complex is significantly 
less than the theoretical fluorescence of the complex being calculated from the 
sum of the fluorescence spectra of the two proteins in free solution. This quench 
in fluorescence occurs upon complex formation and shows that the formation of 
this SpG•Fc complex can be monitored fluorimetrically. The quench is represented 
as a fluorescence difference spectrum, presented in the inset figure in figure 5.3, 
and shows that the difference spectrum has a maximum at 343 nm, suggesting a 
tryptophan residue in a solvent exposed position is being quenched on complex 
formation. 
 
This fluorescence quenching effect seen on complex formation may be 
attributable to the tryptophan of SpG, thus providing a way of following binding 
and further implicates the involvement of this residue in the interaction. This has 
an emission wavelength maximum of 340 nm, which is approximately the same 
as the position of the peak of the difference spectrum in agreement with 
observations of others on a similar system [Sloan and Hellinga, 1998].  
 
The involvement of this tryptophan residue of SpG in binding Fc is further 
supported by NMR studies [Gronenborn and Clore, 1993]. Shifts in SpG 
resonances were observed, which have to have arisen either directly or indirectly 
from contacts with the Fc fragment. No shifts at all arose from regions of SpG 
that were not in contact with Fc, thus it can be said that these regions are 
unaffected by Fc binding. But the most substantial shifts observed was for the 
tryptophan residue, W42, upon complexation [Gronenborn and Clore, 1993], 
clearly indicating the involvement of this side-chain in complex formation.   
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5.6 – Equilibrium binding studies using fluorescence 
titrations 
Equilibrium binding studies can provide valuable information on the binding 
affinity and number of binding sites of the interaction between D-SpGC2-1 and Fc. 
In the following sections, studies are described that were aimed at the 
determination of the stoichiometry and Kd for the binding reaction between D-
SpGC2-1 and Fc. 
 
5.6.1 – Determining the stoichiometry and Kd of D-SpGC2-1 and Fc 
complex 
The binding interaction between D-SpGC2-1 and Fc has been studied through 
fluorescence titrations using the change in fluorescence that occurs upon complex 
formation. Fluorescence emissions at 340 nm were measured, using excitation 
wavelengths of 280nm to study total fluorescence, and 295 nm to study 
tryptophan only fluorescence. 5 µl samples of 100 µM D-SpGC2-1 were titrated 
into 2 ml samples of 1 µM Fc. Data obtained were corrected for dilution and the 
inner filter effect, and further analysed through a Klotz plot, employing the 
following equation: 
 
  Kd          [L]0         
           =            - [E]0                     (Equation 5.7) 
 (1-α)        α 
 
Where α is the fractional saturation of SpG binding sites on Fc, [L]0 is the total 
concentration of SpG and [E]0 is the total number of binding sites on Fc for SpG.  
A plot of 1/(1-α) against [L]0/α will have a gradient of 1/Kd and an x-axis 
intercept of [E]0.   
 
Figure 5.4 presents a typical saturation curve for the binding of Wt D-SpGC2-1 to 
Fc and the subsequent analysis through a modified Klotz plot. All data obtained 
for Wt D-SpGC2-1 characterised by fluorescence titrations are summarised in table 
5.2.  
 
The Kd value for Wt D-SpGC2-1 binding to Fc at 15°C, pH 8.0 was able to be 
described by a single value of 506 ± 0.12 nM. The stoichiometry of binding from 
the intercept [E]0 was 2.13 ± 0.36, confirming that Fc has two identical binding 
sites for Wt D-SpGC2-1.  
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Figure 5.4 - Saturation curve for the titration of Wt D-SpGC2-1 into Fc 
 
The figure shows the saturation curve obtained when samples of 100 µM Wt D-
SpGC2-1 were titrated into a 2 ml solution of 1 µM Fc in 20 mM potassium 
phosphate buffer, pH 8.0 at 15°C. Each point on the titration curve was calculated 
by subtracting fluorescence values observed upon titration of Wt D-SpGC2-1 into 
Fc, from the corresponding values for the titration of Wt D-SpGC2-1 into buffer. 
The inset presents a Klotz plot, by which the titration curves were analysed. From 
the Klotz plot the Kd and stoichiometry of binding were determined.  All titrations 
were carried out in duplicate.  
 
 
TEMPERATURE 
(˚C) 
pH 6.0 
Kd (nM) (n) 
± std dev.  
pH 8.0 
Kd (nM) (n) 
± std dev. 
15 173 ± 0.05 
(n = 1.7 ± 0.2) 
506 ± 0.12 
(n = 2.13 ± 0.36) 
25 250 ± 0.22 
(n = 2.01 ± 0.06) 
1270 ± 0.52 
(n = 2.52 ± 0.81) 
40 ND 4400 ± 0.13 
(n = 1.36 ± 0.49) 
 
Table 5.2 – Summary of dissociation constants (Kd) and the stoichiometry (n) 
determined by titrating Wt D-SpGC2-1 into Fc at varying 
temperatures and pH 
 
ND denotes not determined. 
 
Previous data obtained to determine the equilibrium dissociation constant for the 
interaction of D-SpGC2-1 with Fc are similar to data obtained in these studies. The 
Kd of the interaction between Wt D-SpGC2-1 and Fc has been measured through 
fluorescence titrations carried out at 25˚C, pH 6.0 and by competitive ELISA, and 
was found to have values of 306 ± 65 nM and 310 nM, respectively [Walker et al., 
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1995]. Similar values were also obtained by Gallagher [Gallagher, 1994] for the 
B1 (C1) domain of SpG using titration calorimetry, which gave a Kd value of 333 
nM. Data obtained here under the same conditions, using the Wt D-SpGC2-1    
pQE-30 construct gives a Kd value of 250 ± 0.22 nM, as presented in table 5.1. 
This compares well with the previous data, but could indicate that the 
introduction of a 6x His-tag at the N-terminal end of the protein has slightly 
increased the binding affinity of D-SpGC2-1 for Fc.    
 
However, Walker [1994] also performed fluorescence titrations at 25˚C at a 
higher pH (pH 8.0) and obtained a Kd value of 693 ± 100 nM. This does not 
compare as well with data obtained in these studies, which yielded a Kd value of 
1270 ± 0.52 nM at the same pH. These results may indicate a difference in the 
binding affinity of D-SpGC2-1 for Fc due to the different samples of the Fc and    
D-SpGC2-1 domains. 
 
5.7 – Pre-equilibrium binding studies 
Biochemical reactions, such as those involving protein-ligand or protein-protein 
interactions are generally very fast with equilibria being reached within 50 to 100 
milliseconds (ms) [Gore and Bottomley, 2000]. The most common method of 
following these reactions is by absorbance or fluorescence spectrometry, as 
described in section 5.4. However, conventional spectroscopic techniques cannot 
be used when investigating reactions that occur at a sub-second rate, especially 
for measuring the rates of fluorescence changes upon complex formation. If 
reactants are added manually, and then stirred for a few seconds to allow 
adequate mixing, the reaction is over and no changes in spectra are recorded. 
Therefore, pre-equilibrium binding studies using stopped-flow fluorescence 
spectroscopy is one of the most frequently used rapid kinetics techniques. 
Stopped-flow fluorescence provides virtually instantaneous mixing, and can be 
used to determine the rate at which equilibria are obtained, as well as identifying 
potential structural changes and observing complex formation.  
 
5.7.1 – Stopped-Flow fluorescence  
Stopped-flow fluorescence allows the observation of reaction in the millisecond to 
second time scale before equilibrium is reached. This provides rate constants for 
each individual step and allows fluorescence profiles to be measured from 
approximately 1 millisecond after the mixing of reagents. The key components of 
an Applied Photo-Physics stopped-flow fluorescence spectrophotometer platform 
are shown in figure 5.5. 
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Small volumes of protein and ligand solutions are driven from syringes under high 
pressure through a high efficiency mixer. The resultant mixture passes through a 
measurement flow cell and into a stopping syringe, and just prior to stopping, a 
steady state flow is achieved. The solution entering the flow cell is only 
approximately a millisecond old. The age of this reaction mixture is also known as 
the dead time of the stopped-flow system. As the solution fills the stopping 
syringe, the plunger hits a block, causing the flow to be stopped instantaneously. 
Using the manufacturer’s data acquisition and analysis software the kinetics of 
the reaction can be measured in the cell.   
 
 
pneumatic  
push barrier for syringe 
movement 
 Xenon  
 lamp  trigger 
stopping 
syringe  monochromator 
A 
 mixing 
B 
syringes A and B are filled 
with reactants 
 cut off 
filter 
 
 photomultiplier 
Figure 5.5 – An adapted schematic diagram of the components of a stopped-flow 
fluorescence spectrophotometer 
 
The stopped-flow fluorescence spectrophotometer is a simple device designed to 
mix two reagents and to transfer the mixture to an optical cell as rapidly as 
possible. The reactants are placed in two syringes, and upon pressing the 
plunger, the solutions travel separately and only mix upon entering the cell. The 
reactants then enter a further syringe, the stop syringe, where the solutions stop 
flowing into the cell. Data collection then begins immediately, and the kinetics of 
the reaction is measured in the cell.   
 
5.7.2 – Measurement of D-SpGC2-1 and Fc complex  
In the formation of the SpG•Fc complex, the Kd is described by the ratio of the 
rates of association, kass, and dissociation, kdiss, by the relationship Kd = kdiss/kass 
[Walker et al., 1995]. This can be seen below in equation 5.8, followed by 
equation 5.9. 
 
                      kass  
SpG + Fc                        SpG•Fc          (equation 5.8) 
to computer to computer 
                     kdiss  
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 [SpG][Fc]         kdiss (s-1) 
                    =                       = Kd (M)                                        (equation 5.9) 
 [SpG•Fc]         kass (M-1s-1) 
 
 
5.7.2.1 – First-order and second-order reactions 
The order of a reaction is defined as the sum of the exponents in the rate 
equation. Therefore, in the interaction between SpG and Fc, the forward reaction 
obeys a second-order and the reverse reaction obeys a first-order law of kinetics 
and at equilibrium, the rates of both the forward and reverse reactions are equal. 
At constant temperature, reaction rates vary with reactant concentration, and the 
rate of this process is proportional to the frequency with which the reacting 
molecules simultaneously come together.  
 
In order to analyse second-order reactions more easily, conditions are used in 
which the reaction can be considered to be a first order process. One reactant is 
always present in great excess, for example SpG, over the ligand Fc 
concentration, which remains virtually constant throughout the complex 
formation. This allows an apparent first-order rate constant (kapp) to be 
determined from the fluorescence change obtained.  
 
kapp = kass [Fc] + kdiss         (Equation 5.10) 
 
The value of the rates for the association (kass) and dissociation (kdiss) of the 
interaction can be calculated by measuring kapp over a range of protein 
concentrations, all of which have SpG present in a minimum of a 10-fold excess 
over ligand concentration. By plotting kapp against the varying SpG 
concentrations, kass and kdiss can be calculated from the gradient and the intercept 
of the y-axis respectively, resulting in a derived second-order rate constant. 
 
5.7.3 – Determination of rate constants for the D-SpGC2-1 and Fc 
complex 
All solutions of D-SpGC2-1 and human Fc was prepared in 20 mM potassium 
phosphate buffer at pH 8.0. Both solutions were filtered prior to use to minimise 
any interference from light scattering, and were also thermo-equilibrated at the 
correct temperature of 15°C. Stopped-flow runs were completed using the 
maximum rate of data sampling, either set to 1000 data points at lower protein 
concentrations, and 400 data points at higher protein concentrations to reduce 
the amount of noise. 
 
 | 183  
 
Data is presented as reaction progress curves, which were averaged as three sets 
of triplicate traces, with data being averaged and analysed using a single 
exponential curve fitting algorithm, using equation 5.9: 
 
Ft = F0 exp(-kappt) + C                   (Equation 5.11) 
 
Where F0 and Ft are the fluorescence intensities at time 0 and time t respectively, 
kapp is the apparent rate constant for the reaction and C is a constant. 
 
5.7.3.1 – Determination of association rate constant kass  
All measurements were made using an excitation wavelength of 280 nm, and the 
change in fluorescence intensity of the solution after mixing of the reactants was 
followed at 335 nm using a glass cut-off filter. Protein solutions were mixed at a 
1:1 v/v mixing ratio between the ligand, Fc, which was kept at a constant initial 
concentration of 1 µM, with initial concentrations of D-SpGC2-1 proteins varying 
between 60 µM and 100 µM.  
 
Figure 5.6 shows a typical reaction progression curve for wild-type D-SpGC2-1, 
obtained by using a final concentration of 0.5 µM Fc and a final concentration of 
30 µM D-SpGC2-1, after mixing had occurred. 
 
  
 
 
Figure 5.6 – Typical stopped-flow fluorescence profile of the association of                      
Wt D-SpGC2-1 and Fc  
 
A reaction progress curve for the association of Wt D-SpGC2-1 and Fc is 
presented. The association curve shows the fluorescence change upon formation 
of the SpG•Fc complex after mixing 0.5 µM Fc with 30 µM SpG, final 
concentration, at 15˚C, pH 8.0.  
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The association progress curve shows a decrease in the fluorescence intensity as 
the complex between D-SpGC2-1 and Fc is formed. By repeating this reaction at 
various concentration of D-SpGC2-1, data were collected for the determination of 
kass. Figure 5.7 shows typical reaction progression curves obtained by using a final 
concentration of 0.5 µM Fc and final concentrations of D-SpGC2-1 ranging from 10 
µM to 50 µM, after mixing had occurred.  
 
 
40 µM 
45 µM 
50 µM 
35 µM 
30 µM 
 
Figure 5.7 – Typical stopped-flow fluorescence profile of the association of 
varying concentrations of Wt D-SpGC2-1 and Fc   
 
Reaction progress curves for the association of Wt D-SpGC2-1 and Fc are 
presented. The association curves show the fluorescence change upon formation 
of the SpG•Fc complex after mixing 0.5µM Fc with 30-50 µM SpG, final 
concentration, at 15˚C, pH 8.0.   
 
This figure shows the change in fluorescence intensity with increasing 
concentration of D-SpGC2-1. The apparent rate constants and apparent half-times 
for the reactions shown are given in table 5.3, and used in the graphical plot in 
figure 5.9. 
 
 [D-SpGC2-1] 
(µM) 
kapp 
(s-1) 
Half-time of reaction 
(ms) 
30 11.15 0.062 
35 13.39 0.052 
40 14.98 0.046 
45 16.96 0.041 
50 19.03 0.036 
 
Table 5.3 – Summary of half-time of reaction and the apparent rate constant 
(kapp) at varying concentrations of Wt D-SpGC2-1 with Fc 
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5.7.3.2 – Determination of dissociation rate constant kdiss  
The dissociation rate constant may also be independently measured by a 
displacement experiment. In a displacement reaction, a solution containing 
protein (P) and fluorescent ligand (fL) is mixed with an excess of a non-
fluorescent ligand (nfL) the following scheme applies:                  
                           
                       nfL 
           kdiss                             kass        
P•fL            P + fL            P•nfL        (Equation 5.12) 
          kass                        kdiss 
 
The rate of dissociation was determined by the 1:1 dilution displacement of Fc 
from a pre-formed 2:1 ratio (3 µM:1.5 µM) of the SpG•Fc complex with non-
fluorescent 20 mM potassium phosphate buffer, pH 8.0.  
 
Figure 5.8 presents a reaction progress curve for the fluorescence change upon 
dissociation.  
 
 
Figure 5.8 – Typical stopped-flow fluorescence profile of the dissociation of       
Wt D-SpGC2-1 and Fc complex   
 
A reaction progress curve for the dissociation of Wt D-SpGC2-1 and Fc is 
presented. The dissociation curve shows the fluorescence change upon a 1:1 
dilution of 3 µM:1.5 µM SpG•Fc complex, final concentration at 15˚C, pH 8.0.  
 
The Applied Physics data analysis software allowed curves to be fitted to the data.  
The reaction progress curves, presented in figures 5.6 and 5.8, fit well to single-
exponential equations. This suggests that both the association and dissociation of 
the D-SpGC2-1 and Fc complex occur by simple processes.  
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5.7.3.3 – Determination of pre-equilibrium constant Kd  
A plot of the observed rate constant against protein concentration will give a 
straight line with the slope giving the second-order association rate constant and 
the intercept giving the first-order dissociation rate constant. A linear plot of kapp 
(s-1) against final Wt D-SpGC2-1 concentration, as shown in figure 5.9, allows kass 
and kdiss to be determined from the gradient of the line and the intercept of the y-
axis respectively. These values then enable the Kd = kdiss/kass to be calculated. 
 
 
kass = 0.357 µM-1s-1 
kdiss = 0.857 s-1 
Figure 5.9 – Typical stopped-flow fluorescence analysis of the formation of Wt D-
SpGC2-1 and Fc complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of Wt D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and kdiss 
from the pseudo-first-order rates (kapp) can be calculated for each curve. Kass and 
kdiss are determined from the gradient of the line and the intercept of the y-axis 
respectively.  
 
A summary of the rate constants obtained for wild-type D-SpGC2-1 and Fc 
complex formation is presented in table 5.4. 
 
 
kass  
(µM-1s-1) 
± std dev. n≥2 
kdiss  
(s-1) 
± std dev. n≥2 
Kd  
(µM) 
± std dev. n≥2 
0.33 ± 0.05 0.82 ± 0.08 2.52 ± 0.29 
 
Table 5.4 – Summary of the rate constants and binding affinity obtained for the 
interaction of Wt D-SpGC2-1 and Fc 
 
 
Previous stopped-flow experiments studying the binding of Fc to Wt SpGC2-1 have 
obtained a Kd value of 2 µM under the same conditions, at 15˚C, pH 8.0 [Walker 
et al., 1995]. This equilibrium constant is very similar to that obtained in these 
studies, with an average Kd value of 2.52 µM being attained here.  
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It has been suggested that for the SpG•Fc complex to have a 4-fold higher Kd 
value of 2.52 µM using pre-equilibrium techniques than that of a Kd value of 600 
nM obtained in equilibrium studies, is due to a change in affinity that occurs after 
the initial complex formation, and is possibly due to a conformation change in 
either D-SpGC2-1 or the Fc [Walker et al., 1995]. However, it is thought that this 
structural change is relatively small, since the X-ray structure of the backbone of 
SpG in free solution and in the complex is superimposable. However, small 
changes in Kd may occur as side chains become more immobilised in the 
complex. The free energy released on complex formation can be calculated from 
the equation below. 
 
ΔG = -RTln Ka          (Equation 5.13) 
 
Where R is the gas constant, T is the absolute temperature (°Kelvin) and Ka is 
the equilibrium constant. Hence, if Kd is 2.52 µM, then the Ka for the same 
reaction is approximately 4x105 M and at 25°C,  
 
ΔG = -2442 x ln 4x105 
     = -31.5 kJ Mol-1          (Equation 5.14) 
 
Similarly, if the Kd for the reaction is 600 nM, then ΔG can also be determined 
from equation 5.14, to be -34.98 kJ.mol-1. This is of the order of the contribution 
of a single hydrogen bond to the binding interactions. Thus, no large 
conformational change need take place to cause a difference in Kd of 
approximately 4-fold. 
 
5.7.4– Effect of mutagenesis on D-SpGC2-1 and Fc complex 
As previously discussed, mutant constructs of D-SpGC2-1, which have been shown 
to be critical for the binding interaction with Fc, have been produced to engineer 
favourable binding properties, as well as to allow specific amino acid residues and 
their contribution to the biological function of SpG to be evaluated. To achieve 
these objectives, mutants were designed to potentially alter the Fc binding affinity 
from that of the wild-type protein. This strategy is important, as it will give a 
complete overview of the binding interface.  
 
5.7.5 – Determination of rate constants for Fc D-SpGC2-1 mutants  
SpG binds Fc at the hinge region that is situated in the cleft between CH2 and CH3 
domains of Fc. The eight residues within the α-helix and β-strand 3 of SpG that 
have been identified to be involved in the interfacial interactions with the loop 
regions of Fc are Glu26, Lys27, Lys30, Gln31, Asn34, Asp39, Glu41 and Trp42 
[Sauer-Eriksson et al., 1995]. Six of these residues, Glu26, Lys27, Gln31, Asn34, 
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Glu41 and Trp42, formed the basis of this study and were mutated to different 
side-chains to characterise the interaction. However, Lys27A was not successfully 
expressed so could not be characterised any further. The rates of the association 
and dissociation of the complex between D-SpGC2-1 constructs and Fc, as well as 
the pre-equilibrium Kd, are summarised below in table 5.5. 
 
D-SpGC2-1 
construct 
kass  
(µM-1s-1) 
± std dev. n≥2 
kdiss  
(s-1) 
± std dev. n≥2 
Kd  
(µM) 
± std dev. n≥2 
Wt 0.33 ± 0.05 0.82 ± 0.08 2.52 ± 0.29 
E26A ND ND ND 
Q31A 0.44 ± 0.001 1.18 ± 0.03 2.68 ± 0.08 
Q31E 0.27 ± 0.001 2.56 ± 0.05 9.41 ± 0.15 
Q31H 0.43 ± 0.02 1.01 ± 0.05 2.34 ± 0.01 
N34A 0.37 ± 0.03 14.38 ± 2.20 38.43 ± 3.42 
N34D 0.03 ± 0.003 0.99 ± 0.04 28.75 ± 1.17 
E41A 0.38 ± 0.01 0.95 ± 0.02 2.50 ± 0.08 
E41Q 0.43 ± 0.04 0.72 ± 0.03 1.69 ± 0.23 
W42F 
 
ND ND ND 
W42Y ND ND ND 
C56A 0.56 ± 0.02 1.15 ± 0.01 2.06 ± 0.03 
 
Table 5.5 – Summary of the rate constants and binding affinity obtained for the 
interaction of D-SpGC2-1 mutants and Fc 
 
ND denotes little or no binding determined. 
 
The results obtained for D-SpGC2-1 mutants Q31A, Q31H, E41A and E41Q studied 
by stopped-flow show very little difference in their rates of association and 
dissociation with Fc, and the Kd values to that of wild-type D-SpGC2-1, confirming 
ITC studies (see chapter 6) that these mutants have not grossly affected the 
binding of D-SpGC2-1 with Fc. Results also show that neither alanine nor 
glutamine side-chain replacements of glutamate 41 affected Fc binding, indicating 
that this glutamate residue is not significantly involved in the interaction with Fc. 
However, six mutant constructs were found to affect the binding affinity of D-
SpGC2-1 with Fc, namely E26A, Q31E, N34A, N34D, W42F and W42Y. These 
results again agree with those obtained by equilibrium methods, such as ITC (see 
chapter 6). 
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The second glutamate residue implicated in the interaction between SpG and Fc, 
namely Glu26, is implicated in the major interfacial binding site, and is situated 
on the C-terminal end of the α-helix. This residue forms hydrogen bonds with 
backbone nitrogen atoms of Fc residues Ile253 and Ser254, and is part of the 
hydrogen network that forms in the complex. Results obtained by stopped-flow 
studies showed that no binding was observed with Fc. This total loss of affinity 
suggests that this residue plays a significant role in the interaction and is 
essential to Fc binding.   
 
Characterising amino-acid Gln31 by stopped-flow demonstrated that when this 
residue is mutated to either an alanine or a histidine residue, Fc binding is not 
affected. Gln31 is implicated in the major interfacial interaction of SpG with Fc 
and is located around the middle of the α-helix, forming a hydrogen bond with the 
oxygen atom of the side-chain of Fc residue Gln438. The mutant Q31A results in 
the loss of the hydrogen bond, but values obtained for the association and 
dissociation of the complex, and the binding affinity are very similar to those 
obtained for wild-type, suggesting that this residue does not play a significant 
role in the binding of D-SpGC2-1 with Fc. This was also seen with the conservative 
mutant Q31H. 
 
In contrast, replacement by glutamate dramatically affects Fc binding, which is 
reduced approximately 4-fold, and a typical stopped-flow fluorescence analysis of 
Q31E is presented in figure 5.10. Either an increase in kass or a decrease in kdiss, or 
a combination of both may bring about an increase in Kd of the complex. The 
calculated Kd value of the complex formed between Q31E and Fc is 9.41 ± 0.15 
µM, compared to the Kd value of 2.52 ± 0.29 µM for the equivalent complex 
formed by wild-type. This increase in Kd is due to a 3-fold increase in the 
dissociation rate, whilst the association rate shows no significant change. This, 
therefore, implicates the significance of this ionisable group in the binding 
interface between D-SpGC2-1 and Fc, and will be characterised further in pH 
studies. 
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 kass = 2.56 µM-1s-1 
kdiss = 0.27 s-1 
 
Figure 5.10 – Typical stopped-flow fluorescence analysis of the formation of Q31E 
D-SpGC2-1 and Fc complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of Q31E D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss are determined from the gradient of the line and the intercept of the y-axis 
respectively.  W42 
 
The exclusive tryptophan residue in the D-SpGC2-1 gene, Trp42, has also been 
implicated in the interfacial interaction with Fc, and is situated on the N-terminal 
end of β-strand 3. Although this tryptophan residue is not directly involved in 
binding to Fc through a hydrogen bond network, it was decided to make W42F 
mutant in order to collaborate the work performed by Walker [Walker, 1994]. 
Results obtained show that although this mutation is in a slightly different 
construct, the effect was still the same and a loss of binding was found. This 
further supports the previous studies, indicating that tryptophan 42 is very 
important for the binding interaction of SpG with Fc.  
 
This was also apparent for mutant W42Y. Tyrosine is a polar residue by nature 
and can normally be found at the surface and the interior of proteins. Tyrosine 
was chosen to substitute the tryptophan residue for its ability to form hydrogen 
bonds, and a study by Stone et al [Stone et al., 1989] has shown that tyrosine 
residues are likely to be involved in SpG’s interaction with Fc fragment at the 
CH2-CH3 domain interface. Therefore, it was thought that by introducing a 
tyrosine residue, a hydrogen bond is formed with the Fc residue Asn434, which 
may result in the possibility that this interaction may restore Fc binding. However, 
results obtained by stopped-flow studies showed that no binding was observed 
with Fc. This result lends itself to two possible interpretations. Either that the loss 
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of binding is a direct consequence of the loss in affinity, as with W42F, or that this 
mutant construct can still bind Fc, but no significant fluorescence change is 
observed as the tryptophan residue that reports changes in fluorescence upon Fc 
binding has been removed. Walker did not study this mutant, so there is no 
supporting data available as in the case with W42F to explain these results. 
However, further characterisation can be achieved by a non-fluorescent 
technique, ITC, which was used as a thermodynamic approach to study the 
association of the complex between D-SpGC2-1 and Fc. 
 
Trp42 is also in close proximity with a hydrogen network centralised around 
asparagine residue 34. Figures 5.11 and 5.12 present stopped-flow results 
obtained for mutant constructs N34A and N34D, respectively. As mentioned 
previously, either an increase in kdiss or a decrease in kass, or a combination of 
both may bring about an increase in Kd of the complex. The calculated Kd value 
of the complex formed between N34A and Fc is 38.43 ± 3.42 µm, compared to 
the Kd value of 2.52 ± 0.29 µM for the equivalent complex formed by wild-type. 
This 15-fold increase in Kd is due to a 17-fold increase in the dissociation rate, 
whilst the association rate shows no significant change. The calculated Kd value 
of the complex formed between N34D and Fc is 28.75 ± 1.17 µm, and in 
contrast, this 11-fold increase in Kd is due to a 11-fold decrease in the 
association rate, whilst the dissociation rate shows no significant change. 
Asparagine 34 is implicated in the interfacial interaction of SpG with Fc, and is 
located at the C-terminal end of the α-helix. This residue’s side-chain forms a 
hydrogen bond with the side-chain of Fc residue Asn434, and continues this vast 
hydrogen bond network by also forming hydrogen bonds with two other Fc 
residues, Tyr436 and His433. These results strongly suggest that this residue 
plays a significant role in SpG’s interaction with Fc, and the close proximity of the 
bulky tryptophan residue may also play a part. 
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 kass = 0.37 µM-1s-1 
kdiss = 14.38 s-1 
 
Figure 5.11 – Typical stopped-flow fluorescence analysis of the formation of 
N34A D-SpGC2-1 and Fc complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of N34A D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss are determined from the gradient of the line and the intercept of the y-axis 
respectively.  
 
 
 
 
kass = 0.03 µM-1s-1 
kdiss = 0.99 s-1 
 
Figure 5.12 – Typical stopped-flow fluorescence analysis of the formation of 
N34D D-SpGC2-1 and Fc complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of N34D D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss are determined from the gradient of the line and the intercept of the y-axis 
respectively.  
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5.7.6 – Observing the effect of temperature on D-SpGC2-1 and Fc 
complex 
Measurements of binding thermodynamics can extend from the determination of 
affinity through to the estimation of changes in free energy, enthalpy and entropy 
by employing Arrhenius and van’t Hoff plots.  
 
The kinetic energy of the reactant molecules is dependent upon temperature, and 
an increase in temperature causes an increase in both the rate constant of 
association and that of dissociation. Calculations based upon reactant 
concentration and kinetic energy indicates that only a small portion of collisions 
result in a chemical reaction. In order for a collision to result in a chemical 
reaction, the colliding molecules must be in the correct orientation and possess a 
critical amount of energy required for the reaction. Thereby, conducting a 
reaction at a higher temperature delivers more energy into the system and 
increases the reaction rate by causing more collisions between particles, as 
explained by the collision theory. This is because more of the colliding particles 
will have the necessary activation energy, resulting in more successful collisions, 
when bonds are formed between reactants. Reaction rates for many reactions 
double or triple for every 10 degrees Celsius increase in temperature, although 
the effect of temperature may be very much larger or smaller than this. 
 
5.7.6.1 - Activation energy 
The minimum energy requirement of a molecule in order to allow it to react is 
defined as the activation energy (Ea) for the reaction. In a reaction between two 
or more molecules to from a product, the energy level often passes through a 
maximum called the activated or transition state, as shown in figure 5.13.  
 
 Activated state 
 
Reactants 
Ea for forward 
reaction Ea for reverse 
reaction 
Energy 
 
 
 
 
 
 
 
 
 Products  
Figure 5.13 – A schematic diagram of the activation energy of a reaction 
 
This energy barrier can be explained by the requirement of many products to be 
produced as a result of breaking of bonds to produce new ones. Zero activation 
energy only seems to occur when there is no breaking of chemical bonds [Laidler, 
1978].  
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If the activation energy for a particular reaction is high only a small proportion of 
the molecules present will possess sufficient energy to react and therefore, the 
rate of the reaction will be slow. Conversely, if the activation energy for a reaction 
is low a large proportion of the molecules will have sufficient energy to react and 
the rate of reaction will be high. 
 
5.7.6.2 - The Arrhenius law 
The relationship between the rate constant, influence of temperature and 
activation energy is described by the Arrhenius equation, as shown in equation 
5.15. The connection between the rate constant (k) of a reaction with absolute 
temperature (T) was expressed by van’t Hoff and Arrhenius in 1887, and later 
extended by Arrhenius, to become the Arrhenius law. In addition, Ea is the 
activation energy (enthalpy), A is a constant independent of temperature and R is 
the universal gas constant. 
 
k = A exp( – Ea/ RT)                           (Equation 5.15) 
 
The approach of van’t Hoff to this equation focussed on thermodynamics and 
energy levels. At equilibrium, the constant K is equal to the ratio of the rate 
constants kass and kdiss, and that these vary as shown in equation 5.16.  
 
   dln kass         dln kdiss               ΔHo 
                 –                 =                   (Equation 5.16) 
      dT              dT                RT2 
 
This can be split into two separate equations and integrated to produce equations 
5.17 and 5.18. In these equations, E is the activation energy, and A is the 
frequency factor of the reaction. This can be done because the difference between 
the activation energies (enthalpies) E1 and E-1 is equal to ΔHo.  
 
kass = A1 e – E 1/RT                                                          (Equation 5.17) 
 
kdiss = A-1 e – E-1/RT            (Equation 5.18) 
 
Arrhenius reasoned that most collisions in chemical reactions occur with 
insufficient energy for products to be formed. The Arrhenius law (equation 5.15) 
resembles the Boltzmann distribution law (equation 5.19), which represents the 
fraction of molecular collisions that are equal to or in excess of particular energy, 
E.  
 
e – E/RT            (Equation 5.19) 
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For the Arrhenius law, this is the activation energy, Ea. To use the law, natural 
logs can be taken to produce equation 5.20.  
 
lnk =  ln A -   Ea 
                                                          (Equation 5.20) 
            RT 
 
In a moderate temperature range, Ea and A should remain approximately 
constant, and as such, an Arrhenius plot of ln k against 1/T gives a negative 
slope, which has a gradient equal to –Ea /R and an intercept on the ordinate axis 
of ln A. 
 
5.7.6.3 - van’t Hoff’s equation 
ΔG can also be obtained relatively easily from the binding experiment using 
equation 5.21, where R is the gas constant and T is the absolute temperature in 
Kelvin.  
 
ΔG = - RT lnK                           (Equation 5.21) 
 
van’t Hoff combined this equation with equation 5.22, which relates ΔG to ΔH  
 
ΔG = ΔH - TΔS                                                          (Equation 5.22) 
 
And this forms van’t Hoff’s equation (equation 5.23).  
 
     ΔHo                  ΔSo 
ln K =               +                                                           (Equation 5.23) 
               RT   R 
 
Similarly to an Arrhenius plot, over a moderate temperature range, ΔH and ΔS 
should remain approximately constant. A van’t Hoff plot of lnK against 1/T gives a 
negative slope, which has a gradient equal to –ΔHo/R and an intercept on the 
ordinate axis of ΔSo/R.  
 
5.7.7 - Determining the effect of temperature on D-SpGC2-1 and Fc 
complex 
The high melting point of the binding domains of SpG promoted interest in the 
effect of temperature on the rate constants of complex formation. Fast kinetic 
stopped-flow studies were carried out under identical conditions at various 
temperatures to measure the thermodynamic constants of a binding reaction 
between a domain of SpG and its ligand, Fc. The temperatures of both solutions 
were thermostatically controlled and kapp was measured as before.  
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The net effect of temperature on the affinity of the complex formed between     
D-SpGC2-1 and Fc is dependent upon the activation energies of each step of the 
binding interaction. The values for the association and dissociation rate constants, 
as well as the pre-equilibrium Kd, were measured over the temperature range of 
10 to 35 °C, in order to determine the activation energy of each rate constant. 
Typical plots, presented in figure 5.14, show the effect of increasing temperature 
on the association, dissociation and Kd constants respectively. The activation 
energy of the association and dissociation of the wild-type D-SpGC2-1 binding 
interaction with Fc can be calculated from an Arrhenius plot of the natural 
logarithm (lnk) against 1/T, shown in figures 5.15 and 5.16, respectively. The 
gradient of the Arrhenius plots gives a negative slope, which has a gradient equal 
to –Ea /R and an intercept on the ordinate axis of ln A. 
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 Association kass (µM-1s-1) 
 
 
 
 
Figure 5.14 – Typical plots of the effect of temperature on the Wt D-SpGC2-1 and 
Fc complex   
 
These plots show the effect of temperature on the association constant kass (µM-
1s-1), dissociation kdiss (s-1) and Kd (M) plotted against temperature, at pH 8.0 
between Wt D-SpGC2-1 and Fc.  
 
Dissociation kdiss (s-1) 
Kd (M) 
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Ea = 26 kJ.mol-1 
 
Figure 5.15 – Typical Arrhenius plot of the effect of temperature on association of 
the Wt D-SpGC2-1 and Fc complex   
 
This graphical determination represents an Arrhenius plot of the lnk against 
1/varying temperatures (°K), at pH 8.0, for the association of the Wt D-SpGC2-1 
and Fc complex.  
 
 
 
Ea = 59 kJ.mol-1 
 
Figure 5.16 – Typical Arrhenius plot of the effect of temperature on dissociation 
constant of the Wt D-SpGC2-1 and Fc complex   
 
This graphical determination represents an Arrhenius plot of the lnk against 
1/varying temperatures (°K), at pH 8.0, for the dissociation of the Wt D-SpGC2-1 
and Fc complex.  
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A summary of the effect of temperature on the association, dissociation and the 
binding affinity of the complex between wild-type D-SpGC2-1 and Fc is presented 
in figure 5.17 and table 5.6.  
 
 
35°C 
30°C 
25°C 
20°C 
15°C 
10°C 
Figure 5.17 – Typical stopped-flow analysis of the Wt D-SpGC2-1 and Fc complex 
at varying temperatures   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of Wt D-SpGC2-1 at temperatures 10 °C to 35 °C, pH 8.0. The rate 
constants kass and kdiss can be determined from the gradient of the line and the 
intercept of the y-axis respectively.  
 
 
Temp 
(°C) 
°Kelvin 
(+ 273) 
kass  
(µM-1s-1) 
± std dev. n≥2 
kdiss 
(s-1) 
± std dev. n≥2 
Kd  
(µM) 
± std dev. n≥2 
10 283 0.2842 0.5112 1.80 
15 288 0.3587 0.8651 2.41 
20 293 0.437 1.143 2.62 
25 298 0.5322 1.689 3.17 
30 303 0.6349 2.547 4.01 
35 308 0.6925 4.246 6.13 
 
Table 5.6 – Summary of the effect of temperature on the rate constants and 
binding affinity obtained for the interaction of Wt D-SpGC2-1 and Fc 
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Results obtained by stopped-flow to determine the effect of increasing 
temperature on the association and dissociation of the complex between wild-
type D-SpGC2-1 and Fc, give positive activation energy values and show that 
increasing the temperature leads to an increase in the rate constants. Figure 5.18 
presents a typical van’t Hoff plot for the interaction of wild-type D-SpGC2-1 with 
Fc. From the plot of the lnKa against 1/ temperature °Kelvin, thermodynamic 
parameters can be determined for the reaction. ΔH = slope = -ΔH/R; ΔS = 
intercept = ΔS/R and ΔG = ΔH – TΔS. A summary of Kd and ΔG values at 15 °C 
(288 °K) are presented in table 5.7. 
 
 
ΔH = -32362.25 J.mol-1 
ΔS = -4.15 cal.mol-1.deg-1
 
Figure 5.18 – Typical van’t Hoff plot of the effect of temperature on the Wt D-     
SpGC2-1 and Fc complex   
 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of Wt D-SpGC2-1 and Fc complex, pH 8.0.  
 
 
Temp 
(°C) 
°Kelvin 
(+ 273) 
ΔG  
(cal.mol-1) 
Kd  
(µM) 
10 283 -31187.93 1.75 
15 288 -31167.18 2.22 
20 293 -31146.44 2.80 
25 298 -31125.69 3.50 
30 303 -31104.94 4.34 
35 308 -31084.19 5.35 
 
Table 5.7 – Summary of the effect of temperature on ΔG and the pre-equilibrium 
Kd obtained for the interaction of Wt D-SpGC2-1 and Fc 
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5.7.8 – Determining the effect of temperature on the reaction 
between D-SpGC2-1 mutants and Fc  
The effect of increasing temperature was also studied on a selection of D-SpGC2-1 
mutants and their respective complex with Fc. Figures 5.19 to 5.22 present van’t 
Hoff plots, for mutant constructs Q31E, E41Q N34A and N34D, respectively, from 
which thermodynamic parameters were calculated and compared with values 
obtained for wild-type D-SpGC2-1. All data are summarised in table 5.8. 
 
 
ΔH = -32038.83 J.mol-1 
ΔS = -16.13 cal.mol-1.deg-1
Figure 5.19 – Typical van’t Hoff plot of the effect of temperature on the formation 
of Q31E D-SpGC2-1 and Fc complex   
 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of mutant Q31E D-SpGC2-1 and Fc complex, pH 
8.0.  
 
 
 = 6.20 cal.mol-1.deg-1 
ΔH = -30438.39 J.mol-1 
ΔS
Figure 5.20 – Typical van’t Hoff plot of the effect of temperature on the formation 
of E41Q D-SpGC2-1 and Fc complex   
 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of mutant E41Q D-SpGC2-1 and Fc complex, pH 
8.0.  
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 ΔH = -374.47 J.mol-1 
ΔS = 76.79 cal.mol-1.deg-1
Figure 5.21 – Typical van’t Hoff plot of the effect of temperature on the formation 
of N34A D-SpGC2-1 and Fc complex   
 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of mutant N34A D-SpGC2-1 and Fc complex, pH 
8.0.  
 
 
 
ΔS = 119.44 cal.mol-1.deg-1 
ΔH = 8935.89 J.mol-1 
Figure 5.22 – Typical van’t Hoff plot of the effect of temperature on the formation 
of N34D D-SpGC2-1 and Fc complex   
 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of mutant N34D D-SpGC2-1 and Fc complex, pH 
8.0.  
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 D-SpGC2-1 
Construct 
Kd  
@ 15 °C 
(µM)  
n≥2 
Ea kass 
(kJ.mol-1) 
n≥2 
Ea kdiss 
(kJ.mol-1) 
n≥2 
ΔH  
(cal.mol-1) 
n≥2 
ΔS 
(cal.mol-1.deg-1) 
n≥2 
ΔG  
@ 15 °C 
(cal.mol-1) 
n≥2  
WT 2.22 26.42 58.81  -32362.25 -4.15 -31167.18 
Q31E 10.75 35.92  68.44  -32038.83 -16.13 -27394.11 
N34A 83.58 57.83  58.20 -374.47 76.79 -22489.44 
N34D 24.08 48.87  39.88  8935.89 119.44 -25462.52 
E41Q 1.40 33.26 63.79 -30438.39 6.20 -32223.20 
 
Table 5.8 – Summary of the effect of temperature on the thermodynamic 
parameters and binding affinity rate constants obtained for the 
interaction of D-SpGC2-1 mutants and Fc 
 
Studies to determine the effect of increasing temperature on the interaction 
between D-SpGC2-1 mutants and Fc are presented in table 5.7. Thermodynamic 
constants for each binding interaction with Fc were determined from Arrhenius 
and van’t Hoff plots. ΔG values were calculated at 15 °C so that a direct 
comparison with data obtained from ITC studies, chapter 6.0, can be made. 
 
5.7.9 - Calculating the effect of pH on D-SpGC2-1 and Fc complex 
The native three-dimensional structure of a protein is determined by the 
physicochemical nature of its constituent amino acids. The twenty different types 
of amino acids, depending on their physicochemical properties, can be grouped 
into three major classes, hydrophobic, hydrophilic and charged. Charged residues 
are also known as ionisable groups, and a protein’s structure, stability and 
function, as well as the net charge on a protein depends on the balance of the 
individual positive, negative and neutral charges present on the amino terminus, 
the carboxyl terminus and any ionisable side-chains that are present [Shaw et al., 
2001].  
 
Amino groups of proteins are basic groups and are positively charged except at 
high pH. The overall charge on a protein influences the ionisation of individual 
residues, and the net charge varies with pH, as well as being determined by the 
pK values of the ionisable groups [Thurlkill et al., 2006]. There are two groups of 
ionisable amino-acid side-chains depending on the charge found on the acidic 
form. Type 1 groups are neutral in their acidic form, dissociate to form a proton 
and a conjugate base, and carry a negative charge when the pH is greater than 
the pKa. This group includes the carboxyl group of the C-terminus, as well as on 
 | 204  
 
the side-chains of aspartate (aspartic acid) and glutamate (glutamic acid), and 
the phenolic side-chain of tyrosine. In contrast, type 2 ionisable groups are 
positively charged, dissociate to form a proton and an uncharged conjugate base, 
and carry a positive charge when the pH is less than the pKa. Type 2 groups 
found in proteins include the alpha-amino group of the N-terminus, and the 
amino groups found on the side-chain of lysine, the imidazole side-chain of 
histidine, and the guanidinium group of arginine [Schutz and Warshel, 2001]. 
 
To evaluate the ionisation states in proteins requires the pK to be determined. 
The term pK is related to the state of ionisation or dissociation of a molecule or 
functional group on a molecule and the pKa is a measure of proton binding 
affinity [Pace et al., 2000]. These values provide important electrostatic 
information of the ionised groups in proteins, as well as the electrostatic energies 
in protein binding sites. The ionisation of charged residues in a binding interaction 
depends on their appropriate ionisation states at physiological pH [Pace et al., 
2000], and the distribution of surface-charged residues is also critical for protein-
protein association. Furthermore, changes in the distribution of charge can occur 
at the site of the interaction [Sheinerman et al., 2000]. Ionisable groups can be 
influenced by the chemical structure and when proteins fold and interact, the 
perturbations of the pKs of the ionisable groups on the surface of the protein are 
determined mainly by charge-charge interactions with other ionisable groups. 
However, large positive and negative perturbations often occur if these groups 
are partially or fully buried in the protein interior [Schutz and Warshel, 2001]. 
 
If a functional group on a protein is said to have a low pK (<2.5), it has a low 
affinity for protons and gives them up readily, whereas a high pK (>3.0) binds 
protons strongly, and gives them up reluctantly. The pKa rule for predicting the 
dissociation and therefore, determining the ionisation state of a molecule or 
functional group is that when the pH of a solution is below the pK of a molecule 
then the un-dissociated molecule and the acid form of the compound 
predominates. Whereas, when the pH of a solution is the same as the pK of a 
molecule then the concentration of the un-dissociated molecules is equal to the 
concentration of the dissociated molecules, and when a solution pH is above the 
pK of a molecule then the dissociated molecule and the conjugate base [Thurlkill 
et al., 2006]. 
 
The effect of an ionisation process on the binding interaction can be determined 
by using stopped-flow to study the pH dependence of the apparent second-order 
complex-formation rate constant (kass) and of the first-order complex-dissociation 
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rate constant (kdiss) of D-SpGC2-1 with Fc. These kinetic parameters will change as 
the reaction pH increases or decreases below the pK, depending on whether the 
group is protonated or deprotonated in order to function.  
 
The pH profile of the reaction can be constructed by employing an adapted Dixon-
Webb plot, whereby the log of Kd is plotted against the varying pH values of the 
study [Dixon and Webb, 1979]. If an ionisation process has an effect on the 
interaction, the adapted Dixon-Webb plot will consist of straight-line sections 
joined by short curved parts. The pK of the ionising group in one of the 
components is defined by the curve, concurrently with the straight-line sections 
that intersect at a pH and correspond to the pK [Dixon and Webb, 1979].    
 
5.7.10 – Determining the effect of pH on D-SpGC2-1 and Fc complex 
To enable the binding interaction between SpG and Fc to be fully characterised, 
knowledge of the contribution from each amino-acid involved is required. The pK 
changes of ionisable groups that may occur upon binding can be determined by 
the pH dependence of the kinetics of Fc binding. From these studies it is possible 
to obtain information regarding the charge and pK values of the important 
residues. 
 
A detailed pre-equilibrium binding study of the electrostatic nature of the 
interaction was performed using a triple buffer system to buffer a wide range of 
pH conditions, namely pH 4.0 to pH 9.0, at which both proteins were considered 
stable. The pH dependence of the second-order association rate constant kass and 
of the first-order dissociation rate constant kdiss for wild-type D-SpGC2-1 and Fc is 
presented in figure 5.23. The effect on the Kd binding affinity is also presented in 
figure 5.23, and a summary of all the values obtained is shown in table 5.9. 
These results show that the interaction between wild-type D-SpGC2-1 and Fc is pH 
dependent, exhibiting a maximum binding affinity at pH 6.0, which compares well 
with results obtained by Walker [Walker, 1994]. This also agrees with results 
obtained by immobilisation techniques for SpG [Pilcher et al., 1991].  
 
The different affinities at pH values outside this range may be contributed to a 
change in the association and dissociation rates or a combination of both. The 
results obtained for both of these rate constants show that the effect of pH on the 
Kd appears to be mediated through changes in the rate of association of the 
complex, as the dissociation is virtually unchanged over the same pH range. This 
seems to indicate that charged residues are involved in the formation of the 
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complex between wild-type D-SpGC2-1 and Fc, but not with the dissociation of the 
complex. These results also compare well with results obtained by Walker 
[Walker, 1994]. 
 
pH kass  (µM-1s-1) 
± std dev. n≥2 
kdiss  
(s-1) 
± std dev. n≥2 
Kd  
(µM-) 
± std dev. n≥2 
4.0 0.43 ± 0.04 
1.29 
± 0.06 
2.99 
± 0.13 
5.0 1.04 ± 0.14 
2.10 
± 0.46 
2.08 
± 0.74 
6.0 1.01 ± 0.10 
1.54 
± 0.15 
1.51 
± 0.23 
7.0 0.65 ± 0.04 
1.23 
± 0.25 
1.90 
± 0.13 
8.0 0.34 ± 0.02 
1.08 
± 0.11 
3.21 
± 0.54 
9.0 0.24 ± 0.02 
1.02 
± 0.04 
4.23 
± 0.24 
 
Table 5.9 – Summary of the effect of pH on the rate constants and binding affinity 
obtained for the interaction of D-SpGC2-1 mutants and Fc 
 
 
The influence of the ionisation process of one or more of the residues 
participating in the interaction is then determined from the adapted Dixon-Webb 
plot, presented in figure 5.24. This plot indicates that an ionisable group with a 
pK of around 6.3 may be important for binding.  
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Figure 5.23 – pH profiles of the effect of pH on the Wt D-SpGC2-1 and Fc complex   
 
These plots represent pH profiles of the association, dissociation rate constants 
and Kd against varying pH, at 15 °C, between Wt D-SpGC2-1 and Fc.  
Association kass (µM-1s-1) 
Dissociation kdiss (s-1)  
Kd (µM)  
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 pK = 6.3 
 
Figure 5.24 – Dixon-Webb plot of the effect of pH on the formation of Wt D-
SpGC2-1 and Fc complex   
 
This graphical determination represents a Dixon-Webb plot of the formation of 
Wt D-SpGC2-1 and Fc against varying pH at 15 °C.  
 
There are a number of ionisable residues in SpG that are involved in the 
interfacial interaction with Fc, namely Glu26, Lys27, Lys30, Asp39 and Glu41. At 
high pH, tyrosines on the Fc, which have been implicated in binding [Stone et al., 
1989] may also begin to ionise and disrupt the interaction. The pK of around 6.3 
suggests that one or more of the acidic residues Glu26, Asp39 or Glu41 may be 
responsible for this pH effect. 
 
5.7.11 – Determining the effect of pH on D-SpGC2-1 mutants and Fc 
complex 
 
To further determine the effect of pH on the formation of the complex between 
SpG and Fc, the pK of the ionisable groups derived from aspartate, glutamate and 
histidine in a range of mutant constructs of D-SpGC2-1 was calculated and 
compared with pK values obtained for wild-type. The mutant constructs 
possessing these ionisable groups are Q31E, Q31H and N34D, and will allow the 
effect of pH on the individual charged amino acid side-chains to be determined. 
The effect of removing an ionisable group was also investigated with E41Q, as 
this mutant has been shown to affect the binding of SpG with Fc. 
 
The influence of the ionisation process of one or more of the residues 
participating in the interaction is then determined from the adapted Dixon-Webb 
plot, presented in figure 5.25 for mutants Q31E, Q31H and N34D, respectively. A 
summary of the Dixon-Webb plots of these mutants compared with wild-type is 
presented in figure 5.26. 
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Q31E D-SpGC2-1  
 
 
Q31H D-SpGC2-1  
 
Figure 5.25 – Typical Dixon-Webb plots of the effect of pH on the formation of D-
SpGC2-1 constructs and Fc complex   
 
This graphical determination represents a Dixon-Webb plot of the formation of   
D-SpGC2-1 constructs (as indicated) and Fc against varying pH at 15 °C.  
N34D D-SpGC2-1  
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 N34D 
Q31E 
Q31H 
Wt 
E41Q 
 
Figure 5.26 - Summary pH profile of the effect of pH on Kd of the formation of D-
SpGC2-1 mutants and Fc complex 
 
This graphical determination represents a summary pH profile of the Kd (µM) 
against varying pH, at 15 °C, between D-SpGC2-1mutant constructs and Fc.  
 
The mutations Q31E and N34D have both altered the pH vs log Kd profile 
indicating that ionisation of the replacement is affecting the Kd of the complexes. 
The Q31H and the E41Q mutants have both got wild-type profiles, suggesting 
these mutations have little or no effect on pH sensitivity. 
 
5.8 – Discussion 
In this chapter fluorescence has been employed to study the binding interaction 
between SpG and Fc. The presence of a native tryptophan residue in SpG and its 
implication with Fc has allowed this residue to be exploited as a reporter group for 
monitoring Fc binding. In addition, this binding interaction has permitted the 
characterisation of the reversible interactions in terms of binding, stoichiometry, 
kinetics and thermodynamics, and enabled the reliable determination of these 
parameters.  
 
Equilibrium studies using fluorescence titrations provided a simple and effective 
method for determining the true dissociation constant for the complex and 
allowed the number of binding sites to be calculated. Pre-equilibrium studies 
employed fast kinetic stopped-flow to determine the rates of association and 
dissociation of the complex between SpG and Fc. Temperature and pH studies 
also showed that the interaction was dependent on these environmental 
 | 211  
 
 | 212  
 
conditions. The results suggest that amino acid residues at positions 31 and 34 
should be neutral for maximum binding affinity.  
 
  
 
 
CHAPTER 6.0 
 
ISOTHERMAL TITRATION  
CALORIMETRIC STUDIES  
ON THE SPG-FC  
BINDING INTERACTION 
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6.1 – Introduction 
Molecular recognition events involving macromolecules, such as proteins, are 
fundamental to almost every cellular process, and understanding the basis for 
protein-protein interactions is aided by the full characterisation of the 
thermodynamics of their association. Determination of reaction thermodynamics 
can extend the determination of affinity and stoichiometry to the estimation of 
changes in free energy, enthalpy, entropy and heat capacity.  
 
These and other important parameters of a reaction may be derived from 
secondary graphical plots of kinetic and equilibrium data (Arrhenius and van’t 
Hoff analyses) obtained at different temperatures, but can also be obtained 
directly from calorimetric studies. The direct assessment of the thermodynamics 
associated with a binding reaction by Isothermal Titration Calorimetry (ITC) often 
provides more information than that gained by equilibrium studies such as 
fluorescence titrations. Firstly, it is sometimes necessary to engineer a 
fluorescence reporter group into one reactant which may alter the structure of 
that molecule and hence the stability of the complex. Secondly, changes in the 
thermodynamical contributions of a reaction are not always accompanied by 
changes in affinity. The value of ΔG (from which the Kd of a complex is 
calculated) may remain unchanged even if the contributions of enthalpy and 
entropy to the binding reaction both change. Thus, Kd would not reflect the 
difference of the changes in bonding characteristics. The enthalpy of binding 
involves the formation and breaking of non-covalent bonds, particularly hydrogen 
bonds and van der Waals; a negative ΔH value indicates a net gain of the 
strength or number of these bonds, whereas a positive ΔH value indicates a loss 
[Holdgate and Ward, 2005].  
 
In the following studies, ITC was used as a direct thermodynamic approach to 
study the association of the complex between SpG and its ligands Fc and Fab, and 
to provide a complete characterisation of the binding energetics of the reaction. 
This technique is based on the measurement of the heat absorbed or released 
(the enthalpy change) upon titration of a solution of one reactant with that of a 
second reactant. This is because every molecular interaction either generates 
heat or absorbs small amounts of heat in direct proportion to the amount of 
binding that occurs [Doyle, 1997]. When the macromolecule becomes saturated 
with the ligand, the heat signal diminishes until only the background heat of the 
dilution of the titrating reactant is observed. If the reactants are in the 
appropriate concentration range and if the Kd of the equilibrium is fairly small 
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(e.g. Kd > µM) then ITC experiments can detect these small changes in heat. ITC 
therefore represents a very powerful tool for the characterisation of protein-
protein ligand interactions. 
 
6.2 - ITC instrumentation 
An Isothermal Titration Calorimeter instrument is composed of two, thermally 
insulated and identical cells - a sample cell and a reference cell. Sensitive 
thermocouple circuits are used to detect temperature differences between the 
reference cell (which is filled with water or buffer) and the sample cell which 
contains the non-titrating reactant. Both cells are surrounded by an inner shield, 
which is maintained at the same temperature as the cells to minimise any heat 
flow. The outer shield is also maintained at a constant temperature, to 
compensate for any changes in room temperature. A long-needle syringe, fitted 
with a paddle on its end, contains the ligand. After filling, the syringe is seated 
into the holder, which is coupled to an injector system under software control. 
The syringe paddle is located inside the sample cell and the entire syringe 
assemble rotates at a pre-selected speed to continuously provide mixing to the 
ligand contents of the sample cell. The main components of a MicroCal VP-ITC 
system employed for all ITC experiments are presented in figure 6.1.  The binding 
of the two proteins causes heat to be either taken up or evolved, depending on 
the nature of the reaction.  
 
 
 
 
 
 
 
injection  
system 
stirring  
mechanism 
inner shield 
reference  
cell 
 
outer shield 
syringe +                
paddle 
 
sample cell 
 
 
 
 
 
 
 
Figure 6.1 – An adapted diagram of the components of an isothermal titration 
calorimeter [Chellani, 1999] 
 
The VP-ITC instrument employs two identical cells. All binding processes occur in 
the sample cell. An experiment consists of series of injections of a ligand (in this 
case SpG solution) from the syringe into a solution of Fc contained in the sample 
cell. 
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In an exothermic reaction, the temperature in the sample cell increases upon 
addition of ligand. This causes the feedback power to the sample cell to be 
decreased, and power is applied to the reference cell in order to maintain an 
equal temperature between the two cells. In an endothermic reaction, the 
opposite occurs, and the feedback circuit increases the power to the sample cell 
in order to maintain a constant temperature.  
 
Observations are plotted as the power in μcal/sec needed to maintain the 
reference and the sample cell at an identical temperature. These pulses of power 
are integrated with respect to time, giving the total power applied per injection. 
The power applied (equivalent to heat (ΔH) released) upon each injection is 
presented in the top panel of the isotherm (see figure 6.2). As successive 
amounts of the ligand are titrated into the cell, the quantity of heat absorbed or 
released is in direct proportion to the amount of binding occurring. The majority 
of the added ligand becomes bound during the initial injections because of the 
excess macromolecules, and gives a measure of ΔH. The heat change becomes 
smaller throughout the titration as the available binding sites are filled. As the 
system reaches saturation, the signal changes diminish until only the heat of 
dilution of the ligand are observed. A binding curve, together with a line of best 
fit, is then obtained from a plot of the heat values from each injection against the 
ratio of ligand and binding partner in the cell, and allows the estimation of Kd. 
This is presented in the lower panel of the isotherm. The isotherm describing 
complex formation as a function of the molar ratio of ligand to macromolecule can 
then be analysed to give the thermodynamic parameters of the interaction under 
study. In addition, assuming that the concentrations of the SpG and Fc or Fab are 
known, the stoichiometry of the complex is easily calculated. 
 
6.3 - Calculation of thermodynamic constants from ITC data 
The main factor contributing to the entropic component of a binding reaction is 
the effect of the movement of water molecules from an ordered state - when 
hydrating one or more components - to a disordered state if they are “squeezed 
out” from binding interfaces when a complex forms, in which case their entropy 
increases. That is the burial of the water-accessible surface areas of reactants on 
binding, results in the release of solvent molecules and contributes a positive 
effect to the total entropy of the interaction, which is usually greater than the 
decrease in entropy caused by the reactant molecules becoming more ordered. 
Negative entropy values are proposed to be due to conformational restrictions 
that must be overcome for complex formation [Perozzo et al., 2004].  
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Gibbs free energy (ΔG) can be the same for a binding reaction, which has positive 
ΔH and ΔS values, denoting that binding is dominated by the hydrophobic effect, 
as complex formation, which has negative ΔH and ΔS values, denoting that 
binding is dominated by specific interactions [Holdgate and Ward, 2005]. The 
change in ΔG for the formation of the SpG•Fc complex, as shown in equation 6.2, 
is related to the standard Gibbs free energy change (ΔG°), under defined 
conditions, using the following relationship:  
                               [SpG•Fc]  
ΔG = ΔG° + RTln                                                        (Equation 6.1) 
                              [SpG][Fc] 
 
At equilibrium, under standard conditions, where ΔG=0, equation 6.1 may 
become: 
                        [SpG•Fc]  
ΔG° = - RTln                     = - RTlnKa = - RTln(1/Kd)              (Equation 6.2) 
                       [SpG][Fc] 
 
Where, R is the gas constant and is equal to 8.314472 kJ-1mol-1, T is the absolute 
thermodynamic temperature in °Kelvin and is equal to 288 at 15 °C, Ka is the 
equilibrium association constant and Kd is the equilibrium dissociation constant.  
 
This relationship demonstrates that the value of Kd is dependent upon the free 
energy of binding, ΔG°, and can be measured using a variety of methods. 
However, a full thermodynamic characterisation requires that the enthalpy 
change, which reflects the heat released or taken up during the association 
reaction, will also be measured. Free energy changes associated with protein-
protein interactions are usually the result of strong enthalpic and entropic 
contributions [Pierce et al., 1999]. The relationship between the free energy 
change, and enthalpy and entropy changes, is given by equation 6.3. 
 
ΔG = ΔH - TΔS            (Equation 6.3) 
                  
This is known as the Gibbs-Helmholtz equation, and is a thermodynamic equation 
used for calculating changes in the Gibbs energy of a system as a function of 
temperature. 
 
6.4 – Observation of the formation of the Wt SpG•Fc complex 
by ITC  
During a typical binding experiment, a solution of SpG (ligand in syringe) was 
titrated in precisely known volumes against a solution of Fc or Fab fragments, 
located in the sample cell, at constant temperature. Typically a solution of 600 µM 
Wt D-SpGC2-1 was titrated into 2.0 ml of 10 µM Fc using injections of 1 × 2 µl and 
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then between 20 and 49 × 5 µl. This method produces a binding isotherm for the 
Fc-Wt D-SpGC2-1 interaction with a minimum of -0.3 µcal/sec, which is sufficient 
to be analysed. Data were analysed using the manufacturer’s Origin™ software. 
Figure 6.2 presents a binding isotherm of Wt D-SpGC2-1 titrated into 2.0 ml of 20 
mM phosphate buffer at pH 8.0, and figures 6.3 and 6.4 present typical binding 
isotherms of Wt D-SpGC2-1 titrated into 2.0 ml of Fc observed by ITC at 15 °C 
and 25 °C respectively. These experiments demonstrate that it is the addition of 
Fc that produces the heat released upon the interaction. Titrations were carried 
out in triplicate for the wild-type protein with Fc, and typical isotherms of the data 
obtained are presented. Analysis of all data by the Origin™ software, is also 
presented as an inset to each binding isotherm. Formation of the SpG•Fc complex 
is an exothermic reaction, with heat being released upon complex formation, 
therefore injections of SpG into Fc resulted in a decrease in the electrical energy 
required to maintain the temperature difference between the sample and 
reference cells.  
 
Thermodynamic constants, ΔH and ΔS, and the equilibrium dissociation constant, 
Kd, obtained by titrating 600 µM Wt D-SpGC2-1 into 10 µM Fc, are presented in 
table 6.1 which shows that the binding reaction is driven by negative enthalpic 
changes (ΔH = -50.02  ± 5.15 kJ.mol-1) although entropic changes (ΔS = -56.07 
± 17.15 J.mol-1.deg-1) are unfavourable for the reaction in this direction. The 
Gibb’s free energy change (ΔG) of -33.93 ± 0.48 kJ.mol-1 shows that the reaction 
occurs spontaneously with a Kd of the complex under these conditions of 677 nM 
± 154.1. This latter value is very similar to that determined by fluorescence 
titrations performed under the same experimental conditions in which the Kd 
value for Wt D-SpGC2-1 binding to Fc was found to be 506 nM ± 0.1 (see chapter 
5). This also compares reasonably well with previous data obtained by Gallagher 
[Gallagher, 1994] for the B1 domain of a different SpG construct using titration 
calorimetry, which gave a Kd value of 333 nM. Although these values are slightly 
different, the slight increase in Kd found for the construct described in this thesis 
could indicate that the introduction of a 6x His-tag at the N-terminal end of the 
protein has slightly decreased the binding affinity of SpG for Fc. Similarly, the 
stoichiometry of binding for the interaction between SpG and Fc compares well for 
the two different experiments. Data from the ITC experiments gave a 
stoichiometry of 1.70 ± 0.05 equivalents of SpG to 1 equivalent of Fc, whereas 
the stoichiometry of binding from the fluorescence titrations was 2.1  ± 0.4 mol 
SpG: mol Fc.  
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Figure 6.2 – Binding isotherm of the interaction between Wt D-SpGC2-1 and buffer 
 
The analysis of the binding interaction between Wt D-SpGC2-1 and buffer 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into phosphate buffer using injections of 1 x 2 µl and 39 x 5 µl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 – Binding isotherm of the interaction between Wt D-SpGC2-1 and Fc  
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The analysis of the binding interaction between Wt D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 29 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0.  
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Figure 6.4 – Binding isotherm of the interaction between Wt D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between Wt D-SpGC2-1 and Fc measured 
by ITC at 25 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 49 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
 
 
6.5 – Effect of mutagenesis on the stability of the SpG•Fc 
complex 
Mutant constructs of SpG that have substitutions of residues that may be critical 
for the binding interaction with Fc have been produced to allow the contribution of 
these residues to the biological function of SpG to be evaluated. This is important, 
as it may give a complete overview of the binding interface and should greatly 
add to the understanding of the binding interaction. ITC is well placed to 
characterise the binding activities of these mutant protein constructs because it 
does not require the development of a new assay, and as well as being precise it 
does not demand catalytically active protein to generate a product to follow the 
reaction. Thus, titrations were performed as described above on all D-SpGC2-1 
mutant constructs. 
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 D-SpGC2-1 
Kd  
 
± std dev. 
n≥2 
ΔH  
(kJ.mol-1) 
± std dev.  
n≥2 
ΔS  
(J.mol-1.deg-1) 
± std dev. n≥2 
ΔG  
(kJ.mol-1) 
± std dev. 
n≥2 
N 
 
± std dev. 
n≥2 
Wt 677 nM 
± 154.1 
-50.02 
± 5.15 
-56.07 
± 17.15 
-33.93 
± 0.48 
1.7 
± 0.1 
E14W 856 nM 
± 76.4 
-39.14 
± 0.81 
 
-19.67 
± 2.00 
-33.51 
± 0.24 
2.40 
± 0.0 
E14W,W42F 4.5 µM 
± 1.4 
-15.53 
± 3.33 
48.54 
±14.23 
-29.55 
±0.76 
0.8 
± 0.1 
E26A ND ND ND ND ND 
C56A 290 nM 
± 4.2 
-47.26 
± 3.64 
-38.91 
± 12.55 
-36.08 
± 0.02 
1.7 
± 0.1 
Q31A 664 nM 
± 43.1 
-44.65 
± 5.98 
-36.82 
± 21.34 
-34.10 
± 0.19 
1.9 
±0.1 
Q31E 4.5 µM 
±0.7 
-46.59 
± 0.74 
-58.58 
± 1.25 
-29.69 
± 0.37 
1.8 
± 0.1 
Q31H 651 nM 
± 19.1 
-51.51 
±2.01 
-60.25 
± 7.11 
-34.14 
± 0.07 
2.0 
±0.0 
N34A 7.0 µM 
± 0.6 
-11.77 
± 0.84 
57.32 
± 3.35 
-28.28 
± 0.17 
1.6 
± 0.4 
N34D 8.5 µM  
± 3.7 
-30.66  
± 3.39 
-7.53 
± 15.90 
-28.32  
± 3.83 
3.3  
± 0.2 
E41A 517 nM 
± 142.8 
-28.18 
± 1.77 
-19.67 
±7.53 
-33.76 
± 0.42 
2.1 
± 0.0 
E41Q 320 nM 
± 24.0 
-30.24 
± 0.89 
-24.27 
± 2.93 
-34.89 
± 0.81 
2.1 
±0.1 
W42F ND ND ND ND ND 
W42Y 40 µM 
±12.0 
-40.92 
± 5.92 
-57.32 
± 17.99 
-24.42 
± 0.79 
0.8 
± 0.1 
 
Table 6.1 – Summary of the thermodynamic parameters obtained from 
titrating Wt and mutant D-SpGC2-1 constructs into Fc 
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6.6 - Determination of the thermodynamic constants for Fc 
mutants 
The thermodynamic data obtained for all Fc mutants is given in figures 6.5 to 
6.17 and the thermodynamic parameters summarised in table 6.1. In general, the 
Kd values for the mutants E14W, Q31A, Q31H, and E41A (figures 6.5 to 6.8) 
show very little difference, within error, from the Kd of 677 nM that was 
determined for wild-type SpG interacting with Fc. This indicates that the 
replacement of these residues thought to be involved in the binding of SpG and 
Fc does not result in a reduced binding affinity. However, although the overall Kd 
does not change greatly, the thermodynamic constants of the reaction 
contributions are different. The enthalpic contributions of these reactions are 
around -40 to -50 kJ.mol-1 for the Wt, E14W, Q31A and Q31H proteins, but for 
the E41A protein, it is lower at -28.18 kJ.mol-1. However, compensatory changes 
in the entropic contribution result in very similar Kd values. Thus, the overall 
conclusion is that these residues may contact the Fc, but have a minor 
involvement in stabilising interactions with Fc. It is of course also possible that 
the substitutions made have compensated for the loss in enthalpic changes. 
Hydrophobic changes may for example have caused some water molecules to be 
released thus increasing entropy in relative terms (e.g. from -55.95 cal.mol-1deg-1 
to -19.70 cal.mol-1deg-1). Residue E41 has been implicated in Fc binding by virtue 
of the fact that in the C3 domain (which has a higher affinity for human IgG than 
C1), a valine is found at this position. It is therefore interesting that for the 
mutant E41Q (figure 6.9), the removal of the negative charge and its 
replacement by a more hydrophobic amide side chain causes an increase in 
affinity (Kd = 320 nM). This, compared with that for the E41A mutant (517 nM), 
suggests that the amide side chain may play an important role in the interaction 
and that the loss of the negative charge may not, by itself, be sufficient to 
increase affinity.  
 
The binding affinities of mutants Q31A and Q31H with Fc do not change when 
observed by ITC, even though the replacement of the glutamine residue with an 
alanine residue removes the hydrogen bond, and hence part of the stabilising 
hydrogen network with Fc residue Gln438. In all cases the stoichiometry of 
binding remains close to the expected value of 2 due to the presence of two 
identical binding sites for SpG on Fc. However, the mutation Q31E also involves 
the loss of the hydrogen bond between the two proteins, and presents a negative 
charge. Results obtained show that this mutant, and the mutants N34A, N34D 
and W42Y, do show greatly reduced affinities for Fc. Figures 6.10 to 6.13 present 
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typical binding isotherms for these D-SpGC2-1 mutants respectively, under the 
same conditions. Kd values were 4.5 µM, 7 µM, 8.5 µM and 40 µM, respectively. 
Titrations involving the mutant N34D gave irreproducible analyses, possibly due 
to some instability in this protein, therefore the standard deviation is high and the 
Kd value and stoichiometry should be taken as estimates only. 
 
In general, these mutants show lower enthalpic contributions suggesting that 
fewer bonds are being made although in some cases (e.g. Q31E and W42Y) there 
is a higher loss of entropy, which is unfavourable for binding. The results 
emphasise the importance of Q31E, N34A, N34D and W42Y residues in the 
binding of SpG with Fc. In most cases the stoichiometry calculated was close to 2 
mol SpG to 1 mol of Fc, however the difficulty encountered in fitting the data to a 
binding profile where Kd is very large (e.g. N34D and W42Y) results in a what is 
believed to be a poor estimate for the stoichiometry (see table 6.2). 
 
Figures 6.14 and 6.15 present typical binding isotherms obtained for each of the 
mutants E26A and W42F D-SpGC2-1 titrated into Fc. No heat changes were 
observed for either of these mutants, indicating very large losses or total loss of 
binding activity. The latter data support previous data on the mutant W42F 
obtained by Walker [1994], who implicated the importance of this tryptophan 
residue in Fc binding by ELISA studies. Clearly E26 has an important role in 
binding Fc. 
 
Mutants E14W (see figure 6.5) and E14W-W42F D-SpGC2-1 (see figure 6.16) were 
specifically constructed to study the interaction between SpG and Fab. By using 
the W42F D-SpGC2-1 construct as a template, it was planned that the re-
introduction of a tryptophan residue at the alternative position of residue E14, 
would allow the effect of Fab mutations to be probed by fluorescence studies 
without any background signal changes from position 42 (normally a tryptophan). 
To ensure that the E14W-W42F D-SpGC2-1 construct had not been affected by the 
introduction of tryptophan at an alternative position, the ability of this mutant to 
bind Fc, and that of E14W D-SpGC2-1 (which contains two tryptophan residues 
W42 and E14W) was also studied by ITC as controls. Figures 6.5 and 6.16 
present typical binding isotherms that were obtained for mutants E14W and 
E14W-W42F D-SpGC2-1, respectively, titrated into Fc.  
 
Results obtained show that E14W-W42F D-SpGC2-1 has a much higher Kd value 
(4.5 µM) and thus a reduced binding affinity for Fc compared to values obtained 
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for wild-type SpG (677 nM ±154 nM) and E14W (856 nM ± 76 nM), which 
contains two tryptophan residues, and binds with a similar Kd value to that 
obtained for wild-type SpG. These results confirm that residue W42 plays an 
important part in the binding of SpG with Fc. However, due to the lack of binding 
exhibited by construct W42F, it would seem that the addition of tryptophan E14W 
in the construct may weakly compensate for the absence of W42. Again the low 
affinity resulted in a low estimate of the binding stoichiometry. 
 
Finally, figure 6.17 shows the binding isotherm for the mutant C56A (made to 
remove the carboxyl terminal cysteine), as its substitution removes any 
possibility of formation of dimers between the SpG domains and the need for the 
presence of a reducing agent. C56A was found to have a similar Kd (290 µM) to 
that of the wild-type protein, confirming that the presence of the cysteine has 
little or no effect on the affinity for Fc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 – Binding isotherm of the interaction between E14W D-SpGC2-1 and Fc 
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The analysis of the binding interaction between E14W D-SpGC2-1 and Fc 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into 10 µM Fc using injections of 1 x 2 µl and 24 x 5 µl. All titrations were carried 
out in 20 mM potassium phosphate buffer, pH 8.0. 
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Figure 6.6 - Binding isotherm of the interaction between Q31A D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between Q31A D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 - Binding isotherm of the interaction between Q31H D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between Q31H D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
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Figure 6.8 - Binding isotherm of the interaction between E41A D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between E41A D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 - Binding isotherm of the interaction between E41Q D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between E41Q D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
-1.0
-0.5
0.0
600µM E47A SpGC2-1 pQE-30 and 10µM Fc
20mM PO4 pH 8.0, 15°C
1x2µl and 39x5µl injections
Time (min)
µc
al
/s
ec
0 2 4 6 8 10
-10
-8
-6
-4
-2
0
Data: A210905a_NDH
Model: OneSites
Chi^2 = 16443.5
N 2.049 ±0.01247
K 1.482E6 ±9.689E4
ΔH -9801 ±83.01
ΔS -5.773
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
0 20 40 60 80 100 120 140 160
-1.5
-1.0
-0.5
0.0
600µM E47Q SpGC2-1 pQE-30 and 10µM Fc
20mM PO4 pH 8.0, 15°C
1x2µl and 39x5µl injections 
Time (min)
µc
al
/s
ec
0 2 4 6 8 10
-12
-10
-8
-6
-4
-2
0
Data: A220905a_NDH
Model: OneSites
Chi^2 = 15930.7
N 2.060 ±0.00954
K 2.159E6 ±1.292E5
ΔH -1.099E4 ±72.67
ΔS -9.159
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
 | 226  
 
 
 0 20 40 60 80 100 120 140 160
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 - Binding isotherm of the interaction between Q31E D-SpGC2-1 and Fc 
 
The analysis of the binding interaction between Q31E D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11 - Binding isotherm of the interaction between N34A D-SpGC2-1 and Fc  
 
The analysis of the binding interaction between N34A D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
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Figure 6.12 - Binding isotherm of the interaction between N34D D-SpGC2-1 and Fc  
 
The analysis of the binding interaction between N34D D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 - Binding isotherm of the interaction between W42Y D-SpGC2-1 and Fc  
The analysis of the binding interaction between W42Y D-SpGC2-1 and Fc 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into 10 µM Fc using injections of 1 x 2 µl and 39 x 7 µl. All titrations were carried 
out in 20 mM potassium phosphate buffer, pH 8.0 
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Figure 6.14 – Binding isotherm of the interaction between E26A D-SpGC2-1 and Fc  
 
The analysis of the binding interaction between E26A D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0 
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Figure 6.15 - Binding isotherm of the interaction between W42F D-SpGC2-1 and Fc   
The analysis of the binding interaction between W42F D-SpGC2-1 and Fc 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into 4 µM Fc using injections of 1 x 2 µl, 2 x 5µl and 24 x 5 µl. All titrations were 
carried out in 20 mM potassium phosphate buffer, pH 8.0 
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Figure 6.16 - Binding isotherm of the interaction between E14W-W42F D-SpGC2-1 
and Fc  
 
The analysis of the binding interaction between E14W-W42F D-SpGC2-1 and Fc 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into 10 µM Fc using injections of 1 x 2 µl and 29 x 5 µl. All titrations were carried 
out in 20 mM potassium phosphate buffer, pH 8.0 
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Figure 6.17 - Binding isotherm of the interaction between C56A D-SpGC2-1 and Fc  
The analysis of the binding interaction between C56A D-SpGC2-1 and Fc measured 
by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated into 10 µM Fc 
using injections of 1 x 2 µl and 39 x 5 µl. All titrations were carried out in 20 mM 
potassium phosphate buffer, pH 8.0 
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6.7 - The effect of temperature on the binding interaction 
between Wt SpG and Fc 
By performing similar equilibrium experiments over a range of temperatures it is 
possible to examine the effect of temperature on the reaction and derive values 
of ∆H° and ∆S° from a van’t Hoff plot. The equation for the plot used was derived 
by van’t Hoff by combining equation 6.2 with equation 6.3. 
 
∆G = -RTlnKa = -∆H – T∆S                (Equation 6.4) 
 
This can be re-arranged to give the van’t Hoff equation below: 
 
lnKa = -∆H°/RT + ∆S°/R                                                 (Equation 6.5)   
 
Thus a plot of lnKa against 1/T will yield a line of slope -∆H°/R and an intercept of 
∆S°/R. These values will therefore be derived not from a single experimental 
point, but from the average of all experiments carried out at different 
temperatures. The range of temperatures able to be used will depend upon the 
stabilities of the proteins used, in this case SpG and Fc. Both of these are stable 
up to 35 °C and therefore a temperature range of 10 °C to 35 °C was chosen with 
experiments being carried out at 5 °C intervals.  
 
For these experiments wild-type SpG was titrated into Fc as described above, 
except that the solutions were equilibrated at different pre-determined 
temperatures for the titration. The data given in table 6.2 show the temperatures 
in °C and the values of the average Ka determined from each titration. These 
data are used to generate the van’t Hoff plot seen in figure 6.18. 
 
From the data it is clear that the affinity of SpG for Fc decreases as temperature 
increases from 10 °C to 35 °C. This is as expected since increased temperature 
raises the level of molecular motion and destabilises the complex. This also 
suggests that the complex is stabilised by hydrogen bonds and not stabilised by 
hydrophobic or ionic interactions alone, since an increase in temperature should 
increase the strength of these latter interactions. This follows because a 
hydrophobic interaction is normally regarded as resulting in an increase in 
entropy due to the exclusion of water molecules from the interface. Thus the 
entropic force (T∆S) would increase with T.  Similarly, ionic interactions are 
described by Coulomb’s law in which the attractive force between two oppositely 
charged particles is reciprocally related to the Dielectric constant (D) of the 
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solvent. In this case the solvent is water whose dielectric constant decreases as 
temperature rises. 
 
Temperature  
(°C) 
Kd  
(µM)  
± std dev. n≥2 
10 2.233  ±  0.025 
15 1.237 ±  0.039 
20 0.699 ± 0.0741 
25 0.611 ±  0.056 
30 0.482 ± 0.025 
35 0.325 ± 0.031 
 
Table 6.2 – Summary of the average dissociation constant (Kd) at different  
temperatures by titrating Wt D-SpGC2-1 into Fc  
 
 
 
 
Figure 6.18 - A van’t Hoff plot of data from Table 6.2 
This graphical determination represents a van’t Hoff plot of the effect of varying 
temperatures on the formation of Wt D-SpGC2-1 and Fc complex. All experiments 
were observed by ITC in triplicate and carried out in 20 mM phosphate buffer, pH 
8.0.   
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The van’t Hoff plot gives ∆H = -52.19 kJ.mol-1. Similarly, the intercept results in a 
value for ∆S of 65.18 J.mol-1.deg-1. From these values the calculated ∆G at 15 °C 
(288K) is -33.42 kJ.mol-1, which yields a Kd for the reaction at this temperature 
of around 1150 nM in close agreement with that obtained from a single titration 
at 15 °C (677 ± 154 nM). Thus, the data obtained over the temperature range 
appear to confirm that the plot is linear (R = 0.931) and that the two methods for 
estimating the thermodynamic parameters for the reaction are comparable.  
 
6.8 - Discussion 
The results of the experiments above show that the affinity of SpG for Fc can be 
dramatically altered by substitution of some key residues. It is clear that W42 is 
essential for binding activity as previously found by Walker [Walker, 1994]. 
However, it appears that some restoration of activity is brought about by the 
placement of a tryptophan at residue 14 and a Kd of 4.5 µM was observed. In 
practice this may be a useful protein for affinity chromatographic applications as a 
Kd in the micromolar range is ideal for affinity ligands where easy elution of the 
bound target protein (in this case IgG or Fc) is required (personal communication 
Dr. Jim Pearson, Affinity Chromatography Ltd).  
 
These studies also show that in addition to the importance of W42, residues E26, 
Q31 and N34 play an important role in the binding. In the case of E26, 
substitution by alanine results in no significant change in the Kd value of the 
complex, but substitution by a glutamate residue increases Kd by approximately 
6-fold, demonstrating that a negative charge at this position is detrimental to 
binding. Residue N34 is clearly more important for binding since the N34A 
substitution increases Kd by about 10-fold and the N34D substitution effectively 
eliminates all apparent binding activity. 
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7.1 – Introduction 
The Fab region is composed of one constant and one variable domain from each 
heavy and light chain of the antibody, as shown in figure 7.1. The variable 
domains from the heavy and light chains provide a framework that supports three 
regions of hypervariability in sequence called the complementarity-determining 
regions (CDRs). These are located in the loops that connect the beta strands of 
the variable Ig domains. When the VL and VH chains pair up in the antibody 
structure, the CDR-containing loops are brought together to form the antigen 
binding site at each amino terminal end of the Fab fragment [Hurst et al., 2007]. 
They are responsible for the specificity and affinity of the epitope on their specific 
antigens. 
 
 
 
 
 
 
 
 
Figure 7.1 – An adapted illustration of two Fab fragments 
 
This model presents two Fab fragments, which are composed of one constant (C) 
and variable (V) domain from each heavy (H) and light (L) chain of the antibody. 
At the bottom of each Fab fragment is the hinge region, where each heavy chain 
extends into the Fc fragment. 
 
7.2 – Interaction of SpG with Fab 
Single Ig-binding domains of SpG have been shown to bind to Fab by forming an 
anti-parallel interaction with the last β-strand of the CH1 domain of Fab [Derrick 
and Wigley, 1992; Lian et al., 1994; Derrick and Wigley, 1994; Sauer-Eriksson et 
al., 1995]. SpG’s binding site for the interaction with Fab lies predominantly 
within β-strand 2, but also involves a minor region at the C-terminal end of the  
α-helix [Derrick and Wigley, 1994]. The amino acid residues that form the major 
contact regions have been identified, and the site of interaction spans residues 
Lys9 to Thr16 from β-strand 2 on SpG and Ser209 to Lys216 from the 7th          
β-strand of the CH1 domain of Fab. In addition, residues Tyr32 to Gly37 from the 
C-terminal end of the α-helix of SpG and Pro125 to Tyr129 on the 1st β-strand of 
the CH1 domain of Fab constitute the minor contact region [Derrick and Wigley, 
1994].  
 
These interfacial interactions between Fab and SpG are stabilised through a 
network of hydrogen bonds and salt links, involving mainly charged and polar 
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residues contributed by the last β-strand of the CH1 domain to the second β-
strand in SpG. The complex is further stabilised by the association of exposed 
non-polar residues from Fab and SpG, providing a continuous hydrophobic core, 
which is shielded from solvent [Derrick and Wigley, 1992]. 
 
As previously mentioned, SpG possesses a unique tryptophan residue at position 
42, located on β-strand 3, which is known for its important role in Fc binding. Its 
substitution by phenylalanine reduces the binding interaction of SpG with Fc 
approximately 300-fold [Walker et al., 1995]. Therefore, by using this W42F     
D-SpGC2-1 construct, IgG Fab binding can be studied without interference from 
any Fc interactions. However, the removal of the tryptophan in the W42F 
mutation would create a non-fluorescent protein, resulting in Fab binding studies 
using fluorimetry being difficult or impossible. Therefore, a tryptophan residue 
was re-introduced at an alternative position (E14W, see chapter 3.6.1) to allow 
the effect of Fab mutations to be probed in fluorescence studies.  
 
By incorporating the E14W mutant close to the proposed Fab binding site it was 
anticipated that this tryptophan residue would act as a reporter group solely for 
SpG binding to the CH1 domain of Fab. Therefore, the mutant W42F D-SpGC2-1 
construct was used to make the E14W mutant and the resulting double mutant, 
E14W-W42F D-SpGC2-1 pQE-30, was then employed as a template for subsequent 
mutants. The single mutant, E14W, was also employed as a control for all 
experiments undertaken in this study.  
 
Six residues were selected to be mutated and used to study and characterise the 
binding affinity of Fab to SpG. A selection of residues from both the major and 
minor contact regions, namely residues Thr10, Glu14, Thr15, Thr16, Tyr32 and 
Asn36 were chosen for their side-chain involvement in the interaction with Fab. 
This complex is stabilised through a network of hydrogen bonds, and the 
importance and effect of these bonds to the stability and nature of the complex 
by removing these key residues was the prime aim of the studies.   
 
7.3 – Determining the emission spectra of D-SpGC2-1 and Fab 
complex 
In order to carry out binding studies between SpG and Fab using fluorescence, a 
measureable change in fluorescence must occur upon complex formation. To 
establish whether or not a spectral change does occur upon binding, the emission 
spectra for E14W-W42F D-SpGC2-1 and Fab, both in free solution and in complex, 
were determined and is presented in figure 7.2. 
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Figure 7.2 - Emission spectra for E14W-W42F D-SpGC2-1 and Fab in complex 
 
The figure shows the emission spectra obtained for 200 nM E14W-W42F D-SpGC2-
1, 200 nM Fab and the SpG•Fab complex. Protein samples were excited at 280 nm 
and fluorescence emissions were measured between 300 and 400 nm. All spectra 
were measured in triplicate and corrected for the buffer fluorescence. The inset 
shows the fluorescence change upon complex formation, calculated by 
subtracting the observed fluorescence intensity of the complex from the 
theoretical fluorescence intensity of the complex.  
 
The spectra presented show that fluorescence intensity obtained for E14W-W42F 
D-SpGC2-1 displays an emission maximum at 345 nm, whereas the peak of the 
Fab spectra and the complex spectra is 340 nm. The spectra also show that the 
fluorescence intensity obtained for the SpG•Fab in complex is slightly less than 
the theoretical fluorescence of the complex, being calculated from the sum of the 
fluorescence spectra of the two proteins in free solution. This quench in 
fluorescence seems to occur upon complex formation and shows that the 
formation of the SpG•Fab complex can be monitored fluorimetrically. The quench 
is represented as a fluorescence difference spectrum, and is presented in the 
inset figure in figure 7.2. The inset shows that the difference spectrum also has a 
maximum at 345 nm, which suggests that tryptophan 14, like tryptophan 42, is 
in a solvent exposed position, and is being quenched on complex formation. 
 
7.4 – Equilibrium binding studies   
Equilibrium binding studies were carried out to provide valuable information on 
the binding affinity and number of binding sites of the interaction between SpG 
and Fab. In the following sections, studies are described that were aimed at the 
determination of the Kd for the binding reaction between SpG and Fab. 
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7.4.1 - Fluorescence titration 
The binding interaction between SpG and Fab has been studied through 
fluorescence titrations using the change in fluorescence that occurs upon complex 
formation. Fluorescence emissions at 340 nm were measured, using excitation 
wavelengths of 280 nm to study total fluorescence, and 295 nm to study 
tryptophan only fluorescence. 5 µl samples of 100 µM D-SpGC2-1 were titrated 
into 2 ml samples of 1 µM Fab. Data obtained were corrected for dilution and the 
inner filter effect, and further analysed through a Klotz plot, employing equation 
5.5 as defined in Chapter 5. 
  
Figure 7.3 presents a typical saturation curve for the binding of E14W-W42F      
D-SpGC2-1 to Fab and the subsequent analysis through a modified Klotz plot. The 
curve obtained for E14W-W42F D-SpGC2-1 binding to Fab at 15 °C, pH 8.0 was 
able to be described by a single Kd value of 3.33 ± 1.40 µM. The stoichiometry of 
binding from the intercept [E]0 was 1.17 ± 0.18, confirming that Fab has one 
binding site for E14W-W42F D-SpGC2-1. This is expected as Fab fragments have 
one heavy CH1 domain with a potential binding site for SpG. 
 
 
Figure 7.3 - Saturation curve for the titration of E14W-W42F D-SpGC2-1 into Fab 
 
The figure shows the saturation curve obtained when samples of 100 µM E14W-
W42F D-SpGC2-1 were titrated into a 2 ml solution of 1 µM Fab in 20 mM 
potassium phosphate buffer, pH 8.0 at 15 °C. Each point on the titration curve 
was calculated by subtracting fluorescence values observed upon titration of 
E14W-W42F D-SpGC2-1 into Fab, from the corresponding values for the titration 
of E14W-W42F D-SpGC2-1 into buffer. The inset shows the Klotz plot of the data 
(n = 3).  
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7.4.2 – Isothermal Titration Calorimetry (ITC) 
7.4.2.1 – Determination of Wt SpG•Fab binding by ITC  
Analysis of the binding of Fab to SpG by ITC is typically carried out by injecting a 
small volume of SpG at high concentration into a large volume of Fab fragment at 
a lower concentration. Therefore, a solution of 400 µM Wt D-SpGC2-1 was titrated 
into 20 µM Fab using injections of 1 × 2 µl and between 20 and 30 × 7 µl. This 
method aims to produce a binding isotherm that is sufficient to be analysed, with 
a minimum -0.3 µcal/sec value.  
 
Figure 7.4 presents a binding isotherm of Wt D-SpGC2-1 titrated into 20 mM 
phosphate buffer at pH 8.0, and figures 7.5, 7.6 and 7.7 present typical binding 
isotherms of wild-type, E14W-W42F and E14W D-SpGC2-1, respectively, titrated 
into Fab at 15 °C. 
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Figure 7.4 – Binding isotherm of the interaction between Wt D-SpGC2-1 and buffer 
observed by ITC 
 
The analysis of the binding interaction between Wt D-SpGC2-1 and buffer 
measured by ITC at 15 °C is presented. A solution of 600 µM SpG was titrated 
into phosphate buffer using injections of 1 x 2 µl and 39 x 5 µl.  
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Figure 7.5 – Binding isotherm of Wt D-SpGC2-1 and Fab observed by ITC 
 
The analysis of the binding interaction between Wt D-SpGC2-1 and Fab measured 
by ITC at 15 °C is presented. A solution of 400 µM SpG was titrated into 20 µM 
Fab using injections of 1 x 2 µl and 29 x 7 µl.  
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Figure 7.6 – Binding isotherm of E14W-W42F D-SpGC2-1 and Fab  
 
The analysis of the binding interaction between E14W-W42F D-SpGC2-1 and Fab 
measured by ITC at 15 °C is presented. A solution of 400 µM SpG was titrated 
into 20 µM Fab using injections of 1 x 2 µl and 29 x 7 µl. All titrations were 
carried out in 20 mM potassium phosphate, pH 8.0.  
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Figure 7.7 – Binding isotherm of E14W D-SpGC2-1 and Fab observed by ITC 
 
The analysis of the binding interaction between E14W D-SpGC2-1 and Fab 
measured by ITC at 15 °C is presented. A solution of 400 µM SpG was titrated 
into 20 µM Fab using injections of 1 x 2 µl and 29 x 7 µl. 
 
These results demonstrate that it is the addition of Fab that produces the heat 
released upon the interaction. The area underneath each injection peak shown in 
the top panel is equal to the total heat released for that injection. When these 
raw data - the total heat per injection - are plotted against the molar ratio of 
ligand (Fab) added to macromolecule (SpG) in the cell, a complete binding 
isotherm for the interaction is obtained, presented in the bottom panel. Titrations 
were carried out in triplicate for the wild-type protein with Fab, and typical 
isotherms of the data obtained are presented.  
 
Studying the interaction between D-SpGC2-1 and Fab has shown that the data 
obtained were found to fit well to a one binding site model and less rationally to 
other models. Formation of the SpG•Fab complex is an exothermic reaction, with 
heat being released upon complex formation, therefore injections of SpG into Fab 
resulted in a decrease in the electrical energy required to maintain the 
temperature difference between the sample and reference cells.  
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7.4.2.2 - Determination of the thermodynamic constants for Fab binding   
to D-SpGC2-1 constructs 
Thermodynamic constants, ΔH and ΔS, and the equilibrium dissociation constant, 
Kd, for these reactions were obtained by titrating 400 µM D-SpGC2-1 constructs 
into 20 µM Fab, and are presented in table 7.1. ΔG was calculated using the 
Gibbs-Helmholtz equation ΔG = ΔH – T ΔS, as stated in equation 6.13 in Chapter 
6. 
 
The Kd values obtained for the interaction between wild-type D-SpGC2-1, E14W-
W42F and E14W with Fab are reasonably close at 1.24 µM ± 0.16, 607.19 nM ± 
128.21 and 694.17 nM ± 229.66, respectively. This suggests that the introduction 
of the tryptophan residue to the alternative position at residue 14, as well as the 
removal of the Fc reporter tryptophan residue 42, do not greatly affect the 
interaction of SpG with Fab.  
 
D-SpGC2-1 
construct 
Kd  
± std dev.  
n≥2 
ΔH  
(kJ.mol-1) 
± std dev. 
n≥2 
ΔS  
(J.mol-1.deg-1) 
± std dev.  
n≥2 
ΔG  
(kJ.mol-1) 
± std dev. 
n≥2 
N 
± std dev. 
n≥2 
Wt 1.24 µM 
± 0.16 
-26.08 
± 4.30 
22.63 
± 15.64 
-32.59 
± 0.25 
0.40 
± 0.11 
E14W 607.19 nM 
± 128.21 
-24.22 
± 1.36 
 
-35.11 
± 2.93 
-34.33 
± 0.37 
0.47 
± 0.02 
E14W-W42F 694.17 nM 
± 229.66 
-23.41 
± 2.39 
37.03 
±10.04 
-34.07 
±0.53 
0.51 
± 0.01 
 
Table 7.1 – Summary of the thermodynamic binding constants obtained by 
titrating D-SpGC2-1 constructs into Fab 
 
 
The thermodynamic values presented in table 7.1 are indicative that the binding 
of Fab to wild-type SpG is dominated by specific interactions with major enthalpy 
changes dominating the reaction.  
 
7.5 – Pre-equilibrium binding studies 
7.5.1 – Determination of rate constants of D-SpGC2-1 and Fab 
complex formation using stopped-flow fluorescence 
 
All solutions of D-SpGC2-1 and human Fab were prepared in 20 mM potassium 
phosphate buffer at pH 8.0. In addition, 0.5 µl/ml of 1M 2-Mercaptoethanol was 
added to the solution of Fab in order to prevent dimerisation via C-terminal 
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disulphide bonds. Both solutions were filtered prior to use to minimise any 
interference from light scattering, and were also thermo-equilibrated at the 
operating temperature of 15 °C. Data were analysed as detailed in chapter 5. 
 
7.5.1.1 – Determination of association rate constant kass 
Figure 7.8 shows typical reaction progression curves obtained by using a final 
concentration of 1.5 µM Fab and final concentrations of E14W-W42F D-SpGC2-1 
ranging from 30 µM to 50 µM, after mixing had occurred. The association 
progression curves show a decrease in the fluorescence intensity as the complex 
between the SpG domain and Fab is formed. By repeating this reaction at various 
concentrations of E14W-W42F D-SpGC2-1, data were collected for the 
determination of both kass and kdiss. 
 
 
 
50 µM 
45 µM 
40 µM 
35 µM 
30 µM 
 
 
Figure 7.8 – Typical stopped-flow fluorescence profile of the association of 
varying concentrations of E14W-W42F D-SpGC2-1 and Fab   
 
A reaction progression curve for the association of E14W-W42F D-SpGC2-1 and 
Fab is presented. The association curve shows the fluorescence change upon 
formation of the SpG•Fab complex after mixing 1.5 µM Fab with 30-50 µM SpG, 
final concentration, at 15˚C, pH 8.0.   
 
7.5.1.2 – Direct determination of the dissociation rate constant kdiss  
The dissociation rate constant may also be independently measured by a 
displacement experiment. The rate of dissociation was determined by the 1:1 v/v 
dilution and displacement of Fab from a pre-formed 1:1 mol:mol ratio (3 µM:3 
µM) of the SpG•Fab complex by rapid addition of 30 µM non-fluorescent Fc 
mutant construct W42F D-SpGC2-1.  
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Figure 7.9 – Typical stopped-flow fluorescence profile of the dissociation of       
E14W-W42F D-SpGC2-1 and Fab complex   
 
A reaction progression curve for the dissociation of E14W-W42F D-SpGC2-1 and 
Fab is presented. The dissociation curve shows the fluorescence change upon a 
1:1 v/v dilution of 3 µM:3 µM SpG•Fab complex, final concentration, with 30 µM 
W42F D-SpGC2-1, at 15˚C, pH 8.0.  
 
Figure 7.9 presents a typical reaction progression curve for the fluorescence 
change upon dissociation. The half time for this first order reaction is 5.5 s and 
the rate of this reaction is therefore 0.12 s-1 and is the value of kdiss under these 
conditions. 
 
The dissociation rate constant obtained was used to set the intercept of the y-
axis, kdiss, to form the gradient of the line and the intercept of the y-axis, 
respectively.  
 
7.5.1.3 – Calculation of the pre-equilibrium Kd for the SpG•Fab complex 
A plot of the observed rate constant (kapp ) for the association reaction against 
final SpG concentration will give a straight line with the slope giving the second-
order association rate constant (kass M-1s-1), and the intercept (or the rate of 
dissociation determined from the displacement reaction described above) giving 
the first-order dissociation rate constant (kdiss s-1). A linear plot of kapp (s-1) 
against varying E14W-W42F D-SpGC2-1, is shown in figure 7.10, allows kass (0.14 
µM-1s-1 ) and kdiss (0.12 s-1) to be determined from the gradient of the line and the 
intercept of the y-axis respectively. These values then enable the pre-equilibrium 
Kd = kdiss / kass to be calculated as 857 nM. 
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 kass = 0.14 µM-1s-1 
kdiss = 0.12 s-1 
 
Figure 7.10 – Typical stopped-flow fluorescence analysis of the formation of 
E14W-W42F D-SpGC2-1 and Fab complex   
 
A linear plot of kapp (s-1) against varying concentrations of E14W-W42F D-SpGC2-1 
at 15°C, pH 8.0 is presented. 
 
The reaction progression curves, presented in figures 7.8 and 7.9, fit well to 
single-exponential equations. Assuming that the fluorescence change occurs on 
complex formation and dissociation, it suggests that both the association and 
dissociation of the SpG and Fab complex occur by simple processes. However, a 
more complex situation could exist in which a rapid, non-rate limiting 
conformational change may precede or follow the binding reaction. Alternatively, 
a non-rate limiting or rate limiting structural change may occur before or after 
the dissociation process. However, these possibilities can almost certainly be 
ignored since the structure of the domain and the Fab appear to be unchanged 
before and after complex formation [Gronenborn et al., 1991; Achari et al., 1992; 
Derrick and Wigley, 1992; Lian et al., 1992; Gallagher et al., 1994; Derrick et al., 
1994; Sauer-Eriksson et al., 1995]. 
 
By incorporating the E14W mutant close to the proposed Fab binding site it has 
been shown that this tryptophan residue acts well as a reporter group solely for 
SpG binding to the CH1 domain of Fab. Therefore, the resulting double mutant, 
E14W-W42F D-SpGC2-1 pQE-30, was then employed as a template for subsequent 
Fab mutants. The single mutant, E14W (which comprises two tryptophan 
residues, E14W-W42) was also employed as a control for all experiments 
undertaken in this study. This was to ensure that the incorporation of the 
tryptophan residue at the alternative position of 14 has not affected the binding 
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potential or structure of the SpG construct. A linear plot of kapp (s-1) against 
varying E14W D-SpGC2-1 is shown in figure 7.11, and a summary of the rate 
constants obtained for both E14W-W42F and E14W D-SpGC2-1 and Fab complex 
formation is presented in table 7.2. 
 
 
kass = 0.14 µM-1s-1 
kdiss = 0.15 s-1 
 
Figure 7.11 – Typical stopped-flow fluorescence analysis of the formation of 
E14W D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of E14W D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis respectively.  
 
 
D-SpGC2-1 
Construct 
k1  
(µM-1s-1) 
± std dev. n≥2 
k-1  
(s-1) 
± std dev. n≥2 
Kd  
(µM) 
± std dev. n≥2 
E14W-W42F 0.14 ± 0.02 0.12 ± 0.001 0.86 ± 118.89 
E14W 0.14 ± 0.02 0.15 ± 0.02 1.09 ± 0.04 
 
Table 7.2 – Summary of the comparison of rate constants and binding affinity 
obtained for the interaction of E14W-W42F and E14W D-SpGC2-1 with 
Fab 
 
 
The association and dissociation rate constants and the Kd values obtained for 
the binding interaction between both E14W-W42F and E14W D-SpGC2-1 
constructs with Fab are very similar. This suggests that these tryptophan 
mutations do not affect the binding of SpG to Fab, and shows that the 
incorporation of the tryptophan residue at position 14 reports the binding of Fab 
very well. 
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7.5.2 – Effect of mutagenesis on the binding constants for the D-
SpGC2-1 and Fab complex 
As previously discussed, mutant constructs of SpG, which have been shown to be 
critical for the binding interaction with Fab, have been produced to engineer 
favourable binding properties, as well as to allow specific amino acid residues and 
their contribution to the biological function of SpG to be evaluated. To achieve 
these objectives, new mutants were specifically designed to potentially alter the 
Fab binding affinities from the “wild-type” protein, which is E14W-W42F            
D-SpGC2-1 for these Fab studies. This is important, as it will give a complete 
overview of the binding interface.  
 
The Kd and rate constants for the complex formed between all D-SpGC2-1 mutant 
constructs were determined by stopped-flow fluorimetry. The binding association 
and dissociation of Fab to E14W-W42F SpG, presented in figures 7.8 and 7.9, has 
shown that these reactions each produce a signal that can be easily analysed by 
stopped-flow. This can then be compared with signals obtained by the mutant 
constructs, as well as the rate constants, in order to identify residues that are 
important to the interaction.  
 
7.5.3 – Determination of rate constants for Fab D-SpGC2-1 mutants  
SpG’s interaction with the CH1 domain of Fab lies predominantly within β-strand 
2, but also involves a minor region at the C-terminal end of the α-helix. The site 
of interaction spans residues Lys9, Thr10, Leu11, Lys12, Gly13, Glu14, Thr15 and 
Thr16 from β-strand 2 on SpG, with residues Tyr32, Ala33, Asn34, Asp35, Asn36 
and Gly37 from the C-terminal end of the α-helix of SpG constituting the minor 
contact region [Derrick and Wigley, 1992; Lian et al., 1994; Derrick and Wigley, 
1994; Sauer-Eriksson et al., 1995]. Six of these fourteen residues, from both the 
major and minor contact regions, namely residues Thr10, Glu14, Thr15, Thr16, 
Tyr32 and Asn36 formed the basis of this study and were mutated to different 
side-chains to characterise their side-chain involvement in the interaction with 
Fab. 
 
The rates of the association and dissociation of the complex between D-SpGC2-1 
constructs and Fab, as well as the pre-equilibrium Kd, are summarised below in 
table 7.3. 
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D-SpGC2-1 
construct 
kass  
(µM-1s-1) 
± std dev. n≥2 
kdiss  
(s-1) 
± std dev. n≥2 
Kd  
(µM) 
± std dev. n≥2 
Wt ND ND ND 
E14W-W42F 0.14 ± 0.02 0.12 ± 0.01 0.906 ± 118.89 
E14W 0.14 ± 0.02 0.15 ± 0.02 1.09 ± 0.04 
T10A ND ND ND 
T10S 0.09 ± 0.01 0.52 ± 0.04 5.74 ± 0.91 
T15A ND ND ND 
T15S 0.07 ± 0.01 0.68 ± 0.02 10.20 ± 1.36 
T16A 0.08 ± 0.02 0.33 ± 0.02 4.07 ± 0.97 
T16S 0.08 ± 0.02 0.30 ± 0.01 3.81 ± 1.03 
T15A-T16A ND ND ND 
Y32F 0.08 ± 0.01 0.14 ± 0.01 1.75 ± 0.13 
N36A ND ND ND 
N36D ND ND ND 
N36Q ND ND ND 
 
Table 7.3 – Summary of the rate constants and binding affinity obtained for the 
interaction of D-SpGC2-1 mutants and Fab 
 
 
As previously mentioned, the results obtained for the D-SpGC2-1 construct E14W-
W42F studied by stopped-flow fluorimetry shows very little difference in its 
association and dissociation with Fab, as well as the overall binding affinity, within 
error, to that of E14W SpG. This indicates that the introduction of the tryptophan 
residue at position 14 reports Fab binding as proposed and the removal of 
tryptophan residue 42 did not affect the interaction of SpG with Fab. In addition, 
the overall binding profile for the mutant Y32F with Fab compares quite well with 
that of E14W-W42F, with only a slight increase in Kd and decrease in the 
association constant. The dissociation constant of the SpG and Fab complex 
compares very well to that of the Wt domain and Fab, suggesting that, overall, 
this tyrosine residue is not significantly involved in the interaction with Fab.  
 
However, six mutant constructs were found to affect the binding affinity of SpG 
with Fab, namely T10A, T15A, T15A-T16A, N36A, N36D and N36Q. In addition, 
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during these stopped-flow studies, no significant fluorescence change was 
observed between Wt SpGC2-1 and Fab, suggesting that, although tryptophan 
residue 42 reports changes in fluorescence upon Fc binding, it does not report the 
binding of Fab to SpG.  
 
Three threonine β-strand 2 amino acid residues were selected to be mutated, 
namely Thr10, Thr15 and Thr16. These threonine amino acids appear to play 
important roles in the stabilising hydrogen bond network and have been shown to 
constitute the major contact region. Threonine 10 forms a hydrogen bond with 
Fab residue Lys215 located on the 7th β-strand on the CH1 domain. Threonine 15 
forms a hydrogen bond with Ser209 and Thr211, with threonine 16 also forming 
hydrogen bonds with Ser209 as well as with Ser210. Results obtained by 
stopped-flow studies showed that no apparent binding was observed with Fab 
when Thr10 and Thr15 were mutated to alanine residues, as shown in figure 
7.12. This near total loss of affinity suggests that these residues play significant 
roles in the interaction and are essential to Fab binding.  
 
The three threonine residues at positions 10, 15 and 16 were also mutated to 
serine residues, due to their very similar side-chains.  The aim of these mutations 
was to study the effect of replacing a threonine residue with another uncharged, 
polar residue on its interaction with Fab. Both threonine and serine possess 
uncharged, polar side-chains, as well as hydroxyl groups, which provide polarity 
to their otherwise hydrophobic side-chains, and threonine differs only in that it 
has a hydroxymethyl group in place of a hydrogen group found in serine. It was 
proposed that by replacing threonine 10 with serine, the hydrogen bond with its 
corresponding Fab residue will remain intact, but will be in a different orientation. 
A typical stopped-flow fluorescence analysis of T10S is presented in figure 7.13. 
Either an increase in kdiss or a decrease in kass, or a combination of both may bring 
about an increase in Kd of the complex. The calculated Kd value of the complex 
formed between T10S and Fab is 5.74 ± 0.91 µM, compared well with to the Kd 
value of 0.906 ± 118.89 µM for the equivalent complex formed by E14W-W42F. 
This 6-fold increase in Kd is due to the combination a 4-fold increase in the 
dissociation rate and a 1.5-fold decrease in the association rate.  
 
These results compare well with the T15S mutant construct, and a typical 
stopped-flow fluorescence analysis of T15S is presented in figure 7.14. The 
calculated Kd value of the complex formed between T15S and Fab is 10.20 ± 
1.36 µM, which is a 11-fold increase compared to the Kd value for the equivalent 
complex formed by E14W-W42F, and is nearly double to that obtained for the 
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T10S mutation. The increase in Kd is due to a 6-fold increase in the dissociation 
rate and a 2-fold decrease in the association rate.  
 
Characterising the interaction between T16A and T16S mutants and Fab by 
stopped-flow demonstrated that this amino acid produces a 4-fold increase in Kd 
regardless of whether it is mutated to an alanine or a serine residue. In addition, 
both mutations produce a 2.5-fold increase in the dissociation rate and a 1.75-
fold decrease in the association rate. This suggests that Thr16 only plays a small 
role in the interaction with Fab, and is not affected by mutation. Furthermore, no 
binding was observed with Fab for the double mutant construct T15A-T16A, which 
was not surprising as a total loss of binding was found with the T15A mutant, 
even though T16A retained Fab binding.  
 
From calculations based on the Kd of the complexes formed between the T15S 
and T16S and Fab it can be estimated that the Kd for the double mutant T15S-
T16S interaction with Fab would be around 40 µM assuming the presence of two 
mutations does not perturb the protein fold. 
 
Asparagine residue 36 has been implicated in the minor interfacial interaction of 
SpG with Fab. It is situated on the very end of the C-terminal end of the α-helix 
and forms a hydrogen bond with the backbone of Fab residue Val128. Asn36 also 
forms part of a stabilising hydrogen network, with its side-chain nitrogen atom 
and its backbone nitrogen each forming a hydrogen bond with the oxygen atom 
of the backbone of SpG residue Tyr32. This tyrosine residue in turn completes the 
hydrogen network, with its side-chain oxygen atom forming a hydrogen bond with 
Fab residue, Pro126. It was decided to mutate this asparagine to alanine (N36A), 
aspartic acid (N36D) and glutamine (N36Q) residues. However, no significant 
fluorescence change was observed between each of these asparagine mutations 
with Fab. These results lend themselves to three possible interpretations. Either 
that the loss of binding is a direct consequence of the loss in affinity, or that this 
particular residue can still bind Fab, but the fluorescence change is limited by the 
event of a structural change upon mutation. However, there is no supporting data 
available to explain these results, and unfortunately due to the lack of availability 
of Fab protein, further characterisation could not be achieved by other methods. 
The third possibility could be that not all Fab molecules have affinity for SpG. 
Different stocks of Fab protein may exhibit widely varying binding affinity, and it 
has been stated that only approximately 50% of human Fab fragments are 
believed to bind to SpG [Erntell et al., 1983].  
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Figure 7.12 – Typical stopped-flow fluorescence analysis of the no Fab complex 
formation with a selection of D-SpGC2-1 mutant constructs   
 
This graphical determination represents a resulting linear plot of kapp (s-1) 
against varying concentrations of D-SpGC2-1 at 15°C, pH 8.0, when the formation 
of the Fab complex cannot be measured.  
 
 
kass = 0.09 µM-1s-1 
kdiss = 0.52 s-1 
Figure 7.13 – Typical stopped-flow fluorescence analysis of the formation of T10S 
D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of T10S D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis, respectively.  
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 kass = 0.07 µM-1s-1 
kdiss = 0.68 s-1 
 
Figure 7.14 – Typical stopped-flow fluorescence analysis of the formation of T15S 
D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of T15S D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis, respectively.  
 
 
 
kass= 0.08 µM-1s-1 
kdiss = 0.33 s-1 
 
Figure 7.15 – Typical stopped-flow fluorescence analysis of the formation of T16A 
D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of T16A D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis, respectively.  
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 kass = 0.08 µM-1s-1 
kdiss = 0.30 s-1 
 
Figure 7.16 – Typical stopped-flow fluorescence analysis of the formation of T16S 
D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of T16S D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis, respectively.  
 
 
 
kass = 0.08 µM-1s-1 
kdiss = 0.14 s-1 
 
Figure 7.17 – Typical stopped-flow fluorescence analysis of the formation of Y32F 
D-SpGC2-1 and Fab complex   
 
This graphical determination represents a linear plot of kapp (s-1) against varying 
concentrations of Y32F D-SpGC2-1 at 15°C, pH 8.0. The rate constants kass and 
kdiss can be determined from the gradient of the line and the intercept of the y-
axis, respectively.  
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7.6 – Discussion 
In this chapter fluorescence has been employed to study the binding interaction 
between SpG and Fab. The introduction of a tryptophan residue at position 14 in 
D-SpGC2-1 has allowed this residue to be exploited as a reporter group for 
exclusively monitoring Fab binding. In addition, this binding interaction has 
permitted the characterisation of the reversible interactions in terms of binding, 
stoichiometry, kinetics and thermodynamics, and enabled the reliable 
determination of these parameters.  
 
Equilibrium studies using fluorescence titrations provided a simple and effective 
method for determining the true dissociation constant for the complex and 
allowed the number of binding sites to be calculated. Pre-equilibrium studies 
employed fast kinetic stopped-flow fluorimetry to determine the rates of 
association and dissociation of the complex between SpG and Fab. Further 
characterisation of this interaction was achieved by investigating the role of 
individual amino-acids that have been implicated in the binding interface between 
SpG and Fab.    
 
The region of Fab interaction with SpG has been defined by structural studies and 
shown to lie within the CH1 domain of the heavy chain [Derrick and Wigley, 
1992]. The Fab binding site is distinct from the Fc binding site through which the 
binding of IgG is mediated, and previous studies have shown that SpG interacts 
with the Fab regions of human IgG with a 10-fold lower affinity than determined 
for the human Fc region [Bjorck and Kronvall, 1984]. However, there is no data 
available to support any of the results obtained, and unfortunately due to the lack 
of availability of Fab protein, further characterisation cannot be achieved by other 
methods.  
 
Method  
@ 15°C, pH 8.0 
SpG + Fc SpG + Fab 
Titrations 0.5 µM 3 µM 
ITC 0.7 µM 0.6-1 µM 
Stopped-Flow 2.5-3 µM 1 µM 
 
Table 7.4 – Comparison of Kd values obtained for SpG with Fc and Fab 
obtained by various measuring techniques  
 
 
 
 
        CHAPTER 8.0 
 
GENERAL 
DISCUSSION 
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8.1 - Introduction and aims 
Protein G is a multi-domain protein associated with the cell wall from certain 
Streptococci that functions as a binding unit to several proteins including IgG. It 
has a high affinity for the interface between the CH2-CH3 domains of Fc of IgG, 
where it blocks the binding to the Fc receptor. Protein G (and SpG) also binds IgG 
at the CH1 domain, which explains its cross-reactivity with Fab without affecting 
the antigen-antibody interaction. The 208 bp single Ig-binding domain gene 
construct (SpG) based on the wild-type SpGC2-1 gene encoding the C2 domain, 
was successfully cloned into the N-terminal 6xHis tagged pQE-30 expression 
vector. Specific amino acid residues that contribute to the Fc and Fab binding 
interactions via a network of hydrogen bonds were identified and effectively 
modified by a programme of two-sided SOE-ing site-directed mutagenesis.  
 
Generating a library of constructs that offers a range of binding affinities enables 
various biotechnological uses. Serum antibodies have many applications, such as 
for the construction of affinity columns, as a coating reagent or for labelling in an 
immunoassay. However, the majority of these applications require some degree 
of antibody purification, and to obtain the accepted level of >80% purity requires 
a large amount of the antibody. As a result, the discovery and isolation of Ig-
binding proteins, such as protein A, G and L, has led to the use of these proteins 
in biotechnology as immunochemical reagents for identifying and purifying 
antibodies. Furthermore, as the use of antibodies in research and medicine has 
increased dramatically over recent years, the development of rapid and efficient 
techniques for Ig purification has become increasingly important. Ig-binding 
proteins are already heavily exploited immunochemical reagents in the screening 
and isolation of monoclonal antibodies, but they all possess limitations in their 
application. Thus, further investigations on these proteins, such as SpG and its 
interaction with Fc and Fab undertaken in this study, should increase our 
knowledge and understanding of this Ig-binding protein, as well as to increase its 
use in immunochemistry and biotechnology. For example, to remove Ig or Ig 
complexes from sera, a high affinity SpG ligand would be beneficial. Alternatively, 
to purify Ig from solution, an affinity ligand with a lower affinity would offer 
advantages for the elution of the Ig from the column. Therefore, it was for these 
reasons that an extensive series of mutant proteins were produced. A high level 
of expression for the wild-type, Fab and all but one of Fc mutant constructs, was 
achieved to evaluate the contribution of specific amino acids to the biological 
function of SpG with the aim of engineering proteins with different IgG subclass 
affinities or pH dependencies.  
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To enable the binding interaction between SpG with Fc and Fab to be fully 
characterised, knowledge of the contribution from each amino-acid involved is 
required. The solvent exposure and polarity of the environment surrounding 
several residues located on both binding sites for both Fc and Fab has been 
investigated in this study using fluorescence spectroscopy, as has the stability of 
the Ig-binding domain when various mutants are introduced into the protein. 
These studies have been achieved by exploiting unique tryptophan residues at 
key positions within each binding interface. The presence of a native tryptophan 
(W42) buried in the folded state, and the introduction of a tryptophan residue at 
position 14 (E14W) allowed these residues to be exploited as reporter groups and 
have proved instrumental in elucidating the polarity of the environment at 
different positions within each binding site. The spacial arrangements of the 
secondary-structure elements, in which an α-helix is positioned diagonally across 
a β-sheet, means that SpG is highly stable and therefore, provided an excellent 
model for conformation stability studies using fluorimetry and circular dichroism 
(CD), as well as by guanidine hydrochloride solvent denaturation experiments. 
Thus, polarity and stability changes in the mutant constructs surrounding these 
fluorophores, designed to probe the interaction with Fc or Fab respectively, were 
exclusively monitored. Certain residues will change the susceptibility of each 
tryptophan residue and alter the environment, as will the binding of either Fc or 
Fab fragments. 
 
Since an ideal protein for biotechnology applications must be not only 
thermodynamically stable, but also offer the appropriate affinity, the binding 
properties of SpG and its mutant constructs were characterised thoroughly by a 
combination of fluorescence titration and isothermal titration calorimetry (ITC), 
and kinetic measurements of real-time binding using stopped-flow fluorescence 
spectroscopy. The binding interactions of SpG with Fc and Fab permitted the 
characterisation of the reversible interactions in terms of binding, stoichiometry, 
kinetics and thermodynamics, and enabled the reliable determination of these 
parameters.  
 
8.2 - Analysis of wild-type SpG binding interactions 
Studies performed on wild-type SpG were carried out to study the native 
properties of the binding interaction with both Fc and Fab fragments. Equilibrium 
studies using fluorescence titrations provided a simple and effective method for 
determining the true dissociation constant for the complex and allowed the 
number of binding sites to be calculated. The Kd value for Wt D-SpGC2-1 binding 
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to Fc was able to be described by a single value of 506 ± 0.12 nM at 15°C, pH 8.0 
and 250 ± 0.22 nM at 25˚C, pH 6.0, and the stoichiometry of binding confirmed 
that Fc has two identical binding sites for SpG. Previous data obtained under the 
same conditions to determine the equilibrium dissociation constant for the 
interaction of D-SpGC2-1 with Fc are similar to the latter data obtained in these 
studies. Walker obtained a value of 306 ± 65 nM and Gallagher also obtained a Kd 
value of 333 nM for the B1 (C1) domain of SpG using titration calorimetry. This 
compares well, but could indicate that the introduction of a 6x His-tag at the N-
terminal end of the protein has slightly increased the binding affinity of D-SpGC2-1 
for Fc.  
 
Conversely, fluorescence titration results showed that E14W-W42F D-SpGC2-1 
binding to Fab was able to be described by a single Kd value of 3.33 ± 1.40 µM, 
and the stoichiometry of binding confirmed that Fab has one binding site for SpG. 
This is expected as Fab fragments have one heavy CH1 domain with a potential 
binding site for SpG. By incorporating the E14W mutant close to the proposed Fab 
binding site it has been successfully shown that this tryptophan residue acts well 
as a reporter group solely for SpG binding to the CH1 domain of Fab. The 
association and dissociation rate constants and the Kd values obtained for the 
binding interaction between both E14W-W42F and E14W D-SpGC2-1 constructs 
with Fab are very similar. This suggests that these tryptophan mutations do not 
affect the binding of SpG to Fab, and shows that the incorporation of the 
tryptophan residue at position 14 reports the binding of Fab very well. Moreover, 
the spectra obtained for E14W-W42F D-SpGC2-1 suggests that tryptophan 14, like 
tryptophan 42, is in a solvent exposed position, and is being quenched on 
complex formation.  
 
ITC experiments were also performed and demonstrated that it is the addition of 
both Fc and Fab that produces the heat released upon the formation of each 
complex in an exothermic reaction. Further analysis indicated that these binding 
reactions occur spontaneously and are driven by negative enthalpic changes, 
although entropic changes are unfavourable for the reaction in this direction. A Kd 
of 677 nM ± 154.1 was obtained for the SpG•Fc complex under these conditions. 
This value is very similar to that determined by fluorescence titrations performed 
under the same experimental conditions in which the Kd value for Wt D-SpGC2-1 
binding to Fc was found to be 506 nM ± 0.1. This also compares reasonably well 
with previous data obtained by Gallagher [Gallagher, 1994] for the B1 domain of 
a different SpG construct using titration calorimetry, which gave a Kd value of 
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333 nM. Although these values are slightly different, the slight increase in Kd 
found for the construct described in this thesis could indicate that the introduction 
of a 6x His-tag at the N-terminal end of the protein has slightly decreased the 
binding affinity of SpG for Fc. Similarly, the stoichiometry of binding for the 
interaction between SpG and Fc compares well for the two different experiments. 
Data from the ITC experiments gave a stoichiometry of 1.70 ± 0.05 equivalents 
of SpG to 1 equivalent of Fc, whereas the stoichiometry of binding from the 
fluorescence titrations was 2.1  ± 0.4 mol SpG: mol Fc. In contrast, the Kd values 
obtained for the formation of the wild-type D-SpGC2-1, E14W-W42F and E14W 
SpG•Fab complex are reasonably close at 1.24 µM ± 0.16, 607.19 nM ± 128.21 
and 694.17 nM ± 229.66, respectively. This suggests that the introduction of the 
tryptophan residue at the alternative position at residue 14, as well as the 
removal of the Fc reporter tryptophan residue 42, does not greatly affect the 
interaction of SpG with Fab. The thermodynamic values are indicative that the 
binding of Fab to wild-type SpG is dominated by specific interactions with major 
enthalpy changes dominating the reaction.  
 
Stopped-flow experiments indicated that the fluorescence intensity decreases as 
the complex between the Wt SpG domain with either Fc or Fab is formed. These 
experimental results also suggest that both the association and dissociation of the 
SpG complexes occur by simple processes. However, a more complex situation 
could exist in which a rapid, non-rate limiting conformational change may precede 
or follow the binding reaction in either Wt D-SpGC2-1 or the ligand. This would 
explain the discrepancy in results obtained for the SpG and Fc complex formation, 
with a 4-fold higher Kd value of 2.52 µM being obtained using pre-equilibrium 
techniques compared to a Kd value of 600 nM obtained in equilibrium studies. 
Alternatively, a non-rate limiting or rate limiting structural change may occur 
before or after the dissociation process or it is possible that small changes in Kd 
may occur as side chains become more immobilised in the complex. However, it 
is thought that this structural change is relatively small and these possibilities can 
almost certainly be ignored since the structure of the domain and its ligands 
appear to be unchanged before and after complex formation. Furthermore, the X-
ray structure of the backbone of SpG in free solution and in the complex is super-
imposable. 
 
A detailed pre-equilibrium binding study of the electrostatic nature of the 
interaction was performed at a wide range of pH conditions, namely pH 4.0 to pH 
9.0, at which SpG is considered stable. Results demonstrated that the interaction 
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between wild-type D-SpGC2-1 and Fc is pH dependent, exhibiting a maximum 
binding affinity at pH 6.0, which compares well with results obtained by Walker. 
This also agrees with results obtained by immobilisation techniques for SpG. The 
results obtained for the association and dissociation rate constants show that the 
effect of pH on the Kd appears to be mediated through changes in the rate of 
association of the complex, as the dissociation is virtually unchanged over the 
same pH range. This seems to indicate that charged residues are involved in the 
formation of the complex between wild-type D-SpGC2-1 and Fc, but not with the 
dissociation of the complex. There are a number of ionisable residues in wild-type 
SpG that are involved in the interfacial interaction with Fc, namely Glu26, Lys27, 
Lys30, Asp39 and Glu41. At high pH, tyrosines on the Fc, which have been 
implicated in binding, may also begin to ionise and disrupt the interaction. The pK 
of around 6.3 suggests that one or more of the acidic residues Glu26, Asp39 or 
Glu41 may be responsible for this pH effect. 
 
8.3 - Analysis of D-SpGC2-1 mutant constructs designed to 
perturb Fc binding interactions  
SpG binds Fc at the hinge region that is situated in the cleft between CH2 and CH3 
domains of Fc. Eight residues within the α-helix and β-strand 3 of SpG have been 
identified to be involved in the interfacial interactions with the loop regions of Fc, 
namely Glu26, Lys27, Lys30, Gln31, Asn34, Asp39, Glu41 and Trp42. Six of these 
residues, Glu26, Lys27, Gln31, Asn34, Glu41 and Trp42, formed the basis of this 
study, and were produced to potentially alter the Fc binding affinity from that of 
the wild-type protein. Engineering favourable binding properties allowed specific 
amino acid residues and their contribution to the biological function of SpG to be 
evaluated, providing a complete overview of the binding interface. However, 
Lys27A was not successfully expressed so could not be characterised any further.  
 
The exclusive tryptophan residue in the D-SpGC2-1 gene, W42, has been 
implicated in the interfacial interaction with Fc, and is situated on the N-terminal 
end of β-strand 3. Although this tryptophan residue is not directly involved in 
binding to Fc through a hydrogen bond network, it was decided to make W42F 
mutant in order to collaborate the work performed by Walker. Results obtained 
the pre-equilibrium studies showed that even though this mutation is in a slightly 
different construct, the effect was still the same and a loss of binding was found. 
It is also clear from the ITC experiments that W42 is essential for binding activity, 
which further supports the previous studies, indicating that tryptophan 42 is very 
important for the binding interaction of SpG with Fc. However, it appears that 
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some restoration of activity is brought about by the placement of a tryptophan at 
residue 14 (E14W) and a Kd of 4.5 µM was observed when in complex with Fc. In 
practice this may be a useful protein for affinity chromatographic applications as 
a Kd in the micromolar range is ideal for affinity ligands where easy elution of the 
bound target protein is required.  
 
These studies go further to show that in addition to the importance of W42, 
residues E26, Q31 and N34 play an important role in the binding. A dramatic 
reduction in the affinity of SpG for Fc was obtained for the E26A mutation. This 
finding is fully supported by results obtained by Sloan and Hellinga [1999] and 
Strop et al., [2000], who found that a single alanine mutation of E26 was found 
to virtually abolish the stable complex formation, with a >4,000-fold decrease in 
binding affinity. Their studies also proposed that the binding interface between 
SpG and Fc is polar in character and involves two well-defined “knobs-into-holes” 
interactions. Of the residues contributing to the hydrogen bonds across the 
interface, the most critical interaction was found to be formed by E26, which acts 
as a charged knob on the surface of SpG, inserting into a polar hole on the Fc 
fragment.  
 
The second “knob-into-hole” interaction proposed by Sloan and Hellinga is formed 
by the protrusion of Fc surface residues into a hole of SpG bordered by residues 
N34, D35, D39, E41 and W42. Aside from the W42 residue, as previously 
discussed, only the N34 residue was found to significantly affect binding, with a 
50-fold increase in affinity for the N34A mutation. Asparagine 34 is implicated in 
the interfacial interaction of SpG with Fc, and is located at the C-terminal end of 
the α-helix. This residue’s side-chain forms a hydrogen bond with the side-chain 
of Fc residue Asn434, and continues this vast hydrogen bond network by also 
forming hydrogen bonds with two other Fc residues, Tyr436 and His433. Again, 
data obtained by Sloan and Hellinga, as well as studies by Gülich et al., [2002] 
fully support the combined results presented here from conformational stability, 
equilibrium and pre-equilibrium temperature and pH binding studies. The N34 
substitutions were found to be the only mutant constructs that led to major 
consequences on protein stability. This may be significant as both residue N34 
mutations also led to changes in binding characteristics during equilibrium and 
pre-equilibrium studies, whereby the N34A substitution increased Kd by about 
10-fold and the N34D substitution effectively eliminates all apparent binding 
activity compared to the binding affinity for the equivalent complex formed by 
wild-type. These results also strongly suggest that this residue plays a significant 
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role in SpG’s interaction with Fc, and the close proximity of the bulky tryptophan 
residue may also play a part.  
 
Mutants were also investigated to determine the electrostatic nature of the 
interactions and their sensitivity to changes in pH performed at a wide range of 
pH conditions. Results obtained demonstrated that the interaction between SpG 
and Fc was dependent on these environmental conditions. The results also show 
that mutations Q31E and N34D have both altered the pH vs log Kd profile, thus 
indicating that ionisation of the replacement is affecting the Kd of the complexes. 
The glutamine residue at position 31 is of particular interest for its possible use in 
biotechnological applications. The substitution by alanine resulted in no significant 
change in the Kd value of the complex, whereas the substitution by a glutamate 
residue increased Kd by approximately 6-fold, demonstrating that a negative 
charge at this position is detrimental to binding. Reduced binding affinities were 
also obtained, with values of 4.5 µM from ITC equilibrium studies and 9 µM from 
pre-equilibrium binding studies, suggesting that this would be an ideal protein to 
purify Ig from solution. The lower affinity and the influence from the ionisable 
group would offer advantages for the elution of the Ig from the column.  
 
8.4 - Analysis of D-SpGC2-1 mutant constructs designed to 
perturb Fab binding interactions  
An additional aim of this research was to study the role of various amino acids 
that form the major contact regions in the binding of SpG with Fab, as very little 
is known of the binding properties and characteristics of this interaction. Single 
Ig-binding domains of SpG have also been shown to bind to Fab by forming an 
anti-parallel interaction with the last β-strand of the CH1 domain of Fab. SpG’s 
binding site for the interaction with Fab lies predominantly within β-strand 2, but 
also involves a minor region at the C-terminal end of the α-helix. The amino acid 
residues that form the major contact regions have been identified, and the site of 
interaction spans residues Lys9 to Thr16 from β-strand 2 on SpG and Ser209 to 
Lys216 from the 7th β-strand of the CH1 domain of Fab. In addition, residues 
Tyr32 to Gly37 from the C-terminal end of the α-helix of SpG and Pro125 to 
Tyr129 on the 1st β-strand of the CH1 domain of Fab constitute the minor contact 
region. A selection of six residues from both the major and minor contact regions, 
namely residues Thr10, Glu14, Thr15, Thr16, Tyr32 and Asn36, were chosen for 
their side-chain involvement in the interaction with Fab and selected to be 
mutated and used to study and characterise the binding affinity of Fab to SpG. 
This complex is stabilised through a network of hydrogen bonds, and the 
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importance and effect of these bonds to the stability and nature of the complex 
by removing these key residues was the prime aim of the studies.   
 
As previously mentioned, SpG possesses a unique tryptophan residue at position 
42, located on β-strand 3, which is known for its important role in Fc binding. Its 
substitution by phenylalanine reduces the binding interaction of SpG with Fc 
approximately 300-fold. Therefore, using this W42F D-SpGC2-1 construct enabled 
IgG Fab binding to be studied without the interference from any Fc interactions. 
However, the removal of the tryptophan in the W42F mutation created a non-
fluorescent protein, resulting in Fab binding studies using fluorimetry being 
impossible. Therefore, a tryptophan residue was re-introduced at an alternative 
position (E14W) to allow the effect of Fab mutations to be probed in fluorescence 
studies. By incorporating the E14W mutant close to the proposed Fab binding site 
this tryptophan residue successfully acted as a reporter group solely for SpG 
binding to the CH1 domain of Fab and results compares very well to that of wild-
type D-SpGC2-1. Therefore, the mutant W42F D-SpGC2-1 construct was used to 
make the E14W mutant and the resulting double mutant, E14W-W42F D-SpGC2-1 
pQE-30, was then employed as a template for subsequent mutants to allow the 
exclusive study of the anti-parallel interaction that takes place in forming the 
SpG•Fab complex. The single mutant, E14W, was also employed as a control for 
all experiments undertaken in this study.  
 
The region of Fab interaction with SpG has been well defined by structural studies 
and shown to lie within the CH1 domain of the heavy chain. The Fab binding site 
is distinct from the Fc binding site through which the binding of IgG is mediated 
and previous studies have shown that SpG interacts with the Fab regions of 
human IgG with a 10-fold lower affinity than determined for the human Fc region. 
For the mutations designed to explore Fab binding interactions none led to 
significantly reduced stabilities, indeed mutants with decreased affinities for Fab 
had, if anything, slightly higher conformational stability than wild-type. However, 
there is no data available to support any of the stability results obtained, and 
unfortunately due to the lack of availability of Fab protein, further 
characterisation cannot be achieved by other methods.  
 
However, during pre-equilibrium studies six mutant constructs were found to 
affect the binding affinity of SpG with Fab, namely T10A, T15A, T15A-T16A, 
N36A, N36D and N36Q, with no significant fluorescence change being observed. 
From the three threonine β-strand 2 amino acid residues shown to constitute the 
major contact region due to their important roles in the stabilising hydrogen bond 
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network, namely Thr10, Thr15 and Thr16, results obtained showed that no 
apparent binding was observed with Fab when Thr10 and Thr15 were mutated to 
alanine residues. This near total loss of affinity suggests that these residues play 
significant roles in the interaction and are essential to Fab binding. Furthermore, 
no binding was observed with Fab for the double mutant construct T15A-T16A, 
which was not surprising as a total loss of binding was found with the T15A 
mutant, even though T16A retained Fab binding.  
 
Asparagine residue 36 has been implicated in the minor interfacial interaction of 
SpG with Fab. It is situated on the very end of the C-terminal end of the α-helix 
and forms a hydrogen bond with the backbone of Fab residue Val128. Asn36 also 
forms part of a stabilising hydrogen network, with its side-chain nitrogen atom 
and its backbone nitrogen each forming a hydrogen bond with the oxygen atom 
of the backbone of SpG residue Tyr32. This tyrosine residue in turn completes the 
hydrogen network, with its side-chain oxygen atom forming a hydrogen bond with 
Fab residue, Pro126. It was decided to mutate this asparagine to alanine (N36A), 
aspartic acid (N36D) and glutamine (N36Q) residues. However, no significant 
fluorescence change was observed when each of these asparagine mutants were 
reacted with Fab. These results lend themselves to two possible interpretations. 
Either that the loss of binding is a direct consequence of the loss in affinity or that 
this particular mutant can still bind Fab, but the fluorescence change does not 
take place as usual.  
 
8.5 - Future work 
Hybrid proteins of PpL having the ability to bind to light chains of all Ig and also 
to bind to light and heavy chains of immunoglobulin G can assist the formation of 
a more stable Ig-binding domain with binding sites of comparable affinity for 
exploitation as versatile biotechnology tools. One common feature of proteins G 
and L is that they both possess multiple copies of Ig-binding domains, each 
containing approximately 60–70 residues. Within each protein these domains are 
highly conserved, although some sequence differences can exist that will give rise 
to a range of binding affinities that causes Igs to be eluted from affinity columns 
in non-symmetrical peaks. Furthermore, the interactions are so strong that the 
pH at which the elution occurs is very low and thus these native proteins are not 
ideal ligands for affinity purification. However, the Ig-binding properties of PpL 
and SpG have just been recently successfully combined through the construction 
of a novel hybrid protein, LG, consisting of a single Ig-binding domain of L 
produced in this lab and the domain of SpG used in these studies [Harrison et al., 
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2008]. These studies have shown that despite the small size of the protein, each 
domain exhibits all complexes to bind (Fc, CH1 to SpG and VL1 to PpL 
simultaneously). The binding affinity of each participant L and G can be 
engineered such that each releases its complex partner under similar conditions.  
Thus a library of such hybrids can be produced for various uses.   
 
Despite their limited binding properties, such Ig-binding proteins have found 
worldwide use in the purification of antibodies, in immunoassays and in some 
therapies to remove immune complexes from serum to minimise autoimmune 
disease and renal transplant rejection. Overall, these studies have improved our 
knowledge of SpG and its interactions with both Fc and Fab fragments. However, 
further development of SpG as an immunological tool is still necessary to fully 
understand the nature of its interaction with Fc and Fab. It is hoped that the 
significant results obtained from the work carried out on the SpG mutants 
described in this study, can be exploited to create a universal Ig-receptor binding 
protein, increasing its use in immunochemistry and biotechnology applications. 
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